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Abstract 
 
Cardiac arrest in paediatric patients often results in death or survival with severe brain injury. 
Therapeutic hypothermia, lowering of core body temperature to 32 to 34⁰C may reduce 
injury to the brain in the period after circulation has been restored. This thesis comprises 
studies related to the feasibility of performing a randomised controlled trial (RCT) of 
therapeutic hypothermia for neuroprotection after cardiac arrest in the UK. 
A systematic Cochrane review of paediatric evidence finds no published RCTs supporting or 
refuting the use of therapeutic hypothermia after cardiac arrest. Four on-going RCTs are 
identified which will add to the future evidence base; however, a future UK RCT is 
recommended.    
Additional support for a RCT is demonstrated by two UK surveys of paediatric intensive care 
and emergency care clinicians. Current UK practice is varied and clinical equipoise exists 
regarding post cardiac arrest temperature management.   
A national, retrospective study of all admissions to paediatric intensive care after out of 
hospital (OHCA) and in hospital cardiac arrest (IHCA) shows an overall survival of 76 and 
50% respectively. Important differences between IHCA and OHCA populations are 
identified, recommending separation in a RCT. The incidence rate of cardiac arrest 
admissions to PICU in the UK is too low to recruit to a UK only RCT, after consideration of 
sample size requirements. 
A large, multi-centre, retrospective, observational study of OHCA patients identified multiple 
factors associated with survival. A survival prediction model, incorporating: pupillary 
reaction, blood lactate level and duration of cardiac arrest, is described. The model could be 
used as a tool for stratified randomisation within a RCT. 
Finally, therapeutic hypothermia is retrospectively compared with standard, normothermic 
temperature management after OHCA. In a limited population, no difference in survival is 
found; however, important information on application, logistics and safety of the intervention 
are evaluated.  
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 1 General Introduction 
 
 
 
“We‟re going on a bear hunt,  
We‟re going to catch a big one. 
What a beautiful day!  
We‟re not scared” 
In: We‟re going on a bear hunt: Michael Rosen (children‟s novelist; born 1946) 
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1.1 INTRODUCTION 
The death of an infant or child is always a tragedy. Saving an infant or child whose heart 
stops beating can be seen as a medical miracle. However, for survivors, the loss of a normal 
future life and quality existence as a result of neurological injury can be a greater tragedy. 
The hunt for ways to improve post cardiac arrest care and reduce the burden of suffering in 
this precious population will be a challenge, but the effects on the patients and families may 
be immeasurable. This thesis starts that journey; to search, question, investigate, analyse 
and set the future research path, to establish if the use of simple temperature manipulation 
(therapeutic hypothermia) in these patients may be the key to improving their chances of a 
normal life after cardiac arrest. 
This first chapter aims to introduce the concept of cardiac arrest in children including the 
current understanding of the incidence and aetiology of paediatric cardiac arrest followed by 
the impact of the post cardiac arrest syndrome caused by ischaemia reperfusion injury after 
initial successful resuscitation, with a focus on neurological injury. An overview of 
therapeutic hypothermia follows. This is a potentially beneficial therapy that may prevent or 
attenuate the secondary neurological injury following cardiac arrest. The potential 
mechanism of action, evidence from animal and human clinical trials and important issues 
regarding actual delivery of therapeutic hypothermia will be outlined. Finally, the feasibility 
challenges of undertaking a paediatric critical care randomised controlled trial, which will 
need to be addressed in this thesis, is considered. 
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1.2 CARDIAC ARREST 
1.2.1 Definition and classification 
Knowledge of the accepted definition of cardiac arrest, understanding of the four phases of 
the disorder and the classification of location of cardiac arrest are fundamental building 
blocks for paediatric cardiac arrest research. Cardiac arrest (also known as cardiopulmonary 
arrest) is defined as „the cessation of cardiac mechanical activity, determined by the inability 
to palpate a central pulse, unresponsiveness and apnoea‟ (Zaritsky et al, 1995). However, 
adaptations to this definition have been made in numerous clinical trials, particularly due to 
difficulties of confirming absent pulses (Tibballs & Russell, 2009; Eberle et al, 1996), and 
therefore the „pragmatic definition‟ of cardiac arrest requiring chest compressions or 
cardiopulmonary resuscitation (CPR)  for a minimum of duration of one minute was 
suggested (Nichol et al, 2008a). Cardiopulmonary resuscitation (CPR) is a broad term 
meaning an attempt to restore spontaneous, effective ventilation and circulation (Zaritsky et 
al, 1995). CPR can be sub-classified into basic (simple airway manoeuvres, mouth to mouth 
ventilation and chest compression able to be performed by the lay-public without additional 
medical equipment) and advanced resuscitation techniques (requiring use of specialist 
equipment; e.g. endotracheal intubation, intravenous medication or extracorporeal life 
support)  (Zaritsky et al, 1995). 
In contrast to adults, cardiac arrest in the paediatric age group (infants and children from 
birth to their 18
th
 birthday) is often preceded by a respiratory deterioration leading to a 
hypoxia induced cardiac arrest, although primary cardiac disease and ventricular 
arrhythmias can occur in up to 14% of paediatric cases (Nadkarni et al, 2006). Cardiac 
arrest and subsequent resuscitation consists of four phases: 1) pre-arrest phase (prevention 
stage and preceding medical state), 2) no-flow „arrest‟ (period of cardiac arrest prior to 
starting CPR, 3) low flow „resuscitation‟ (whilst CPR is in progress) and 4) post resuscitation 
phase (period from minutes to days after achieving return of spontaneous circulation) (Berg 
et al, 2008). The effect of each phase with regards duration, management and resistance to 
treatment for each individual patient is important and affects chances of a sustained return of 
a spontaneous circulation (ROSC) and subsequent outcome.  
Chapter 1 
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Categorising the location of cardiac arrest appears to be important. For example, out of 
hospital cardiac arrest (OHCA), occurring outside of health care facilities, are less frequently 
witnessed leading to a more prolonged no-flow phase compared with in-hospital cardiac 
arrest (IHCA). Other differences between OHCA and IHCA include differences in aetiologies 
precipitating the cardiac arrest and potential identification of deterioration sooner for IHCA 
owing to physiological monitoring allowing resuscitation to be started earlier. Within the 
IHCA group, arrests occurring in a critical care environment, versus standard ward area, 
may also differ owing to variability in continuous physiological monitoring, adjunctive 
therapies such as mechanical ventilation and the severity of underlying medical or surgical 
conditions.  
Each individual patient‟s cardiac arrest will be unique. Multiple factors related to the cardiac 
arrest may be present or absent to varying degrees (e.g. location of arrest, duration of 
arrest, cause of arrest and delay and variation in treatment).  This variability can lead to 
significant heterogeneity in studies when patients are combined. To help identify and control 
for these variables, paediatric „Utstein‟ resuscitation definitions and templates for reporting of 
events surrounding cardiac arrest have been recommended (Zaritsky et al, 1995). Carefully 
outlining cardiac arrest and resuscitation definitions, whilst standardising with recommended 
Utstein definitions, will hopefully improve the overall quality of individual studies. In addition, 
this will allow more useful comparison (and where possible, combination) with other 
published studies to the benefit of the wider critical care community. 
1.2.2 Incidence of cardiac arrest and outcome 
 
So how common is paediatric cardiac arrest in the UK and how serious is the problem? 
Incidence of paediatric OHCA in the United States of America (USA) is 8 per 100,000 
person-years (Atkins et al, 2009) with infants (less than 1 year) having a nine fold increase 
(72 per 100,000 person-years). This is similar to a smaller study from Helsinki where all 
cause OHCA rates were 9.8 per 100,000 person-years (Kuisma et al, 1995) and a more 
recent Japanese OHCA registry study reporting 7.3 per 100,000 person-years (Nitta et al, 
2011). However, a study in Melbourne reported an incidence of only 5 per 100,000 person-
years for the same age range (Deasy et al, 2010). Unfortunately, UK population OHCA 
Chapter 1 
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incidence rates are currently not known and may also vary owing to differences in age, 
population, race and emergency medical provision hence the search for UK specific data is 
justified. 
Survival and outcome data also vary widely in the reported literature. Table 1-1, Table 1-2 
and Table 1-3 outline the main OHCA and IHCA studies published over the last 18 years. 
Most observational studies and data registries are based on patients in the USA after IHCA 
or small, often single centre, observational studies after OHCA. The patient population of 
interest, with respect to post cardiac arrest neuroprotection research, are those successfully 
resuscitated after cardiac arrest but still at risk of neurological morbidity and death. This is 
often as a consequence of the original cardiac arrest, hypoxic ischaemic injury and resultant 
post-cardiac arrest syndrome (Nolan et al, 2008). Many published studies include all cardiac 
arrest victims and only a small proportion of patients with a return of spontaneous circulation 
(ROSC). Survival and good neurological outcome rates also vary because of different 
definitions for cardiac arrest, inclusion of varying patient populations (e.g. sudden infant 
death syndrome or traumatic arrests), and variable outcome measurements or follow up 
duration. Traumatic cardiac arrests in particular have traditionally been associated with 
poorer outcomes. Table 1-1 and Table 1-2 have therefore separated (where possible) the 
OHCA studies including and excluding traumatic cardiac arrest patients to allow comparison. 
Patients suffering OHCA reportedly have a lower survival rate to hospital discharge (8 to 
12%) (Young & Seidel, 1999; Donoghue et al, 2005) compared to IHCA (24 to 28%) (Young 
& Seidel, 1999; Nadkarni et al, 2006; Meaney et al, 2006), when all cardiac arrest victims 
are included. The proportion of patients achieving ROSC after OHCA is approximately 20 to 
30% and after IHCA, 50 to 70%, although the published ranges, again vary considerably 
(OHCA: 5 to 47%, IHCA 50 to 82%) (Tables 1-1, 1-2 &1-3). Moler et al (2009) published the 
only large, observational study reporting outcomes for patients after OHCA and IHCA who 
achieved a sustained ROSC greater than 20 minutes and were admitted to a paediatric 
intensive care unit (PICU). Survival rates to hospital discharge and favourable neurological 
rates were 38% and 49% respectively for OHCA and 49% and 77% for IHCA. However, 
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extracting the  survival rates for patients achieving ROSC in the other cardiac arrest studies 
produces similarly wide and unreliable variation (OHCA: 14 to 62%, IHCA: 25 to 58%). 
 
 
 
 
 
2
1
 
Table 1-1 OHCA studies (all causes excluding trauma if possible), number of patients and outcomes 
Study Setting Study Design Country No. of 
paediatric 
patients 
ROSC 
(%) 
Survival to discharge
a
 
% All           % ROSC 
Favourable 
neurology
b
 
% survivor 
Donoghue et al (2005) All Systematic Review All 5363 31 12 nr 33 
Donoghue et al (2005) Excluding trauma Systematic Review All 3752 23 7 n/a 33 
Young and Siedel (1999)
c
 All Systematic Review All 1568 nr 8 nr nr 
Nitta et al (2011) Excluding trauma Prospective observational Japan 740 25 7 30 37 
Deasy et al (2010) All Prospective observational Australia 209 23 7 29 79 
Atkins et al (2009) All Prospective observational USA 624 nr 6 nr nr 
Moler et al (2009)
d
 ROSC > 20mins Retrospective USA 138 100 nr 38 49 
Herlitz et al (2007) All Prospective observational Sweden 702 nr 6 nr nr 
Ong et al (2006) All Retrospective Canada 474 8 2 23 nr 
Lopez-Herce et al (2005) All Prospective observational Spain 95 47 26 56 nr 
Young et al (2004) All Prospective observational USA 594 29 9 30 53 
Engdahl et al (2003) All Prospective observational Sweden 98 18 5 28 60 
Sirbaugh (1999) All Prospective observational USA 300 11 2 18 17 
Suominen et al (1997) All Retrospective Finland 50 26 16 62 75 
Schindler et al (1996) All Retrospective Canada 80 54 8 14 0 
Dieckmann and Vardis 
(1995) 
All Retrospective USA 65 5 3 67 50 
Kuisma et al (1995) All Retrospective Finland 34 29 15 50 80 
Mogayzel et al (1995) Excluding SIDS Retrospective USA 157 27 10 36 47 
Hassan et al (1997) All Retrospective UK 43 35 12 33 80 
nr: not reported, n/a: not applicable, ROSC: return of spontaneous output. 
a
 hospital discharge or first available outcome (e.g. one month). 
b 
author defined 
favourable neurology. 
c
favourable neurology only available from one study in review by Young and Seidel (1999) (28/68 patients). 
d
 data also published in 
Moler et al (2011). 
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Table 1-2  OHCA studies (traumatic arrests only), number of patients and outcomes 
Study Setting Study Design Country No. of 
paediatric 
patients 
ROSC 
(%) 
Survival to discharge
a
 
% All           % ROSC 
Favourable 
neurology
b
 
% survivor 
Donoghue (2005) Traumatic arrest only Systematic Review All 1830 nr 401 22 31 
Nitta et al (2011) Traumatic arrest only Prospective Observational Japan 135 25 1 1 100 
Crewdson et al (2007) Traumatic arrest only Retrospective UK 80 nr 7 9 nr 
Calkins et al (2002)  Traumatic arrest only National trauma registry USA 25 nr 2 8 nr 
Perron et al (2001)  Traumatic arrest only National trauma registry USA 729 nr 165 23 nr 
Li et al (1999) Traumatic arrest only National trauma registry USA 957 nr 225 20 33 
nr: not reported, 
a
 hospital discharge or first available outcome (e.g. one month). 
b 
author defined favourable neurology 
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Table 1-3 IHCA studies, number of patients and outcomes 
Study Setting Study Design Country No. of 
paediatric 
patients 
ROSC 
(%) 
Survival to discharge
a
 
% All           % ROSC 
Favourable 
neurology
b
 
% survivor 
Young and Siedel (1999) All In-hospital Systematic Review All 544 nr 24 nr 60 
Moler et al (2009)
c
 ROSC > 20mins Retrospective USA 353 (100) nr 49 77 
de Mos (2006)  PICUs only Retrospective Canada 91 82 25 31 43 
Meaney et al (2006)
d
 PICUs only Prospective NRCPR USA 464 50 23 45 64 
Nadkarni  et al (2006)
d
 All In-hospital Prospective NRCPR USA 880 52 27 51 65 
Samsom et al  (2006)
d
 All In-hospital Prospective NRCPR USA 855 50 25 50 88 
Tibbals and Kinney (2006) All In-hospital Prospective Observational Australia 111 73 36 49 nr 
Lopez-Herce et al (2005) All In-hospital Prospective Observational Spain 213 52 21 41 76 
Reis et al (2002) All In-hospital Prospective Observational Brazil 129 64 16 25 90 
Parra et al (2000) Cardiac ICU Retrospective USA 32 75 44 58 57 
Suominen et al (2000) All In-hospital Retrospective Finland 118 63 18 28 nr 
Slonim et al (1997) PICUs only Prospective Observational USA 205 nr 14 nr nr 
Torres et al (1997) All In-hospital Retrospective USA 92 nr 10 nr 78 
nr: not reported, 
a
 hospital discharge or first available outcome (e.g. one month). 
b 
author defined favourable neurology 
c
data also published in Meert et al 
(2009). 
d
NRCPR different study time periods 
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1.2.3 Aetiology of cardiac arrest 
The underlying cause of cardiac arrest has a profound effect on chances of ROSC and 
eventual outcome (Young et al, 2004). However, development of a clear definition for 
categorising causes of cardiac arrest has not yet been achieved (Jacobs et al, 2004). There 
remains significant variation in the style of coding strategies for allocating cause of arrest 
and therefore comparisons between studies can be difficult.  Large IHCA resuscitation 
registries tend to code for preceding physiological derangements (e.g. hypotension, 
metabolic disturbance etc), or associations with post surgical complications (Meaney et al, 
2006), whereas OHCA studies tend to allocate by clear diagnostic events (e.g. drowning, 
poisoning, asphyxia etc). Allocation of OHCA can be made solely on the assessment of 
immediate first responders and Emergency Medical Service personnel at the scene without 
additional hospital data (Atkins et al, 2009), or using enhanced data accuracy with national 
Coroner‟s data (Deasy et al, 2011a). However, when these two methods are compared they 
often poorly correlate (Ong et al, 2007; Ong et al, 2006). Finally, variation in the upper age 
limits of studies can also skew incidence rates for diagnoses more common in adolescents 
and young adults, for example two OHCA reports by Deasy and colleagues from Melbourne 
reported incidence of hanging in 0 to 15 years old as 5% (9/193) (Deasy et al, 2010); 
however, in a similar time period they reported incidence in 0 to 18 year olds of 8% (53/680) 
(Deasy et al, 2012). Table 1-4 highlights these differences between published studies of 
OHCA aetiologies. 
Additional problems exist with combining aetiologies into groups. Traumatic cardiac arrest 
has been associated with poorer survival in paediatric patients (Donoghue et al, 2005; 
Crewdson et al, 2007). However, there exists considerable variation in the allocation of 
diagnoses to the „trauma‟ group. For example, drowning in some is classified as a traumatic 
aetiology and in others a respiratory aetiology. Therefore, the solution to this problem is not 
straightforward. Consideration of the population being studied and suitability of 
categorisation systems for aetiologies will be required to facilitate comparison of the studied 
population with other relevant published data. 
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Table 1-4 Published rates of presumed aetiology for OHCA  
 Young 
et al 
(2004) 
Herlitz 
et al 
(2007) 
Atkins  
et al 
(2009) 
Moler 
et al 
(2009) 
Deasy 
et al 
(2010) 
Deasy 
et al 
(2012) 
Nitta 
et al 
(2011) 
No. of patients n = 601 n= 702 n = 624 n = 138 n = 193 n= 680 n = 875 
Age range 
0 to 
<13yrs 
0 to 
<18yrs 
0 to 
<20yrs 
1day to 
<18yrs 
0 to 
<16yrs 
0 to 
<19yrs 
0 to 
<18yr 
No obvious 
cause or 
unknown 
20 (3) 49 (7) 420 (67) 1 (1) 14 (7) nr 5 (1) 
Cardiac 48 (8) 98 (14) nr 20 (15) 58 (30) 224 (33) 266 (30) 
Respiratory nr 41 (6) nr 98 (72) 22 (11) 48 (7) 82 (9) 
Neurological 35 (6) nr nr 5 (4) nr 27 (4) 27 (3) 
Sudden Infant 
Death 
Syndrome 
136 (23) 207 (29) 38 (6) nr 40 (21) 129 (19) nr 
Trauma 118 (20) nr nr 15 (11) 16 (8) 96 (14) 135 (16) 
Drowning 73 (12) 70 (10) 29 (5) 43 (31) 20 (10) 38 (6) 41 (5) 
Hanging nr nr 34 (6) 0 (0) 9 (5) 53 (8) 22 (3) 
Overdose nr nr 17 (3) 4 (3) nr nr 16 (2) 
Foreign body 12 (3) nr 4 (1) nr nr nr nr 
Suffocation 21 (3) 36 (5) 17 (3) nr nr nr 138 (16) 
 
Values expressed as Number (percent). nr: not reported 
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1.2.4 Post cardiac arrest syndrome 
The recent International Liaison Committee on Resuscitation consensus statement 
emphasises the existence of the „post-cardiac arrest syndrome‟ (Nolan et al, 2008) which 
was first described by Dr Vladimir Negovsky in 1972 . This syndrome is the consequence of 
prolonged whole body ischaemia and reperfusion inflammatory injury affecting the brain and 
myocardium as well as systemic effects similar to those seen in severe sepsis.  
The brain is the most vulnerable organ in the body when subjected to hypoxic ischaemia 
during cardiac arrest. It is the only organ in the human which cannot be replaced or 
transplanted. Resuscitation during the low-flow phase aims to achieve effective, 
uninterrupted cardiac compressions and ventilation in order to maintain cerebral perfusion 
with oxygenated blood. However, even „excellent‟ closed chest CPR can only achieve 10 to 
25% of normal coronary perfusion and 30 to 40% normal cerebral blood flow (Swenson et al, 
1988). The cascade of neurologically damaging processes after cardiac arrest occurs in two 
phases: 1) Primary neuronal cell death, as a result of immediate (within five to seven 
minutes) cellular hypoxia and exhaustion of adenosine tri-phosphate (ATP) energy stores 
and 2) Delayed neuronal cell death which leads to neurodegeneration over hours to days. 
Damage occurs as a result of a biological cascade leading to: calcium mediated injury in the 
mitochondria, excitotoxic injury, activation of intracellular enzymes (protease, phospholipase, 
protein kinase and endonuclease), activation of nitric oxide, formation of oxygen free-
radicals, release of free fatty acids, cell death signalling (analogous to developmental 
apoptosis), gene damage with up-regulation of immediate and late gene expression, and 
recruitment of inflammatory cells. The consequences of these processes are: impaired 
cerebrovascular reactivity, cytotoxic cerebral oedema and cerebral hyperaemia (Lopez-
Neblina et al, 2005; Eltzschig & Eckle, 2011; Borgens & Liu-Snyder, 2012). 
The extent of damage is dependent on numerous factors including the duration of cardiac 
arrest and the area of the brain which is affected. For example, primary neuronal cell death 
can affect layers III and IV of the cerebral cortex (watershed areas) causing laminar necrosis 
or can cause cerebral infarcts via loss of CA1 and CA3 neuronal areas of the hippocampus, 
basal ganglia and cerebellum (Huang & Castillo, 2008). The subsequent brain injury can 
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manifest as seizures, cognitive dysfunction, memory loss, myoclonus, signs of stroke, coma, 
persistent vegetative state and brain death (Nolan et al, 2008). Age dependent selective 
vulnerability is also present. Apoptosis is greater in the immature brain (less than one year of 
age) with increased areas of neuronal development with dense regions of excitotoxins (e.g. 
glutamate) in the hippocampus, which can lead to a relative sparing of the cerebral cortex 
and cerebellum (Zhu et al, 2005).  
Improved basic science knowledge of the post-cardiac arrest syndrome and biological 
mechanisms for hypoxic ischaemic damage to the brain now enable us to assess potential 
therapeutic strategies to prevent, inhibit or modulate the harmful effects of brain ischaemia 
reperfusion and potentially enhance the body‟s own innate protective mechanisms. 
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1.3 THERAPEUTIC HYPOTHERMIA 
1.3.1 Temperature and cardiac arrest  
Humans are homeotherms and have developed a tight temperature homeostatic 
mechanism, controlled by the hypothalamus to maintain core body temperature between 
36.5 and 37.4°C in response to much more extreme external temperature variation 
(LeBlanc, 1975).  Temperature can be reduced through convection, conduction, radiation 
and evaporation mechanisms, as a consequence of hypothalamus driven changes in 
arteriolar vasodilatation and sweat gland activation. It can be increased by arteriolar 
vasoconstriction, piloerection of hair follicles, shivering, muscle use and mitochondrial 
energy production through brown fat usage. Babies and infants are more vulnerable than 
adults to heat loss due to larger surface area to weight ratio, lack of shivering mechanism, 
higher metabolic rates and inability to self-care (i.e. put on more clothes, search out heat 
source etc). However, they have a developed compensatory mechanism such as heat 
generation by specialised fat deposits (brown fat). 
Disruption to the homeostatic mechanism can be caused by illness, particularly infection, 
leading to an advantageous hyperthermic (core temperature > 38°C) state, resetting the 
hypothalamic control level. However, damage to the hypothalamus through brain injury, 
leading to hyperthermia, has resulted in poor neurological outcome or death after cardiac 
arrest (Bembea et al, 2010; Suffoletto et al, 2009; Hickey et al, 2000; Zeiner et al, 2001), 
traumatic brain injury (Natale et al, 2000), hypoxic ischaemic encephalopathy in neonates 
(Laptook et al, 2008) and stroke  (den Hertog et al, 2009; Lakhan & Pamplona, 2012). 
Hyperthermia has also been independently associated with increased mortality and length of 
hospital stay in adult neuro-critical care patients (Diringer et al, 2004). International 
resuscitation guidelines have therefore repeatedly stressed the need to avoid hyperthermia 
after paediatric cardiac arrest (ILCOR, 2006; Kleinman et al, 2010).  
Although the potential benefit of therapeutic hypothermia as a post resuscitation therapy was 
not fully appreciated until the 20
th
 century, the protective effects of hypothermia in humans 
had been known for thousands of years. The Egyptians in 2500 BC used low temperatures 
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to treat injuries and inflammation. Hippocrates (460-370 BC) is reported to have commented 
that limbs survived longer when covered with ice and snow. Baron Larrey, Napoleon‟s 
Surgeon-General, noted that soldiers died more quickly if they were left sitting closer to a fire 
(Larrey, 1832). However, the use of „modern‟ therapeutic hypothermia after cardiac arrest 
resuscitation was not attempted until the 1950s. This followed successful use of hypothermia 
under general anaesthesia before cardiac bypass, protecting the brain during cardiac 
surgery (Bigelow et al, 1950). Initial use after cardiac arrest had varying success. Although, 
it was believed that temperatures 33 to 30°C and below were required to be beneficial and 
this led to significant complications (shivering, vasospasm, increased plasma viscosity, 
bleeding, arrhythmias and lower resistance to infection) (Friedman et al, 1956; Reuler, 1978; 
Steen et al, 1980; Steen et al, 1979). Therapeutic hypothermia was also used for prolonged 
periods (up to ten days) in combination with barbiturates, before the development of critical 
care units, ventilators and monitors, to manage these side effects. Its use continued in the 
1960s and 1970s; however, paediatric reports of increased harm, especially during 
treatment of drowning victims, stopped its use in the 1980s (Bohn et al, 1986; Biggart & 
Bohn, 1990). 
Basic science research „rediscovered‟ the benefits of milder therapeutic hypothermia (33 to 
34°C) in the late 1980s. Initially by accident, Hossmann et al (1988) identified the beneficial 
effects of hypothermia (33 to 35°C) prior to a one hour hypoxic insult in cat‟s 
electroencephalography recovery. At the same time similar research with dogs discovered 
the benefits on neurological outcome of hypothermia before cardiac arrest (Safar, 1988). 
Further studies followed, investigating the use of „milder‟ hypothermia (33 to 34°C) after 
prolonged normothermic cardiac arrest, confirming that neurological and histological 
protection could still be demonstrated and leading to a decade of further experimentation 
into refining the limits of therapeutic hypothermia (Sterz et al, 1991; Weinrauch et al, 1992; 
Kuboyama et al, 1993; Safar et al, 1996).  
1.3.2 Therapeutic hypothermia - definition 
Therapeutic hypothermia is the active reduction of core body temperature to prevent or 
attenuate the secondary cellular injury after ischaemia reperfusion. Terminology has often 
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been confusing with descriptors such as „mild, moderate, severe, extreme, deep etc‟ 
referring to variable ranges of temperature (Safar & Behringer, 2003). To clarify this situation 
the term „targeted temperature management‟ has been recommended along with explicit 
temperature profile (e.g. 32 to 34⁰C) to improve clarity (Nunnally et al, 2011). In this thesis, 
patients receiving active targeted temperature management will be referred to as having 
therapeutic hypothermia, with inclusion of explicit numerical temperature values in 
parentheses. 
Therapeutic hypothermia has three key stages (Figure 1-1): reduction of temperature from 
current temperature to a lower temperature (“induction”), maintenance of lower temperature 
for a treatment period (“maintenance”) and then return to a normothermic temperature either 
through active rewarming or through intrinsic physiological control (“rewarming”) (Nunnally et 
al, 2011). 
Figure 1-1 Stages of therapeutic hypothermia 
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1.3.3 How therapeutic hypothermia might work 
The pathophysiological mechanism by which therapeutic hypothermia (TH) may exert its 
neuroprotective effect is complex. There is evidence that it modulates a number of the key 
biochemical, metabolic and pathophysiological events in the brain which occur after cerebral 
ischaemia reperfusion injury. These include reduction of cerebral metabolism and balancing 
out energy failure by the protection of ATP stores during cessation of cerebral blood flow 
(Steen et al, 1983; Takasu et al, 1996); attenuation of the biosynthesis, release and uptake 
of excitotoxic compounds such as glutamate and dopamine (Busto et al, 1989; Suehiro et al, 
1999); and attenuation of the production of proteins important in apoptosis (Bax and Bcl-2) 
(Xu et al, 2002; Yenari et al, 2002). TH has also been shown to reduce free radical 
production (Kil et al, 1996), improve delayed hypoperfusion (Karibe et al, 1994) and be 
involved in neuronal anti-inflammatory effects (Sutcliffe et al, 2001; Suehiro et al, 2004).  
The modulation of these biological cascade mechanisms by therapeutic hypothermia have 
been demonstrated through experimental animal studies during and after hypoxic ischaemic 
insults (Busto et al, 1987; Colbourne & Corbett, 1995; Colbourne & Corbett, 1994; 
Colbourne et al, 1999; Fink et al, 2004; Gunn et al, 1997). However, efficacy is affected by 
the experimental model (animal species, focal or global ischaemic insult) (van der Worp et 
al, 2007), duration of ischaemic insult (Chopp et al, 1991), time to commencement of 
therapeutic hypothermia (earlier to target temperature produces greater effect) (Coimbra & 
Wieloch, 1994; Busto et al, 1989; Kuboyama et al, 1993; Markarian et al, 1996; Iwata et al, 
2007), duration of therapy (longer duration more efficacious especially with increasing delay 
to start of cooling) (Colbourne et al, 1999), depth of therapy (Iwata et al, 2005), speed of 
rewarming (too rapid rewarming can reverse neuroprotective effect of therapeutic 
hypothermia (Suehiro et al, 2003)) and adjunctive anaesthesia or neuroprotective 
medication (Xenon gas appears to augment neuroprotection of therapeutic hypothermia) 
(Hobbs et al, 2008; Ma et al, 2005). Also, animal models have limitations when applied to 
humans. For example, lack of co-morbidities, controlled ischaemic insults and different 
neuronal development patterns. Therefore, demonstration of efficacy and evaluation of dose 
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requirement (e.g. depth of hypothermia, duration of therapy, timing of intervention, induction 
and rewarming rates) in human clinical studies is required. 
1.3.4 Clinical studies 
Table 1-5 outlines the main therapeutic hypothermia clinical trials in adults, neonates and 
paediatrics with reported absolute effects sizes. The benefit of therapeutic hypothermia in 
reducing poor neurological survival after witnessed, ventricular fibrillation cardiac arrest was 
demonstrated in two landmark RCTs from Europe and Australia in 2002 (HACA, 2002; 
Bernard et al, 2002). The larger European study recruited 275 patients following out of 
hospital ventricular fibrillation cardiac arrest. Therapeutic hypothermia was induced within a 
median of 8 (IQR [4-16]) hours to between 32 to 34°C via surface cooling for 24 hours, 
followed by rewarming to normothermia. Fifty five percent receiving therapeutic hypothermia 
had a favourable outcome (survival with good neurological recovery) versus 38% after 
standard therapy (HACA, 2002). The Australian study recruited 77 patients, again only 
including patients with ventricular fibrillation induced cardiac arrest (Bernard et al, 2002). 
Therapeutic hypothermia was induced by paramedics after return of spontaneous circulation 
using surface ice packs with a median duration to target temperature of 33°C of two hours 
and continued for 12 hours prior to rewarming to normothermia. Forty nine percent of 
patients receiving therapeutic hypothermia had survived with a good neurological outcome 
compared to 26% receiving standard therapy. Numbers needed to treat, to achieve one 
successful neurological survival, were between four and seven. No serious adverse events 
were reported after therapeutic hypothermia therapy, although a trend towards increased 
infection was noted in the European study. However, both studies had weaknesses. The 
main criticism of the European study was that greater than 25% of the control group 
experienced a core temperature greater than 38°C, potentially increasing harm in the control 
group and biasing the study. In the Australian study the quasi-randomisation by alternate 
day allows bias to be introduced in the randomisation process. No power calculation was 
performed prior to starting the trial and the study was continued for 12 months after analysis 
of the first 62 patients as „outcome was better that previously published‟ with apparently no 
statistical adjustment for interim analysis which can therefore  lead to inflation of the false 
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positive rate (Harris et al, 2008). Finally, the significant improvement in good neurological 
outcome quoted a „significant‟ p value of 0.049 using unadjusted odds ratios. However, if the 
results are reanalysed using the standard Chi
2 
statistical test, the difference in primary 
outcome between therapeutic hypothermia and normothermia is non-significant (p=0.06). 
Despite these weaknesses, two additional small RCTs (Hachimi-Idrissi et al, 2001; Laurent 
et al, 2005), numerous observational studies and subsequent meta-analyses of all the RCTs 
(Arrich et al, 2009; Holzer et al, 2005; Cheung et al, 2006) lead to international consensus 
guidelines recommendations that TH should be used in adults after OHCA witnessed, 
ventricular fibrillation cardiac arrest and may be considered in patients presenting after 
OHCA in a non-shockable rhythm or after IHCA presenting in any rhythm (Peberdy et al, 
2010). However, further studies are on-going to investigate the use after IHCA and after 
non-VF cardiac arrest (NCT00457431; NCT01020916), owing to concerns that the current 
level of evidence for these groups is incomplete (Nielsen et al, 2011) 
Paediatric out-of-hospital cardiac arrest (OHCA) often presents with a non-shockable 
rhythm. The evidence from the adult population regarding the benefits of TH in this 
population is more uncertain than if presenting in a shockable rhythm. A systematic review 
and meta-analysis of two randomised and ten non-randomised studies of the use of TH in 
adults presenting with a non-shockable initial rhythm, cautiously reported an improved in-
hospital mortality rate in pooled patients receiving TH (risk ratio (RR): 0.84 [95% confidence 
interval (CI); 0.71-0.92]) but no improvement in neurological outcome (RR 0.93 [95% CI; 
0.88-1.00]) (Kim et al, 2012). Caution was expressed owing to the high heterogeneity 
amongst studies, substantial risk of bias and quality of evidence grade as „very low‟ using 
the GRADE profile (Guyatt et al, 2008). The authors concluded that further prospective 
evaluation of TH after non-shockable cardiac arrest was needed. This recommendation is 
also supported by the authors of a systematic review performed to update the 2010 ILCOR 
guidelines (Walters et al, 2011).  Therefore, the strength of evidence supporting the use of 
TH in adult patients groups more closely applicable to the majority of paediatric patients is 
also weak. 
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Nielson et al (2011), using critical evidence evaluation and the GRADE profile (Guyatt et al, 
2008), also questioned the strength of the evidence regarding the use of TH after adult 
patients presenting in a shockable rhythm. They re-examined the five randomised controlled 
trials of TH after shockable rhythms (Bernard et al, 2002; HACA, 2002; Mori et al, 2000; 
Hachimi-Idrissi et al, 2001; Laurent et al, 2005).  They concluded that all trials had 
substantial risk of bias. Even the largest study (HACA 2002), owing to the exclusion of 92% 
of screened OHCA patients and lack of control for fever causing potential confounding effect 
in the control group, could not be graded as low risk of bias.  Trial Sequential Analysis of the 
studies identified that insufficient information had been gained from the combined 424 
patients to reject or detect an intervention effect of 16% relative risk reduction of all-cause 
mortality, therefore recommending further prospective evaluation of TH in patients 
presenting in both shockable and non-shockable rhythms and ensuring a methodological 
approach with a low risk of bias. 
Over the same time period, neonatologists were investigating the use of therapeutic 
hypothermia in newborn infants with evidence of hypoxic ischaemic encephalopathy in the 
first few hours after birth. Six large RCTs have now been performed (Azzopardi et al, 2009; 
Gluckman et al, 2005; Shankaran et al, 2008; Eicher et al, 2005; Simbruner et al, 2010; 
Jacobs et al, 2011). Therapeutic hypothermia, targeting 33 to 34⁰C, was commenced within 
six hours of birth (and presumed hypoxic insult). This continued for 72 hours in five and 48 
hours in the sixth study (Eicher et al 2005) and assessed the composite primary outcome of 
death or severe disability at eighteen months. Only Shankaran et al (2008) demonstrated a 
statistically significant improvement in the primary outcome, although one of remaining five 
studies was terminated early owing to lack of clinical equipoise in clinicians following the 
publication of earlier studies (Simbruner et al, 2010). Meta-analysis of these studies has, 
however, shown strong support for therapeutic hypothermia within six hours of birth. There 
was increased survival with normal neurological function in infants receiving TH in the first 
18 months of life than in infants treated by standard care (risk ratio 1.53, 95% CI [1.22 to 
1.93]), with a number needed to treat of eight (95% CI 5 to 17) (Edwards et al, 2010). This 
led to recommendations for adoption of this therapy in national guidelines (NICE, 2010). 
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Caution regarding the transfer of the positive findings of the adult and neonatal RCTs 
directly to the paediatric cardiac arrest population is required. The only large, multicentre, 
RCTs of therapeutic hypothermia in children have been conducted after traumatic brain 
injury (Hutchison et al, 2008). In the Hypothermia after Paediatric Traumatic Brain Injury 
Trial, patients receiving therapeutic hypothermia had a worse primary outcome (six month 
survival with good neurological outcome (PCPC score 1-3) (Fiser, 1992)). Also, a more 
recent study (CoolKIDS) was terminated early, by the data monitoring committee, due to 
lack of benefit from therapeutic hypothermia (Personal communication: D. Adelson 2012), 
although formal results are awaited (NCT00222742). Therapeutic hypothermia has been 
researched in other conditions at risk of neurological injury in adults. However, systematic 
reviews of limited RCTs, with significant heterogeneity, also showed no clear benefit after 
stroke (Lyden et al, 2006; Correia et al, 2000), coronary artery bypass (Rees et al, 2001), or 
during neurosurgical procedure (Li et al, 2012; Milani et al, 2011). 
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Table 1-5 Clinical randomised controlled trials of therapeutic hypothermia and effect size 
 
Reference Study name Population 
Target 
temperature 
(°C) 
Time to 
initiate 
cooling  
Cooling 
duration 
(hours) 
Primary outcome 
Primary outcome 
absolute effect 
size 
Survival only 
absolute effect 
size 
Bernard et al (2002) 
 
Adult OHCA 32 to 34 a 12 
Survival with good 
neurological outcome 
23% 17% 
HACA et al (2002) HACA study Adult OHCA 32 to 34 b 24 
Survival with good 
neurological outcome 
16% 14% 
Gluckman et al (2005) 
Cool Cap 
study 
Neonatal 
HIE 
34 to 35 ≤ 6 hours 72 
Death and severe 
neurological injury 
18% 5% 
Shankaran et al (2005) NICHD study 
Neonatal 
HIE 
33.5 ≤ 6 hours 72 
Death and severe 
neurological injury 
18% 13% 
Eicher et al (2005)   
Neonatal 
HIE 
33.5 ≤ 6 hours 48 
Death and severe 
neurological injury 
32% 11% 
Azzopardi et al (2009) TOBY  study 
Neonatal 
HIE 
33 to 34 ≤ 6 hours 72 
Death and severe 
neurological injury 
8% 1% 
Jacobs et al (2011) ICE study 
Neonatal 
HIE 
33 to 34 ≤ 6 hours 72 
Death and severe 
neurological injury 
15% 13% 
Simbruner et al (2010) 
neo.nEuro. 
network  
Neonatal 
HIE 
33 to 34 ≤ 6 hours 72 
Death and severe 
neurological injury 
32% 19% 
Hutchison et al (2008) 
HypPIT 
study 
Paediatric 
TBI 
32 to 33 ≤ 6 hours 24 
Death and severe 
neurological injury 
-9% -9% 
a. no inclusion time limit set; cooling commenced in the field by paramedics. b. no inclusion time limit set; cooling commenced in the emergency department 
after randomisation 
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1.3.5 Dose of therapeutic hypothermia 
The „pharmacodynamics‟ of therapeutic hypothermia appear critical to the success and 
safety of the intervention and intense research (although mostly in animal pre-clinical 
studies) has focused on the optimal timing, duration, depth and rewarming rates. However, 
there still remain considerable knowledge gaps regarding the application in clinical practice. 
The optimal therapeutic window for TH is not known although beneficial effects in RCTs 
have been identified when commencement of TH occurs less than six hours after hypoxic 
ischaemic insult or ROSC (Table 1-5). Evidence from animal studies is that time to target 
temperature after ROSC should be as short as possible, although benefit has been 
demonstrated up to six hours after insult (Coimbra & Wieloch, 1994; Busto et al, 1989; 
Kuboyama et al, 1993; Markarian et al, 1996). Achieving target temperature rapidly after 
adult cardiac arrest has been associated with improved outcome (Wolff et al, 2009). 
However, others have observed that in some patients,  a faster decline in body temperature 
to 34°C target appears to predict an unfavourable neurologic outcome, possibly owing to 
development of a poikilothermic state after more severe brain injury (Haugk et al, 2011). 
The depth of temperature used for therapeutic hypothermia is a trade off between the 
neuroprotective effects of hypothermia and the increasing adverse effects with temperature 
reduction. As discussed previously, the repeated observations that only a 3 to 5⁰C reduction 
in core temperature, reaching 32 to 34⁰C, was required to produce a sustained 
neuroprotective effect in animal studies, re-opened the opportunity to successfully use 
therapeutic hypothermia (Sterz et al, 1991; Weinrauch et al, 1992; Kuboyama et al, 1993; 
Safar et al, 1996).  Table 1-5 demonstrates that the published adult and neonatal therapeutic 
hypothermia have consistently used this temperature range demonstrating improved 
neurological outcomes compared to standard therapy. The methods used in these studies, 
to maintain the target temperature, often resulted in fluctuations of plus or minus 0.5 to 1.0⁰C 
around the target temperature. No published post cardiac arrest studies to date have 
compared two different hypothermia temperatures (e.g. 32 versus 34⁰C) or a hypothermic 
temperature with an „actively‟ controlled normothermic temperature (e.g. 33 versus 37⁰C), 
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rather than allowing usual, standard temperature therapy with the potential to develop 
hyperthermia (greater than 38⁰C).    
The duration of therapeutic hypothermia required to achieve and sustain neuroprotection 
after a hypoxic ischaemic injury appears to be exquisitely dependent on the timing after the 
initial insult. For example, immediate initiation of therapeutic hypothermia resulted in 
improved neuro-histopathological findings in a rodent ischaemic model with three hours of 
post-ischaemic hypothermia (30⁰C) but not when initiation was delayed by 30 minutes 
(Busto et al, 1989).  Rapid initiation of therapy is impractical in the majority of clinical cardiac 
arrest situations, especially after out of hospital cardiac arrest. Therefore, further exploration 
of the relationship with duration of therapeutic hypothermia and delay in initiation was 
explored. Colbourne and colleagues, in a series of experiments using initially a gerbil and 
then rat model, established that sustained neurological benefit up to one month after 
ischaemic insult could be maintained if the progressive delay to initiation of therapeutic 
hypothermia was countered by an increased duration of therapeutic hypothermia.  Their final 
experiments demonstrating that after five minutes ischaemia, 48 hours of therapeutic 
hypothermia produced neuronal protection, even when initiation was delayed by six hours. 
However, this benefit was not seen with 24 hours of therapeutic hypothermia (Colbourne et 
al, 1999; Colbourne et al, 2000). In a fetal sheep model investigating therapeutic 
hypothermia after hypoxic ischaemic encephalopathy, initiation of therapeutic hypothermia 
before the on-set of secondary ischaemic seizures (at 5.5 hours) and maintained for 72 
hours demonstrated partial neuroprotection; however this was not achieved with a delay of 
8.5 hours (Gunn et al, 1998; Gunn et al, 1999). 
In adult cardiac arrest RCTs, therapeutic hypothermia has been used for 12 to 24 hours 
whereas in neonatal RCTs 72 hours duration was chosen. In all scenarios, benefits were 
seen with therapeutic hypothermia; however, the initial choice of duration for these trials was 
potentially a „lucky first guess‟. The Australian post cardiac arrest RCT (Bernard et al, 2002), 
was able to initiate therapeutic hypothermia very quickly after ROSC (median 2 hours) due 
to starting cooling in the ambulance by paramedics, whereas in the European Hypothermia 
after Cardiac Arrest study the median delay was 4 hours as cooling was commenced in the 
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emergency department (HACA, 2002). Therefore, the shorter delay in the Australian study 
may have theoretically required a shorter duration of therapeutic hypothermia to produce a 
sustained neurological benefit.    Median time to randomisation in two of the neonatal HIE 
studies was 4 and 4.7 hours with the target temperature reached by 6 hours (Shankaran et 
al, 2005; Azzopardi et al, 2009). The delay in initiation followed by 72 hours of therapeutic 
hypothermia successfully increased survival with good neurological outcome at 18 months; 
however, comparisons between different durations of therapeutic hypothermia have not 
been performed after either HIE or cardiac arrest. Current ILCOR therapeutic hypothermia 
recommendations are for 12 to 24 hours of therapy after cardiac arrest and for 72 hours after 
neonatal HIE.  
Controlled rewarming and avoidance of overshoot hyperthermia (>38⁰C) are required to 
prevent haemodynamic instability, rapid electrolyte changes and worsening of neurological 
injury. Rapid rewarming can result in peripheral vasodilatation and hypotension. The 
increased metabolic oxygen demand during rapid rewarming and the required increase in 
cardiac output may not be met by a potentially damaged myocardium after the initial cardiac 
arrest. 
1.3.6 Available methods of temperature control 
The current methods of cooling can be divided into surface and internal methods (Table1-6). 
They each aim to reduce, maintain or increase brain temperature through a combination of: 
conduction, convection, radiation and evaporation.  
Simple methods include applying ice packs or wet linen to the skin to areas of high vascular 
blood supply: groins, neck, torso and head. This cools the superficial blood which flows and 
subsequently cools deeper, core structures. These methods are labour intensive requiring 
frequent changing of linen and icepacks as they become warmer and less efficient, although 
they are cheap and effective in resource limited environments. Advances to these methods 
include air and water blankets (Hoedemaekers et al, 2007). These cover the patient‟s skin, 
and a liquid (or air) is cooled mechanically and flows through the blanket. This achieves a 
more consistent temperature in the blanket and the temperature can be automatically 
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increased or decreased in response to feedback from the patient‟s core measured 
temperature, thereby achieving greater stability. A limitation to this method is that patients 
become vasoconstricted due to contact with the cold blankets and therefore redirect capillary 
blood to deeper tissues, reducing the efficiency of cooling.  
Another surface cooling methods is selective head cooling via a tight fitting cap with cold 
liquid circulating through. This only cools the head avoiding systemic cooling side effects. 
The external cooling is transmitted to deeper structures, although the efficacy of this method 
is not clear. This method has been used in neonatal studies of HIE and adult cardiac arrest 
studies, but has not been used in the paediatric cardiac arrest population (Hachimi-Idrissi et 
al, 2001; Gunn et al, 2005). Transnasal evaporative cooling has also been shown to 
effectively reduce core and tympanic temperature during and after adult cardiac arrest 
(Castren et al, 2010).  
Invasive cooling involves additional devices directly accessing blood vessels and the 
circulation. A simple, safe and effective method is the use of intravenous normal saline fluid, 
cooled to 4°C („ice-cold‟) and injected as a bolus. This method has been demonstrated to be 
safe and effective in the pre-hospital setting in adult cardiac arrest patients (Kim et al, 2005; 
Bernard & Rosalion, 2008) and in the paediatric critical care environment (Fink et al, 2012; 
Kelly et al, 2010). This method is effective at temperature reduction but may not be 
adequate for maintenance; requiring additional methods to continue temperature control 
(Kliegel et al, 2007; Larsson et al, 2010). 
Intravenous cooling catheters have a jacket of circulating cold fluid which flows in direct 
proximity of venous blood, continuously cooling or warming the patient. Intravascular cooling 
catheters are useful and effective in the adult population; however, are not manufactured in 
sizes suitable for the smaller veins in most children and there are concerns with the 
increased risk of venous thrombosis (Hinz et al, 2007; Lau et al, 2010). 
Diverting blood flow out of the patient‟s circulation via large catheters and using external 
temperature controlling devices is also very effective although very invasive. This method is 
possible during extracorporeal support (e.g. cardio-pulmonary bypass or extracorporeal life 
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support (ECLS)). Both of these methods involve high volumes of blood (100-150mls/kg/min) 
being removed, oxygenated and returned to the patient after having flowed through a 
temperature controlling water-bath. These methods are used when patients require 
rewarming after extreme hypothermic arrest (temperature less than 30°C) (Walpoth et al, 
1990; Saxena et al, 2009) or during extracorporeal life support CPR (ECPR), a method of 
restoring cerebral perfusion during refractory cardiac arrest resistant to advanced life 
support resuscitation  (Huang et al, 2008; Le Guen et al, 2011a; Raymond et al, 2010). 
Table 1-6 Summary of temperature controlling devices 
Group Method of temperature control 
Surface Ice packs to skin 
Wet linen 
Water blanket  
Air blanket 
Whole body water submersion 
Nasopharyngeal cooling 
Selective head cooling 
Internal Intravascular cooling device 
Intravenous ice-cold (4⁰C) saline 
Extracorporeal life support circuit 
Cardio-pulmonary bypass 
Haemofiltration circuit 
Intrathecal infusion  (animal study only) 
Carotid artery infusion  (animal study only) 
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1.4 FEASIBILITY CHALLENGES OF PAEDIATRIC CRITICAL 
CARE RANDOMISED CONTROLLED TRIALS 
Clinical research involving children has always been a challenge to clinicians, parents and 
the children themselves. There can be a considerable conflict between society‟s protection 
of children from health care research and the quest to advance and improve our 
understanding of paediatric practice (Halpern et al, 2009). Valid concerns regarding the legal 
and ethical restrictions involved in paediatric research and the burdensome bureaucracy 
have limited progress, as have methodological constrictions, most importantly, the number 
of subjects (Macrae, 2009). However, reliance upon extrapolated „adult‟ evidence to 
paediatric practice, where physiological, developmental and disease aetiology differences 
are present, is now acknowledged as being unacceptable (Knellwolf et al, 2011).  
1.4.1 Randomised controlled trials 
Randomised controlled trials (RCTs) remain the gold standard methodological approach to 
comparing the clinical and cost effectiveness of two interventions and determining a cause-
effect relationship between treatment and outcome. Important benefits of RCTs over 
observational studies include: random allocation to intervention groups which ensures no 
systematic difference in known and unknown factors between groups, all intervention groups 
receive identical treatment except for the experimental treatment and patients are analysed 
within the group they were originally allocated (Sibbald & Roland, 1998). However, critical 
care RCTs in adults, have repeatedly failed to deliver evidence of beneficial treatments. 
Ospina-Tascon et al (2008) in a systematic review of critical care trials using mortality as an 
outcome, identified only 10 out of 72 studies showing benefit, with 55 demonstrating no 
effect. Many factors have been identified including: use of heterogeneous populations, lack 
of biological plausibility, use of unblinded RCTs, over estimating potential treatment effects 
based on observational study evidence and importantly under-powering of studies through 
failing to recruit to target (McAuley et al, 2010). This has led some observers to even 
recommend abandoning RCTs in critical care altogether (Vincent, 2010). Because paediatric 
critical care has many fewer patients than adult critical care, this problem is potentially even 
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greater. However, recent successful international and UK multicentre collaborations, in 
paediatric critical care RCTs, set a good basis for future collaborative endeavours (Macrae 
et al, 2010; Hutchison et al, 2008; Lacroix et al, 2007). Establishment of UK paediatric 
critical care networks (e.g. PICANet (Paediatric Intensive Care Audit Network) and PICS-SG 
(UK, Paediatric Intensive Care Study Group)) should also enhance trial success and justify 
choosing the RCT as the ideal method for investigating the presence of a beneficial effect 
with therapeutic hypothermia. 
1.4.2 Risk-stratification and minimisation in randomised controlled trials 
Simple randomisation should theoretically ensure treatment groups in a RCT are 
comparable. However, in small to medium sized RCTs (e.g. less than 400 patients) there is 
a risk of misbalanced groups in terms of numbers in each group and similarity between 
base-line characteristics (Kernan et al, 1999). In addition, as previously discussed, individual 
cardiac arrest patients can have important differences potentially affecting both their chance 
of good outcome and response to an intervention. Simple randomisation followed by the 
conventional method of sub-group analysis, to explore differences in treatment effect, based 
on individual patient characteristics one at a time (e.g. male versus female) has been found 
to perform badly in heterogeneous populations and has limited statistical power (Brookes et 
al, 2001).  
The approaches to dealing with these problems include 1) permuted block randomisation, 2) 
risk-stratified randomisation, 3) minimisation, 4) standard post result subgroup analysis and 
5) risk-stratified post result analysis.  
Permuted block randomisation is a simple method and strongly recommended to ensure 
balanced allocation of numbers of patients in each intervention group but does not address 
any individual patient characteristic. Risk-stratified randomisation uses pre-defined important 
prognostic variables, identified at randomisation, and grouped into strata according to the 
variable. The patients in each stratum are then randomly allocated to interventions, thereby 
preventing imbalance for prognostic features in the two treatment groups. The advantages to 
this method include assurance that comparison groups are similar with respect to known 
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prognostic variables, prevention against type I and type II errors and increased efficiency of 
a trial ensuring the sample population will be effectively balanced or allowing a reduction in 
the sample size requirement (Kalish & Begg, 1985; Hernandez et al, 2004). Risk 
stratification is essential in studies with fewer than 100 patients, desirable if fewer than 400, 
although less important for much larger trials. Chosen prognostic variables should be 
identified before the trial starts (Bulpitt, 1988) and in general, fewer variables are better (e.g. 
three or four) as more patients will be allocated to each stratum, improving statistical 
efficiency (Byar et al, 1976). The use of a multivariate prediction tool for stratification as 
opposed to individual variables may be more advantageous (Miettinen, 1976). The 
combination of multiple prediction variables may be more reliable, it may create greater 
distinction amongst risk groups as variables may be summative or synergistic on outcome 
and the number of strata could be reduced. However, an important disadvantage to consider 
with regards emergency, cardiac arrest trials is the increased administrative burden in 
collecting data for the variables in the prediction tool and therefore potentially complicating 
or delaying emergency treatment (Kernan et al, 1999). 
Minimisation is another method to avoid imbalance between numbers of patients in each 
treatment group over a number of factors (Taves, 2010). It uses information about patients 
already in the trial to influence treatment for new patients. It can be particularly useful in 
small trials (less than 100 patients) and greater than three prognostic factors (Pocock & 
Simon, 1975). It requires pre-specified covariates entered into an algorithm to allocate 
intervention. Its use is supported in the Consolidated Standards of Reporting Trials 
(CONSORT) (Schulz et al, 2010). Minimisation is the only accepted replacement of 
randomisation; however, an additional randomisation process is recommended when the 
intervention cannot be blinded to avoid selection bias (e.g. therapeutic hypothermia) (Taves, 
2010). 
Subgroup analysis assesses differences in treatment effect between different 
subpopulations of patients.  However, reliance on sub-group analysis, to identify if the 
findings from a RCT sample population are generally applicable to a wider population, has 
also been shown to be, at times, wrong (Feinstein & Horwitz, 1997). Especially if multiple 
Chapter 1  
 
45 
 
 
characteristics interact and affect the likelihood of a treatment being beneficial or harmful 
(Hayward et al, 2006). Therefore, some statisticians advocate the use of multivariable, risk-
stratified analysis as a supplement or alternative method to conventional subgroup analysis 
(Hayward et al, 2006; Rothwell, 1995; Kravitz et al, 2004).  Risk-stratified analysis requires 
several patient attributes to be combined into a score that describes a single dimension of 
risk along which a treatment effect is likely to vary (Kent & Hayward, 2007).  The score 
should ideally be an externally created, validated model. A previous example of the use of 
risk-stratified analysis was by Kent et al (2002) who identified a subgroup of patients who did 
not benefit from tissue plasminogen activator (tPA) in the Global Utilisation of Streptokinase 
and tPA for occluded coronary arteries (GUSTO) trial. The original trial demonstrated a 
decrease in mortality if treated with tPA (GUSTO., 1993). The original subgroup analysis did 
not identify subgroups that did not benefit. However, with a new validated model, this was 
possible through risk-stratified analysis and allowed more individualisation of patients, 
identifying who may benefit from treatment and where benefit may be outweighed by net 
harm (Kent et al, 2002).  
In summary, risk stratified randomisation and minimisation are both important techniques to 
avoid imbalance in RCT treatment groups, improve efficiency of a trial and minimise type I 
and II errors. Additionally, risk-stratified analysis may also improve identification of whether a 
RCT is applicable to individual patients. Identification of important prognostic variables for 
paediatric cardiac arrest patients prior to a RCT, will allow development of these essential 
tools. 
1.4.3 Stepwise approach to randomised controlled trial development 
A stepwise approach to RCT development has been recommended to successfully assess 
the feasibility of performing a RCT and to minimise the risks of failure (Figure 1-2) (Marshall 
& Cook, 2009).  This begins with articulation of a study question and research objective. The 
next step is to decide if the research objective should be followed. This requires an 
assessment of what is currently known through a systematic review or meta-analysis of the 
literature in conjunction with an evaluation of current clinical practice. The importance of the 
research question to the health care community requires investigation with clarification of 
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two important areas. First, is the original research question important and worthwhile in the 
context of a resource limited health service and secondly, does clinical equipoise exist 
amongst clinicians?  Clinical equipoise has been defined as 'there existing an honest, 
professional disagreement among expert clinicians about the preferred treatment' 
(Freedman, 1987). Without clinical equipoise, randomisation of patients into a RCT to 
compare two treatments (where the body of belief is that one therapy is more efficacious that 
the other), is unethical (Freedman, 1987). Often individual clinicians have strongly held 
opinions; however, a state of community equipoise may exist. Therefore, it is fundamentally 
important to demonstrate variability in practice to establish clinical equipoise (Marshall & 
Cook, 2009).  
Observational studies follow to allow assessment of prevalence or incidence rate of a 
disorder and risk factors associated with the condition and treatment proposed. This is the 
step where the question is asked, „could the RCT be performed?‟ During this stage, areas 
where previous RCTs have been shown to fail can be investigated. For example, are there 
sufficient patients to recruit to a study and therefore be adequately powered to demonstrate 
an effect? Are the right patients identified or is it a question of severity of the condition 
requiring risk-stratification? Is the timing of the intervention important and is it feasible to 
implement the therapy within those time constraints? Are interventions effective in 
observational studies? Finally, are the risks and adverse effects of an intervention 
acceptable? (McAuley et al, 2010; Vincent, 2010). During the observational studies, 
opportunities will also arise to enhance the basic understanding of the condition and the 
intervention evaluated, beginning the stage of assessing how would a RCT be performed. 
This can then input into the design and development of a study protocol of a RCT. With 
acknowledgement that RCTs are not the final step and translation of knowledge into clinical 
practice poses an even greater hurdle (Kahn, 2009). 
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Figure 1-2 Stepwise model of RCT feasibility assessment (adapted from a 
programmatic research model) (Marshall et al 2009) 
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2 Study Aims and Outline of the 
Thesis 
 
 
 
 “First comes thought; then organisation of that thought, into ideas and plans; then 
transformation of those plans into reality.  
The beginning, as you will observe, is in your imagination” 
Napoleon Hill (American Author Born 1883) 
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2.1 STUDY AIMS 
Survival with a good neurological outcome after paediatric cardiac arrest remains rare 
despite advances in resuscitation practices in the UK. Neuro-protective therapies are 
desperately needed to improve these poor outcomes. Therapeutic hypothermia is a potential 
therapy; however, paediatric evidence appears limited. Demonstration of increased efficacy 
and cost effectiveness in children of therapeutic hypothermia compared to standard 
„normothermic‟ temperature therapy requires a randomised controlled trial (RCT). Before this 
can be undertaken in the UK, the following feasibility questions need to be addressed: 
should we, could we and how would we design a RCT?   
 
The main research questions of this thesis are therefore: 
 
1. Is there currently sufficient evidence to support or refute the beneficial effects of 
therapeutic hypothermia after paediatric cardiac arrest? 
2. What is currently practiced in the UK regarding therapeutic hypothermia after 
paediatric cardiac arrest?  
3. Does clinical equipoise exist amongst the paediatric intensive and emergency care 
communities? 
4. What is the current epidemiology of children who are successfully resuscitated and 
admitted to PICU after cardiac arrest in the UK?  
5. What is the potential size of the paediatric post-cardiac arrest population admitted to 
PICU and is this sufficient for a UK RCT of therapeutic hypothermia? 
6. Can outcome after paediatric cardiac arrest be predicted to assist risk-stratification 
of patients in a RCT? 
7. Can therapeutic hypothermia be implemented quickly, safely and consistently in 
children? 
8. Does therapeutic hypothermia improve survival after out of hospital cardiac arrest 
and are there significant physiological adverse effects? 
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2.2 OUTLINE OF THE THESIS  
This thesis presents a consecutive series of studies answering the above questions 
regarding the feasibility of performing a RCT of therapeutic hypothermia after paediatric 
cardiac arrest in the UK and is outlined in Figure 2-1. 
 
Chapter 3 starts with a systematic literature review conducted in accordance with strict 
Cochrane methodology to investigate the current and on-going research supporting the use 
of therapeutic hypothermia after paediatric cardiac arrest, in order to justify the need for 
further research.  
 
The current use of therapeutic hypothermia by UK paediatric critical care and emergency 
medicine specialists is investigated in Chapter 4, allowing an opportunity to explore current 
practice and the important position of clinical equipoise amongst clinical staff.  
 
Chapter 5 allows a broader look at the paediatric cardiac arrest population in the UK. 
Through the use of national PICU admission data of IHCA and OHCA patients, an 
epidemiological analysis of the UK cardiac arrest population is possible. Differences 
between IHCA and OHCA patients can be assessed and essential population numbers can 
be collected to calculate whether the UK has a large enough paediatric cardiac arrest 
population to adequately recruit to a RCT. 
 
A more in-depth analysis of patients admitted to three large PICUs after OHCA will follow in 
Chapter 6. Factors available at the time of resuscitation and at admission to PICU will be 
analysed in an attempt to identify important prognostic factors for survival. This would then 
allow selection or risk-stratification of post-OHCA patients randomised in a future study. 
 
In Chapter 7, through the use of a subset of OHCA patients from Chapter 6, post cardiac 
arrest therapeutic hypothermia can be compared to standard temperature therapy. This will 
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allow an assessment of efficacy and safety of therapeutic hypothermia in addition to 
identifying practical barriers to implementing the therapy in a future research setting. 
 
Finally, based on the previous exploratory parts of this thesis, a summary of findings and a 
conclusive answer to the feasibility research question will be presented. Short comings of 
the thesis will be discussed and a proposal for future research. 
 
 
Figure 2-1 Stepwise model of RCT feasibility assessment mapped to thesis chapters 
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3 Hypothermia for 
neuroprotection in children 
after cardiac arrest: a 
systematic Cochrane review. 
 
“Absence of evidence is not evidence of absence” 
Leonardo da Vinci (painter, scientist & mathematician: Born 1452) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Part of this chapter has been published in: 
 
Scholefield B, Morris K, Duncan H, Davies P, Gao-Smith F, Khan K. Hypothermia 
for neuroprotection in children after cardiopulmonary arrest (protocol). Cochrane 
Database of Systematic Reviews 2011, Issue 11. Art. No.: CD009442. DOI: 
10.1002/14651858.CD009442. (Appendix 9.4 p305) 
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3.1 ABSTRACT 
3.1.1 Introduction 
Cardiac arrest in paediatric patients often results in death or survival with severe brain injury. 
Therapeutic hypothermia, lowering of core body temperature to 32 to 34 °C, may reduce 
injury to the brain in the period after the circulation has been restored. This therapy has been 
effective in neonates with hypoxic ischaemic encephalopathy and adults after ventricular 
fibrillation cardiac arrest. The effect of therapeutic hypothermia after cardiac arrest in 
paediatric patients is unknown. 
3.1.2 Aims 
To assess the clinical effectiveness of therapeutic hypothermia after paediatric cardiac 
arrest. 
3.1.3 Methodology 
We searched the Cochrane Anaesthesia Review Group Specialized Register; Cochrane 
Central Register of Controlled Trials (CENTRAL) (The Cochrane Library, 2011 issue 11); 
Ovid MEDLINE (1966 to December 2011); Ovid EMBASE (1980 to December 2011); Ovid 
CINAHL (1982 to December 2011); Ovid BIOSIS (1923 to December 2011); Web of Science 
(1945 to December 2011). We searched the trials registry databases for ongoing trials. We 
also contacted international experts in therapeutic hypothermia and paediatric critical care to 
locate further published and unpublished studies. 
We planned to include randomised and quasi-randomised controlled trials comparing 
therapeutic hypothermia with normothermia or standard care in children, aged 24 hours to 
18 years, after paediatric cardiac arrest. Two authors independently assessed articles for 
inclusion. 
3.1.4 Results 
We found no studies that satisfied the inclusion criteria. We found four on-going randomised 
controlled trials which may be available for analysis in the future. We excluded 18 non-
Chapter 3  
 
54 
 
 
randomised studies. Of these 18 non-randomised studies, three compared therapeutic 
hypothermia with standard therapy demonstrating no difference in mortality or proportion 
with good neurological outcome and a narrative report is presented.   
3.1.5 Conclusion 
Based on this review, we are unable to make any recommendations for clinical practice. 
Randomised controlled trials are needed and the results of on-going trials will be assessed 
when available. 
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3.2 INTRODUCTION 
Therapeutic hypothermia has been shown clinically to be neuroprotective in neonates with 
hypoxic ischaemic encephalopathy secondary to birth asphyxia (Jacobs et al, 2007) and in 
adults (greater than 18 years old) after witnessed, ventricular fibrillation cardiac arrest  
(Holzer et al, 2005; Arrich et al, 2009). Its role after cardiac arrest in children has not been 
established although the International Liaison Committee for Resuscitation guidelines 
recommend consideration of its use in this setting (Kleinman et al, 2010). This systematic 
review of the literature will investigate the neuroprotective effects of therapeutic hypothermia 
in children after cardiac arrest. 
3.2.1 Description of the condition   
Cardiac arrest in children is a devastating event. Survival rates to discharge from hospital for 
children who suffer an IHCA are 15% to 30% whilst those who suffer an OHCA have a 
worse survival rate (5% to 12%) (Donoghue et al, 2005; Nadkarni et al, 2006). Only 0.3% to 
4% of children who suffer an OHCA survive neurologically intact (Donoghue et al, 2005). 
Neurological consequences of hypoxic ischaemic damage to the brain range from mild 
concentration, attention and short-term memory problems to much more severe damage to 
the cerebral cortex, hippocampus, basal ganglia and cerebellum. Severe damage can result 
in significant long-term loss of function with development of cerebral palsy, blindness, 
seizures, hypothalamic and pituitary insufficiency. Very severe damage can produce a 
persistent vegetative state or be fatal. Those children who do survive often have significant 
neurological disability with resultant emotional, time and financial impacts on themselves, 
their families, their educational and care needs, rehabilitation and society as a whole 
(Duncan & Frew, 2009; Ronco et al, 1995; Morris et al, 1993);  
Neurological outcomes are often assessed by the use of the Paediatric Cerebral 
Performance Category (PCPC) score (Fiser, 1992) (Table 3-1). The PCPC scores can 
classically be combined into a good outcome (PCPC 1 and 2) and poor outcome (PCPC 3 to 
5). If children with preceding disability are included then a good outcome may be recorded 
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as no change from baseline. Other neurological outcome scores, for example the Vineland 
Adaptive Behaviour Scales (Sparrow S et al, 1984), have also been validated for use in 
assessing the neurological outcomes in children. 
Table 3-1  Paediatric Cerebral Performance Category (Fiser, 1992) 
 Category  
(neurological function) 
Description 
1 Normal Healthy alert, regular classroom 
2 Mild disability 
Age appropriate interactions, but possible mild 
neurologic deficit, grade not appropriate 
3 Moderate disability 
Independent activity of daily living but special 
educational classroom or learning deficit 
4 Severe disability 
Conscious but dependent on others because of 
neurologic deficit 
5 
Coma/ Persistent vegetative 
state 
Any degree of coma; unconscious, unaware 
6 Dead  
 
The aetiology for paediatric cardiac arrest is different to that of adults, with respiratory 
disorders leading to hypoxia often preceding cardiac arrest in children (Young et al, 2004). 
The commonest causes of OHCA in children are sudden infant death syndrome, drowning 
and trauma (Atkins et al, 2009). IHCA are predominantly secondary to respiratory 
insufficiency, hypotension, hypoperfusion, congestive cardiac failure or infection (Nadkarni et 
al, 2006). The neonates studied while receiving therapeutic hypothermia after hypoxic 
ischaemic encephalopathy often did not have a cardiac arrest and therefore retained some 
cerebral blood flow in comparison to the absent cerebral blood flow during cardiac arrest 
(Azzopardi et al, 2009). Therefore, the pattern of neurological injury in adults and neonates 
may be different to children and the efficacy of therapeutic hypothermia may be altered. 
3.2.2 Description of the intervention   
Therapeutic hypothermia is defined as the process of lowering core body temperature to 
between 32 and 34 degrees Celsius. Therapeutic hypothermia can be administered through 
systemic cooling (by surface or invasive methods) and selective surface head cooling. 
Sedation and often neuromuscular blockade are required to tolerate the intervention and 
avoid shivering. 
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3.2.3 Why it is important to do this review   
Cardiac arrest in children is an important condition with a poor survival rate and a high 
chance of neurological injury leading to significant long-term impact on individuals, families 
and society. There are currently no interventions available to decrease neurological injury 
other than supportive care in the intensive care unit, which is why this evaluation is 
important. Paediatric specific data are needed regarding the effect of therapeutic 
hypothermia owing to the different aetiology and resultant pathophysiology compared to 
adults and neonates. Therapeutic hypothermia is used by some in paediatric critical care 
after cardiac arrest (Haque et al, 2006; Scholefield et al, 2010) and a meta-analysis of the 
clinical trial data is therefore highly important. 
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3.3 AIMS 
1. To systematically review the literature and, if feasible, perform a meta-analysis 
concerning the neuroprotective effects of therapeutic hypothermia after cardiac 
arrest in children. 
2. To determine whether therapeutic hypothermia is effective in improving the primary 
outcome of good neurological survival after cardiac arrest in children and the 
secondary outcome of improving overall survival. 
3. To determine the extent of adverse effects and effects on quality of life in this 
context. 
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3.4 METHODOLOGY 
3.4.1 Criteria for considering studies for this review   
3.4.1.1 Types of studies   
We planned to include randomised controlled trials (RCTs) and quasi-randomised controlled 
trials evaluating therapeutic hypothermia as a neuroprotective intervention after cardiac 
arrest in children. We excluded non-randomised studies from the meta-analysis but provided 
a narrative summary of these studies in the review‟s discussion section. 
3.4.1.2 Types of participants   
We planned to include all studies with children who are successfully resuscitated after a 
cardiac arrest in any setting. We sought to include neonates older than 24 hours of age and 
with a corrected gestational age of greater than or equal to 35 weeks, children and 
adolescents up to their 18th birthday. We excluded neonates whose cardiac arrest occurs at 
the time of birth and adults greater than 18 years of age as these have been studied 
separately (Arrich et al, 2009; Jacobs et al, 2007) and the presumed cause of the cardiac 
arrest is different to children. 
3.4.1.3 Types of interventions   
Therapeutic hypothermia, regardless of how body temperature is reduced, applied within a 
few hours after return of spontaneous circulation after cardiac arrest. Therapeutic 
hypothermia is defined as a target temperature of 32 to 34 degrees Celsius. We defined the 
control intervention as treatment according to the standard treatment after cardiac arrest at 
the time of the trial. 
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3.4.1.4 Types of outcome measures   
3.4.1.5 Primary outcomes   
1. Best neurological outcome at hospital discharge and within the first year as 
assessed by the Paediatric Cerebral Performance Category score and other 
validated outcome scores for use in children (e.g. Vineland Adaptive Behaviour 
Scales) 
3.4.1.6 Secondary outcomes   
1. Survival to intensive care discharge 
2. Survival to hospital discharge  
3. Survival up to six months and long-term survival (long term defined as greater than 
one year) 
4. Adverse event incidents as reported by authors 
5. Quality of life indicators at six months and at long term 
3.4.2 Search methods for identification of studies   
3.4.2.1 Electronic searches   
We searched the Cochrane Anaesthesia Review Group Specialized Register; Cochrane 
Central Register of Controlled Trials (CENTRAL) (The Cochrane Library, latest issue); Ovid 
MEDLINE (1966 to December 2011); Ovid EMBASE (1980 to December 2011); Ovid 
CINAHL (1982 to December 2011); Ovid BIOSIS (1923 to December 2011); Web of Science 
(1945 to December 2011). 
The Ovid MEDLINE specific search terms are described in Appendix 9.1 (p299). We based 
the search strategies for the other databases on the one for MEDLINE. We combined the 
Ovid MEDLINE and EMBASE searches with the sensitive strategies described in Section 6.4 
of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins JPT et al, 
2011) to search for RCTs. 
BIOSIS and Web of Science contain book articles and abstracts of conference presentations 
published in a wide range of relevant specialist journals. 
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We did not use language or publication type restrictions. 
3.4.2.2 Searching other resources   
We searched the bibliographies of all retrieved and relevant publications identified by these 
strategies for further studies. We searched the Current Controlled trials 
(http://www.controlled-trials.com/), Clinical Trials (http://clinicaltrials.gov/), Trials Central 
(http://www.trialscentral.org),  Chinese clinical trials registry 
(http://www.chictr.org/en/proj/search.aspx), International World Health Organisation (WHO) 
trials registry (http://apps.who.int/trialsearch/) databases of ongoing trials. We searched 
Zetoc (http://zetoc.mimas.ac.uk/) and OpenSIGLE (http://opensigle.inist.fr/), and contacted 
experts in the field to search for any other published or unpublished literature and on-going 
research. 
3.4.3 Data collection and analysis   
3.4.3.1 Selection of studies   
Potentially eligible published studies were located based on screening of title and abstract 
by two authors (Barnaby Scholefield (BS) and Heather Duncan (HD)). Potentially eligible on-
going trials were located on screening title and trial description by two authors (BS and 
Kevin Morris (KM)). We obtained full copies of potentially eligible studies. There was no 
blinding to the journal, the authors or the institution. Three authors (BS, KM and HD), acting 
independently, decided on inclusion or exclusion of studies based on predefined inclusion 
and exclusion forms. We resolved disagreements by discussion.  
3.4.3.2 Data extraction and management   
We intended to extract data from eligible studies and summarized them in a data extraction 
sheet (Appendix 9.2, p301). We also intended to include baseline data on demographics of 
study and control group participants. This included age and gender. In addition, we planned 
to extract the following information regarding the actual cardiac arrest; location, aetiology, 
duration of arrest; and time to return of spontaneous circulation for each group. We planned 
to record data on the intervention; time to implement intervention; duration, and type of 
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temperature control method. The temperature of the study group and control group at the 
start of a study, during intervention and after the intervention were recorded. We also 
planned to record the healthcare setting in which the interventions were performed. In 
addition, duration of follow up and numbers lost to follow up were planned to be extracted as 
well as outcomes. 
All data regarding the interventions studied were independently extracted by two authors 
(BS and KM or HD). We resolved disagreements by discussion. We intended to contact 
primary authors to obtain missing data or to gain clarification. 
3.4.3.3 Assessment of risk of bias in included studies   
After we included all available eligible studies in the review, we proposed to assign two 
authors (BS and KM or HD) to independently assess each study using The Cochrane 
Collaboration's tool for assessing risk of bias (Higgins JPT et al, 2011). We planned to 
assess six domains: random sequence generation, allocation concealment, blinding, 
incomplete outcome data, selective reporting and other bias (Appendix 9.2, p301). 
Completing a risk of bias table for each eligible study. Any disagreement was planned to be 
discussed amongst authors and consensus agreed. We intended to present our assessment 
of risk of bias using a 'risk of bias summary figure', which presents all of the judgments in a 
cross-tabulation of study by entry. 
3.4.3.4 Measures of treatment effect   
For dichotomous outcomes, we planned to express the estimate of effect of an intervention 
as the risk ratio (RR) together with the 95% confidence interval (CI). For continuous 
outcomes, we planned to use mean differences (MD) and standard deviations and 
summarize the data for each group using mean differences and 95% CIs. 
3.4.3.5 Unit of analysis issues   
We did not anticipate unit of analysis issues. 
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3.4.3.6 Dealing with missing data   
If data were missing from trial reports we attempted to contact the original investigator for 
additional data. Where there were missing data, we planned to 'impute' and carried out a 
sensitivity analysis between studies in which data were 'imputed' for an intention-to-treat 
(ITT) analysis assuming that all missing participants experienced the event, or that all 
missing participants did not experience the event. 
3.4.3.7 Assessment of heterogeneity   
We judged clinical heterogeneity, in particular in the application of therapeutic hypothermia. 
If significant clinical heterogeneity existed, pooling of data was not done; the data from 
individual studies is presented in a tabular format. We planned to test for statistical 
heterogeneity using visible inspection of the forest plot and the I
2
 statistic (Higgins JPT et al, 
2011). We considered an I
2 
statistic > 50% as significant statistical heterogeneity and a value 
< 25% was considered ignorable statistical heterogeneity. 
3.4.3.8 Assessment of reporting biases   
We planned to assess risk of reporting bias by producing a funnel plot if there were sufficient 
number of included studies (more than 10). We took the following steps to reduce reporting 
bias. 
1. Searching of multiple databases, trial registries and conference proceedings as 
described above. 
2. Applying no language restriction. 
3. Excluding duplicate reports of the same study to avoid duplication bias. 
3.4.3.9 Data synthesis   
We intended to summarize the aims, methods and outcome measures of interest 
(neurological outcome, mortality, adverse events and quality of life indicators) for each 
included study. We expressed the outcome measures of interest for survivors relative to 
non-survivors as the risk ratio (RR). 
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For both dichotomous and continuous data we planned to undertake a meta-analysis using a 
random-effects method with inverse variance. We planned to perform a sensitivity analysis 
by comparing this with a meta-analysis using a fixed-effect method with inverse variance. 
We planned to use data at the aggregate (study) level. 
3.4.3.10 Subgroup analysis and investigation of heterogeneity   
We proposed to perform subgroup analysis on the following variables if the data could be 
extracted from included studies. 
1. Age and sex. 
2. Method of inducing therapeutic hypothermia (systemic cooling versus selective head 
cooling). 
3. Location of arrest (in-hospital versus out-of-hospital arrest). 
4. Duration of intervention. 
5. Delay to induction of therapeutic hypothermia (less than six hours versus greater 
than six hours). 
6. Rate of rewarming after therapeutic hypothermia. 
7. First presenting cardiac rhythm (ventricular fibrillation OR pulseless ventricular 
tachycardia versus asystole OR pulseless electrical activity). 
Meta-regression was not performed owing to the small number of included trials. 
3.4.3.11 Sensitivity analysis   
We planned to undertake sensitivity analysis between studies in which data were 'imputed' 
for ITT analysis, assuming that all missing participants experienced the event or that all 
missing participants did not experience the event. 
3.4.3.12 Summary of findings table 
We planned to use the principles of the GRADE system (Guyatt et al, 2008) to assess the 
quality of the body of evidence associated with specific outcomes: 
1. best neurological outcome, 
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2. survival to intensive care discharge, 
3. survival to hospital discharge, 
4. survival up to six months, 
5. long-term survival. 
In our review we planned to construct a 'Summary of findings' (SoF) table using the GRADE 
software. The GRADE approach appraises the quality of a body of evidence based on the 
extent to which one can be confident that an estimate of effect or association reflects the 
item being assessed. The quality of a body of evidence takes into consideration within study 
risk of bias (methodological quality), the directness of the evidence, heterogeneity of the 
data, precision of effect estimates and risk of publication bias. 
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3.5 RESULTS   
3.5.1 Description of studies   
Our sensitive search strategy resulted in 6068 hits by the database searches and 615 by 
other searches (Figure 3-1).  Following removal of duplicates (2770), the remaining 3913 
were screened. 3649 were excluded on reviewing title or abstract resulting in 264 for full 
paper review. The majority (188) were then excluded because they were not relevant or 
because the age of patients was outside the specified age for inclusion in this review (older 
than 24 hours of age and with a corrected gestational age of greater than or equal to 35 
weeks, children and adolescents up to their 18th birthday). 54 on-going studies were 
excluded of which 38 only included adults greater than 18 years and 16 only included 
neonates less than 24 hours old. Finally, 18 studies were evaluated for inclusion and four 
ongoing paediatric RCTs (NCT00754481; NCT00797680; NCT00878644; NCT00880087). 
After contacting experts about possible additional unpublished or on-going relevant studies, 
none were found (Appendix 9-3, p304). The chief investigators of the four ongoing paediatric 
RCTs were all contacted and confirmed that no result data were available. 
There were no RCTs included from our systematic search of the medical databases. 
The remaining 18 studies were all excluded for being non-randomised prospective (five) or 
retrospective (six) cohort studies, database registry studies (one), case studies (three), 
review (one), commentary (one), and protocol outline for future study (one). (See Table 3-2 
Characteristics of excluded studies, for full description of all excluded studies). 
The four ongoing RCTs may potentially be assessed in the future and fulfil this review‟s 
inclusion criteria (see Table 3-3 Characteristics on-going studies awaiting assessment). 
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Figure 3-1  PRISMA search flow diagram 
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Table 3-2 Characteristic of excluded studies (ordered by study ID) 
Study ID Reasons for exclusion 
Abend 2009 
Non-randomised study 
Prospective, cohort study of paediatric post-cardiac arrest patients treated with 
therapeutic hypothermia receiving continuous electroencephalography. Single 
centre, March 2007 to September 2008.  14/19 (74%) survived, four with 
severe neurological morbidity. No comparative normothermia group. 
Bembea 2010  
Non-randomised study 
Database registry of in-hospital paediatric cardiac arrest patients (January 
2005 to December 2007). Relationship of temperature in first 24hours with 
survival and neurological outcome. 86/547 (16%) patients reported to have 
received; therapeutic hypothermia, extracorporeal membrane oxygenation or 
“ice-packs to head”. No survival breakdown for this subgroup. 
Buttram 2010 
(abstract only) 
Non-randomised study 
Prospective, cohort study comparing therapeutic hypothermia with 
normothermia after paediatric out-of-hospital cardiac arrest. Age 1 day to 18 
years. 33/46 (77%) received therapeutic hypothermia. No difference in survival 
to hospital discharge between patients treated with hypothermia (39%) and 
standard therapy (23%), p=0.49.  
Deasy 2010 
Non-randomised study 
Retrospective, cohort study of paediatric out-of hospital cardiac arrest patients 
in Melbourne, Australia (Oct 1999 to 2007). Therapeutic hypothermia applied 
to 23/49 (46%) admitted to PICU with three survivors (OR 2.535, 95%CI [0.64-
9.9], p = 0.184). 
Doherty 2009 
Non-randomised study 
Retrospective, cohort study comparing therapeutic hypothermia with 
normothermia over a two year period (September 2001 to August 2003) in five 
centres in Canada (4) and the UK (1). 29/79 (36.7%) received therapeutic 
hypothermia. 95% in-hospital cardiac arrest. Median duration of therapeutic 
hypothermia 20.8 hours (IQR 12-69 hours) at a mean temperature of 33.7± 
1.3°C. Hypothermia use was associated with higher mortality, more 
resuscitative interventions, higher post resuscitative lactate level and the use of 
ECMO. Non significant association between therapeutic hypothermia after 
adjustment for duration of cardiac arrest, use of ECMO and propensity score 
(Adjusted OR 1.99, 95% CI [0.45-8.85], p=0.502). 
Fink 2010 
Non-randomised study 
Retrospective, cohort study comparing therapeutic hypothermia with 
normothermia over a seven year period (July 2000 to August 2006) in a single 
centre (Pittsburgh, USA). 40/181 (22%) received therapeutic hypothermia. 55% 
in-hospital cardiac arrest. Median duration of therapeutic hypothermia 24.0 
hours (IQR 16-48) at a median temperature of 34.0°C (33.5-34.8°C). No 
difference in hospital mortality; 55% therapeutic hypothermia group versus 
55.3% standard therapy group (p=1.0). Hypothermia not associated with 
survival in univariate (OR 0.99, (95%CI [0.49-2.0]), p=1.0) or multivariate (OR 
0.47 (95%CI [0.15-1.45], p=0.2) analysis. 
Hein 2004 Case study 
Kessler 2010  
Non-randomised study 
Prospective, cohort study of paediatric post-cardiac arrest patients treated with 
therapeutic hypothermia (24 hours, 34°C) and monitored with 
electroencephalography. 21/35 (60%) patients survived. No comparative 
normothermia group. 
Kobr 2011  Review 
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Study ID Reasons for exclusion 
Le Guen 2011  
Non-randomised study 
Prospective, cohort study of extracorporeal support following out-of hospital 
refractory cardiac arrest. Inclusion of patients from 13 years to 70 years 
(Mean(SD) 45years (+-15)). All patients received therapeutic hypothermia. No 
breakdown of paediatric patient population. 
Meert 2009 
Non-randomised study 
Retrospective, cohort study of in-hospital cardiac arrest patients. Conducted in 
15 centres in the USA over 18 months (July 2003-Decemeber 2004). Only 
7/162 (4.1%) survivors and 8/181 (3.3%) non-survivors received therapeutic 
hypothermia. 
Meert 2010  Comment 
Moler 2009 
Non-randomised study 
Retrospective, cohort study comparing in-hospital and out-of hospital paediatric 
cardiac patients in the USA over 18 months (July 2003 to December 2004). No 
outcome data for patients receiving or not receiving therapeutic hypothermia.  
Moler 2011 
Non-randomised study 
Retrospective, study of out-of-hospital cardiac arrest patients. Conducted in 15 
centres in the USA over 18 months (July 2003 to December 2004). Only 1/53 
(2%) survivors and 2/85 (2%) non-survivors received therapeutic hypothermia. 
Sanada 1998  Case study 
Silfvast 2003  Case study 
Takeda 2009 
Protocol for a randomised controlled trial of pharyngeal cooling system during 
cardiac arrest. Age inclusion 16 to 89 years. 
Topjian 2011 
Non-randomised study 
Prospective, intervention study of therapeutic hypothermia after paediatric 
cardiac arrest. Assessing the feasibility and safety of a standardized treatment 
protocol. Single centre, 6/12 (50%) of patients survived to discharge. No 
comparative normothermia group 
ECMO: extracorporeal membrane oxygenation,  
IQR: inter-quartile range 
OR: odds ratio  
CI: confidence interval 
SD: standard deviation 
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Table 3-3 Characteristics of on-going studies (ordered by study ID) 
Study Name 
 
Contact 
Method 
Design 
 
Phase 
Participants 
Age 
 
Cardiac arrest 
Definition 
 
Location 
 
Inclusion
a
 
Intervention 
1 Treatment  
Duration 
Depth 
Rewarm 
 
2 Treatment 
Duration  
Depth 
 
Outcomes 
1 Primary 
 
2 Secondary 
Notes 
NCT00754481 
 
Hypothermia for Cardiac 
Arrest in Paediatrics 
(HypCAP)  
 
Dr Jamie Hutchison, The 
Hospital for Sick Children, 
Toronto, Canada 
Randomised, single 
blind (outcome 
assessor), parallel 
assignment efficacy  
 
Phase II study 
≥ 38 weeks gestation up to and including 
17 yrs 
 
Chest compressions ≥3 minutes  
 
In-hospital  and out-of-hospital arrest 
 
GCS ≤ 10 at 1 hour post- cardiac arrest  
Invasive mechanical ventilation  
Randomised within six hours 
 
1)Therapeutic 
hypothermia: 
48 hours 
33-34°C  
Rewarm 0.5ºC 
every 2 hours  to 
36.5 ºC  
 
2)Therapeutic 
normothermia: 
48 hours 
36.5-37.5ºC  
1) Percentage of children achieving a 
"good outcome", (PCPC score of 1-3) 
at 12 months. 
 
2) Cognitive and motor measures*, 
mortality (assessed at 1, 3, 6, and 12 
months post-arrest), cerebral 
oedema*, adverse effects of 
hypothermia therapy*   
 
(* measured at 12 months post-arrest) 
Planned 
enrolment 
40.  
 
Study 
finished 
recruiting. 
NCT00797680  
 
Duration of Hypothermia 
for Neuroprotection After 
Paediatric Cardiac Arrest  
 
Dr Ericka Fink Children's 
Hospital of Pittsburgh, 
Pennsylvania, USA 
Randomised, open 
label, parallel 
assignment, safety 
and efficacy  
 
Phase II study 
1 wk - 17 yrs. 
 
Chest compressions by a health care 
worker  
 
In-hospital  and out-of-hospital arrest 
 
GCS  ≤ 8 
PICU physician decision to use therapeutic 
hypothermia.  
Central venous or arterial catheter in situ. 
1) Therapeutic 
hypothermia: 
72 hours  
33 ± 1ºC  
 
2) Therapeutic 
hypothermia: 
24 hours  
33 ± 1ºC 
1) Degree of brain injury as measured 
by serum and urine biomarkers and 
Magnetic Resonance Spectroscopy at 
hospital discharge 
 
2 ) Frequency of adverse events at 30 
days 
Planned 
enrolment 
40.  
 
Planned end 
date April 
2014 
a
exclusion criteria not listed 
GCS: Glasgow coma score 
PCPC: Paediatric Cerebral Performance Category (Table 3-1)  
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Table 3-2 Characteristics of on-going studies (ordered by study ID) continued 
Study Name Method 
Design 
 
Phase 
Participants 
Age 
 
Cardiac arrest 
Definition 
 
Location 
 
Inclusion
a
 
Intervention 
1 Treatment  
Duration 
Depth 
Rewarm 
 
2 Treatment 
Duration  
Depth 
Outcomes 
1 Primary 
 
2 Secondary 
Notes 
NCT00878644 
 
Therapeutic Hypothermia to 
Improve Survival After 
Cardiac Arrest in Paediatric 
Patients-(THAPCA-OH) [Out 
of Hospital] Trial  
 
Prof Frank W. Moler, 
University of Michigan, USA 
 
Randomised, 
single blind 
(outcome 
assessor), 
parallel 
assignment, 
safety and 
efficacy  
 
Phase III study 
> 48 hours (with a corrected 
gestational age ≥  38 weeks) 
and < 18 years 
 
chest compressions ≥ 2 
minutes  
 
out-of-hospital cardiac arrest 
only 
 
mechanical ventilation 
randomised within six hours 
1)Therapeutic hypothermia  
48 hours 
 33º C ± 1º C 
 
gradual re-warm to 36.75º 
C±0.75ºC 
 maintained until 120 hours  
 
2)Therapeutic normothermia  
120 hours  
36.75º C±0.75ºC 
1)Survival with good neurobehavioral 
outcome (assessed at 12months) 
 
2)Survival*, change in neurobehavioral 
function from pre-cardiac arrest to 12 
months post-cardiac arrest, 
neuropsychological scores* (for 
participants who survive), neurological 
abnormality scores* (for participants who 
survive).  
 
(*measured at 12months post arrest). 
Planned 
enrolment 
350.  
 
Planned 
study end 
date 
September 
2015 
NCT00880087 
 
Therapeutic Hypothermia to 
Improve Survival After 
Cardiac Arrest in Paediatric 
Patients-(THAPCA-IH) [In 
Hospital]) Trial  
 
Prof Frank W. Moler, 
University of Michigan, USA 
 
Randomised, 
single blind 
(outcome 
assessor), 
parallel 
assignment 
safety and 
efficacy  
 
Phase III study 
> 48 hours (with a corrected 
gestational age ≥  38 weeks) 
and < 18 years 
 
chest compressions ≥ 2 
minutes  
 
in-hospital cardiac  arrest only 
 
mechanical ventilation 
randomised within six hours 
1)Therapeutic hypothermia 
48 hours 
 33º C ± 1º C 
 
gradual re-warm to 36.75º 
C±0.75ºC 
 maintained until 120 hours 
 
2)Therapeutic normothermia  
120 hours  
36.75º C±0.75ºC  
 
1)Survival with good neurobehavioral 
outcome (assessed at 12months) 
 
2)Survival*, change in neurobehavioral 
function from pre-cardiac arrest to 12 
months post-cardiac arrest, 
neuropsychological scores* (for 
participants who survive), neurological 
abnormality scores* (for participants who 
survive).  
 
(*measured at 12months post arrest). 
Planned 
enrolment 
500.  
 
Planned 
end date 
September 
2015 
a
exclusion criteria not listed
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3.5.2 Risk of bias in included studies   
No randomised controlled trials were identified. (see Table 3-2 Characteristics of excluded 
studies and Table 3-3 Characteristics of on-going studies) 
3.5.3 Effects of interventions   
No randomised controlled trials were identified. (see Table 3-2 Characteristics of excluded 
studies and Table 3-3 Characteristics of on-going studies) 
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3.6 DISCUSSION  
3.6.1 Summary of main results   
We found no high quality evidence, in the form of randomised or quasi-randomised 
controlled trials, for or against the use of therapeutic hypothermia in children after cardiac 
arrest. 
3.6.1.1 Excluded studies 
We excluded three cohort studies comparing the use of therapeutic hypothermia and 
normothermia or standard care in the paediatric population; two published (Fink et al, 2010; 
Doherty et al, 2009)  and one in abstract form only (Buttram et al, 2009). A narrative review 
is given below. 
Doherty et al (2009) retrospectively investigated the survival and neurological outcome of 
children by comparing the use of therapeutic hypothermia (n = 29) versus normothermia (n = 
50). Included patients had predominantly suffered an IHCA (95%), often with associated 
chronic cardiac conditions (71%) and after surgery (59%). In patients with an a priori defined 
cardiac arrest duration of at least three minutes and who survived to 12 hours post return of 
spontaneous circulation, the use of therapeutic hypothermia was associated with increased 
30 day mortality (unadjusted odds ratio (OR) [95% confidence interval (CI)] 2.5 [0.99 to 
6.45]; P = 0.054), increased six month mortality (unadjusted OR [95% CI] 3.62 [1.37 to 9.62]; 
P = 0.009) and unfavourable neurological outcome (PCPC score 4 to6) (unadjusted OR 
[95% CI] 2.92 [1.1 to 7.69]; P = 0.031. However, patients receiving therapeutic hypothermia 
were sicker due to a number of factors: longer duration of cardiac arrest, more 
pharmacological interventions during resuscitation, greater post-resuscitation serum lactate 
levels, higher multi-organ dysfunction score and more renal replacement therapies. More 
patients receiving therapeutic hypothermia also received extracorporeal life support. When 
logistic regression modelling was performed to account for these confounding factors, the 
use of therapeutic hypothermia did not statistically increase the risk of 30 day mortality 
(adjusted OR [95% CI] 2.5 [0.55 to 11.49] P = 0.238), six month mortality (adjusted OR [95% 
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CI] 1.99 [0.45 to 8.85] P = 0.502) or unfavourable neurological outcome (adjusted OR [95% 
CI] 2.0 [0.45 to 9.01] P = 0.364). 
Fink et al (2010) in a single centre, retrospective study also showed no significant difference 
in mortality and gross neurological outcomes for patients treated with either therapeutic 
hypothermia or normothermia after cardiac arrest. The patient population differed from the 
study by Doherty et al (2009) and IHCA (55%) and OHCA (45%) patients with predominately 
an asphyxial aetiology (91%) causing the arrest.  Excluded from the population were all 
patients with congenital heart disease. Patients received either therapeutic hypothermia (n = 
40) or standard normothermia therapy (n = 141). Similar to Doherty et al (2009), patients 
receiving therapeutic hypothermia had a longer duration of cardiac arrest, more doses of 
epinephrine and fewer were witnessed arrests and therefore had an increased baseline risk 
of mortality. In patients who were normothermic at the start of therapy, therapeutic 
hypothermia target temperature was reached within a median 8 hours [IQR 5 to 7]. Mortality 
at hospital discharge was similar for patients receiving therapeutic hypothermia (55.0%) and 
standard therapy (55.3%; P = 1.0). Therapeutic hypothermia was not associated with 
survival (adjusted OR [95% CI] for mortality; 0.47 [0.15 to 1.45]; P = 1.0). This study also 
reported no difference in proportion of survivors discharged home after therapeutic 
hypothermia (78%) versus standard therapy (68%; P = 0.46). 
The third study was only available in abridged abstract form (Buttram et al, 2009). This 
prospective study compared therapeutic hypothermia (n = 33) and standard therapy (n = 13) 
in paediatric patients surviving to PICU admission after IHCA and OHCA. Mortality at 
hospital discharge was not significantly different (therapeutic hypothermia: 61%, versus 
standard therapy: 77%, P = 0.49). However, no data is presented to compare the 
demographics of the two groups. 
These three excluded studies were unable to demonstrate a significant difference in survival 
or good neurological outcome at various time points after the use of therapeutic hypothermia 
compared with normothermia. Methodological problems including the non-randomised 
design of the studies are a significant problem. In both Doherty et al (2009) and Fink et al 
(2010), therapeutic hypothermia was used in patients already at higher risk of mortality with 
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associated risk factors known to exist after paediatric cardiac arrest.  In addition, it is difficult 
to compare these two studies owing to significant differences in patient demographics 
between each study. The high proportion of IHCA patients with chronic cardiac conditions in 
the Doherty et al (2009) study will have had an increased chance of survival compared with 
the higher proportion of asphyxial arrest patients and OHCA patients in Fink et al (2010).  
These studies do focus on important safety issues regarding the use of therapeutic 
hypothermia which can usefully inform further prospective randomised studies. Excess 
hypothermia (defined as core temperature less than 32°C) was only reported in patients 
receiving therapeutic hypothermia and occurred in 17.2% (Doherty et al 2009) and 15% 
(Fink et al 2010) of patients. Fink et al (2010) identified that excess hypothermia was 
associated with increased mortality in this group. Hyperthermia (defined as temperature 
greater than 38°C) in post cardiac arrest patients is known to increase mortality and 
neurological injury (Bembea et al, 2010) and international recommendations advocate 
avoidance (Kleinman et al, 2010). However, it occurred in 38% of standard therapy and 17% 
of therapeutic hypothermia treated patients although was not associated with increased 
mortality in this study (Fink et al, 2010). Neither Doherty et al (2009) or Fink et al (2010) 
reported an increase in post cardiac arrest infections, arrhythmias or bleeding, in patients 
receiving therapeutic hypothermia. Therefore, a randomised controlled trial treatment 
protocol will need to actively avoid inadvertent hypothermia and hyperthermia in both the 
therapeutic hypothermia group and normothermia group and continue to monitor for 
potential adverse effects of therapeutic hypothermia. 
We excluded two prospective, non-randomised studies on paediatric patients after cardiac 
arrest who all received therapeutic hypothermia and where there was no comparison group 
(Topjian et al, 2011; Abend et al, 2009). We excluded an additional three retrospective, non-
randomised studies of paediatric patients after cardiac arrest where factors associated with 
survival were reported. Deasy et al reported that 23/46 (46%) of patients admitted to PICU 
after cardiac arrest were treated with therapeutic hypothermia. However, its use was not 
associated with survival (unadjusted OR [95%CI] 2.54 [0.64 to 9.9]; P = 0.184). Two 
retrospective studies of in-hospital cardiac arrest (Meert et al, 2009) and out-of-hospital 
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cardiac arrest (Moler et al, 2011) separately reported proportion of patients receiving 
therapeutic hypothermia, although the proportions were so small (4% and 2% respectively)  
that comparison between groups was inappropriate. 
3.6.1.2 On-going studies 
We found four on-going studies (NCT00754481; NCT00797680; NCT00878644; 
NCT00880087). Two phase III studies (NCT00878644; NCT00880087) using therapeutic 
hypothermia (32 to 34⁰C) for 48 hours with gradual rewarming and further control of 
temperature to normothermia (36.0 to 37.5⁰C) for a further three days are comparing 
children after in-hospital cardiac arrest with out-of hospital arrest. These two studies are 
designed to detect a difference in survival with good neurological outcome at 12 months. 
One phase II (pilot) study (NCT00754481) is comparing therapeutic hypothermia (33 to 
34⁰C) for 48 hours with gradual rewarming to normothermia (36.5 to 37.5⁰C); and a fourth 
phase II (pilot) study (NCT00797680) is comparing 24 versus 72 hours of therapeutic 
hypothermia (32 to 34⁰C) with gradual rewarming. 
All four studies are using a similar therapeutic hypothermia target temperature (33°C ± 1°C) 
which is the target temperature demonstrated to be efficacious in neonatal and adult RCTs. 
Three studies will maintain target temperature for 48 hours and compare with a therapeutic 
active normothermia group (NCT00754481; NCT00878644; NCT00880087). The use of an 
actively controlled normothermia group aims to eliminate the confounding effect of 
hyperthermia (temperature greater than 38⁰C) in the control group. This was noted in the 
adult, European hypothermia after cardiac arrest trial (HACA, 2002) with approximately 25% 
of the patients in the control group experiencing hyperthermia and potentially increasing their 
risk of neurological injury (HACA, 2002).   
Duration of therapy may be an important variable. The fourth study is comparing 24 and 72 
hours of therapeutic hypothermia (NCT00797680). The other three studies are using 48 
hours of therapeutic hypothermia as the treatment duration.  This compares with the two 
adult studies which used 12 hours (Bernard et al, 2002) and 24 hours (HACA, 2002) of 
therapy and the neonatal trials which used 72 hours of therapy (Jacobs et al, 2007; 
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Azzopardi et al, 2009). Despite the wide variation in duration of therapy between studies, 
beneficial effects were still seen and therefore further investigation of this treatment variable 
is important. The advantages of a longer duration of therapy include the potential for greater 
beneficial effect from the intervention and this is supported in experimental animal studies, 
particularly with an increased delay from return of spontaneous circulation to 
commencement of therapy (Clark et al, 2008; Colbourne et al, 1999). However, prolonged 
duration may increase the risk of infection and associated morbidity. The increased duration 
may also have greater financial implications associated with prolonged ventilation and a 
longer stay in PICU which should be taken into account. 
Important functional and neurological outcomes are being assessed in all on-going studies. 
The use of the simple functional outcome scores (e.g. Paediatric Cerebral Performance 
Category (PCPC) (Fiser, 1992)) will give some useful information regarding crude 
functioning. The PCPC score was designed and validated in the post-cardiac arrest 
population but will not be able to demonstrate subtle functional and developmental 
problems. The use of multiple, in-depth neurodevelopmental and neuropsychological tests, 
as planned in two studies, will hopefully give a much clearer and more accurate assessment 
of subtle effects of therapeutic hypothermia at different stages of brain development 
(NCT00878644; NCT00880087). Biomarkers (serological and radiological) are also a 
potential tool  in early prediction of short term survival and also levels of developmental 
outcome over a longer term (NCT00797680).  
In a future Cochrane systematic review we hope to assess these four studies together with 
any additional randomised controlled studies and to perform a meta-analysis as detailed 
above. In addition, we will use individual patient data if possible. 
3.6.2 Overall completeness and applicability of evidence   
Currently the available evidence neither supports nor refutes the use of therapeutic 
hypothermia in the paediatric population. However this lack of evidence justifies further 
randomised controlled trials and the encouragement of researchers and clinicians to 
continue investigation of this therapy. The on-going studies will hopefully provide valuable 
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information regarding this therapy and be available for future systematic assessment, as 
described in this review.  
3.6.3 Quality of the evidence   
We found no high quality evidence for or against the use of therapeutic hypothermia in 
children after cardiac arrest. Formal quality assessment and meta-analysis of non-
randomised studies was not performed (Stroup, 2000). 
3.6.4 Potential biases in the review process   
We undertook a systematic search for evidence using a sensitive search strategy as 
described in Section 6.4 of the Cochrane Handbook for Systematic Reviews of Interventions 
(Higgins JPT et al, 2011) to find randomised controlled trials, in order to limit the risk of 
missing published studies. Contacting experts in paediatric critical care and hypothermia 
research did not uncover further studies and confirmed that the on-going studies identified 
were either still recruiting or undergoing analysis. The possibility of additional un-published 
randomised controlled trials does exist, although we feel this is small. 
Non-randomised trials have been discussed in this review owing to the absence of high 
quality randomised controlled trials. However, owing to the design of the systematic search 
focusing on randomised studies there is a possibility of missing non-randomised studies. 
Experts were asked for any additional published or unpublished non-randomised studies and 
as no additional studies were identified this possibility is also small.  
3.6.5 Agreements and disagreements with other studies or reviews   
The use of therapeutic hypothermia in children after cardiac arrest is outlined in the 
international liaison committee on resuscitation (ILCOR) guidance (Kleinman et al, 2010). 
The use of therapeutic hypothermia (32-34°C) may be beneficial in adolescent children 
presenting in ventricular fibrillation cardiac arrest. In infants and children who remain 
comatose after resuscitation from paediatric cardiac arrest, therapeutic hypothermia (32-
34°C) may be considered. 
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Support for these recommendations is extrapolated from the neonatal evidence of 72 hours 
of therapeutic hypothermia after hypoxic ischaemic encephalopathy within six hours of birth 
(Jacobs et al, 2007; Azzopardi et al, 2009) and the two RCTs of 12 to 24 hours of 
therapeutic hypothermia in adults after ventricular fibrillation cardiac arrest (Bernard et al, 
2002; HACA, 2002). The findings and limitations of the two retrospective cohort studies 
((Doherty et al, 2009; Fink et al, 2010) and the lack of paediatric high quality evidence are 
acknowledged. The recommendations are given with the caution that the benefits or harm of 
therapeutic hypothermia in this population is not known. 
We found no further published randomised or non-randomised paediatric studies since the 
publication of the ILCOR guidelines. Reassessment of the paediatric recommendations will 
be necessary when the on-going studies identified in this review have been completed. 
3.6.6 Limitations of review  
The main limitation of this review is the a priori exclusion of non-randomised controlled 
studies at the protocol stage, which results in no evidence being formally analysed. The 
Cochrane Collaboration principles regarding systematic reviews ensure „the conduct is a 
reliable synthesis of available evidence on a given topic and that the science is cumulative 
and facilitates decisions considering all the evidence of an intervention‟ (Higgins JPT et al, 
2011). This systematic review has adhered to these principles with the opportunities to 
review and revise in the future. However, a restriction that the Cochrane Anaesthesia 
Review Group set out after reviewing the proposal for this systematic review was the a priori 
inclusion of only randomised and quasi-randomised controlled trials in the study protocol.  
The formal use of non-randomised trials in systematic review has been detailed by the Meta-
analysis of Observational Studies in Epidemiology (MOOSE) group (Stroup, 2000). The 
methodological design weaknesses present in observational studies (e.g. lack of blinding 
and risk of exposure being linked to a hidden confounder) and the risks of heterogeneity of 
studies can be amplified in a meta-analysis. One solution is to choose the correct statistical 
tests to assess this (Trinquart & Touzé, 2009). However, the scientific rigour regarding 
analysis of included studies, including assessment of bias and heterogeneity is less well 
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validated than for randomised controlled trials (Wells et al, 2010). Conversely, Shrier et al 
(2007) argues that well designed observational studies with appropriate assessment of 
confounding variables can be included in meta-analysis and give examples where results 
are comparable to meta-analysis of randomised controlled trials only and in some situation 
(i.e. where the number of RCTs are limited or of small size) produce more accurate results. 
They would advocate that non-randomised controlled studies should only be excluded after 
systematic assessment of the study and not a priori at the design stage, as was performed 
in this review. Unfortunately, in the context of this review, the major risk factor of combining 
observational studies is present in the two identified published studies by Fink et al (2010) 
and Doherty et al (2009). The high probability of „confounding by indication‟ (defined as: 
when a treatment is specifically provided to a subject because of their probability of 
experiencing the outcome) (Shrier et al, 2007) as demonstrated through the use of 
therapeutic hypothermia in more severely affected children post cardiac arrest is present 
and risks limiting the strength of the observational findings. Adjustment of confounders at the 
design stage (i.e. inclusion of more severely affected patients) or at the analysis stage (by 
the use of multiple regression analysis or propensity scores) (Greenland et al, 1999) are 
appropriate methodological techniques for limiting this effect. Although, in the context of the 
two studies, even with appropriate statistical adjustments, too many additional limitations 
exist (e.g. the small sample sizes and heterogeneous populations) resulting in a lack of 
confidence in the final outcome findings. 
As detailed in the results, no randomised controlled trials were found, therefore creating 
what Cochrane define as an „empty review‟. This can lead to controversy with variability in 
publication of the review and ambiguity surrounding the presentation and reporting of 
excluded evidence (Montgomery et al, 2011). The publication of this review is justified on the 
grounds that the clinical question is important for practice or policy. Trials are feasible (as 
demonstrated by the on-going studies) although there may need to be amendment to the 
protocol as part of an iterative process in the future. A recent analysis of the Cochrane 
library discovered 376 empty reviews (8.7% of all active reviews) (Montgomery et al, 2011). 
However, they typically contained few, if any on-going studies (0.14 per review (SD 0.49)). 
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The four on-going randomised controlled trials identified in this review are therefore an 
exception to the norm and this review may only be „empty‟ temporarily. 
There is no guidance from Cochrane on the reporting of empty studies, particularly the 
section on implications for practice. Issues have arisen regarding frustration expressed by 
policy-makers on finding no evidence after searching for the guidance in the Cochrane 
library. One approach proposed by Lang et al (2007) suggests that authors of empty reviews 
note observations based on excluded studies so that decision-makers are not left empty 
handed. However, basing conclusions on studies which do not meet inclusion criteria 
increases the risk of bias (Montgomery et al, 2011). The position of not basing conclusions 
on the non-randomised studies has been taken here especially in anticipation of randomised 
controlled trial evidence becoming available in the future.  
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3.7 CONCLUSION 
3.7.1 Implications for practice   
We found no randomised controlled studies, so this review concludes that there is no 
evidence of effect of therapeutic hypothermia in paediatric cardiac arrest rather than 
evidence of no effect. We therefore can neither give a recommendation for or against the 
use of therapeutic hypothermia in clinical practice. Current guidance from the International 
Liaison Committee on Resuscitation recommends consideration of therapeutic hypothermia 
in infants and children and that its use may be beneficial in adolescents with ventricular 
fibrillation cardiac arrest (Kleinman et al, 2010). These recommendations are extrapolated 
from neonatal and adult clinical trials. Further research in the paediatric population is needed 
to confirm these recommendations. 
3.7.2 Implications for research   
More studies are needed to investigate the use of therapeutic hypothermia after paediatric 
cardiac arrest. Continued support for the on-going in-hospital and out-of-hospital cardiac 
arrest studies identified in this review and future studies is essential to enable assessment of 
any effect of therapeutic hypothermia in the paediatric population (NCT00754481; 
NCT00797680; NCT00878644; NCT00880087). The important differences which exist in 
cardiac arrest aetiology and neurological development in the paediatric population compared 
with the studied neonatal and adult populations support this.  
Adequately sized studies will be required to investigate the effect of therapeutic hypothermia 
and to define the duration, temperature depth and rewarming rates during administration. It 
is likely that international collaboration will be required to recruit sufficient numbers of 
patients to ensure adequately powered studies and findings are generally applicable. 
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Table 3-4 Chapter 3 and RCT feasibility 
What have we learnt from this study towards the feasibility of a UK randomised 
controlled trial? 
Confirmation that there are currently no published randomised controlled trial data examining 
therapeutic hypothermia as a neuroprotection therapy in children after cardiac arrest. 
Paediatric randomised controlled trials are on-going, successfully funded and recruiting, 
although only in North America and Canada. 
Future meta-analysis (with individual patient data) may be possible in five to seven years. 
Communication with international experts across the world through this review process has 
revealed a willingness to advise upon, participate in, and support a UK randomised controlled 
trial of therapeutic hypothermia after paediatric cardiac arrest. 
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4 Current practice of targeted 
temperature management and 
future trial acceptability 
 
"New opinions are always suspected, and usually opposed, without any 
other reason but because they are not already common."   
John Locke (English philosopher born 1632). 
 
 
 
 
 
 
 
 
This chapter has been published in two papers 
 
B.R.Scholefield, H.P. Duncan, and K.P. Morris, Survey of the use of therapeutic 
hypothermia post cardiac arrest. Arch Dis Child, 2010. 95(10): p. 796-9. (Appendix 
9.7, p322) 
B.R.Scholefield, M. Lyttle, K.Berry, H.P. Duncan, and K.P. Morris, Survey of the 
use of therapeutic hypothermia after cardiac arrest in UK paediatric Emergency 
Departments. Emerg Med J Published Online First: 2 March 2012 
doi:10.1136/emermed-2011-200348 (Appendix 9.8, p326) 
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4.1 ABSTRACT 
4.1.1 Introduction 
International resuscitation guidelines recommend consideration of post paediatric cardiac 
arrest therapeutic hypothermia based upon supportive evidence from adult and neonatal 
studies. However, the lack of paediatric evidence may limit the implementation of these 
guidelines in practice. Current UK practice of temperature management after resuscitation in 
the Paediatric Emergency Department and the Paediatric Intensive Care Unit is not known. 
Knowledge of current practice is essential to assess the feasibility of introducing further 
research in this area and to inform trial design. 
4.1.2 Aims 
To ascertain current practice of post cardiac arrest temperature management in UK 
Paediatric Intensive Care Units and Paediatric Emergency Departments, and to assess 
attitudes and opinions of further research in this area. 
4.1.3 Methods 
Two anonymous web-based surveys. Survey one: All UK paediatric intensive care (PIC) 
consultants (n=149). Survey two: A selective sample of UK paediatric emergency medicine 
consultants (n=77) from 28 UK Emergency Departments.  
4.1.4 Results 
Survey one: 113/149 (76%) of PIC consultants surveys were returned. 65% (73/113) 
responded that they do not know if therapeutic hypothermia improves survival after cardiac 
arrest. Despite this 48% (54/113) „always‟ or „often‟ use therapeutic hypothermia after return 
of spontaneous circulation following cardiac arrest in children. Amongst those who rarely or 
never use therapeutic hypothermia the commonest explanation given was „not enough 
research evidence‟ (91% 54/59). With respect to the dose of therapeutic hypothermia the 
median duration of cooling used is 24-48 hours (range 4-72 hours) and median target 
temperature 34-35 °C (range 32 to 37°C).  
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Survey two: 62% (48/77) of surveyed paediatric emergency medicine consultants responded 
from 75% (21/28) of Emergency Departments. 90% (43/48) were aware of the literature 
concerning therapeutic hypothermia after cardiac arrest in adults. However, 63% (30/48) had 
never used therapeutic hypothermia in paediatric practice. All departments had at least one 
method of inducing therapeutic hypothermia (surface cooling; air/water blankets; intravenous 
cold fluid or catheters). Reasons stated for not inducing therapeutic hypothermia included no 
equipment available (26%; 11/42), therapeutic hypothermia not advocated by the local PICU 
(24%; 10/42) and not enough evidence for its use (24%; 10/42). Therapeutic hypothermia 
was considered based on advice from the local PICU (68%; 17/25) or likelihood of recovery 
after arrest (32%; 8/25). 
 
Both surveys reported support for a UK RCT of therapeutic hypothermia versus 
normothermia, an RCT being ethical and accepted the utilisation of deferred consent.  
4.1.5 Conclusions 
 Wide variation in UK paediatric intensive care and paediatric emergency medicine practice 
in the use of therapeutic hypothermia and a state of clinical equipoise is demonstrated by 
these two surveys which show important support for UK multi-centre collaboration in a future 
trial of therapeutic hypothermia after cardiac arrest. The support would potentially enable 
early induction of therapeutic hypothermia in UK Emergency Departments during a UK RCT 
of therapeutic hypothermia after paediatric cardiac arrest. 
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4.2 INTRODUCTION 
In the UK children sustaining an out of hospital cardiac arrest are managed by teams led by 
emergency medicine consultants, often in collaboration with paediatric intensive care 
consultants. The decision whether to use targeted temperature control and initiate 
therapeutic hypothermia is therefore made by these two groups, informed by their 
understanding of the research evidence, clinical guidelines, institutional practices, 
experience and personal clinical knowledge. They are therefore an ideal source to assess 
current practice and to ascertain whether clinical equipoise exists regarding the use of 
therapeutic hypothermia after paediatric cardiac arrest.  
 
Clinical equipoise has been defined as 'there existing an honest, professional disagreement 
among expert clinicians about the preferred treatment' (Freedman, 1987). Without clinical 
equipoise randomisation of patients into an RCT to compare two treatments (where the body 
of belief is that one therapy is more efficacious that the other) is unethical (Freedman, 1987). 
In addition, research resource limitations in the health service require prioritisation of 
resources. Clinicians are best placed to clarify the importance of a clinical question in 
relation to other clinical needs.  
4.2.1 Current Guidance 
Therapeutic hypothermia (TH) induced to 33±1°C after ventricular fibrillation associated 
cardiac arrest in adults and hypoxic-ischaemic encephalopathy in neonates has been shown 
to significantly improve neurological outcomes (Bernard et al, 2002; Gluckman et al, 2005; 
HACA, 2002; Azzopardi et al, 2009; Shankaran et al, 2005). Whether the same benefit  can 
be achieved after paediatric cardiac arrest is not yet known, although the International 
Liaison Committee for Resuscitation (ILCOR) recommend „considering the use of TH for 12-
24 hours in infants and children who remain comatose after resuscitation‟ (ILCOR, 2006).  
 
An anonymous web based survey conducted in North America highlighted wide variation of 
practice in paediatric intensive care units concerning when therapeutic hypothermia is 
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started and how it is administered (Haque et al, 2006). As this survey was undertaken some 
years ago with little input from UK paediatric intensivists and a poor overall response rate 
(12%) it does not provide an accurate picture of current UK practice.  
4.2.2 Narrow therapeutic window 
Animal studies indicate that there is a narrow therapeutic window for TH, and early treatment 
appears more efficacious in preventing severe hypoxic-ischaemic injury after cardiac arrest 
(Colbourne & Corbett, 1995; Markarian et al, 1996; Kuboyama et al, 1993; Iwata et al, 2007). 
Adult and neonatal studies showing neurological benefit have recruited patients to receive 
TH within six hours of cardiac arrest or hypoxic injury (Bernard et al, 2002; Shankaran et al, 
2005; HACA, 2002; Azzopardi et al, 2009; Gluckman et al, 2005). Whether the same 
therapeutic window applies to paediatric patients following cardiac arrest is as yet unknown. 
 
Paediatric patients resuscitated after cardiac arrest are cared for in Paediatric Intensive Care 
Units (PICUs). With the centralisation of PICUs, these children often require transfer from 
the presenting Emergency Department to a regional PICU, in a different hospital (Pearson et 
al, 2001). Owing to logistical delays in transportation, it may be necessary for TH to be 
commenced in the Emergency Department in order to effectively deliver treatment within the 
narrow therapeutic window.  
 
This chapter therefore aims to address the questions of should we and could we undertake 
an RCT in the UK by ascertaining current practice in UK Emergency Departments and 
PICUs, asking whether clinical equipoise exists amongst medical staff, and investigating 
their willingness to participate in a UK RCT. 
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4.3 AIMS 
4.3.1 Primary Aim 
1. To ascertain current practice amongst paediatric intensive care and emergency 
department physicians regarding the use of TH after paediatric cardiac arrest.  
 
4.3.2 Secondary Aims  
1. Assess if clinical equipoise exists regarding the use of therapeutic hypothermia after 
cardiac arrest. 
2. Establish whether there is support for a future randomised control trial.  
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4.4 METHODOLOGY 
4.4.1 Setting and participants 
Survey one: 149 PIC consultants from 25 UK PICUs were identified by contacting all NHS 
PICUs in the UK. 
 
Survey two: 77 emergency medicine Consultants from 28 UK Emergency Departments were 
invited to participate by selecting known members of the Association of Paediatric 
Emergency Medicine.  Half were from tertiary children‟s hospitals which have PICU on-site 
and see only children within their emergency department, the remainder were from 
secondary general hospitals which have no PICU on-site and see a mix of adults and 
children within their emergency departments. For the purposes of this study we use the term 
emergency medicine consultants to refer to all consultants who participated in survey two.   
4.4.2 Study Design 
Survey one and two: Relevant questions were generated by the study group and piloted on 
a group of ten PIC consultants (survey one) and eight emergency medicine consultants 
(survey two) from three different hospitals for further feedback and hyperlink access testing.  
Survey one: To maximise response rates, as recommended in the Tailored Design Method 
for surveys (Dillman DA, 2007), a personal invitation to participate was sent out on October 
1
st
 2008. Weblinks to the survey were sent out via email three further times and the internet 
link was closed on the 23
rd
 November 2008. Survey two: An invitation to participate was sent 
on the 1
st
 April 2010. Invitations were sent three further times and the internet link was 
closed on the 30
th
 June 2010. Survey questions are shown in appendix 9.5 & 9.6 (p314). 
Both surveys were created using Microsoft ASP.NET 2008 (Microsoft, Seattle, WA). 
4.4.3 Data collection 
Data was collected electronically and imported into Microsoft Excel (Microsoft, Seattle, WA). 
Responders were identified by a unique code; this ensured that email reminders were only 
sent to non-responders. 
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4.4.4 Statistical Analysis 
Microsoft Excel (Microsoft, Seattle, WA) was used for data analysis and results are 
presented as percent of survey responders, or mean (standard deviation). Agreement was 
defined as percentage responding „agree‟ or „strongly agree‟ from a five point Likert scale 
(strongly agree, agree, neutral, disagree and strongly disagree). An inter-rater agreement 
score was calculated for responses from emergency medicine consultants from the same 
Emergency Department. 
4.4.5 Ethics 
This study was reviewed by Birmingham Children‟s Hospital research and development 
department who categorised it as clinical evaluation involving NHS clinical staff (Paediatric 
Intensive Care and Emergency Medicine Consultants) and evaluating practice within their 
professional role. Therefore, Regional Ethics Committee waivered requirement for approval. 
Formal advice has recently been published by the National Research Ethics advisory 
Service confirming this as a widely accepted decision (National Research Ethics Service, 
2011).   
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4.5 RESULTS   
4.5.1 Survey one 
Of 149 consultants surveyed 113 responses (76%) were received. Consultants responded to 
questions about their current use of therapeutic hypothermia (Table 4-1), how they select 
patients (Table 4-2), what „dose‟ of hypothermia they use (Figure 4-1), methods of cooling 
(Table 4-3) and their views on further research (Table 4-4). 
4.5.2 Use of therapeutic hypothermia 
65% (73/113) reported not knowing if therapeutic hypothermia after cardiac arrest improves 
survival. 48% (54/113) always or often use therapeutic hypothermia with the remaining 52% 
(59/113) stating they seldom or never use it. The commonest reason given by those who 
seldom or never use hypothermia was „not enough research evidence‟ (91%; 54/59). 
4.5.3 Patient selection 
65% (51/78) of PIC consultants who have used therapeutic hypothermia would not change 
their practice according to whether the cardiac arrest occurred in or out of hospital.  
 
The time to return of spontaneous circulation (ROSC) after cardiac arrest was influential in 
decision making for 66% (50/76) (Table 4-2). A higher proportion would commence 
therapeutic hypothermia for ROSC times between 5 and 30 minutes, though 23% (17/76) 
would even consider therapeutic hypothermia for a ROSC delay exceeding 60 minutes. 
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Table 4-1 Use of therapeutic hypothermia (survey one) 
 n Yes 
n(%) 
No 
n(%) 
Don't 
know 
n(%) 
  
Do you believe that therapeutic 
hypothermia improves survival after 
cardiac arrest in children? 
113 29 (26) 11 (10) 73 (65) 
  
Does your clinical practice change if 
the child has an in-hospital cardiac 
arrest rather than an out-of hospital 
cardiac arrest?  
 
78
a
 
 
27 (35) 
 
51 (65) 
 
  
   Never 
n (%) 
Seldom 
n (%) 
Often 
n (%) 
Always 
n (%) 
% Often 
or 
Always 
Do you use induced hypothermia as a 
therapy after resuscitation from cardiac 
arrest in children who have a return of 
spontaneous circulation? 
113 37 (33) 22 (19) 44 (39) 10 (9) 48 
Do you induce hypothermia as a 
therapy after in-hospital cardiac arrest 
in children?  
77
a
 1 (1) 30 (39) 36 (47) 10 (13) 60 
Do you induce hypothermia as a 
therapy after out-of-hospital cardiac 
arrest in children?  
76
 a
 4 (5) 19 (25) 35 (46) 18 (24) 70 
a
 response from those who „always‟, „often‟ or „seldom‟ use therapeutic hypothermia only 
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Table 4-2 Patient selection and dose of hypothermia (survey one)  
 n Yes 
n (%) 
No 
n (%) 
Don't know 
 n (%) 
Which [if any] of the following influences your current use 
of hypothermia as a therapy after cardiac arrest? [you 
can select more than one]  
    
    Return of spontaneous circulation 76
 a
 50 (66) 21 (28) 5 (7) 
    Delayed opportunity to cool 74
 a
 22 (30) 42 (57) 10 (14) 
    Witnessing arrest 76
 a
 21 (28) 46 (61) 9 (12) 
    Pupillary reaction 74 20 (27) 46 (62) 8 (11) 
    Age 76
 a
 2 (3) 68 (90) 6 (8) 
Does your unit have a specific protocol for implementing 
hypothermia therapy?  
76 5 (7) 69 (90) 2 (3) 
Where would you actively start to induce hypothermia in 
your patients? 
    
   Emergency Department 73 24 (33) 49 (67)  
   Referring hospital 74 34 (46) 40 (54)  
   Intensive care unit 77 77(100) 0 (0)  
Do you have a fixed length of time [as opposed to 
variable length] you would routinely maintain 
hypothermia?  
75 33 (44) 42 (56)  
Do you control the speed of rewarming?  76 38 (50) 38 (50)  
Do you use active rewarming devices?  77 19 (25) 58 (75)  
a 
percent total greater than 100 due to rounding.  
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4.5.4 Methods of inducing and maintaining therapeutic hypothermia 
90% (69/76) of PIC consultants do not have a protocol for the use of therapeutic 
hypothermia in their unit. 
 
Various combinations of cooling methods were reported, with a circulating water blanket the 
most commonly used (78%; 59/76) (Table 4-3). 
 
Table 4-3 Method of inducing therapeutic hypothermia (survey one) 
Method of Cooling 
 
n (%)
a
  
 
Water blanket 59 (78) 
Ice packs to skin 47 (62) 
Air blanket 32 (42) 
Intravascular cooling device 6 (8) 
Wet linen 4 (5) 
Intravenous ice-cold (4°C) saline 4 (5) 
 
4.5.5  ‘Dose’ of hypothermia 
Duration: The stated duration of induced hypothermia ranged from 4 to 96 hours. The 
maximum duration of cooling used is shown in Figure 4-1. The majority cool for a duration of 
up to 24-48 hours (85%; 65/76) with 15% (11/76) having a maximum cooling time longer 
than 48 hours.  
 
Depth of cooling ranged from 32-37 °C with only 33% (25/76) targeting 33±1°C (Figure 2). 
The two responders (3%) who stated 36-37°C commented that they use cooling methods to 
actively avoid hyperthermia rather than to induce hypothermia. 
 
Speed of rewarming is controlled by 50% (38/76) of responders with a range of 0.1-
1.0°C/hour given as the target temperature increase.  
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Figure 4-1 Maximum stated duration of therapeutic hypothermia used (n=65) 
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4.5.6 Views on future research into therapeutic hypothermia 
There continues to be a state of clinical equipoise in the UK regarding the use of therapeutic 
hypothermia after cardiac arrest according to 73% (82/113) of PIC consultants. 
 
86% (97/113) would randomise their patients into a RCT of therapeutic hypothermia in 
cardiac arrest. There was greatest support for a comparative trial of hypothermia versus 
normothermia. There was strong support for a randomised controlled trial of therapeutic 
hypothermia being ethical (89%; 101/113), and utilising deferred consent (85%; 96/113).  
 
Although 83% (94/113) of those surveyed felt that publication of a large multi-centre study 
undertaken in the United States would inform them of the benefit or lack of benefit of 
therapeutic hypothermia to their own patient population, 47% (53/113) agree that a UK trial 
is needed in addition to a US trial. 
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 Table 4-4 Opinions regarding current and further research (survey one) 
Statement 
 
n  Agreement † 
n (%) 
Mean‡   SD 
The publication of a large randomised controlled 
trial currently being designed in the USA in the use 
of hypothermia in children after cardiac arrest would 
convince me of the benefit or lack of benefit for its 
use in my patient population  
112 93 (83) 3.9 ± 0.6 
A multi-centre randomised controlled trial 
conducted in the United Kingdom in the use of 
hypothermia in children after cardiac arrest is 
necessary in addition to a USA study to convince 
me of its use in my patient population 
113 53 (47) 3.2 ±1.1 
I currently feel there is clinical equipoise regarding 
the use of hypothermia versus normothermia after 
cardiac arrest in children. 
113 82 (73) 3.8 ± 0.8 
It is ethical to perform a randomised controlled trial 
of hypothermia therapy in children after cardiac 
arrest 
111 99 (89) 4.2 ± 0.9 
 It is ethical to use deferred consent in clinical trials 
investigating therapies immediately after cardiac 
arrest 
113 99 (88) 4.1 ± 0.9 
† Agreement = percentage responding „agree‟ or „strongly agree‟ 
‡ Mean score on a Likert scale: 5 (strongly agree), 4 (agree), 3 (neutral), 2 (disagree) and 1 
(strongly disagree)  
*SD = standard deviation 
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4.5.7 Survey two 
Of 77 emergency medicine consultants surveyed, 62% (48/77) responded. 75% (36/48) were 
consultants solely in Paediatric Emergency Medicine, and 25% (12/48) held dual 
accreditation in Adult and Paediatric Emergency Medicine. Responses were from 75% 
(21/28) of Emergency Departments.  Ten Emergency Departments were located in tertiary 
children‟s hospitals which only see children.  Eleven were located in secondary general 
hospitals where consultants manage both adult and paediatric patients.   
Consultants responded to questions about their current use of TH (Table 4-5), how they 
select patients (Table 4-6), methods of cooling available (Table 4-7) and their views on 
further research (Table 4-8).  
Table 4-5 Use of therapeutic hypothermia (survey two) 
Question n Yes 
n (%) 
No 
n (%) 
Don‟t 
know 
n (%) 
  
Do you look after children post-cardiac 
arrest in ED? 
48 48(100) 0 0   
Are you aware of published research 
regarding TH in adults post-cardiac 
arrest? 
48 43 (90) 5 (10) 0   
Do you have a TH protocol for adults? 46
 a
 8 (17) 25 (52) 13 (27)   
Do you have a TH protocol for 
children? 
47 0 46 (98) 1 (2)   
Do you believe TH improves outcome 
after paediatric cardiac arrest? 
47 5 (11) 0 42 (89)   
 n Always 
n (%) 
Often 
n (%) 
Seldom  
n (%) 
Never 
n (%) 
N/A 
n (%) 
Do you use TH after adult cardiac 
arrest? 
48 2 (4) 11 (23) 6 (13) 5 (10) 24 (50) 
Do you use TH after paediatric cardiac 
arrest? 
46
 a
 0 2 (4) 14 (30) 30 (65) 0 
TH: therapeutic hypothermia, 
a 
percent total greater or less than 100 due to rounding. 
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4.5.8 Knowledge of the use of therapeutic hypothermia 
90% (43/48) of emergency medicine consultants were aware of the literature regarding the 
use of TH in adults post cardiac arrest.  
Very few used TH after paediatric cardiac arrest; 65% (30/46) reported use as „never‟ and 
30% (14/46) „seldom‟. No responder had a paediatric specific TH protocol in their 
Emergency Department. 
A larger proportion used TH after adult cardiac arrest; 27% (13/48) reported „always‟ or 
„often‟. However, half answered „not applicable‟ as they did not manage post-cardiac arrest 
adults. 17% (8/46) reported being aware of an adult TH protocol in their Emergency 
Department. 
The majority (89%; 42/47) did not know if TH improved outcome after paediatric cardiac 
arrest. 
4.5.9 Patient selection 
A number of variables were involved when deciding which patients should receive TH.  
There were also a number of reasons reported by clinicians for not using TH after cardiac 
arrest (table two). 52% (25/48) responded to the „reasons stated for selecting patients for 
TH‟ and 88% (42/48) responded to the „reason stated for not using TH post cardiac arrest. 
The most frequent reason for selecting patients was „on advice from the regional PICU‟. 
Similarly, 24% (10/42) would not use TH as it was not advocated by the regional PICU and 
14% (6/42) would transfer patients quickly to PICU and felt therapy could be commenced 
there with minimal delay rather than in the Emergency Department. The likelihood of patient 
recovery was also important for 32% (8/25) who used TH in choosing which patients should 
receive it.  
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Table 4-6 Selection of patients for therapeutic hypothermia (survey two) 
 n (%) 
Factors stated in selecting patients for TH post paediatric cardiac arrest  
(n = 25) 
 
 On advice from PICU 17 (68) 
 Likelihood of patient recovery after the arrest 8 (32) 
 Absence of life limiting condition 6 (24) 
 Availability of equipment 6 (24) 
Reasons stated for not using TH post paediatric cardiac arrest  
(n = 42) 
 
 No equipment available 11 (26) 
 Not enough research evidence 10 (24) 
 Not advocated by regional PICU 10 (24) 
 Not in the Advanced Paediatric Life Support guidelines 9 (21) 
 Rapid transfer to PICU where TH is usually started 6 (14)  
 Technically too difficult  6 (14) 
 Not considered for children 3 (7) 
 Not an Emergency Department priority or too infrequent 3 (7) 
 The cooling method available is too slow 2 (5) 
 
  
Chapter 4  
 
103 
 
4.5.10 Methods of inducing hypothermia 
Availability of equipment was reported as a factor in patient selection for TH, and conversely, 
lack of equipment was reported as a reason for not using TH (Table 4-6). 
A wide variety of equipment was available in Emergency Departments (Table 4-7). 
Equipment was considered available if any Consultant from an Emergency Department 
reported it available. Notably, there were discrepancies between responses from within the 
same Emergency Department regarding available equipment (mean inter-responder 
agreement score within each Emergency Department was 0.37; standard deviation 0.06). 
86% (18/21) of Emergency Departments had access to wet linen and 81% (17/21) to ice 
packs. Cold air circulating blankets were reported to be present in 62% (13/21) of 
Emergency Departments although only 36% (15/42) of individuals reported it being 
available. There was a median of three methods of cooling (range 1-6) at each Emergency 
Department.  
 
Table 4-7 Availability of methods for inducing therapeutic hypothermia reported by 
individuals and per Emergency Departments (survey two) 
 Methods Consultant       Response 
(n=42) 
Emergency Department  
availability (n=21) 
 n (%)* n (%)* 
Wet linen 35 (83) 18 (86) 
Ice-pack to skin 24 (57) 17 (81) 
Cold air blanket 15 (36) 13 (62) 
Iced cold (4°C) intravenous 
saline 
9 (21) 5 (24) 
 
 
  
Chapter 4  
 
104 
 
4.5.11 Opinions regarding future research into therapeutic hypothermia after 
paediatric cardiac arrest. 
A position of clinical equipoise is defined as the existence of an honest, professional 
disagreement among expert clinicians about the preferred treatment (Freedman, 1987).  
52% of emergency medicine consultants agreed or strongly agreed that this exists regarding 
the use of TH after paediatric cardiac arrest. Only 7% „disagreed‟ and the remainder were 
neutral (Table 4-8).  
91% would agree to their patients being recruited into a RCT of TH after paediatric cardiac 
arrest. There was greater support for a trial of TH versus normothermia than there was for a 
method of cooling trial. There was strong support that a RCT of TH is ethical (87%), and that 
deferred consent is appropriate (74%).  
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Table 4-8 Opinions regarding therapeutic hypothermia randomised controlled trial 
(survey two) 
Statement: n Agreement †   n 
(%) 
Mean 
‡ 
SD* 
I currently feel there is clinical equipoise 
regarding the use of hypothermia versus 
normothermia after cardiac arrest in children 
46 24 (52) 3.5 0.69 
It is ethical to perform a randomised 
controlled trial of hypothermia therapy in 
children after cardiac arrest 
46 40 (87) 4.2 0.72 
It is ethical to use deferred consent in clinical 
trials investigating therapies immediately 
after cardiac arrest 
46 34 (74) 3.8 1.10 
Would you: n Yes 
n (%) 
No 
n (%) 
Don’t Know 
n (%) 
Support a comparative intervention 
trial? 
47 40 (85) 2 (4) 5 (11) 
Support a method of cooling study? 45 34 (76) 5 (11) 6 (13) 
Allow your patients to be recruited to an 
RCT? 
47
 a
 43 (91) 1 (2) 3 (6) 
Use a trial protocol in your ED? 48 41 (85) 1 (2) 6 (13) 
† Agreement = percentage responding „agree‟ or „strongly agree‟ 
‡ Mean score on a Likert scale: 5 (strongly agree), 4 (agree), 3 (neutral), 2 (disagree) and 1 
(strongly disagree)  
*SD = standard deviation   
a 
percent total greater or less than 100 due to rounding.  
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4.6 DISCUSSION 
These two surveys suggests that very few UK Emergency Medicine consultants currently 
initiate therapeutic hypothermia (TH) after paediatric cardiac arrest in their Emergency 
Departments and there is wide variation in the use of TH after cardiac arrest in children in 
PICUs in the UK.  
4.6.1 Use of therapeutic hypothermia 
Approximately 50% of PIC consultants report „always‟ or „often‟ using it, despite an absence 
of published, paediatric specific, literature to support its use. However, the vast majority of 
emergency medicine and PIC consultants in these surveys do not know if TH improved 
neurological outcome after paediatric cardiac arrest. There is awareness amongst the 
emergency medicine consultants of adult post-ventricular fibrillation cardiac arrest TH 
studies which have demonstrated a reduction in bad neurological outcome when treated with 
TH rather than normothermia (Bernard et al, 2002; Arrich et al, 2009; HACA, 2002).  
The 2006 International Liaison Committee on Resuscitation guideline recommended the 
consideration of hypothermia therapy after paediatric cardiac arrest (ILCOR, 2006). A more 
recent edition of the ILCOR guideline has been published since these surveys were carried 
out (Kleinman et al, 2010). However, the recommendations have changed only for 
adolescents, suggesting that TH is beneficial after ventricular fibrillation cardiac arrest in this 
group. There has been no paediatric specific RCT.  Only two retrospective observational 
cohort studies (Fink et al, 2010; Doherty et al, 2009) have been published in this area, but 
they use unbalanced groups and show no difference in outcomes of patients receiving TH 
compared with normothermia.  This lack of evidence may therefore explain the 
demonstrated lack of uptake of this recommendation. The ongoing Therapeutic Hypothermia 
After Paediatric Cardiac Arrest (THAPCA) multi-centre RCT (NCT00878644; NCT00880087) 
in North America and Canada may gather important data on safety and efficacy to 
strengthen any future guidance. 
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The role of the regional paediatric intensive care team appears to strongly influence the 
management of paediatric post cardiac arrest patients in the Emergency Department.   Of 
emergency medicine consultants who would consider using the therapy, 68% reported that 
they would only commence it if their regional PICU requested and advocated it. Also, if the 
time taken to admit to PICU was anticipated to be short then therapy would be delayed until 
that point.  
4.6.2 Methods for inducing therapeutic hypothermia 
A number of methods of cooling appear to be accessible in most Emergency Departments. 
However, between consultants from the same Emergency Department, there is discrepancy 
in the perception of what equipment is available.   There was a belief that the PICU would 
have access to more sophisticated cooling equipment and be able to administer the therapy 
more safely.  This may be due to lack of personal experience and infrequent use of the 
equipment. The regional variation of paediatric intensive care practice and the low proportion 
of PIC consultants who would consider starting the therapy in the Emergency Department 
support the findings from survey two. 
Simple surface methods of cooling were used by all PIC consultant responders, with the 
majority reporting using more than one method. Of interest is the small number (5%) who 
reported to use 4ºC iced intravenous saline to induce therapeutic hypothermia, a method 
demonstrated to be both safe and effective in adults and children in inducing therapeutic 
hypothermia   (Bernard et al, 2003; Kim et al, 2005; Kim et al, 2007; Fink et al, 2010). 
4.6.3 ‘Dose’ of hypothermia 
The „dose‟ of hypothermia appears to be an important element in the potential efficacy of 
therapeutic hypothermia. The wide variation reported by PIC consultants in duration and 
depth of cooling and also rate of rewarming reflects the lack of clear evidence. Very few 
centres reported following a unit protocol which would assist in unifying centre practice. 
Uncertainty may also be present after the reporting of a trend towards increased harm in an 
RCT using  therapeutic hypothermia after paediatric traumatic brain injury (Hutchison et al, 
2008). 
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85% (55/65) of PIC consultants stated they select duration of cooling between 24 to 48 
hours although durations outside this range are also considered. The two adult therapeutic 
hypothermia RCTs used 12 or 24 hours duration (Bernard et al, 2002; HACA, 2002) whilst 
the neonatal studies of hypoxic ischaemic encephalopathy have used 72 hours duration 
(Gluckman et al, 2005; Shankaran et al, 2005; Eicher et al, 2005; Azzopardi et al, 2009).  
Survey one demonstrates a stated duration of treatment falling between the two sets of 
published data. Without specific safety data in children the potential risks of longer duration 
of cooling are not known. 
4.6.4 Clinical equipoise, trial support and deferred consent 
73% (82/113) of PIC consultants and 52% (24/46) of emergency medicine consultants 
agreed that there is clinical equipoise regarding the use of TH after paediatric cardiac arrest, 
although another 41% (19/46) of emergency medicine consultants were „neutral‟. The 
presence of clinical equipoise remains a fundamental pre-requisite to undertaking a 
randomised controlled trial (Freedman, 1987). There is strong support among emergency 
medicine consultants (85%; 40/47), although less (47%; 53/113) amongst PIC consultants 
for a comparative trial of TH versus normothermia in paediatric patients post cardiac arrest.   
The recently commenced Therapeutic Hypothermia After Paediatric Cardiac Arrest 
(THAPCA) trials (NCT00878644; NCT00880087) in North America and Canada will 
hopefully start to answer the question of safety and efficacy of this treatment in children. 
There is agreement (83%; 92/112) that the results of these trials are likely to inform clinical 
practice in the UK, but the support for a study also to be undertaken in the UK perhaps 
reflects that a number of trials showing an effect are required to change clinician‟s 
behaviour.  
The use of deferred consent is a new area in paediatric resuscitation research in the UK. 
Recent changes in April 2008 to the Medicines for Human Use (Clinical Trials) Regulations, 
UK  2004 have allowed the use of deferred consent (with Ethics Committee approval) to be 
applied to emergency resuscitation research (Department of Health, 2008). In these surveys 
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88% (99/113) of PIC and 74% (34/46) emergency medicine consultants supported the use of 
deferred consent.  The use of deferred consent in a clinical trial may enable earlier 
instigation of therapy within the narrow therapeutic window and therefore maximise the 
potential beneficial effects.   
4.6.5 Strengths and limitations of surveys 
One of the strengths of these surveys is the high response rates of 76% (113/149) and 62% 
(48/77). A targeted approach, in survey one, to a defined population of UK PIC consultants 
with direct clinical involvement and decision making regarding patient care enable a degree 
of confidence that these findings reflect the current UK PIC community practice. However, 
not all UK emergency medicine consultants were surveyed in survey two, potentially missing 
some of those who manage paediatric cardiac arrest patients. As with all surveys however, 
the findings only represent self-reported behaviour and do not necessarily equate to actual 
clinical behaviour.  The findings give additional support for the need and willingness to 
undertake further investigative research into the use of therapeutic hypothermia after 
paediatric cardiac arrest. 
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4.7 CONCLUSION 
These surveys of practice and opinions found that very few UK emergency medicine 
consultants initiate therapeutic hypothermia in their Emergency Departments and only 50% 
of paediatric intensive care consultants currently use TH use after paediatric cardiac arrest. 
Regional paediatric intensive care units and consultants play significant roles in influencing 
the management of paediatric cardiac arrest patients in the Emergency Department. With 
their support, Emergency Department consultants would consider using therapeutic 
hypothermia. Although simple methods of cooling patients are already available in most 
Emergency Departments, their use is limited owing to clinician concerns regarding safety, 
lack of protocols, and lack of evidence of improved outcomes. 
There is support among UK paediatric intensive care and emergency medicine consultants 
for further research into the safety and efficacy of therapeutic hypothermia. This research 
would require involvement of emergency medicine consultants and their departments in 
order to be able to initiate therapeutic hypothermia early. These surveys support the 
proposal that the feasibility of the Cold-PACK (Post Arrest Cooling In Kids) Study of 
therapeutic hypothermia versus normothermia commenced in the Emergency Department 
after paediatric cardiac arrest should be assessed further. 
 
Table 4-9 Chapter 4 and RCT feasibility 
What have we learnt from this study towards the feasibility of a UK randomised 
controlled trial? 
In the UK approximately half of paediatric intensive care consultants use therapeutic 
hypothermia after paediatric cardiac arrest 
It is infrequently used in the emergency department and only after advice from a 
paediatric intensivist 
There is widespread variation in the dose and duration of therapeutic hypothermia used  
Clinical equipoise exists and there is currently support for a UK multicentre trial  
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5 Cardiac arrest requiring 
intensive care admission: A 
United Kingdom epidemiology 
study. 
 
  
"The essence of knowledge is, having it, to apply it;  
not having it, to confess your ignorance."  
 
Confucius (Chinese teacher and social philosopher: 551–479 BC) 
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5.1 ABSTRACT 
5.1.1 Introduction 
The incidence rate of paediatric cardiac arrest admissions to PICU in the UK is not known 
and extrapolation of international data to the UK population may not be appropriate when 
planning a UK post cardiac arrest intervention trial. Different patient characteristics and 
outcome after in-hospital cardiac arrest (IHCA) and out-of-hospital cardiac arrest (OHCA) 
may also preclude combining the populations in a unified trial. An understanding of the UK 
paediatric cardiac arrest population admitted to PICU is therefore essential. 
5.1.2 Aims 
To compare the epidemiology of children (0-18yrs) admitted to UK paediatric intensive care 
units (PICUs) after IHCA and OHCA in order to evaluate PICU admission characteristics and 
patient populations critical to the design of a post cardiac arrest intervention trial. 
5.1.3 Methods 
Extraction and analysis of IHCA and OHCA admissions from the prospectively collected 
national PICANet Database containing information on admissions to 30 PICUs in the UK and 
Eire between January 2003 and June 2010. 
5.1.4 Results 
1703 children were admitted to PICU following cardiac arrest (51% IHCA, 49% OHCA). 
Median age of IHCA was significantly lower (0.6 (IQR [0.2-3.0] vs. 1.1 (IQR [0.2-7.8]) years). 
Pre-existing chronic conditions were more common in IHCA (79%) than OHCA patients 
(48%). 74% of OHCA were admitted from other hospitals requiring inter-hospital 
transportation to PICU compared to 41% of IHCA.  Pupils were fixed and dilated in 24% of 
OHCA versus only 5% of IHCA admissions (p<0.001) and associated with a 96% and 84% 
PICU mortality respectively. PICU survival was significantly higher for IHCA patients (76% 
versus 50%; p<0.01). OHCA admission to PICU population incidence rate was 1.3 per 
100,000 children (0 to 15 years) per year (patients <1 year of age incidence rate = 8.9). 
IHCA and OHCA each accounted for 0.8% (IQR [0.6–1.0]) of all PICU admissions. A UK 
Chapter 5  
114 
 
interventional trial of IHCA would require 482 patients and take 3.7 years, and an OHCA 
would require 776 patients and take 6.9 years if powered to show a 10% absolute 
improvement in survival (IHCA [76% to 86%] and OHCA [50% to 60%]). 
5.1.5 Conclusions 
Survival rates to PICU discharge after IHCA and OHCA appear higher than previously 
reported. Differences between IHCA and OHCA population demographics, aetiology of 
arrest and survival rates would preclude combining both groups in a single cardiac arrest 
study.  The UK population incidence rates suggest that international collaboration will be 
required for a post cardiac arrest intervention trial to be delivered in a reasonable timescale.  
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5.2 INTRODUCTION 
A fundamental requirement before undertaking research in children after cardiac arrest is to 
fully understand the population. The answers to three important questions are essential. 
First, how large is the potential population affected by cardiac arrest in the UK and therefore 
available for inclusion in a trial, secondly, can we combine patients after both in-hospital 
cardiac arrest (IHCA) and out-of-hospital cardiac arrest (OHCA) in the same trial, and thirdly 
what are the current outcome rates after cardiac arrest in contemporary UK practice? 
Without answering these questions an interventional trial risks failing to recruit enough 
patients, being underpowered to detect a treatment effect or including a heterogeneous 
population where the treatment effect differs significantly across subjects, culminating in a 
waste of resources (time and money) and importantly exposing critically ill children to 
unnecessary risks in a trial which fails to answer its primary objective.  
There are currently no UK paediatric cardiac arrest incidence or outcome data available to 
answer these questions. Extrapolating OHCA incidence rates from other national population 
studies may be inappropriate. Published incidence rates of OHCA alone range from 5 to 20 
per 100,000 person-years across different populations with rates of return of spontaneous 
circulation (ROSC) ranging from 5-47% (Donoghue et al, 2005; Deasy et al, 2010; 
Dieckmann & Vardis, 1995; Lopez-Herce et al, 2005; Nitta et al, 2011). Using these wide 
ranges, the number of patients in the UK admitted to PICU after OHCA would be estimated 
at between 50 and 1000 children per year and therefore completely unhelpful for confidently 
planning a clinical trial. 
It is anticipated that the number of patients in the UK surviving to PICU admission after IHCA 
and OHCA will be relatively small. Combining the two populations would therefore be an 
attractive option; however, if this creates a heterogeneous population further problems are 
created. Critical care randomised controlled trials in adults have repeatedly failed to deliver 
evidence of beneficial treatments owing to use of heterogeneous populations, lack of 
biological plausibility, over estimating potential treatment effects based on observational 
study evidence and importantly under-powering of studies through failing to recruit to target 
(McAuley et al, 2010).Therefore, the assessment of the differences between IHCA and 
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OHCA including the survival rates is a high priority to avoid creating too great a 
heterogeneous population. In addition, an accurate estimation of the patient population to 
assess trial feasibility, prior to costly investment, is required. 
This study therefore aims to answer the three fundamental questions outlined above using 
data collected through the Paediatric Intensive Care Audit Network (PICANet). This is a 
national data collection programme of all Paediatric Intensive Care Unit (PICU) admissions 
in the UK and Eire. Analysis of the cardiac arrest population in this database will allow an 
assessment of incidence, patient population size, key patient characteristics and outcome to 
hopefully inform future trial development. 
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5.3 AIMS 
5.3.1 Primary Aim 
1. To identify a population of children (0 to 17yrs) admitted to UK paediatric intensive 
care units (PICUs) after in-hospital (IHCA) and out-of-hospital cardiac arrest 
(OHCA).  
5.3.2 Secondary Aim 
1. To ascertain PICU survival rates and associated factors after IHCA and OHCA. 
2. Calculate the incidence of IHCA and OHCA admissions to PICU in the UK. 
3. Estimate the size of the cardiac arrest population available for inclusion in a post 
cardiac arrest intervention trial.   
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5.4 METHODOLOGY 
5.4.1 Design 
A standardised dataset consisting of casemix and PICU outcomes of all patients admitted to 
all 30 PICUs from the United Kingdom and Eire has been prospectively collected since 2002 
by the Paediatric Intensive Care Audit Network (PICANet, 2010). Training on data definition 
and data collection has been performed by the PICANet team with local and central quality, 
validation, illogicality and completeness checks on data (PICANet, 2010). 
5.4.2 Settings and participants 
In October 2010, we retrospectively searched the PICANet database from Jan 2003-June 
2010 for all patients admitted to PICU after cardiac arrest. Inclusion and exclusion criteria 
are listed below. 
Inclusion criteria 
1. Aged 0 to 17 years and 
2. Admitted to PICU after either IHCA or OHCA and 
3. Patients requiring intubation and ventilation on admission 
Exclusion criteria 
1. Cardiac arrest occurring after admission to PICU 
Cardiac arrest was defined a priori by PICANet as either documented absent pulse or the 
requirement for external cardiac compression (PICANet, 2007). This PICANet definition did 
not specify a length of CPR, therefore, to exclude very minor, short cardiac arrests (e.g. brief 
episode of bradycardia) and patients likely to still be comatose, the additional requirement of 
intubation and ventilation at time of PICU was added. Accurate data on cardiac arrest 
occurring on PICU were only recorded through the Paediatric Critical Care Minimum Data 
Set (PCCMDS) (an addition to the main PICANet dataset) which commenced in June 2008. 
Owing to a low number of PICUs submitting PCCMDS data it was not possible to ascertain 
accurate in-PICU cardiac arrest events; therefore this group was excluded from analysis. 
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Readmissions to PICU were analysed as separate admissions because each admission 
represented a separate opportunity for a PICU outcome. 
5.4.3 Data collection and search criteria 
Search criteria and codes to identify eligible patients are listed in Table 5-1. The PICANet 
data collection form had a place to record either IHCA or OHCA as a high risk diagnosis in 
the patient‟s medical history when clinicians scored the Paediatric Index of Mortality 2 score 
(PIM2 score) on admission to PICU (PICANet, 2006; Slater et al, 2003). An OHCA was 
referred to as „preceding hospital CPR‟ in the PICANet coding and an IHCA as „preceding 
CPR‟. A group of patients after June 2008 had additional PCCMDS data collected daily 
during their PICU admission, indicating if CPR occurred on day one of admission or after 
day one implying that the cardiac arrest occurred whilst on the PICU. In addition, at 
discharge, all patients had final diagnostic codes entered into the database. This  allowed 
entry of a text descriptions of cardiac arrest diagnosis combined with NHS Read Codes (a 
coded thesaurus of clinical terms) (Bentley et al, 1996). Examples of text diagnosis include: 
„arrested whilst drowning‟ indicating an OHCA, „arrested in theatre‟ indicating an IHCA and 
„arrested during intubation on PICU‟ indicating an in-PICU arrest (IPICA). Ideally, all patients 
would be reliably allocated to IHCA and OHCA using only the admission PIM2 coding. 
However, in some PICUs both „preceding hospital CPR‟ and „preceding CPR‟ were selected 
for OHCA patients and frequently, the coding of IHCA and OHCA arrest location in PIM2 
was missing in the dataset. Therefore, owing to the inconsistent primary coding of location of 
arrest, an allocation matrix was created using a combination of all the coding criteria in the 
PICANet dataset referring to cardiac arrest in order to code patients into four categories; 1) 
IHCA, 2) OHCA 3) In PICU (after PIC admission) arrest and 4) other (unclassifiable). The 
Allocation Matrix is displayed in Table 5-2. The matrix consisted of a combination of the 
PIM2 codes from admission, additional PCCMDS codes during admission and final 
diagnostic text codes. Thereby including: preceding hospital CPR, preceding CPR, CPR on 
day one of PICU admission, CPR after day one of PIC admission, text diagnosis with OHCA 
description, IHCA description, and IPICA and source of admission (e.g. emergency 
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department for OHCA but not IHCA). Patients with incomplete information, where location of 
arrest could not be ascertained were categorised „other‟ and therefore excluded.  
5.4.4 Casemix, resource use and outcome 
In addition to the variable used to allocate cardiac arrest location, additional casemix 
variables collected were; admitting PICU, year of admission, age, sex, source of admission 
(e.g. ward or emergency department), primary and secondary diagnoses, probability of 
death  (estimated from PIM 2 score) and  transfer status to PICU (e.g. admitted from own 
hospital emergency department or secondary hospital). PIM2 is a prediction of mortality 
score calculated within one hour of contact with the paediatric intensive care team (either on 
PICU or a specialist critical care transport) (Slater et al, 2003). Age was subdivided using 
two grouping classifications. Firstly, Utstein derived age strata (0 to 30 days, 31 days up to 1 
year, 1 year up to 4 years, 4 years up to 12 years and 12 years up to 18 years) (Zaritsky et 
al, 1995) for comparison with other published cardiac arrest databases and Office of 
National Statistics (ONS, 2010) age strata (1 day up to 1 year, 1 year up to 4 years, 4 years 
up to 10 years, 10 years up to 15 years and 15 years up to 18 years) for incidence rate 
calculations.  
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Table 5-1 Search codes for cardiac arrest patients 
Domain Cardiac arrest description 
PIM2 medical history Preceding hospital cardiac arrest  
PIM2 medical history Preceding CPR episode  
Text diagnostic codes Cardiac arrest, cardiopulmonary arrest, cardiorespiratory arrest & 
ventricular fibrillation (or VF), ventricular tachycardia (or VT), asystole, 
pulseless electrical activity (or PEA) 
NHS Read codes G5740 Cardiac arrest - ventricular fibrillation 
L09y1 Cardiac arrest following abortive pregnancy 
SP110 Cardiac arrest as a complication of care 
X202m Cardiopulmonary arrest 
X202n Cardiac arrest with successful resuscitation 
X208V Cardiac arrest with electromechanical dissociation 
X77CB Cardiac arrest - asystole 
X90DE Circulatory arrest 
XE0V5 Cardiac arrest 
XaC2L Cardiac arrest, unspecified 
Xa08p Infant showing no response to resuscitation 
Xa8S8 CPR - Cardiopulmonary resuscitation 
PIM2 denotes: paediatric index of mortality 2 score 
 
Table 5-2 Allocation matrix 
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+ +/- +/-      OHCA 
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 - - +/-  +    OHCA 
- + +      IHCA 
- + -     - IHCA 
- + n/a n/a -  -  IHCA 
- - +/-  - + -  IHCA 
- - + +     IPICA 
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- -     +  IPICA 
- + - + - - - + Other 
- + n/a n/a - - - + Other 
- - - - - - - +/- Other 
Plus sign = present, minus sign = absent, n/a = not applicable 
CPR: cardiopulmonary resuscitation, PCCMDS (paediatric critical care minimum dataset), 
IPICA: in-PICU arrest, ED: emergency department 
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Data on resources used on PICU were collected which included renal replacement therapy 
(including haemofiltration, haemodialysis and peritoneal dialysis), vasoactive drug use, 
intracranial pressure monitoring and extracorporeal life support (ECLS). Primary outcome 
was survival to PICU discharge. Survival data after this point (e.g. hospital survival) was not 
accurately collected in the PICANet dataset. Length of ventilation and stay on PICU was 
recorded. These were both calculated in days, where ventilation or stay on PICU for any part 
of the period from midnight to midnight counted as one day (PICANet definition) (PICANet, 
2007). 
5.4.5 Chronic condition coding 
Chronic condition diagnostic groups were decided a priori: respiratory, neurological, cardiac, 
liver, haematology, oncology, metabolic and endocrine, gastrointestinal, renal, genetic, 
immunodeficiency and other.   All diagnostic text codes contained in the database were 
listed and duplicates removed. Each diagnostic code and free text diagnostic description 
was allocated to a chronic condition group and subgroup (Appendix 9.9, p330). Individual 
patients could be allocated into multiple coding groups (e.g. neurological, genetic and 
cardiac condition). 
5.4.6 Cause of arrest coding 
A separate coding system was used for cause of arrest. Admissions were allocated to only 
one cause of arrest: respiratory, sepsis, neurological (non-trauma), primary cardiac, trauma, 
airway obstruction, hanging (or strangulation), burns, toxin ingestion, near-drowning or 
unknown or not clearly defined.  This was performed by individually allocating each patient 
based on final discharge diagnosis information. If the diagnosis may have referred to an 
event after PIC admission then cause of arrest was recorded as „not known‟.  
5.4.7 Denominator population 
Individual PICU admission numbers were extracted from the main PICANet dataset to 
calculate unit-specific admission rates for IHCA and OHCA patients. Age specific population 
counts were extracted from the mid-2008 population estimates for Great Britain (Office of 
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National Statistics) (ONS, 2010). This allowed calculation of age-specific incidence rates for 
OHCA admission to PICU. It was not possible to calculate IHCA admission to PICU 
incidence rates. Ideally total in-patient numbers per year for all hospitals referring to each 
individual PICU would be required. However, owing to cross over of secondary hospital to 
PICU referrals (i.e. patients from a secondary hospital could be sent to more than one PICU) 
and significant inconsistencies in the data in the Hospital Episode Statistics database (HES, 
2012), this was not calculated.  
5.4.8 Population size calculations 
To estimate the population size available for inclusion into a randomised controlled post 
cardiac arrest intervention trial, individual PICU-specific patient numbers were extracted for 
IHCA and OHCA admissions between 2007 and 2009. We anticipate the need for additional 
exclusion criteria in a randomised control trial. Therefore, the following patients were 
excluded from the dataset for sample size estimation: patients admitted after traumatic brain 
injury, patients with severe developmental delay (coded on PIM2 high risk medical history), 
patients aged 16 years and older and finally, those dying within six hours of PICU admission.  
Patients with traumatic brain injury were excluded because of the current evidence of 
therapeutic hypothermia causing harm in the population (Hutchison et al, 2008). Patients 
with severe developmental delay may already have limitation of intensive care support plans 
on admission and have very poor baseline level of neurological function, and patients aged 
16 and over are often admitted into adult ICUs, although regional variation across the UK 
exists. Excluding patients dying within six hours will exclude patients at the very severe end 
of the spectrum who would be very unlikely to benefit from post cardiac therapeutic 
hypothermia therapy.  
5.4.9 Statistical analysis 
Data were tested for normality by using the Shapiro-Wilk‟s W test. Descriptive data were 
reported as median and interquartile range (IQR) or mean ± standard deviation (95% 
confidence interval of the mean) for continuous variables and as number and percentages 
for categorical variables. Casemix, cause of arrest, resource use and outcomes were 
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compared between IHCA and OHCA patient groups. Parametric continuous data were 
analysed using the unpaired Student t-test and non-parametric continuous data with the 
Mann Whitney U test or Kruskal-Wallis as appropriate.  Length of ventilation and length of 
stay were log-transformed prior to analysis. Categorical data were analysed using the Chi
2
 
or Fisher‟s exact tests as appropriate. Linear by linear association (SPSS) was used for age 
related ordinal categorical data. 
A multivariate logistic regression analysis was used to identify variables that were 
independently associated with survival. Normality and linearity of continuous variables was 
assessed. Initially, associations with outcome were identified by univariate logistic 
regression analysis. Then all variables with p <0.1 for survival were included in a multivariate 
logistic regression analysis model. Forward stepwise selection was applied to this group of 
potential predictors to obtain the final model. The criteria for variable selection were a 
significance level (p value based on likelihood ratio test) to enter of 0.05 and a significance 
level to stay of 0.10. Hosmer Lemeshow goodness of fit and area under the receiver 
operator characteristic (ROC) curve were calculated to assess model fit (Hanley & McNeil, 
1982; Hosmer et al, 1997).  
5.4.10 Statistical analysis: sample size calculation 
Incidence rate of OHCA admission to PICU was calculated using Wilcoxon Signed Rank test 
to calculate the median (95% confidence interval (CI)) rate on data from a subset of patients 
admitted between 2007 and 2009. Denominator data was extracted from the Office of 
National Statistics mid-2008 population estimates (as detailed above) (ONS, 2010). 
Future trial sample size calculations were performed on unadjusted mortality rates and 
individual PICU patient population admission rates. They were estimated over a range of 
treatment effects (7% - 20%) with increasing numbers of PICUs, using two-sided 
significance (α) level of 0.05 and power (1-β) of 80%.  
A two sided p value of <0.05 was considered statistically significant throughout. Data 
analysis was performed using either IBM-SPSS Statistics version 19.0 software (SPSS Inc, 
Chicago, USA) or Minitab 16 (USA). 
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5.4.11 Ethics 
PICANet has ethical approval granted by the Trent Medical Research Ethics Committee (ref 
05/MRE04/17) and national information governance board approval by the Patient 
Information Advisory Group http://www.dh.gov.uk/ab/index.htm to collect personally 
identifiable data without consent. The original search for this study (described above) of the 
main PICANet dataset was performed by Dr Phil McShane (PICANet Senior Epidemiologist). 
Patient identifiable data and the name of admitting PICU were then anonymized before 
encrypted transfer to the author for analysis.  
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5.5  RESULTS 
Figure 5-1 shows the study plan. 2924 patients were identified as cardiac arrest cases. After 
exclusion of cases older than 18 years (n=21) or not intubated and ventilated on PIC 
admission (n=91), 2812 remained. These patients were allocated to their source of arrest 
groups using the Allocation Matrix (Table 5-2). 64% (1812/2812) were coded directly as 
IHCA or OHCA preceding PIC admission in the PIM2 dataset, the remaining 36% required 
allocation through text diagnosis or CPR event history. This resulted in 862 IHCA cases, 
representing 0.8% (IQR [0.6 – 1.0%]) of total PICU admissions and 841 OHCA cases, 0.8% 
(IQR [0.7% - 1.0%]) of total PICU admissions during this period. A further 801 only had a 
cardiac arrest whilst on the PICU and were excluded in addition to 308 patients who could 
not be categorised.  
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Figure 5-1 Study flow chart 
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5.5.1 Demographics 
Age of patients admitted after IHCA and OHCA are presented within Utstein and ONS age 
limits (Table 5-3). IHCA patients were significantly younger than OHCA (p<0.01). A 
significant left skew to age was identified for both groups (Figure 5-2). 58% and 49% of 
patients were less than 1 year of age for IHCA and OHCA respectively. An increase in 
proportion of OHCA patients aged 10-15yrs was identified. There was no difference in 
survival with increasing age for OHCA (p=0.582); however IHCA survival showed a statically 
significant survival increase across Utstein (p=0.05) and ONS (p<0.001) age groups (Figure 
5-4).  
Chronic conditions were more common in IHCA patients (79% versus 48%; p<0.001). Of 
which cardiac, neurological and respiratory conditions predominated in both groups. After 
OHCA, patients with no recorded chronic conditions had a higher mortality compared to 
those with one or more chronic condition (60% vs. 40%; p<0.001). Comparison of chronic 
conditions and corresponding PICU mortality rates are displayed in Table 5-4. 
Nearly three quarters (635/841) of patients admitted after OHCA were transported from 
another hospital for PIC admission compared to 41% (381/862) after IHCA. Overall mortality 
risk score (calculated using Paediatric Index of mortality 2) on admission was lower after 
IHCA (25% vs. 38%; p<0.001). Fixed and dilated pupils on admission were recorded in 24% 
(192/841) OHCA and 5% (41/862) IHCA with a very high associated mortality rate (96% and 
84% respectively). 
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Table 5-3 Age casemix for admission comparing IHCA and OHCA 
 IHCA No. died 
(% group) 
OHCA No. died 
(% group) 
Comparison 
of IHCA and 
OHCA  
p
b
  
Overall  n=862 209 (24%) n=841 423 (50%)  
Age (years; median, IQR) 0.6 
(0.2 – 3.0) 
 1.1 
(0.2 – 7.8) 
 
< 0.01 
Age category (Utstein
a
)     <0.001 
0 -30 days 163 (19%) 44 (27%) 119 (14%) 54 (45%)  
31 days to <1 yr 339 (39%) 64 (19%) 295 (35%) 149 (51%)  
1yr to <4yrs 174 (20%) 43 (25%) 162 (19%) 85 (53%)  
4yrs to <12yrs 107 (12%) 32 (30%) 129 (15%) 69 (54%)  
12yrs to <18yrs 79 (12%) 26 (24%) 136 (15%) 66 (49%)  
Age category (ONS)     <0.001 
0  to <1yr 503 (58%) 108 (22%) 415 (49%) 204 (49%)  
1yr to <4yrs 173 (20%) 43 (25%) 161 (19%) 84 (52%)  
4yrs to <10 yrs 86 (10%) 27 (31%) 93 (11%) 47 (51%)  
10yrs to <15 yrs 66 (8%) 16 (24%) 126 (15%) 71 (56%)  
15yrs to <18yrs 34 (4%) 15 (44%) 46 (5%) 17 (37%)  
Male 518 (56%)  505 (58%)  0.678 
a 
Utstein pre-defined age groups (Zaritsky et al, 1995). Results expressed as Median (Inter-
quartile range) or number (percent). 
b 
Chi
2 
test was used for categorical variable and Mann 
Whitney U test for continuous variables to compare IHCA and OHCA groups. 
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Figure 5-2 Comparison of age distribution for IHCA and OHCA patients admitted to 
PICU 
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Figure 5-3 Comparison of Utstein defined age groups for IHCA and OHCA patients 
admitted to PICU 
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Figure 5-4 Survival comparison for IHCA and OHCA across Utstein age groups 
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Table 5-4 Chronic condition casemix for admission after IHCA and OHCA 
 IHCA 
N=862 
No. died  
(%condition) 
OHCA 
N=841 
No. died 
(%condition) 
P
a
  
No Chronic condition 185 (21%) 49 (27%) 440 (52%) 263 (60%) <0.001 
Any chronic condition 677 (79%) 160 (31%) 401 (48%) 160 (40%) <0.001 
Cardiac 318 (37%) 72 (23%) 160 (19%) 48 (30%)  
Neurological 151 (18%) 39 (26%) 122 (14%) 61 (50%)  
Respiratory 213 (25%) 32 (15%) 108 (13%) 28 (26%)  
Prematurity 72 (8%) 11 (15%) 54 (6%) 23 (43%)  
Genetic 70 (8%) 16 (23%) 28 (3%) 14 (50%)  
Metabolic 58 (7%) 19 (33%) 39 (5%) 18 (46%)  
Gastroenterological 51 (6%) 12 (24%) 17 (2%) 6 (35%)  
Renal 30 (4%) 7 (23%) 15 (2%) 5 (33%)  
Oncology 35 (4%) 13 (37%) 6 (1%) 2 (33%)  
Liver 25 (3%) 7 (28%) 7 (1%) 2 (29%)  
Immunological 14 (2%) 3 (21%) 3 (0.4%) 1 (33%)  
Haematological 10 (1%) 6 (60%) 6 (1%) 1 (17%)  
Other 71 (8%) 16 (23%) 55 (7%) 24 (44%)  
Results expressed or number (percent). 
a 
Chi
2 
test or Fishers exact test was used for categorical variable and Mann Whitney U test 
for continuous variables to compare IHCA and OHCA groups. 
 
 
Table 5-5 Additional demographic details on admission IHCA and OHCA 
 IHCA 
N=862 
No. died 
(%group) 
OHCA 
N=841 
No. died  
(%group) 
p
a
  
Transported from 
different admitting 
hospital n (%) 
381 (41.4) 103 (28%) 635 (72.9) 321 (52%) <0.001 
Mortality Risk (PIM2) 
(Med: IQR) 
25% (13-46) n/a 38% (21-73) n/a <0.001 
Two unresponsive pupils 
n (%)
b
 
41 (5.0%) 36% (84%) 192 (23.6%) 183 (96%) <0.001 
Results expressed or number (percent) or median (interquartile range). 
a 
Chi
2 
test was used 
for categorical variable and Mann Whitney U test for continuous variables between IHCA 
and OHCA groups. 
 b
Pupil reaction missing in 49 IHCA, 28 OHCA cases 
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5.5.2 Cause of arrest 
Cause of arrest was not known or not ascertainable in 63% (544/862) IHCA cases and 48% 
(406/841) OHCA cases. Trauma related causes predominated in OHCA group including; 
hanging or strangulation, near drowning and trauma (including traumatic brain injury and 
other traumatic injury). Sepsis and respiratory aetiology were more common in IHCA cases. 
Airway obstruction as a cause of arrest was similar for IHCA and OHCA; however the 
mortality rates were significantly higher after OHCA (47% vs. 0%; p = 0.001)  
The relationship between increased mortality in OHCA patients with no chronic conditions is 
explored in Figure 5-5. Patients with no recorded chronic conditions predominately arrested 
secondary to high risk aetiologies; burns, hanging and near-drowning. 
Amongst the cause of arrest for OHCA, age related trends were observed (Table 5-7). 
Younger patients were more likely to have an unknown or sepsis cause for cardiac arrest. 
Hanging or strangulation, toxic ingestion and a presumed cardiac cause predominated in the 
12 to 18 year stratum, whilst near-drowning was commonest in the one to four year old age 
stratum. 
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Table 5-6 Aetiology of arrest 
Cause of arrest IHCA 
N=862 
No. died  
(% 
aetiology) 
OHCA 
N=841 
No. died  
(% 
aetiology) 
p
a
 
Not Known 544 (63%) 133 (24%) 406 (48%) 203 (50%) <0.01 
Respiratory 123 (14%) 24 (20%) 100 (12%) 30 (30%) 0.146 
Sepsis 108 (13%) 31 (29%) 44 (5%) 25 (57%) <0.001 
Neurological 
(non-trauma) 
28 (3%) 10 (36%) 58 (7%) 46 (79%) 0.001 
Cardiac 16 (2%) 1 (6%) 34 (4%) 8 (24%) 0.008 
Trauma
b
 21 (2%) 7 (33%) 69 (8%) 46 (67%) <0.001 
Airway 
obstruction 
19 (2%) 0 21 (2%) 9 (47%) 0.809 
Hanging or 
strangulation 
0 (0) 0 28 (3%) 19 (68%) <0.001 
Burns 3 (<1%) 0 5 (<1%) 3 (60%) 0.457 
Toxin Ingestion 0 (0) 0 15 (2%) 8 (53%) <0.001 
Near-Drowning 0 (0) 0 61 (7%) 28 (46%) <0.001 
Results expressed or number (percent). 
a
Chi
2 
test or Fishers exact test was used for 
categorical variables comparing IHCA and OHCA groups. 
b
Trauma including traumatic brain 
injury and other injuries 
  
Chapter 5  
135 
 
Figure 5-5 Chart of association between acute aetiology of OHCA and presence of 
chronic condition 
 
 
 
Table 5-7 Aetiology of OHCA by patient age group (Utstein) 
Cause of arrest 1-30 days
a
 31 days to 
<1 yr 
1yr to 
<4yrs 
4yrs to 
<12yrs 
12yrs to 
<18yrs 
p
b
 
No of patients n =119 n = 295 n = 162 n = 129 n = 136  
Not Known 74 (62) 176 (60) 55 (34) 62 (48) 41 (30) <0.001 
Respiratory 15 (13) 38 (13) 13 (8) 17(13) 17 (13) 0.915 
Sepsis 17 (14) 13 (4) 7 (4) 4 (3) 3 (2) <0.001 
Neurological 
(non-trauma) 
7 (12) 26 (9) 8 (5) 12 (9) 5 (4) 0.352 
Cardiac 0 (0) 6 (2) 5 (3) 6 (5) 17 (13) <0.001 
Trauma
c
 3 (3) 25 (9) 15 (9) 14 (11) 12 (9) 0.38 
Airway 
obstruction 
1 (5) 6 (2) 8 (5) 2 (2) 2 (2) 0.861 
Hanging or 
strangulation 
0 (0) 0 (0) 4 (3) 8 (6) 16 (12) <0.001 
Burns 0 (0) 1 (<1) 1 (<1) 2 (2) 1 (<1) 0.192 
Toxin Ingestion 0 (0) 1 (<1) 4 (3) 0 (0) 10 (7) <0.001 
Near-Drowning 1 (1) 8 (3) 42 (26) 4 (4) 5 (4) 0.013 
a
Utstein pre-defined age groups (Zaritsky et al, 1995). 
b
Chi
2 
test – linear by linear trend 
association across age groups. 
c
Trauma including traumatic brain injury and other injuries 
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5.5.3 Interventions on PICU and outcome 
Vasoactive drugs were used in 60% of both IHCA and OHCA patients, although renal 
replacement therapy, intracranial pressure (ICP) monitoring and extracorporeal life support 
(ECLS) were infrequently performed on post cardiac arrest patients in both groups (only 2-
10% of cases) (Table 5-8). There was significantly more renal support preformed in the 
IHCA group (10% vs. 3%; p<0.001) whereas ICP monitoring and ECLS use was similar.  
The overall length of mechanical ventilation and stay in PICU was significantly shorter after 
OHCA than IHCA; however, survivors and non-survivors, when compared between IHCA 
and OHCA groups had similar length of ventilation and PIC stay. The overall difference in 
length of mechanical ventilation and stay in PIC between IHCA and OHCA is therefore 
explained by the significantly higher survival after IHCA (76% vs. 50%; p<0.001) (Table 5-9).  
Multivariable logistic regression analysis showed that the odds of mortality after both IHCA 
and OHCA significantly increased with increasing PIM2 score, the use of vasoactive drugs 
and presenting with two fixed and dilated pupils. In addition, odds of mortality after OHCA 
was increased in patients admitted from a secondary hospital, with a preceding chronic 
genetic condition or an acute neurological aetiology for arrest, and odds of mortality was 
decreased in patients with a preceding chronic respiratory or chronic cardiac condition. This 
differed from IHCA where a chronic neurological or haematological preceding condition or 
requirement for renal replacement therapy after PIC admission significantly increased the 
odds of mortality. Hosmer Lemeshow goodness-of-fit (0.08 and 0.77) and area under the 
received operating characteristic curve (0.84 and 0.77) for both IHCA and OHCA models 
respectively were satisfactory, indicating a good model fit and prediction performance. 
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Table 5-8 Comparison of Resource use in paediatric intensive care for IHCA and 
OHCA cases 
 IHCA 
N=862 
No. died 
(% group) 
OHCA 
N=841 
No. died 
(% group) 
p
b
  
Renal replacement 
therapy 
88 (10%) 37 (42%) 29 (3%) 9 (32%) <0.001 
ICP Device 20 (2%) 9 (45%) 32 (4%) 20 (63%) 0.06 
Vasoactive drugs 519 (60%) 168 (32%) 505 (60%) 288 (57%) 0.96 
ECLS 38 (5%) 16 (42%) 22 (3%) 9 (41%) 0.05 
Resource use data missing for 24 IHCA and 14 OHCA. Results expressed as number 
(percent), missing values were excluded from calculations. 
ECLS denotes extracorporeal life support, ICP intracranial pressure monitoring 
b 
Chi
2 
test or Fishers exact test was used for categorical variable comparing IHCA and 
OHCA cases. 
 
 
 
Table 5-9 Outcomes 
 IHCA 
N=862 
OHCA 
N=841 
p
a
  
Length of ventilation (LOV) (all) 5 (2-10) 4 (2-7) <0.001 
LOV (survivors) 5 (3-10) 5 (3-9) 0.322 
LOV (non-survivors) 2 (1-6) 2 (1-4) 0.908 
Length of stay (LOS) in PIC (all) 6 (3-12) 4 (2-8) <0.001 
LOS (survivors) 7 (4-13) 7 (4-11) 0.25 
LOS (non-survivors) 2 (1-7) 3 (2-5) 0.687 
Mortality at PICU discharge 209 (24%) 423 (50%) <0.001 
Results expressed as days (median: Interquartile range), or number (percent) 
a 
Chi
2 
test was used for categorical variable and Mann Whitney U test for continuous 
variables. 
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Table 5-10 IHCA: Multivariable regression analysis odds of mortality at PIC discharge 
IHCA  No. of 
admissions 
No of 
deaths  
(% group) 
Adjusted  
odds ratio 
95% CI p value 
PIM2 Probability of death n/a n/a 8.8 3.8-20.8 <0.001 
Two fixed and unreactive 
pupils 
43 36 (84%) 19.17 8.04-45.7 <0.001 
Vasoactive drugs 519 168 (32%) 3.20 1.99-5.13 <0.001 
Renal replacement 
therapy 
88 37 (42%) 1.95 1.16-3.28 0.011 
Chronic neurological 
Condition 
112 39 (26%) 1.9 1.15-3.04 0.012 
Chronic haematological 
Condition 
10 6 (60%) 6.99 1.75-27.94 0.006 
Variables entered into model: Age (continuous variable), sex, PIM2 (probability of death), all 
twelve chronic condition groups, all nine acute cause of arrest groups, transferred from 
secondary hospital, use of ECLS, use of renal replacement therapy, use of vasoactive drugs 
and presence of two fixed and unreactive pupils on PICU admission 
 
71/862 (8.2%) cases were missing. Hosmer Lemeshow test goodness-of-fit = 0.74 
Area under the receiver operating characteristic (ROC) Curve = 0.77 (95%CI: 0.74-0.81) 
 
 
 
Table 5-11 OHCA: Multivariable regression analysis odds of mortality at PIC discharge 
OHCA  No. of 
admissions 
No of 
deaths  
(% group) 
Adjusted  
odds ratio 
95% CI p value 
PIM2 Probability of death all n/a 10.97 4.68-25.74 <0.001 
Two fixed and unreactive 
pupils 
191 183 (96%) 11.63 4.76-28.41 <0.001 
Vasoactive drugs on PIC 505 288 (57%) 1.76 1.21-2.56 0.003 
Acute neurological 
aetiology 
58 46 (79%) 2.73 1.23-6.07 0.014 
Transferred from 
secondary hospital 
621 321 (52%) 1.94 1.23-3.03 0.004 
Chronic respiratory 
condition 
108 28 (26%) 0.37 0.21-0.65 0.001 
Chronic cardiac condition 160 48 (30%) 0.39 0.25-0.62 0.001 
Variables entered into model: Age (continuous variable), sex, PIM2 (probability of death), all 
twelve chronic condition groups, all nine acute cause of arrest groups, transferred from 
secondary hospital, use of ECLS, use of renal replacement therapy, use of vasoactive drugs 
and presence of two fixed and unreactive pupils on PICU admission. 
 
45/841 (5.4%) cases were missing. Hosmer Lemeshow test goodness-of-fit = 0.08 
Area under the receiver operating characteristic (ROC) Curve 0.84 (95%CI: 0.81-0.87) 
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5.5.4 Incidence of children admitted to PICU after cardiac arrest in UK 
Figure 5-6 and Figure 5-7 shows a significant step increase in the number of cardiac arrest 
cases for both IHCA and OHCA coded from the PICANet dataset during the years 2005-6 
and 2007-9 although mortality rates remained constant. Sensitivity analysis showed this was 
not accounted for by the exclusion of the in-PICU arrest patients or the „other‟ non-
classifiable group.  Incidence calculations were therefore performed on the 2007-2009 
cohorts only. The 2010 cohort only included available submitted data up to the 1
st
 June; 
however, the majority of PICUs were at least two months behind on data submission 
explaining the small number of patients. Therefore this year group was also excluded. 
Using national population denominator data from the Office for National Statistics for Great 
Britain (ONS, 2010), incidence rates for OHCA patients admitted to PICU were calculated 
(Table 5-12). Overall (0-15yrs) incidence rate was 1.3 per 100,000 person-years (95% CI: 
1.0-1.5). Infants (<1 year) had an incidence rate 6.8 times higher than older children (8.9 per 
100,000 person-years (95%CI: 6.9-11.3). 
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Figure 5-6  Number of IHCA cases in PICANet database per year 
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2010 data submission was incomplete. Only data submitted by the 1
st
 June was available 
 
Figure 5-7 Number of OHCA cases in PICANet database per year 
 
 
 
Data submission for 2010 year was incomplete. Only submitted data on 1
st
 June was 
available. 
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Table 5-12 Table of Age specific and overall incidence rates of OHCA admitted to 
PICU per 100,000 UK population per year (2007-2009). 
 
Age 
Group 
Population
a
  
(n) 
2007 
b
(rate: 95%CI) 
2008 
(rate: 95%CI) 
2009 
(rate: 95%CI) 
2007-9
c
 
(rate 95%CI) 
<1 year 
762700 9.3 (7.2-11.7) 8.7 (6.7-11.0) 8.8 (6.8-11.2) 8.9 (6.9-11.3) 
1-4 
years 
2818000 0.9 (0.6-1.4) 1.3 (0.9-1.8) 1.1 (0.7-1.6) 1.1 (0.7-1.6) 
5-10 
years 
3971570 0.4 (0.2-0.6) 0.4 (0.3-0.8) 0.5 (0.3-0.8) 0.4 (0.3-0.7) 
11-15 
years 
3583593 0.8 (0.2-0.5) 0.7 (0.2-0.5) 0.5 (0.2-0.4) 0.7 (0.2-0.5) 
0-15 
years 
11135863 1.2 (1.0-1.5) 1.3 (1.1-1.6) 1.2 (1.0-1.5) 1.3 (1.0-1.5) 
 
a
Age group and population data from Office of National Statistics (mid 2008 statistics) (ONS, 
2010).  
b
Rates expressed as admissions per 100,000 population (95% confidence interval) 
c
combined average rate for 2007-2009. 
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5.5.5 Sample size calculation 
Additional exclusion criteria which would be required in a post cardiac arrest interventional 
study (excluding patients >15 years, following traumatic brain injury or with severe 
developmental delay on presentation) were applied to the 2007-2009 cohort (Figure 5-8). 
Figure 5-9 shows the variation of total number of IHCA and OHCA combined admissions to 
UK and Eire individual PICUs in 2007-2009. 
Numbers of admissions per unit were calculated. Table 5-13 shows the potential incremental 
increase in study size population as the number of „recruiting‟ PICUs rises. The top 10 
admitting PICUs admitted 80% of the potentially eligible IHCA and 66% OHCA study 
patients. An addition of 10 further PICUs only increased the proportion of potential patients 
by 15% for an IHCA study but by a further 28% for an OHCA study. 
Finally, using the crude mortality results for IHCA and OHCA patients for the total cohort a 
sample size calculation grid was created (Table 5-14). Maintaining a two-sided significance 
level of 0.05 and power of 80% to detect survival as a primary outcome, trial sample size 
requirements were calculated in order to identify the increased treatment effect size of an 
intervention (e.g. therapeutic hypothermia). Duration of the trial is presented for increasing 
the number of recruiting PICUs in the UK (initially assuming 100% inclusion, randomisation 
and follow up). Therefore, for an OHCA study attempting to assess a 10% absolute increase 
in treatment effect (50 to 60% survival) with 20 recruiting UK PICUs, 776 patients are 
required and would take approximately 6.9 years. However, the same treatment effect size 
assessment (10% absolute increase from 76 to 86%) in IHCA for the same number of 
recruiting units would take 3.7 years. In reality, refused consent, drop-out rate and loss to 
follow-up will further reduce the patient population to approximately 50% expected, therefore 
requiring nearly 14 years to recruit to an OHCA RCT and 7 years for an IHCA RCT. 
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Figure 5-8 Study flow chart for IHCA and OHCA eligible population for sample size 
estimation 
 
 
 
 
 
Exclusion of patients using severe developmental delay (coded as high risk medical 
diagnosis on PIM2 calculation), trauma and traumatic brain injury cardiac arrest aetiology 
and death within six hours of PIC admission. 
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Figure 5-9 Graph of total IHCA and OHCA admissions for individual PICUs (2007-2009) 
 
Individual PICUs ordered by sum total of IHCA and OHCA admission (2007-2009) 
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Table 5-13 Potential sample population for increasing number of PICUs 
No. of 
PICUs
a
 
IHCA  
in 3 years 
IHCA 
per yr 
% total 
IHCA 
OHCA 
In 3 yrs 
OHCA 
per yr 
% total 
OHCA 
8 301 100 73 208 69 58 
10 329 110 80 233 78 66 
15 365 122 89 292 97 82 
20 389 130 95 336 112 94 
30 412 137 100 357 119 100 
a
Ranked PICUs by combined number of IHCA and OHCA admission (2007-2009)  
IHCA and OHCA admissions excluding; patients ≥16 years, traumatic brain injury aetiology, 
patients dying within 6 hours of admission and associated severe developmental delay. 
 
 
Table 5-14 Table of sample size requirement for variable treatment effect size and time 
to recruit 
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10 
PICUs 
20 
PICUs 
30 
PICUs 
OHCA Primary outcome survival  Time to recruit (years) 
50% 
57% 7% 
0.05 0.8 
796 1592  20.4 14.2 13.4 
60% 10% 388 776  9.9 6.9 6.5 
62% 12% 268 536  6.9 4.8 4.5 
65% 15% 170 340  4.4 3.0 2.9 
70% 20% 93 186  2.4 1.7 1.6 
IHCA Primary outcome survival  Time to recruit (years) 
76% 
83% 7% 
0.05 0.8 
521 1042  13.0 8.0 7.6 
86% 10% 241 482  6.0 3.7 3.5 
88% 12% 160 320  4.0 2.5 2.3 
91% 15% 95 190  2.4 1.5 1.4 
92% 20% 47 94  1.2 0.7 0.7 
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5.6 DISCUSSION 
5.6.1 Summary of findings 
This is the largest cohort study of paediatric cardiac arrest patients admitted to PICU in the 
UK. 1.6% of PICU admissions were following cardiac arrest with half of patients aged below 
one year. Survival rates for patients admitted to PICU after cardiac arrest were significantly 
higher for IHCA compared to OHCA (76% vs. 50%; p=0.001) but also significantly higher 
than previous published data. We identified important differences in factors associated with 
survival between these two groups which will be important when considering the planning for 
a post cardiac arrest interventional trial. However, the estimated population sample size, 
available for an intervention study, may be too small for the UK realistically to undertake 
alone. 
5.6.2 Survival rates 
Previously, survival rates for IHCA patients achieving a ROSC have ranged between 40-
50% and after OHCA: 20-40% (Donoghue et al, 2005; Nitta et al, 2011; Young et al, 2004; 
Meaney et al, 2006; Nadkarni et al, 2006; Tibballs & Kinney, 2006); both considerably lower 
ranges than the PICU survival rates found in our current study. The closest comparable 
studies were from the Pediatric Emergency Care Network (PECARN) in the USA (Meert et 
al, 2009; Moler et al, 2011; Moler et al, 2009). These included patients with duration of 
cardiac arrest of at least one minute plus sustained ROSC of at least 20 minutes. The 
reported survival rates were lower: 49% for IHCA and 38% OHCA patients. A number of 
differences identified between studies populations may help explain this, although there are 
also limitations in the current dataset which also require consideration.  First, in the current 
study, two unresponsive pupils were strongly associated with increased mortality after both 
IHCA (Adjusted OR 19.2 (95%CI [8.04-45.7]) and OHCA (Adjusted OR 11.6 (95%CI [4.76-
28.41]). Pupil reaction was also strongly associated with survival after both the IHCA and 
OHCA paediatric PECARN studies although the rates were considerably different. 
Unresponsive pupils were reported in the current study for only 5% of IHCA and 24% of 
OHCA patients, compared with 25% and 68% of patients respectively in the PECARN 
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studies. Unresponsive pupils are often a sign of significant neurological injury, reflecting a 
major hypoxic ischaemic insult in the context of cardiac arrest. Therefore, the severity of 
injury experienced by our cohort of patients may have been less than the PECARN study 
cohort. As the PICANet database is not a cardiac arrest resuscitation database, it does not 
collect other key factors to assist stratifying and comparing cardiac arrest severity (e.g. 
length of cardiac arrest, bystander CPR, epinephrine doses etc). The PICANet definition for 
cardiac arrest was „a documented absent pulse or the requirement for external cardiac 
compression‟, which follows the Utstein cardiac arrest definition „the cessation of cardiac 
mechanical activity, determined by the inability to palpate a central pulse, unresponsiveness, 
and apnoea‟. (Zaritsky et al, 1995). However, it is possible that patients with „minor‟ episodes 
of cardiac arrest were included, despite the a priori inclusion criteria of requiring invasive 
mechanical ventilation and intubation at PIC admission to attempt to only include more 
severe cases.  
One possible explanation for potentially over-estimating survival, was that survival outcome 
in the PICANet database was measured at PICU discharge. This is a relatively short time 
window to assess survival and it is possible that deaths occurred after PICU discharge (for 
example patients being discharged to hospices for palliative care). Another possibility is that 
the original coding may have been incorrect and the diagnosis of cardiac arrest was 
reflecting a past history of arrest and not a current problem, which would lead to a further 
overestimation of cardiac arrest survival. Sensitivity analysis of survival rates, for only the 
64% of patients, where the PIM2 IHCA and OHCA „cardiac arrest preceding PIC admission‟ 
coding boxes were recorded, did not show a difference in survival rate from the total cohort. 
Therefore, the inclusion of patients with the text diagnosis of cardiac arrest does not appear 
to account for the higher observed survival rates.  
5.6.3 Age 
The age distribution of post cardiac arrest patients, with a significant skew to the left, is 
similar to the overall PICU population admission profile (PICANet, 2010) and compares 
similarly to the other published paediatric cardiac arrest studies. Donoghue et al (2005), in a 
systematic review of 41 studies of OHCA, reported 47.5% (1036/2180) of patients in 
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paediatric OHCA studies were less than 1 year old.  Similar to Moler et al (2009), we did not 
find a relationship between age and OHCA survival. This is perhaps due to the inclusion of 
only patients with a sustained ROSC and not all cardiac arrest patients. Previous cohort 
studies of OHCA have included infants failing resuscitation after sudden infant death 
syndrome, which increases the proportion of deaths in infants (Young & Seidel, 1999; Atkins 
et al, 2009).  
 Survival rates for IHCA did vary with age, with the highest survival rates in infants of one 
month to one year of age. Meaney et al (2006), in a large cohort of paediatric cardiac arrest 
occurring in the PICU, also identified the same relationship with infants. In their study, 
survival rates doubled in this age stratum compared to older children. However, this 
relationship has not previously been shown in patients arresting outside of the PICU. 
Differences between USA and UK critical care admission criteria and PICU size may mean 
that a proportion of the patients having an in-hospital arrest in our study would have been 
managed in a critical care environment in the USA. For example, 40% of patients in the 
study by Meaney et al (2006) were not mechanically ventilated and therefore may not have 
been cared for on a PICU in the UK.  
5.6.4 Chronic condition. 
A significant proportion of paediatric patients suffering cardiac arrest have associated co-
morbidities. Through a re-classification of the diagnostic coding in the PICANet database, 
we were able to report 79% of IHCA patients and 48% of OHCA had at least one chronic 
condition (Table 5-4). Moler et al (2009) in a multicentre retrospective study, collected data 
on 353 IHCA and 138 OHCA patients and reported very similar proportions of one or more 
chronic conditions in 88% of IHCA and 49% of OHCA. In their comparative study of 
survivors and non-survivors after IHCA only (Meert et al, 2009), there was an equal 
proportion with chronic conditions; however, the combined group with haematological, 
oncological or immunological chronic conditions had an increased odds of mortality (OR 
2.61 (95%CI [1.27-5.35]). In our study, through multivariate logistic regression, a chronic 
respiratory or chronic cardiac condition was in fact associated with improved survival after 
OHCA. 
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A cautious approach to interpretation of the relevance of having a chronic condition is 
required. Absence of a chronic condition was also associated with a higher mortality; 
however, further analysis showed that this group of patients presented more frequently with 
aetiologies associated with higher mortality rates which is a more likely explanation than 
chronic conditions having a „protective‟ effect on outcome. Also the relationship of the 
chronic condition and the actual cause of arrest were not ascertainable in this dataset.   
5.6.5 Aetiology of cardiac arrest 
When comparing the cause of arrest identified in this study with previous studies, certain 
considerations are required. There is significant variation in the coding strategies used for 
allocating cause of arrest of IHCA and OHCA patients. Large IHCA resuscitation registry 
databases use codes for preceding physiological derangements (e.g. hypotension, 
metabolic disturbance etc), or associations with post surgical complications (Meaney et al, 
2006), whereas OHCA studies tend to allocate on clear diagnostic events (e.g. drowning, 
poisoning, asphyxia etc). Allocation can be made solely on the assessment of immediate 
Emergency Medical Service personnel at the scene without additional hospital data (Atkins 
et al, 2009), or using enhanced data accuracy with national Coroners‟ data (Deasy et al, 
2011a). However, when these two methods are compared they often poorly correlate (Ong 
et al, 2007; Ong et al, 2006). Finally, variation in the upper age limits of studies can also 
skew incidence rates for diagnoses more common in adolescents and young adults. For 
example two OHCA reports by Deasy and colleagues from Melbourne reported incidence of 
hanging in 0 to 15 years old as 5% (9/193) (Deasy et al, 2010), however, in a similar time 
period, reported incidence in 0 to 18 year olds of 8% (53/680) (Deasy et al, 2012). 
Owing to the inherent limitations of the PICANet dataset, allocation of aetiology for both 
groups was difficult, resulting in 62% of IHCA and 48% of OHCA causes being unknown. 
These rates are similar to the unknown diagnosis rate of 67% in the OHCA study by Atkins 
et al (2009); however, other large OHCA reports have reported less than 7% missing or 
unknown cause (Young et al, 2004; Herlitz et al, 2007; Moler et al, 2009; Deasy et al, 2010). 
Allocation of arrest aetiology was easier in older children and where „events‟ were identified, 
such as episodes of trauma, hanging or drowning. This explains the low allocation to IHCA 
Chapter 5  
150 
 
events as medical deterioration descriptions were often not recorded in the PICANet data. 
Even where diagnoses such as „drowning‟ were documented, the potential for other causes 
to have precipitated drowning (e.g. epilepsy, arrhythmias and long-QT syndrome), and were 
not coded, remains possible (Quan & Cummings, 2003; Diekema et al, 1993; Bradley et al, 
1999).  
Acknowledging the limitations of the dataset, there were a number of important findings in 
the OHCA group. Age related differences in arrest secondary to hanging or strangulation, 
cardiac cause, toxin ingestion and near-drowning were noted. Hanging or strangulation 
occurred in 3% (28/841) of cases overall, but was more common in the 12 to 17 year age 
stratum, occurring in 12% (16/136). Although it was not frequently documented whether it 
was deliberate or accidental, it is known that hanging is a common method of attempted 
suicide resulting in death of  adolescents in the UK (Pearson, 2008). Whereas, the four 
identified patients aged one to four years who arrested secondary to hanging are more likely 
to have been accidental. The mortality rate for this cause of death was 68% overall. Deasy 
et al (2012) reported on 53 (8% of 680 patients) cases of hanging related OHCA. ROSC was 
only achieved in 13% (7/53), of which 43% (3/7) died, with only one survivor neurologically 
intact. Our current cohort is the largest study of children achieving ROSC after hanging 
related OHCA and we identified a higher mortality rate than previously reported.  
Mortality rates were marginally lower than the overall average for patients after near-
drowning (46%; 28/61). Near-drowning occurred in 7% (61/841) of cases and was much 
more common in the one to four year age stratum accounting for 26% (42/162) of cases in 
that group. Near-drowning as a proportion of OHCA aetiology has generally been reported 
between 5-12% (Young et al, 2004; Herlitz et al, 2007; Deasy et al, 2010), although Moler et 
al (2009) identified near-drowning as a cause in 31% (43/138) of OHCA cases where ROSC 
for greater than 20 minutes was obtained. Perhaps this reflected a higher ability to 
successfully resuscitate these children compared to other aetiologies (Young et al, 2004) or 
a variation in frequency of near drowning rate  by geography and climate (Peden & McGee, 
2003). However, drowning remains the second commonest cause of unintentional death 
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after road traffic accidents in young children and an essential group of patients in which to 
investigate therapies to reduce neurological injuries (Salomez & Vincent, 2004). 
In summary, this study identified important variations across age strata of the frequency and 
survival rates of cardiac arrest aetiologies after OHCA. Limitations of the dataset prevented 
confident analysis of the IHCA cause of arrest and non-trauma related OHCA causes; 
however, this study identifies the mixed heterogeneous population presenting to PICU after 
both IHCA and OHCA and the inherent impact on crude survival rates. This information 
justifies the separation of IHCA and OHCA populations when assessing interventions on 
outcome. Even within IHCA and OHCA populations there is considerable heterogeneity 
which will require consideration in future trial design and analysis.  
5.6.6 Requirement for transportation 
Transportation from another hospital for PIC admission occurred for 76% of OHCA and 48% 
of IHCA patients.  Risk-adjusted mortality rate (using PIM2) increased for patients admitted 
from another hospital compared with admission to the hospital co-located with the PICU 
after OHCA but not IHCA. This contrasts with a much larger review of the use of specialist 
retrieval teams in the UK also using the PICANet database (Ramnarayan et al, 2010). The 
study identified that risk-adjusted mortality was lower for patients admitted from other 
hospitals versus those from within the same hospital (OR 0.65 95%CI [0.53-0.80]) although 
this included all emergency unplanned admissions and not only post cardiac arrest patients. 
A possible explanation for this observed difference is that following centralisation of 
paediatric critical care services, the majority of PICUs are co-located in specialist children‟s 
hospital (Pearson et al, 2001). The presence of a PICU co-located and specialist, paediatric 
trained, emergency department staff may give an advantage to patients admitted after 
OHCA directly to a large children‟s hospital. Conversely, limited exposure and reduced skills 
in advanced paediatric resuscitation in smaller district general hospitals may lead to 
suboptimal resuscitation of OHCA patients. This important finding warrants further 
evaluation of confounding factors (e.g. casemix) and may indicate an important area in 
which to target paediatric cardiac arrest resuscitation training.  
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5.6.7 PICU intervention 
The use of renal replacement therapy was independently associated with a worse outcome 
after IHCA (OR 1.95 (95%CI [1.16-3.3]) although it was only used in 10% of IHCA and even 
less frequently after OHCA (3%). Renal replacement therapy is used infrequently after 
paediatric cardiac arrest.  Moler et al (2009) also reported only 5% use after IHCA and 0% 
for the OHCA. Its minimal use may reflect the perceived futility of treatment in many post 
cardiac arrest patients, or that renal function in children may be preserved even after 
significant ischaemia reperfusion injury to other vital organs. However, it has been 
suggested that high volume continuous veno-venous haemofiltration (one form of renal 
replacement therapy) may be beneficial in treating the post cardiac arrest syndrome (Nolan 
et al, 2008) or, as an alternative to cardiopulmonary bypass or ECLS, for rewarming after 
extreme hypothermia (Alfonzo et al, 2009). Also, its use after baseline characteristic 
adjustment in conjunction with and without therapeutic hypothermia was found to improve 
six month survival outcome in a study of 88 adult VF cardiac arrest patients (Odds ratio 4.4 
(95%CI [1.1-16.6]) (Laurent et al, 2005). Therefore, although its use in a small proportion of 
patients in this study was associated with worse outcome there may be a future role for renal 
replacement therapy in treating post-cardiac arrest patients and its use in an interventional 
study should be closely monitored and carefully protocolised. 
5.6.8 Length of stay and ventilation 
Length of stay in PICU is shorter after OHCA than IHCA. However, survivors and non-
survivors length of stay and length of invasive ventilation was similar between IHCA and 
OHCA. Meert et al (2009) reported that PIC length of stay was 15 (IQR [6-28]) days for 
survivors versus 6 (IQR [1.0-27]) days for non-survivors. This is twice as long as the length 
of stay reported in the current study (IHCA survivors: 7 (IQR [4-13]) versus non-survivors: 2 
(IQR [1-7] days). Multiple factors may account for this observed difference. The higher 
survival rates in our study may be due to lower illness severity for IHCA patients and length 
of stay may reflect this. However, UK and USA critical care bed numbers and usage also 
differ (Wunsch et al, 2011). Therefore discharge practice variation may be an explanation 
(i.e. earlier discharge to the ward area in the UK). Unfortunately, owing to the lack of data on 
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length of hospital stay in our study we are unable to compare time to hospital discharge. For 
non-survivors, a difference in clinical practice regarding length of time before withdrawal of 
intensive care in patients with devastating injury after cardiac arrest may also be an 
explanation; unfortunately this level of data is also missing. Overall length of stay for OHCA 
patients is similar to the US data (Moler et al, 2009); however, no breakdown of length of 
stay for survivors and non-survivors is given specific to OHCA patients and therefore cannot 
be compared (Moler et al, 2011).  
Length of invasive ventilation is relevant, when considering the impact of a post-cardiac 
arrest interventional study of therapeutic hypothermia, as invasive ventilation will be required 
throughout the process of hypothermia until rewarming. Median length of invasive ventilation 
was two days shorter than PIC length of stay for both IHCA and OHCA patients. Durations of 
24-72 hours of therapeutic hypothermia have been previously used in clinical trials with a 
requirement of an additional 18-24 hours of ventilation during the rewarming phase. The 
impact this may have on our reported length of ventilation for current survivors may be 
minimal, as the median length of stay after IHCA and OHCA is five days. However, for non-
survivors there may be a significant increase. Length of ventilation for non-survivors was 2 
(IQR [1-6]) days after IHCA and 2 (IQR [1-4]) days after OHCA.  A proportion of patients die 
within the first 12-24 hours of PIC admission due to cardiac and respiratory deterioration; 
however, a significant proportion of patients‟ deaths are associated with withdrawal of 
intensive care after neurological assessment. This is a group of patients that therapeutic 
hypothermia may potentially benefit; however, the therapy will prolong length of ventilation 
and time to neurological assessment (as the patient is required to have reached 
normothermia prior to this).  In this study, the use of therapeutic hypothermia following 
cardiac arrest was not recorded although following the survey of practice of PIC consultants 
described in Chapter 4, its use was likely to have been infrequent during 2003-2008.  
However, regardless of current clinical use of therapeutic hypothermia, a randomised 
controlled trial treatment protocol would increase the length of ventilation and resultant PIC 
stay in a proportion of survivors and non-survivors. The health care cost of increased PICU 
care and the emotional effect on families as a result of therapeutic hypothermia is therefore 
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an essential component requiring investigation through health economic and qualitative 
analysis alongside a clinical efficacy study. 
5.6.9 Incidence rates  
We identified an overall incident rate of OHCA with ROSC admitted to PICU of 1.3 (95%CI 
[1.0-1.5]) children per 100,000 person-years in the UK, with a seven fold increase in the 
under one year olds (8.9 (95%CI [6.9-11.3]). Comparison with other studies is difficult as 
previous incidence figures have been published representing the total cardiac arrest 
population including patients failing to achieve ROSC. In the USA, OHCA incidence is 8 per 
100,000 person-years (Atkins et al, 2009) with infants (less than 1 year) having a nine fold 
increase (72 per 100,000 person-years). This is similar to a smaller study from Helsinki 
where the rates of OHCA including all patients were 9.8 per 100,000 person-years (Kuisma 
et al, 1995) and a more recent Japanese OHCA registry study reporting 7.3 per 100,000 
person-years (Nitta et al, 2011). However, a study in Melbourne reported an incidence of 
only 5 per 100,000 person-years for the same age range (Deasy et al, 2010).  
Without knowledge of the UK total incidence rate of cardiac arrest in children, extrapolation 
of the identified rate to the total population is speculatory. If our OHCA rates were similar to 
USA rates then this equates to a 16% ROSC rate to achieve the incidence rate quoted, 
whereas, compared to the Melbourne data, our ROSC rate would be 26%, closer to the rate 
calculated in the meta-analysis of OHCA studies (Donoghue et al, 2005). Similar to Atkins et 
al (2009), we identified a significant increased incidence in the under ones. However, the 
increase identified was smaller (seven versus nine times) and likely to reflect the high 
proportion of infants with sudden infant deaths syndrome who fail to be resuscitated in their 
study and were not included in ours.  
IHCA incidence figures were not calculated owing to difficulty obtaining accurate 
denominator data from the Hospital Episode Statistics database (HES, 2012) and because 
of the exclusion of cardiac arrests occurring within PICU after admission. Accurate 
assessment of IHCA rates have been identified as problems globally, with few paediatric or 
adult published studies (Merchant et al, 2012; Sandroni et al, 2007). The exception is the 
study by Tibballs et al (2006) who reported a rate of IHCA of 1.06 per 1000 hospital 
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admissions from a single centre study. Improved information may be available in the future 
with initiatives such as the National Cardiac Arrest Audit in the UK (ICNARC, 2012). 
However, only the total numbers of cardiac arrest admissions to PICU, rather than 
population rates, are available in the current study to assist trial sample size estimations, 
although the inclusive coverage of the all UK PICUs significantly reduces the risk of estimate 
inaccuracies and bias. 
5.6.10 Sample size calculation 
Sample size calculations for randomised controlled trials are recommended by international 
CONSORT guidelines (ICH, 1999; Moher et al, 2001); ethically important (Altman, 1980)  
although at best an educated guess (Charles et al, 2009; Schulz & Grimes, 2005). They are 
required to identify whether the hypothesis test has a good chance of showing a desired 
difference (if it exists), demonstrating the study has a chance of obtaining conclusive results 
whilst utilising only a reasonable amount of resources (e.g. money and time). Important pre-
requisites are required, including: that the study sample comes from the same or similar 
populations to the pilot study population, the population of interest is not changing over time 
and that a desired difference exists. Regarding these assumptions, the PICANet data are an 
attempt to minimize the difference between pilot and sample study population and the 
cardiac arrest population does not appear to be changing over recent years. However, the 
potential impact of new treatments (e.g. therapeutic hypothermia) has not formally been 
assessed in this study.  The existence of a desired treatment effect is not conclusive. On the 
one hand, adult cardiac arrest studies have demonstrated an absolute reduction in mortality 
with therapeutic hypothermia of 16% (33% to 55%) (HACA, 2002)  and 23% (26% to 49%) 
(Bernard et al, 2002) survival with good neurological outcome. On the other, no 
observational study has yet demonstrated a beneficial (or harmful) effect in children (Fink et 
al, 2010; Doherty et al, 2009). Within the constraints of these assumptions, we undertook a 
sample size estimation calculation using the PICANet data. 
Using the survival event rates for IHCA and OHCA patients, a range of potential treatment 
effect sizes for therapeutic hypothermia with calculated study sample sizes has been 
presented. The length of time to recruit the number of patients has also been calculated 
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using individual unit cardiac arrest admission rates, albeit using the assumption of 100% 
recruitment and follow up. Unfortunately, this final assumption is the most challenging and 
has the highest risk of altering the number of available patients and duration of trial length. 
The two therapeutic hypothermia studies in the USA (NCT00878644; NCT00880087) are 
currently only randomising one in seven patients presenting after both IHCA and OHCA, 
owing to inclusion and exclusion criteria, informed consent procedures and arriving to PICU 
within the six hour time window (Personal communication: F. Moler Chief Investigator 
(March 2011). Included in the sample size population we excluded patients with severe 
developmental delay and cardiac arrest secondary to trauma; however, there are likely to be 
more exclusion criteria in the main study. Information regarding time to admission to PICU 
after cardiac arrest is not available and potential delays making patients ineligible for a study 
are not known. The use of informed consent or the use of deferred consent may also impact 
on recruitment, although the use of deferred consent in paediatric emergency medicine is 
still novel and lessons from the only on-going trial using this consent method are still awaited 
(NCT01029717). However, even with an optimistic ratio of 50% identified patients being 
entered into a study due to refused consent or failure to recruit, the UK would require 
funding for nearly 14 years to recruit to an OHCA study and 7.5 years for an IHCA study 
using 20 PICUs to demonstrate a 10% absolute difference in outcome. 
 A prospective pilot study with appropriate inclusion and exclusion criteria, consent 
processes and treatment protocols is therefore an essential component to minimise the 
variability and assumptions presented here. It would also allow a more accurate estimation 
of the potential treatment effect of therapeutic hypothermia in the paediatric population and 
consider justification for further investment in a definitive and costly phase three clinical trial. 
Even with this information, our estimations would be that the UK is too small to have 
sufficient patients for timely recruitment and therefore international collaboration would need 
to be explored.  
5.6.11 Limitations 
The strength of this study, through the use of the PICANet database, is that complete 
national coverage of patients admitted to all 30 PICUs in UK and Eire is achieved. Robust 
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internal validation checks occurred and data monitoring procedure aimed to limit error and 
potential bias (PICANet, 2010). However, this study does have some inherent weaknesses. 
As previously mentioned, the most important is that PICANet database is not a primary 
cardiac arrest database or registry. Although PICANet uses a modification of the Utstein 
defined definition for cardiac arrest and has clear guidance for coding in the primary dataset 
allocation to either IHCA or OHCA prior to PICU admission, this was missing in 36% of 
cases and led to the inability to allocate 11% (308/2812) to any of the three cardiac arrest 
groups, potentially introducing case-selection bias and resulting in an underestimation of the 
population sizes.  
Survival outcomes were significantly higher than previously reported. Overestimation of both 
IHCA and OHCA rates due to short follow up time, missing data and potentially inclusion of 
patients who were not admitted immediately after a cardiac arrest is possible. Use of these 
elevated survival rates in the sample size calculation will also affect the number of patients 
required to show the same absolute treatment effect; however, even using the previously 
published survival rates by Moler et al (2009), the overall conclusion that both trials would 
take in excess of seven years is not altered.   
We excluded in-PICU arrest from analysis. These patients would be potentially eligible for 
inclusion and therefore increase the numbers in an IHCA study. Future analysis of this 
population may be possible as more UK PICUs submit validated PCCMDS data. 
PICANet does not record Utstein defined resuscitation information such as length of cardiac 
arrest, presenting cardiac rhythm, doses of epinephrine etc (Jacobs et al, 2004; Zaritsky et 
al, 1995). Therefore, the multiple logistic regression models presented in this study lack 
important confounding factors needed for case adjustment. Further in depth evaluation of 
this level of clinical detail is required to develop and validate accurate prediction models for 
these populations and would allow an assessment of the severity of cardiac arrest in 
relationship to outcome. In addition PICANet only collects complete data to PICU discharge. 
Hospital discharge data is collected but often incomplete and neurological outcome data are 
not part of the PICANet dataset. Therefore the outcome data presented here only represents 
a short survival outcome and may overestimate longer term survival. 
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The coding of chronic conditions and causes of cardiac arrest were undertaken 
systematically; however, conditions may have fallen into both an acute and chronic 
diagnosis or occurred after the primary cardiac arrest and rely on accuracy of original data 
entry. These difficulties with identifying diseases in electronic health records has been 
previously recognised and further validation of the findings presented in this study are 
required (Manuel et al, 2010). 
Finally, sample size calculations have been estimated here using the effect of the treatment 
on survival as the primary outcome. This was required as no neurological outcome data was 
collected. All previous therapeutic hypothermia studies in adults after cardiac arrest and 
neonates after hypoxic ischaemic encephalopathy have used the combined outcome of 
death and severe neurological disability. This composite outcome has reported increased 
effect size changes compared to survival alone (Chapter 1, Table 1-5).   A re-evaluation of a 
potential treatment effect size will be required in a future pilot study, collecting both survival 
and neurological outcome data. 
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5.7 CONCLUSION 
This is the largest cohort study of paediatric cardiac arrest patients admitted to PICU in the 
UK. 1.6% of PICU admissions were following cardiac arrest with half of patients aged below 
one year.  Survival rates for patients admitted to PICU after cardiac arrest were significantly 
higher for IHCA compared to OHCA (76% vs. 50%) but also significantly higher than 
previous published data. We identified important differences in factors associated with 
survival and case mix between these two groups, supporting the need for two separate 
trials. However, the estimated population sample size, available for an intervention study, 
may be too small for the UK to realistically undertake alone and so require international 
collaboration. Limitations of this study have been presented including the lack of 
resuscitation specific patient data, neurological outcome data and potential case selection 
bias.  
 
Table 5-15 Chapter 5 and RCT feasibility 
What have we learnt from this study towards the feasibility of a UK randomised 
controlled trial? 
Survival rates in children admitted to PICU after cardiac arrest are significantly higher for 
arrests occurring in-hospital and separation of IHCA and OHCA patients in a trial is 
recommended.  
Two unresponsive pupils, the use of vasoactive drugs, presence of certain chronic 
conditions or transfer from another hospital to PICU are all important factors affecting 
survival after IHCA and OHCA 
Length of ventilation and stay on PICU may be prolonged for patients receiving 
therapeutic hypothermia in the context of an intervention trial with health care cost 
implications. 
Cardiac arrest rates and estimation of required study sample size for an intervention study 
indicates that the UK would not be able to perform the trial without international 
collaboration. 
 
Chapter 5  
160 
 
5.8 ACKNOWLEDGEMENT 
PICANet is funded by the National Clinical Audit and Patient Outcomes Programme through 
Healthcare Quality Improvement Partnership, Health Commission Wales Specialised 
Services, National Health Service (NHS) Lothian and National Service Division NHS 
Scotland, the Royal Belfast Hospital for Sick Children, and the Pan Thames PICU 
Commissioning Consortium. We thank all the staff in participating hospitals who gathered 
data for PICANet. A full list of participating PICUs and steering group and clinical advisory 
group membership is available on the latest PICANet Annual Report. 
http://www.picanet.org.uk/Documents/General/Annual%20Report%202010/2010%20PICAN
et%20Annual%20Report.pdf.  
We thank Dr Philip McShane for extracting the study data from the PICANet database and 
Dr Paul Davies for his statistical advice and guidance. 
5.9 CONTRIBUTORSHIP 
Dr Scholefield designed the current study protocol, created the new database, re-coded and 
cleaned data, performed all statistical analysis and drafted study manuscript. Study design 
and Interpretation of data was performed with supervisory assistance from Drs Morris & 
Duncan, Profs Gao-Smith & Perkins and with external advice from Dr Parslow (University of 
Leeds and PICANet) and Prof Tasker (University of Cambridge and Harvard Medical 
School).  Dr Paul Davies provided statistical advice. Dr McShane performed extraction of the 
primary dataset from the PICANet database with full guidance from Dr Scholefield. 
Chapter 6  
161 
 
6  Predictive factors for survival 
to PICU discharge after 
paediatric out-of-hospital 
cardiac arrest: A UK 
multicentre, retrospective, 
cohort study. 
 
 
 
 
“Prediction is very difficult, especially if it‟s about the future!” 
 
Thomas Alva Edison (American Inventor, born 1847) 
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6.1 ABSTRACT 
6.1.1 Introduction  
Despite initial successful resuscitation after paediatric out-of-hospital cardiac arrest (OHCA), 
a large proportion of patients will not survive to PICU or hospital discharge. Accurate 
prediction of likely survivors or patients at high risk of mortality is of benefit to clinicians, 
when choosing appropriate patient care and counselling families; and to researchers 
targeting interventional studies on patients most likely to benefit from therapies or for risk-
stratified randomisation. However, no OHCA data to formulate prediction currently exists 
with respect to the UK paediatric population. 
6.1.2 Aims 
To identify predictive factors for survival to PICU discharge, available at the time of 
resuscitation or at admission to PICU, in children achieving a return of spontaneous 
circulation after OHCA.  
6.1.3 Method 
A retrospective, multi-centre, cohort study of infants (older than 24 hours) and children 
(before their 16
th
 birthday) admitted to three large UK PICUs after OHCA over a seven year 
period (Jan 2004- Dec 2010) was performed. Identified variables, associated with PIC 
survival, were analysed and included in a multivariate logistic regression model and 
Correlation and Regression Tree (CART) analysis to create a prediction tool. 
6.1.4 Results 
One hundred and fifty five OHCA patients met study entry criteria. 32% (50/155) survived to 
PIC discharge. Age, bystander CPR and witnessing of arrest were not associated with 
survival. Factors available before or during resuscitation, associated with increased survival, 
included; presenting in a rhythm that can be cardioverted (referred to as a „shockable 
rhythm‟ i.e. ventricular fibrillation or ventricular tachycardia), shorter duration of cardiac 
arrest, return of spontaneous cardiac output prior to arrival in the emergency department 
and lower number of epinephrine doses. Additional factors associated with survival and 
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available within four hours of PICU admission included; higher blood pH, lower blood lactate, 
lower maximum blood glucose, higher arterial base excess, lower Paediatric Index of 
Mortality (PIM2) score and two reactive pupils. A multivariate logistic regression model with 
factors available before and during resuscitation identified presenting in a shockable rhythm 
as strongly associated with survival. Including factors available up to four hours after PIC 
admission identified raised blood lactate and two unresponsive pupils as strong predictors of 
mortality. A decision tree identifying patients with high risk of mortality was created using 
both regression coefficients and CART analysis. 
6.1.5 Conclusion 
This study has identified multiple factors associated with survival after return of spontaneous 
circulation in UK children after OHCA. Two unresponsive pupils and raised lactate within 
four hours of PIC admission remained strong predictors after multivariate logistic regression 
and CART analysis for mortality. This information will be of value in determining potential 
inclusion and exclusion criteria for an intervention trial and could be considered as a tool for 
risk-stratified randomisation within a RCT of therapeutic hypothermia after cardiac arrest.  
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6.2  INTRODUCTION 
Survival rates for children after out-of-hospital cardiac arrest (OHCA) are generally poor, 
although vary widely in the published literature (Donoghue et al, 2005; Young et al, 2004; 
Deasy et al, 2010; Atkins et al, 2009). The heterogeneity of cardiac arrest aetiologies within 
studies and cardiac arrest definitions between studies are some of the major causes for this 
variation. Attempts to standardise resuscitation reporting in studies, by adoption of the 
Utstein template, have resulted in some improvement (Zaritsky et al, 1995). However, most 
studies are small case series or include all patients suffering cardiac arrest and report only a 
small proportion with return of spontaneous circulation (ROSC). Therefore, in addition to 
variations in outcome definitions and paediatric populations outside the UK, these limitations 
reduce the ability to use currently reported outcome rates to plan a UK post cardiac arrest 
therapeutic intervention clinical trial (e.g. the use of therapeutic hypothermia after OHCA). 
Prediction of survival or mortality after OHCA is of importance to both clinicians caring for 
patients and to researchers designing clinical trials. The ability to predict outcome for 
individual patients can help clinical decision making regarding therapeutic options or whether 
continued therapy may be futile, thereby assisting in the counselling of parents and families. 
Researchers can use prediction tools in a similar way but for a different purpose.  The 
inclusion of patients in a clinical trial with very high or very low risk of survival, who are likely 
to survive or die irrespective of any therapeutic intervention, risks masking the beneficial or 
harmful effects of a therapy. Critical care, randomised controlled trials have repeatedly 
struggled with the problems of heterogeneity in study populations resulting in a low signal 
(meaningful information) to noise (unwanted signal) ratio and resulting in no effect from the 
intervention despite often strong evidence from pre-clinical, observational and single centre 
randomised controlled trials (Vincent, 2010). Focusing the study population on a group who 
are most likely to benefit from the therapy is one approach to improve this. Therefore, 
understanding the potential study population and identifying key factors which may be useful 
inclusion or exclusion criteria and may allow more efficient research into a targeted 
population (Vincent et al, 2010).  However, a downside to this approach is the risk of 
targeting sub-populations which are too small and not reflective of the general ICU 
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population. The results of the study may therefore fail to be generally applicable. A relevant 
example of this is the European Hypothermia After Cardiac Arrest (HACA) trial which 
identified a positive effect of therapeutic hypothermia in adult OHCA patients presenting in a 
shockable rhythm (HACA, 2002). A criticism of the study, and potential reason for slow 
uptake of the therapy over the 10 year period since publication was that only 8% of the total 
screened OHCA population was included in the study. Therefore, the therapy was not tested 
on the majority (92%) of OHCA patients presenting to these ICUs. A potential second 
approach to using prediction tools in research could be to use the knowledge of strong 
predictive factors in stratifying populations in an RCT either at the outset, before 
randomisation or during a risk-stratified analysis of the RCT outcome (Kent & Hayward, 
2007). This would enable a balance of the final comparative populations and in addition, 
increase the power to detect subgroups of patients who are likely to benefit or be harmed by 
the intervention (Hayward et al, 2006; Kent & Hayward, 2007)  
There have been considerable efforts to identify important prediction factors in children after 
OHCA over the last few decades. Various factors predicting mortality have been reported 
from observational studies including; prolonged duration of cardiac arrest (Schindler et al, 
1996; Suominen et al, 1997; Young et al, 2004), no ROSC at scene or resuscitation required 
after arrival to the emergency department (O'Rourke, 1986; Ronco et al, 1995; Sirbaugh et 
al, 1999; Moler et al, 2011), no-bystander CPR (Abe et al, 2012), arrest not witnessed 
(Atkins et al, 2009; Donoghue et al, 2005), age (Engdahl et al, 2003), increased number of 
doses of epinephrine (Schindler et al, 1996; Young et al, 2004), presenting in a non-
shockable rhythm (Mogayzel et al, 1995; Atkins et al, 2009; Moler et al, 2011) and in the 
setting of cardiac arrest associated with trauma. However, no single factor or combination of 
factors in the paediatric population has been incorporated into a prediction rule for either 
guaranteed survival or termination of resuscitation. In addition, over time, prediction factors 
have changed. For example, in the 1980s, Zaristky et al (1987) and Gillis et al (1986) 
reported survival futility if CPR duration was greater than 10 minutes and 15 minutes 
respectively. By the 1990s Schindler et al (1996) extended the time duration considered 
futile to greater than 20 minutes of CPR in the emergency department, and in the 2000s 
Young et al (2004) reported that CPR greater than 31 minutes in the emergency department 
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was deemed futile. There have been attempts in the adult population to create termination of 
resuscitation rules using large sample sizes in retrospective studies and included 
combinations such as: witnessing of the arrest by emergency medical personnel, the lack of 
need for cardiac defibrillation and lack of return of spontaneous output out-of hospital 
(Morrison et al, 2006; Morrison et al, 2007; Sasson et al, 2008). However, even in the adult 
OHCA population, as the quality of pre-hospital resuscitation improves (Margey et al, 2011), 
experimental neuroprotective interventions such as therapeutic hypothermia during CPR  
are explored (Bernard et al, 2010) and further data on the outcome variability between 
individual centres and countries emerge (Berdowski et al, 2010; Nichol et al, 2008b), these 
rules also become less and less precise as time moves on. 
Moler et al (2011) published the only large multicentre cohort study investigating a 
population of post-OHCA children with ROSC and admission to PICU. This study was 
funded and performed by the large Pediatric Emergency Care Applied Research Network 
(PECARN) in the USA and aimed to describe patient and cardiac arrest event characteristics 
after OHCA and early hospital management. In addition they sought to identify factors most 
strongly associated with hospital survival which they subsequently used in designing the 
Therapeutic Hypothermia after Pediatric Cardiac Arrest (THAPCA) studies (NCT00878644; 
NCT00880087). Over a period of 18 months, 138 OHCA patients from 15 sites were 
included. Survival rate to hospital discharge was 38% (53/138). The event characteristics 
most associated with survival included; weekend arrest, cardiopulmonary resuscitation not 
on-going at hospital arrival, arrest rhythm not asystole, shorter duration of cardiac arrest, 
and drowning or asphyxial arrest event. Additional factors available in the first 12 hours post 
resuscitation associated with survival included: absence of vasopressor or inotropic support, 
higher body temperature, higher pH, lower lactate, lower maximum glucose, and normal 
pupillary response.  In a multivariate logistic regression analysis of factors available during 
or immediately after resuscitation, after accounting for age, gender, race and presenting 
cardiac rhythm, they found the administration of atropine or epinephrine to be associated 
with increased mortality. A second model which included post-resuscitation factors identified; 
pre-existing lung or airway disease, aetiology of drowning or asphyxia, higher pH and two 
reactive pupils to be associated with lower mortality. However, duration of cardiac arrest and 
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lactate levels were excluded from both multivariate analyses due to missing data. Although 
this study does gives valuable information regarding the post-OHCA population, potential 
differences between the UK and USA may exist. These include; the patient population, 
aetiology of cardiac arrest, healthcare provision, choices of intensive care therapies and 
approaches to palliative and end of life care (Wunsch et al, 2011). 
The Paediatric Intensive Care Audit Network (PICANet) database, as detailed in chapter 
five, allowed useful epidemiological assessment of the UK post-cardiac arrest population 
admitted to PICUs and identified that the survival to PICU discharge for patients admitted to 
PICU after OHCA was 50%. However, the ability to investigate resuscitation specific factors 
was severely limited as these were not included in the collected dataset. It was not possible 
to assess the sensitivity and specificity of the matrix model by checking primary records 
which was a potential limitation due to the unexplained high survival rate in relationship to 
other published studies and there were concerns regarding the accuracy and interpretation 
of the coding system for chronic conditions and acute aetiologies of arrest. Therefore, we 
designed a retrospective study to investigate the UK post-OHCA population admitted to 
PICU collecting Utstein defined resuscitation factors and additional key physiological 
parameters to allow the creation of a prediction tool. The findings of this study will assist the 
methodological design of a randomised controlled intervention study by potentially 
identifying key factors for patient inclusion and exclusion, and identifying potential 
stratification/minimisation criteria for randomisation.   
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6.3 AIMS  
6.3.1 Primary Aims 
1. To identify predictive factors for survival to PICU discharge in children who 
are admitted to PICU after out-of hospital cardiac arrest in the UK. 
6.3.2 Secondary Aims 
1. Ascertain the survival to PICU discharge rate of children who are admitted 
to PICU following out-of-hospital cardiac arrest. 
2. Develop a risk prediction tool utilising preceding or during resuscitation 
factors associated with survival. 
3. Develop a risk prediction tool utilising factors available at the time of PICU 
admission associated with survival. 
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6.4 METHODOLOGY 
6.4.1 Settings and participants 
This retrospective, multi-centre, cohort study included infants and children admitted to PICU 
after out-of-hospital cardiac arrest (OHCA) over a seven year period (January 2004 to 
December 2010). Patients were identified from admission records to the three Paediatric 
Intensive Care Units (PICUs) of Birmingham Children‟s Hospital (BCH), Alder Hey Children‟s 
Hospital (ACH), Liverpool and Great Ormond Street Hospital (GOSH), London. All three are 
large, regional paediatric centres admitting 1100-1700 infants and children per year on to 
PICU, accounting for 23% of all UK PICU annual admissions (PICANet, 2010).  National and 
local databases identified potentially eligible patients. These included the PICANet 
admission coding for preceding cardiopulmonary resuscitation and preceding out-of-hospital 
cardiac arrest, local PICU discharge coding system for terms relating to cardiac arrest and 
out-of-hospital cardiac arrest, and existing cardiac arrest and acute life threatening events 
registries. 
6.4.2 Study Design 
Inclusion: Patients from 24 hours of age up to their 16
th
 birthday, admitted to PICU after an 
OHCA with successful return of spontaneous circulation were included. OHCA was defined 
as no signs of cardiac output and pulseless for more than one minute as confirmed by a 
trained medical practitioner/paramedic prior to arrival at an emergency department.  
Exclusion: Patients were excluded if they were younger than 24 hours of age or had a 
cardiac arrest secondary to birth asphyxia. This age limit was to exclude patients 
experiencing a perinatal event as standard treatment protocols regarding the use of 
therapeutic hypothermia are already established and this patient population is generally 
admitted to a neonatal unit and not to a PICU. 
6.4.3 Data Collection and Assessment  
Retrospective review of individual case notes, PICU nursing charts and computerised patient 
records was performed in each centre.  
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Data were recorded electronically onto a piloted Excel (Microsoft, USA) spreadsheet and 
saved on to a secure NHS Trust fire-wall protected computer server. Encrypted files were 
transferred to the chief investigator at Birmingham Children‟s Hospital via secure encrypted 
nhs.net email server accounts for central data management, data validation, and collation for 
formal statistical analysis. A data-entry guide and instruction booklet was created. One to 
one training was provided for data collectors in each institution by the chief investigator. 
Data were verified at the inputting stage using data-verification limits set in the excel 
programme which generated a warning message for values outside expected ranges. 
Individual queries were cleared directly by the chief investigator with regular reviewing of 
progress. Further data-verification was undertaken during the analysis stage with significant 
outliers, unexpected or improbable values and missing values queried and re-checked with 
the primary records by the relevant data-collector.  
Data were collected using Utstein recommended definitions when available. Figure 6-1 
shows the data collection domains and time points. Demographic data included; age, weight, 
sex, presence of chronic conditions prior to OHCA and requirement for transportation to 
PICU from another hospital. A chronic condition was defined as a pre-existing medical 
condition likely to increase risk of a cardiac arrest. Aetiology of arrest was extrapolated from 
medical documentation using information up to the time of discharge from PICU or from 
post-mortem reports if available. Categories included; pulmonary, cardiac, submersion 
(including near-drowning), neurological (non-traumatic), sepsis, inflicted traumatic brain 
injury, strangulation, (near) sudden infant death, trauma (including traumatic brain injury but 
excluding other injury related aetiologies already listed). Further comparative groupings of 
aetiology included asphyxial versus cardiac aetiology (cardiac group included patients with 
primary shockable rhythm or identified acute cardiac event) and non-traumatic versus 
traumatic aetiology (including all trauma aetiologies; submersion, hanging or strangulation, 
inflicted and non-inflicted traumatic brain, electrocution and „other‟ trauma).  
Cardiac arrest event characteristics were collected including place of arrest, whether it was a 
witnessed arrest, initiation of bystander cardiopulmonary resuscitation, first recorded rhythm 
on ECG monitor by paramedic or emergency medicine staff, use and number of cardiac 
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defibrillation attempts and number of doses of epinephrine. Date and time of important 
events were recorded as illustrated in Figure 6-1. Time intervals were calculated including 
duration of cardiac arrest (time of arrest to ROSC), duration of resuscitation after arrival in 
the emergency department arrival to ROSC, time from ROSC to PICU admission, and length 
of stay in PICU and hospital.  
Physiological variables routinely available between ROSC and PICU admission were 
collected. Data were recorded whilst in the emergency department, during transportation 
and on arrival to PICU. Further data were collected at four hourly intervals after PICU 
admission. Maximum and minimum variables between ROSC and four hours post PICU 
admission were created. The use of data up to four hours post PICU arrival reduced the 
missing data for variables where blood gases were not being immediately sampled from 
patients and reflects the potential „time window‟ of patient recruitment into a clinical trial. 
Additional physiological data was collected up to 24 hours post admission to allow 
comparison of the trend in variables and time to normalisation. 
Core temperature was collected if recorded at additional time points; at the time of out-of-
hospital cardiac arrest, return of spontaneous circulation, admission to ED, leaving ED, 
admission to PICU and every four hours from PICU admission (time zero) to 24 hours post 
admission. Core temperature was defined as either a rectal, oesophageal or bladder 
measurement. Episodes of severe hypothermia, defined as a core temperature less than 
32°C, and hyperthermia, defined as a core temperature greater than 38°C, were recorded.  
Occurrence of seizures within the period from ROSC to 24 hours, presence of two 
unresponsive pupils at PICU admission, and any major complication was also collected.  
Post arrest treatments and investigations included; therapeutic hypothermia, use of 
mechanical ventilation, inotropic support, extracorporeal life support (ECLS), renal 
replacement therapy (including haemofiltration and peritoneal dialysis), insulin therapy, anti-
seizure therapy, use and type of neuro-imaging and neuro-electrophysiological investigation. 
The use of therapeutic hypothermia was defined as documented active targeted temperature 
management to reduce or maintain core temperature to less than 35°C and greater than 
32°C.  
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Primary outcome was survival to PICU discharge. Information on survival to hospital 
discharge and at one year was collected if available. Survival to PICU discharge was chosen 
owing to concerns about missing data in the hospital survival status. Unfortunately, a 
number of patients who survived to PICU discharge were discharged to another hospital and 
their survival status at hospital discharge could not be verified. We attempted to assess 
neurological outcome using information in the medical notes to allocate a patient a 
Paediatric Cerebral Performance Category (PCPC) score (Fiser et al, 2000) at PICU 
discharge and hospital discharge. Unfortunately the recording of information to enable 
category scoring was missing in up to 50% of survivors and therefore neurological outcome 
scoring could not be used in the analysis.  
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Figure 6-1 Study flow chart showing data collection areas at key time points. 
              
 
Model 1: Factors available preceding cardiac arrest and during resuscitation for multivariable 
logistic regression model 1 
Model 2: Inclusion of factors in model 1 and additional physiological and clinical factors 
available up to four hours after PICU admission for multivariable logistic regression model 2 
HR: heart rate, BP: blood pressure (systolic and mean), Mode: conventional ventilation or 
high frequency oscillation, FiO2: fractional inspired concentration of oxygen, ABG: arterial 
blood gas, FBC: full blood count, Chemistry: blood urea, creatinine, and magnesium levels. 
RRT: renal replacement therapy, ECMO: extracorporeal membrane oxygenation, 
EEG/CFAM: electroencephalography and cerebral function monitoring.  
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6.4.4 Statistical Analysis 
We planned a priori two separate analyses of the data.  This chapter reports on an analysis 
comparing survivors with non-survivors to evaluate predictive factors for the survival. A 
secondary analysis in the following chapter 7 will compare patients receiving therapeutic 
hypothermia with those who did not receive therapeutic hypothermia. 
Data were tested for normality by using the Shapiro-Wilk‟s W test. Descriptive data are 
reported as median and interquartile range (IQR) for continuous variables and as 
frequencies and percentages for categorical variables. Parametric continuous data were 
analysed using the unpaired Student t-test and non-parametric continuous data with the 
Mann Whitney U test or Kruskal-Wallis as appropriate.  Categorical data were analysed 
using the Chi
2 
or Fisher‟s exact tests as appropriate. Linear-by-linear association was used 
for ordered categorical testing.  
Logistic regression was used to identify variables that were independently associated with 
survival. Normality and linearity of continuous variables was assessed and appropriate 
transformation was used where necessary.  Firstly, associations with outcome were 
identified by univariate logistic regression analysis. All variables with p <0.1 for survival were 
included in a multivariate logistic regression analysis model. Forward stepwise selection was 
applied to this group of potential predictors to obtain the final model. The criteria for variable 
selection were a significance level to enter of 0.05 and a significance level to stay of 0.10.  
Two logistic regression models were created (as illustrates on Figure 6-1). Model 1 included 
variables available before and during the cardiac arrest resuscitation: age, VF/VT (vs. 
PEA/asystole/bradycardia), defibrillation attempted, doses of epinephrine, duration of 
cardiac arrest (arrest to ROSC interval) and ROSC prior to ED admission. We decided a 
priori to use continuous variables (if available) in the primary logistic regression model. The 
use of dichotomised, continuous variables (splitting the population into two distinct groups) is 
relatively common in medical research; however, it can be associated with a loss of 
statistical power and residual confounding (Altman & Royston, 2006). In addition the use of 
sample data derived cut-off points has the potential to cause significant bias and therefore 
we chose to avoid this in the primary analysis. We did perform a separate post hoc analysis 
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using the dichotomised epinephrine dose (no epinephrine versus one or more epinephrine 
doses) and will report on the implications of this adjusted model. 
Model 2 included variables available from ROSC up to four hours after PIC admission: 
VF/VT (vs. PEA/asystole/bradycardia), defibrillation attempted, duration of cardiac arrest 
(arrest to ROSC interval), ROSC prior to ED admission, PIM2 score on PICU admission, 
maximum and minimum lactate values, maximum base excess, maximum glucose, 
maximum and minimum pH, minimum and maximum temperature, pupillary reaction to light, 
inotrope use and insulin therapy for hyperglycaemia.  Addition of the dichotomised 
epinephrine doses (no epinephrine versus one or more epinephrine doses) and lactate 
greater than or equal to 3 mmol/l (versus less than 3 mmol/l) were included in a secondary 
post-hoc analysis. 
Adjusted odds ratios (OR) and 95% confidence intervals (CI) were calculated for each 
model. Predicted probabilities of survival were calculated based on the logistic regression 
coefficient model. Sensitivity, specificity, positive and negative predictive values were 
calculated. The c-statistic or area under the Receiver Operating Characteristic (ROC) curve 
for the predicted model is reported with the Hosmer Lemeshow goodness of fit assessment 
of the model (Hosmer et al, 1997; Hanley & McNeil, 1982). Missing data were not imputed; 
complete case selection was used when variables were missing.  
The results of the multivariate analyses were compared with a decision tree model created 
using Classification and Regression Tree (CART) analysis software within IBM-SPSS 
statistical package, with survival to PICU discharge as the dependent variable. The potential 
advantages of CART are that the findings are simpler to understand and more applicable to 
clinicians as a bedside tool (Andrews et al, 2002; Forsyth et al, 2008).  In these models, data 
available up to four hours post PICU admission were used to generate a decision tree that 
best predicted death in PICU. A random subset of 50% of cases was selected as a training 
sample for the development of the decision tree and then applied to the remaining 50% test 
sample. Only the test sample results are reported with corresponding sensitivity, specificity, 
positive and negative predicted values for predicting death in PICU. 
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A p value of <0.05 was considered statistically significant throughout. Data analysis was 
performed using both IBM-SPSS Statistics version 19.0 software (SPSS Inc, Chicago, USA) 
and Minitab 16 (USA). 
All statistical analysis was performed by Dr Barney Scholefield (chief investigator and 
author) with advice from Dr Paul Davies (Statistical Advisory Service, Birmingham Children‟s 
Hospital Research & Development department). 
6.4.5 Ethics 
Approval for this study was granted by the research and development department at 
Birmingham Children‟s Hospital (see letter of approval Appendix 9.11, p332). Regional 
ethics committee approval was not required as only medical data, routinely documented 
during hospital admission, were used. The collection of patient data was done by members 
of the patient‟s own health care team. Patient confidentiality and data protection was 
enforced by all three centres with the use of pseudo-anonymized data. Unique study 
identification numbers were created. Original linkage information of the study ID and patient 
record number was securely stored at each respective institution. Full compliance was 
maintained with local and national Good Clinical Practice guidelines and regulatory 
requirements. 
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6.5 RESULTS  
322 patients were identified from database searches. After exclusion of 145 patients not 
fulfilling the inclusion criteria, 155/180 eligible patients were included from the three intensive 
care units. The remaining 25 (14%) of case notes were unobtainable, the majority from unit 
3. Study inclusion flow chart is displayed in Figure 6-2. 
 
Figure 6-2 Flow chart of included patients from individual units 
 
 
  
13 
Chapter 6  
178 
 
6.5.1 Demographics 
Table 5-3 describes baseline demographic and pre-existing chronic conditions for survivors 
and non-survivors after OHCA. Overall survival rate to PICU discharge was 32% (50/155). 
Median age of the total cohort was 1.3 yrs (IQR 0.2-5.5yrs). The majority, 45% (70/155), 
were less than one year of age (Figure 6-3). 62% were male with 42% having a pre-existing 
chronic condition. Neurological disorders were the commonest pre-existing chronic 
condition. There was no difference in age, sex and proportion with pre-existing chronic 
condition between survivors and non-survivors. Survival rates were constant across Utstein 
defined age groups (Figure 6-4). Unit one had the highest survival rate (42%) compared with 
unit two (30%) and unit three (22%), although Chi
2
 statistical test was not significant (p = 
0.142). 73% (111/150) of patients required transportation from a different hospital to the 
PICU and need for transportation was not associated with survival (p = 0.336). However, 
there was a significant difference in the need for transportation between Unit 1 (100%; 
50/50), Unit 2 (51%; 37/71) and Unit 3 (78%; 25/32) (p = 0.001). The 111 patients 
transported to PICU were from 61 different emergency departments (Median 1 (IQR [1 to 2]) 
patient per emergency department). 
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Table 6-1 Demographics and relationship to PICU survival 
 Total Group 
n=155 
Survivors 
n=50 
Non-
survivors 
n=105  
p
b
  missing 
Age (years) 
1.3 
(0.2-5.5) 
1.6 
(0.2-9.1) 
1.2 
(0.3-5.3) 
0.793 0 
Weight (kg)
 a
   
10 
(4.7-20.3) 
12 
(4-25) 
10 
(5-20) 
0.881 17 
Age category (Utstein
b
)    0.875 0 
 1-30 days 21 (14%) 9 (18%) 12 (12%)   
 31 days to < 1yr 50 (32%) 15 (30%) 35 (33%)   
 1yr to < 4yrs 39 (25%) 12 (24%) 27 (26%)   
 4yrs to < 12yrs 20 (13%) 6 (12%) 14 (13%)   
 12yrs to < 16yrs 25 (16%) 8 (16%) 17 (16%)   
Male 95 (62%) 34 (70%) 61 (59%) 0.202 0 
Chronic Condition 65 (42%) 23 (46%) 42 (40%) 0.479 0 
Two or more chronic 
conditions 
23 (15%) 5 (10%) 18 (17%) 0.171 0 
 Neurological 24 (15%) 6 (12%) 18 (17%) 0.408  
 Respiratory 18 (12%) 7 (14%) 11 (10%) 0.522  
 Cardiac 15 (10%) 4 (8%) 11 (10%) 0.626  
 Prematurity 8 (5%) 5 (10%) 3 (3%) 0.113  
 Genetic 8 (5%) 1 (2%) 7 (7%) 0.220  
 Metabolic 5 (3%) 2 (4%) 2 (3%) 0.707  
 Gastrointestinal 2 (1%) 0 2 (2%) ns  
 Renal 2 (1%) 0 2 (2%) ns  
 Haematological 1 (1%) 0 1 (1%) ns  
Admitting PICU     0.142 0 
 Unit 1 50 21 (42%)
c
 29 (58%)   
 Unit 2 73 22 (30%)
c
 51 (70%)   
 Unit 3 32 7 (22%)
c
 25 (78%)   
Transported from 
different admitting 
hospital 
111 (73%) 38 (70%) 73 (78%) 0.336 2 
a 
Recorded weight (both estimated or measured) 
b
Utstein pre-defined age groups with 
modified upper age limit to less than 16 years (Zaritsky et al, 1995). Unavailable (missing) 
values were excluded from calculations of summary statistics. Results expressed as Median 
(Inter-quartile range) or number (percent). 
b 
Chi
2 
test was used for categorical variable and Mann Whitney U test for continuous 
variables. 
 c 
Percent expressed as survivors per unit. 
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Figure 6-3 Chart of percent of survivors and non-survivors by age (years) 
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Figure 6-4 Chart of Utstein defined age groups for survivors and non-survivors 
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6.5.2 Aetiology 
Table 6-2 describes the aetiology of OHCA. The aetiology was unknown in 18% (27/155) of 
patients. Pulmonary and cardiac aetiologies were the most common. There were no 
survivors after strangulation (0/9) and only 1/9 after inflicted traumatic brain injury. When 
analysing the overall groups, cardiac versus asphyxial (non-cardiac) aetiologies (Table 6-3) 
and traumatic versus non-traumatic aetiologies (Table 6-4), similar survival rates within each 
group were demonstrated. 
 
 
Table 6-2 Aetiology of arrest and relationship to PICU survival 
 Total Group 
n=155 
Survivors 
n=50 
Non-
survivors 
n=105 
p
b
 
Not Known 27 (18%) 7 (14%) 21 (20%)  
Pulmonary 28 (18%) 11 (22%) 17 (16%)  
Cardiac 18 (12%) 9 (18%) 9 (9%)  
Trauma (including accidental 
traumatic brain injury) 
13 (8%) 5 (10%) 8 (8%)  
Submersion 12 (8%) 5 (10%) 7 (7%)  
Neurological 11 (7%) 3 (6%) 8 (7%)  
Sepsis 10 (6%) 3 (6%) 7 (7%)  
Inflicted traumatic brain injury 9 (6%) 1 (3%) 8 (8%)  
Strangulation 9 (6%) 0 (0) 9 (9%)  
Sudden infant death syndrome 7 (5%) 1 (2%) 6 (6%)  
Other 10 (6%) 5 (10%) 5 (5%) 0.204 
Unavailable (missing) values were excluded from calculations of summary statistics. Results 
expressed as Median (Inter-quartile range) or number (percent). 
b 
Chi
2 
test was used for overall trend analysis of categorical variable  
  
Chapter 6  
182 
 
Table 6-3 Asphyxia versus cardiac aetiology and relationship to PICU survival 
 Total 
Group 
 
Survivors 
 
Non-
survivors 
 
p
b
 missing 
Asphyxial  109 34 (31%) 75 (69%) 0.118 28 
Cardiac 18 9 (50%) 9 (50%)   
Unavailable (missing) values were excluded from calculations of summary statistics. Results 
expressed as number (percent). 
b 
Chi
2 
test. Percentages calculated across asphyxial and cardiac group 
 
 
 
Table 6-4 Traumatic versus non-traumatic aetiology and relationship to PICU survival 
 Total 
Group 
 
Survivors 
 
Non-
survivors 
 
p
b
 missing 
Traumatic
c
 45 13 (29%) 32 (71%) 0.381 28 
Non-Traumatic 82 30 (37%) 52 (63%)   
Unavailable (missing) values were excluded from calculations of summary statistics. Results 
expressed as number (percent). 
b 
Chi
2 
test Percentages calculated traumatic and non-traumatic groups 
c
Trauma aetiology included inflicted and accidental traumatic brain injury, submersion, 
strangulation, electrocution and „other‟ trauma. 
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6.5.3 Cardiac arrest event factors 
Table 6-5 describes the cardiac arrest event factors and relationship to survival. Arresting in 
the home, having a witnessed arrest or receiving bystander cardiopulmonary resuscitation 
was not significantly associated with survival. Survivors were more likely to present in a 
shockable rhythm (VF or pulseless VT) (p = 0.001) and receive cardiac defibrillation (p = 
0.02) whereas non-survivors were more likely to be asystolic (53% vs. 21%). Non-survivors 
received more doses of adrenaline than survivors (p = 0.01). Figure 6-5 illustrates the 
significant reduction in survival in patients receiving one or more doses of adrenaline versus 
none (p =<0.001); however, unadjusted survival rates remain constant with one or 
increasing doses of adrenaline.  
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Table 6-5 Cardiac arrest resuscitation events and relationship with PICU survival 
Cardiac arrest 
resuscitation events 
Total Group 
N=155 
Survivors 
n=50 
Non-
survivors 
= 105  
p
b
  missing 
Location own home 
(versus public place or 
other) 
104 (71%) 33 (72%) 71 (71%) 0.927 9 
Witnessed arrest 96 (63%) 34 (72%) 61 (59%) 0.122  
Bystander CPR 98 (66%) 33 (72%) 65 (64%) 0.34 6 
VF/VT
a
 (vs. PEA/ 
bradycardia/asystole) 
17 (12%) 11 (29%) 6 (6%) <0.001 16 
 Pulseless electrical 
 activity (PEA) 
17 (12%) 6 (15%) 11 (11%)   
 Bradycardia 44 (32%) 14 (36%) 30 (30%)   
 Asystole 61 (44%) 8 (21%) 53 (53%)   
 Ventricular 
 fibrillation (VF) 
7 (5%) 4 (10%) 3 (3%)   
 Pulseless  Ventricular 
 tachycardia (VT) 
10 (7%) 7 (18%) 3 (3%)   
Defibrillation attempted 26 (17%) 13 (28%) 13 (13%) 0.022 12 
Epinephrine doses during 
resuscitation.Median (IQR) 
3 (1-4) 2 (0-4) 3 (2-4) 0.01 4 
No epinephrine given 
during resuscitation 
18 (12%) 14 (29%) 4 (4%) <0.001 4 
Values expressed as: Numbers (percent of total group, survivors or non-survivors) unless 
stated. CPR denotes cardiopulmonary resuscitation. 
a
First recorded rhythm after cardiac 
arrest. VF: ventricular fibrillation, VT: ventricular tachycardia, PEA: pulseless electrical 
activity 
a
Unavailable (missing) values were excluded from calculations of summary statistics. 
Results expressed as Median (Inter-quartile range) or number (percent). 
b 
Chi
2 
test was used for categorical variable and Mann Whitney U test for continuous 
variables.  
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Figure 6-5 Number of doses of epinephrine and survival status 
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6.5.4 Time factors 
Table 6-6 describes the time interval data in relation to resuscitation and PICU admission. 
Survivors had shorter duration of time from cardiac arrest onset to return of spontaneous 
circulation (ROSC) (p=0.002) and a larger proportion (23 vs. 10%) achieved ROSC prior to 
ED admission (p=0.049). Duration of CPR in the hospital emergency department for those 
not achieving ROSC before admission was similar for survivors and non-survivors.  
Figure 6-6 illustrates decreasing survival rates for longer duration of cardiac arrest, although, 
1 in 4 patients with 30 minutes or more resuscitation survived.  
Figure 6-7 illustrates a similar trend of worsening survival for increasing duration of 
continued CPR after arrival to hospital. 21% (3/14) patients receiving CPR for 21 to 30 
minutes in the emergency department, survived. 35% (7/20) survived with more than 30 
minutes of CPR in hospital. Of the survivors in this group; 0/7 had chronic conditions, 2/7 
arrested secondary to submersion and 5/7 received bystander CPR. Overall 86% of patients 
in the study had continuing CPR at the time of hospital arrival; (however, this occurred in 
more non-survivors (90 vs. 77%; p=0.046).  
Time from ROSC to admission to PICU for the whole group was similar for survivor and non-
survivors (4hrs 45mins vs. 4hrs 15mins;p = 0.177). Length of stay in PICU was significantly 
longer for survivors than non-survivors. Figure 6-8 illustrates the left skewed distribution of 
time to death or discharge of non-survivors versus survivors. 26% (27/105) of non-survivors 
died within 24 hours of ROSC.  
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Table 6-6 Time data 
 Total Group 
N=155 
Survivors 
n=50 
Non-
survivors 
= 105  
p
b
  missing 
Time from cardiac arrest to 
ROSC (mins) 
35 
(20-50) 
22 
(11-45) 
39 
(25-55) 
0.002 19 
ROSC prior to ED 
admission  
20 (14%) 10 (23%) 10 (10%) 0.046 16 
Time from ED admission 
to ROSC (mins)
a
 
15 
(7-25) 
11 
(4-28) 
15 
(8-25) 
0.173 16 
Time from  ROSC to PICU 
admission (hrs:mins) 
4:22 
(2:22-5:37) 
4:45 
(2:25-5:53) 
4:15 
(2:10-5:09) 
0.177 16 
Length of stay in PICU 
(days) 
3.0 
(1.3-6.2) 
6.2 
(2.8-8.1) 
2.3 
(0.9-4.5) 
<0.001 3 
ROSC denotes return of spontaneous circulation. ED: emergency department, PICU 
Paediatric intensive care unit. Unavailable (missing) values were excluded from calculations 
of summary statistics. Results expressed as Median (Inter-quartile range) or number 
(percent of total group, survivors or non-survivors). 
a
 Only patients receiving CPR at ED admission were included in calculation 
b 
Chi
2 
test was used for categorical variable and Mann Whitney U test for continuous 
variables. 
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Figure 6-6 Survival rates for increasing duration of cardiac arrest time 
>3021-3011-200-10
100
80
60
40
20
0
S
u
rv
iv
a
l 
to
 P
IC
 d
is
c
h
a
rg
e
 (
%
) Died
Survived
Status
Survival
Total Duration of arrest to ROSC (mins)
Count n=14 n=19 n=30 n=73
missing values = 19 
 
Figure 6-7 Survival rates for duration of resuscitation time in the ED 
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Figure 6-8 Dot plot of length of stay in PICU for survivors and non-survivors 
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Each dot represents an individual patient. Excludes one outlier who survived to PICU 
discharge after 361 days  
Chapter 6  
190 
 
6.5.5 Physiological and clinical variables after ROSC 
Table 6-7 describes physiological variables available between ROSC and four hours after 
PICU admission. Survivors had significantly less physiological derangement on all reported 
variables compared to non-survivors. This included; higher pH, lower lactate, lower glucose 
and higher base excess. PIM2 score, which included pH, base excess, PaO2/FiO2 ratio, 
pupillary reaction status and additional medical history details, but did not include lactate, 
was significantly lower for survivors. Survivors were more likely to have two responsive 
pupils. However the rates of documented seizures were not statistically different (Table 6-8). 
Using physiological variables up to four hours after PICU admission, compared to only at 
PICU admission, reduced the number of missing values from 17% (27/155) to 12% (16/155) 
for lactate levels and from 13% (20/155) to 6% (9/155) for pH and glucose results.  
Figures 6-9, 6-10, 6-11 and 6-12 show the comparative trend in physiological variables for 
survivors and non-survivors from arrival to the emergency department, PICU admission and 
every four hours up to 24 hours post PICU admission.  
In the emergency department pH and base excess were significantly different between 
survivors and non-survivors; however, there was a large number of missing values. On PICU 
admission pH, lactate, glucose and base excess were all significantly different between 
survivors and non-survivors. There was no significant difference noted after 8 hours for pH, 
after 12 hours for glucose and after 16 hours for lactate. Base excess remained significantly 
different between survivors and non-survivors until 24 hours after PICU admission. 
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Table 6-7 Physiological and laboratory variables (between ROSC to four hours after 
PICU admission) and relationship to PICU survival 
 Total Group 
N=155 
Survivors 
n=50 
Non-
survivors 
= 105  
p
b
  missing 
Minimum pH  
6.90 
(6.70-7.13) 
6.95 
(6.80-7.23) 
6.80 
(6.65-7.12) 
0.015 9 
Maximum pH  
7.34 
(7.24-7.42) 
7.37 
(7.35-7.43) 
7.28 
(7.21-7.4) 
0.003 9 
Minimum lactate 
(mmol/l) 
3.6 
(2.2-8.0) 
2.3 
(1.4-3.9) 
5.3 
(2.8-9.0) 
<0.001 16 
Maximum lactate 
(mmol/l) 
9.0 
(4.7-13.9) 
5.78 
(2.6-12.1) 
9.3 
(5.8-14.8) 
0.009 16 
Minimum glucose 
(mmol/l)  
5.7 
(3.9-9.6) 
4.5 
(3.6-7.0) 
6.5 
(4.3-10.9) 
0.003 10 
Maximum glucose 
(mmol/l) 
15.8 
(12.3-19.6) 
13.8 
(9.2-17.3) 
16.7 
(12.8-20.0) 
0.018 10 
Minimum base excess 
(mEq/L) 
-18.5 
(-24 to -12.4) 
-14.0 
(-21.0 to -8.5) 
-20.1 
(-25.1 to -13.9) 
0.001 7 
Probability of death by 
PIM2
a
 
0.84 
(0.35-0.96) 
0.39 
(0.26-0.75) 
0.92 
(0.58-0.96) 
<0.001 0 
Lactate > 3 on PIC 
admission* 
89 (69%) 18 (43%) 71 (83%) <0.001 27 
a 
PIM2 (Paediatric index of mortality 2) (Slater et al, 2003) calculated on PICU admission 
data for all cases including patients transported by PICU specialist retrieval team 
b 
Unavailable (missing) values were excluded from calculations of summary statistics. Chi
2 
test was used for categorical variable and Mann Whitney U test for continuous variables.  
Results expressed as Median (Inter-quartile range) or number (percent). 
 
 
Table 6-8 Clinical neurological variables and relationship to PICU survival 
 Total Group 
N=155 
Survivors 
n=50 
Non-
survivors 
= 105  
p
b
  missing 
Seizures 48 (31%) 12 (24%) 36 (34%) 0.222 6 
Two unresponsive 
pupils 
87 (66%) 12 (32%) 75 (80%) <0.001 23 
 
Results expressed as number (percent). 
b 
Unavailable (missing) values were excluded from 
calculations of summary statistics. Chi
2 
test was used for categorical variable 
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Figure 6-9 Boxplot of pH for survivors and non-survivors from ED admission to 24 hrs 
post PIC admission 
 
+24hrs+20hrs+16hrs+12hrs+8hrs+4hrsPIC admitED
7.8
7.6
7.4
7.2
7.0
6.8
6.6
6.4
6.2
p
H
Died
Survived
Status
Survival
Time
 
* p<0.05 survivors versus non-survivors, ns = not significant (p ≥ 0.05) 
 
Figure 6-10 Boxplot of lactate for survivors and non-survivors from ED admission to 
24 hrs post PIC admission 
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* p<0.05 survivors versus non-survivors, ns = not significant (p ≥ 0.05) 
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Figure 6-11 Box plot of glucose for survivors and non-survivors from ED admission to 
24 hrs post PIC admission 
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* p<0.05 survivors versus non-survivors, ns = not significant (p ≥ 0.05) 
 
 
Figure 6-12 Box plot of base excess for survivors and non survivors from ED 
admission to 24 hours post PIC admission 
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* p<0.05 survivors versus non-survivors, ns = not significant (p ≥ 0.05) 
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6.5.6 Temperature variability after ROSC 
Table 6-10 describes the core temperature differences between survivors and non-survivors 
during different stages of post-ROSC management. An equal proportion of survivors (33%; 
16/50) and non-survivors (30%; 32/105) received therapeutic hypothermia when admitted to 
PICU. Temperature measurements were available for 77% (115/155) patients in the period 
prior to PICU admission, although measured at varying time points. There was no difference 
in maximum or minimum median temperature between survivors and non-survivors in the 
emergency department; however, survivors appeared to have a higher median core 
temperature prior to leaving the emergency department. 
On admission to PICU, non-survivors had a median core body temperature 1.0⁰C lower than 
survivors (p=0.007) (Table 6-10). Minimum temperature between ROSC and four hours post 
PICU admission was also significantly lower in non-survivors. However, maximum 
temperature was similar. Table 6-11 describes the association of hypothermia or 
hyperthermia with survival. Experiencing a core temperature less than 32⁰C after OHCA 
post ROSC and within 24 hours of PICU admission was associated with increased mortality 
(p=0.017); however, an episode of hyperthermia (temperature >38⁰C) was not associated.  
Figure 6-13 illustrates the relationship of maximum and minimum temperature in the 
emergency department and temperature for 24 hours after PICU admission. Except for 
arrival at PICU, temperature of survivors and non-survivors was similar. 
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Table 6-9 Core temperature measurement in the emergency department (ED) and 
relationship to survival 
 Total Group 
n=155 
Survivors 
n=50 
Non-
survivors 
n=105 
P  Missing 
value 
Core temperature 
readings (°C) 
     
Temperature at arrival 
to ED 
34.3  
(32.3-35.3) 
34.3  
(33.0-35.5) 
34.4  
(32-35.5) 
0.841 91 
Temperature at ROSC 
34.1  
(32.5-35.2) 
34.1  
(34.0-35.4) 
34.1  
(32.5-35.1) 
0.776 90 
Temperature leaving ED 
35.4  
(34-36.5) 
35.9  
(34.9-36.5) 
34.7  
(33.2-36.3) 
0.051 76 
Minimum temperature 
recorded in ED 
34.3  
(32.4-35.5) 
34.8  
(34.0-35.6) 
34.1  
(32.0-35.5) 
0.164 39 
Maximum temperature 
recorded in ED 
35.4  
(34.3-36.2) 
35.3  
(34.8-36.3) 
35.3  
(34.1-36.2) 
0.411 39 
Values expressed as: Median (Interquartile range). Mann Whitney U test was used for 
continuous variables. 
 
 
Table 6-10 Core temperature measurements at PICU admission and relationship to 
survival  
 Total Group 
n=155 
Survivors 
n=50 
Non-
survivors 
n=105 
P  Missing 
value 
Core temperature 
readings (°C) 
     
Temperature at PICU 
admission  
35.8 
(34.0-37.0) 
36.5 
(35.6-37.2) 
35.5 
(33.4-37.0) 
0.007 19 
Minimum temperature  
after ROSC To 4hrs 
post PICU admission 
34  
(32.2.-35.5) 
34.5  
(33.3-36.9) 
33.3  
(32-35.1) 0.011 6 
Maximum temperature  
after ROSC To 4hrs 
post PICU admission 
36.5  
(35.5-37.5) 
36.7  
(36.0-37.5) 
36.3  
(35.2-37.5) 0.150 6 
Values expressed as: Median (Interquartile range). Mann Whitney U test was used for 
continuous variables. 
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Table 6-11  Relationship between hypothermia or hyperthermia with survival 
 Total 
Group 
n=155 
Survivors 
n=50 
Non-
survivors 
n=105 
P  Missing 
value 
Any temperature  <32°C 
ROSC to 24hrs post PICU 
admission 
33 (22%) 5 (10%) 28 (28%) 0.017
a
 6 
Any temperature  >38°C 
ROSC to 24hrs post PICU 
admission 
45 (29%) 50 (32%) 33 (31%) 0.341
b
 6 
Unavailable (missing) values were excluded from calculations of summary statistics. 
a
Fishers Exact test and 
b
Chi
2 
test were used for categorical variable 
 
 
Figure 6-13 Box plot of core temperatures for minimum and maximum ED to 24 hours 
post PICU admission 
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6.5.7 Post cardiac arrest intensive care treatment and investigation 
Table 6-12 describes the treatment and investigations received after resuscitation for 
survivors and non-survivors. 1 in 3 patients received therapeutic hypothermia; however, 
there was significant difference between Unit 1 (6%; 3/50), Unit 2 (52%; 38/73) and Unit 3 
(22%; 7/32) (p = 0.001). All but one patient required mechanical ventilation. Inotrope use 
after ROSC was associated with increased mortality; however the combination of more than 
one type of inotrope was not associated with a change in outcome. Extra-corporeal life 
support (ECLS) and renal replacement therapy was rarely used in OHCA patients, although 
10% received high frequency oscillation ventilation (HFOV). The use of insulin therapy was 
higher in the non-survivors but did not reach statistical significance owing to small sample 
size and half of patients had continued neuromuscular blockade after PICU admission. 
The use of neuro-radiological imaging and neuro-electrophysiological monitoring was similar 
in survivors and non-survivors. 71% (109/155) received neuro-imaging and 43% (53/155) 
neuro- electrophysiological investigation.  
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Table 6-12 Post arrest treatment & Investigational data in relationship to PICU survival 
 Total 
Group 
N=155 
Survivors 
n=50 
Non-
survivors 
= 105  
p
b
  
Treatment     
 Therapeutic hypothermia 48 (31%) 16 (33%) 32 (30%) 0.848 
 Mechanical ventilation 154 (99%) 49 (98%) 105 (100%) 0.323 
 Inotropes after 
resuscitation 
99 (63%) 26 (53%) 73 (70%) 0.047 
 Two or more inotropes 43 (27%) 14 (29%) 29 (28%) 0.902 
 HFOV 15 (10%) 4 (8%) 11 (10%) 0.652 
 ECMO 3 (2%) 1 (2%) 2 (2%) 1.0 
 Renal replacement 
therapy 
0 0 0 1.0 
 Insulin therapy 35 (23%) 7 (14%) 28 (27%) 0.088 
 Neuromuscular blockade 
after PICU admission 
78 (50%) 23 (47%) 55 (53%) 0.529 
 Anti-seizure therapy 48 (31%) 12 (24%) 36 (34%) 0.222 
Investigation     
 Any neuroradiology 109 (71%) 33 (66%) 76 (73%) 0.366 
 MRI scan 37 (24%) 16 (32%) 21 (20%) 0.101 
 CT scan 88 (57%) 25 (50%) 63 (60%) 0.240 
 Any neuro-
electrophysiology 
investigation
c
 
53 (43%) 22 (51%) 31 (39%) 0.185 
 
b
Chi
2 
test was used for categorical variable and Mann Whitney U test for continuous 
variables. 
c
Includes: Electroencephalogram (EEG) and continuous amplitude integrated EEG 
MRI: magnetic resonance imaging, CT: Computer tomography 
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6.5.8 Model one: Univariate and multivariate logistic regression analysis  
Table 6-13 shows the univariate analysis for model one including candidate variables 
available either prior to the cardiac arrest or during resuscitation. Variables with p<0.1 were 
included in the multivariate logistic regression analysis. These included; presenting in a 
shockable rhythm (VF/VT vs. PEA/asystole/bradycardia), defibrillation versus no 
defibrillation, total duration of cardiac arrest (mins) and ROSC prior to ED admission versus 
continued CPR. Presenting in either VF or VT (odds ratio 8.3; p=0.001) was strongly 
associated with increased survival. Model one predicted death in PICU with a sensitivity of 
95% and specificity of 29% (positive predictive and negative predictive value of 77% and 
71% respectively). 
In a post-hoc analysis, inclusion of the epinephrine dose variable by dichotomising to no 
epinephrine versus one or more doses improved the fit of model one. Table 6-15 shows 
results of model one with post hoc adjustment. No epinephrine doses (odds ratio 11.98; 
p=0.003) and presenting in either VF or VT (odds ratio 3.95; p=0.057) were both strongly 
associated with increased survival. Figure 6-14 illustrates the Receiver Operator 
Characteristic (ROC) curve for model one with an Area Under the Curve (AUC or c-statistic) 
of 0.669. Hosmer Lemeshow goodness of fit test statistic was 0.386, indicating the logistic 
model is an acceptable fit. The post-hoc model one predicted death in PICU with a 
sensitivity of 94% and specificity of 43% (positive predictive and negative predictive value of 
80% and 75% respectively). 
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Table 6-13 Model 1: Univariate logistic regression. Analysis of factors associated with 
PICU survival available before or during cardiac arrest 
 
Variable Unadjusted 
Odds Ratio 
for survival 
95% CI P value missing 
Age (yrs) 1.00 1.0-1.0 0.820 1 
Sex (male) 0.67 0.33-1.36 0.265 0 
Chronic condition (vs. no 
chronic condition) 
1.28 0.65-2.52 0.480 0 
Cardiac (vs. asphyxial) 
aetiology 
2.21 0.8-6.05 0.124 28 
VF/VT (vs. 
PEA/asystole/bradycardia) 
6.15 2.09-18.13 0.001 16 
Defibrillation vs. no 
defibrillation 
2.60 1.1-6.16 0.030 3 
Epinephrine doses (increment 
of 1) 
0.90 0.77-1.05 0.174 4 
Time duration from cardiac 
arrest to ROSC (mins) 
0.98 0.96-1.0 0.021 19 
ROSC prior to ED admission 2.61 0.99-6.83 0.051 16 
Minimum temperature (⁰C ) in 
ED 
1.10 0.95-1.27 0.219 39 
Post hoc addition     
No epinephrine (vs. one or 
more doses of epinephrine 
during resuscitation)  
10.2 3.1-33.1 <0.001 4 
VF: ventricular fibrillation, VT: ventricular tachycardia, PEA: pulseless electrical activity, ED 
emergency department, ROSC: return of spontaneous circulation. 95% confidence interval 
(CI). 
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Table 6-14 Model 1: Multivariate logistic regression analysis of factors associated 
with PICU survival before or during cardiac arrest 
Variable 
Odds ratio 
for 
survival 
(n=122) 
95% CI P value 
VF/VT (vs. 
PEA/asystole/bradycardia) 
8.3 2.4-28.7 0.001 
c-statistic: 0.611  Sens = 95%, Spec= 29%, PPV = 77%, NPV = 71% 
Factors entered into model: VF/VT (vs. PEA/asystole/bradycardia), defibrillation attempt, 
ROSC prior to ED admission versus continued CPR on admission and duration of cardiac 
arrest (arrest to ROSC). Total cases in model = 122. 
Sensitivity (Sens), Specificity (Spec), Positive Predicted Value (PPV), Negative Predicted 
Value (PPV). 
 
Table 6-15 Model 1 (post-hoc adjustment): Multivariate logistic regression analysis of 
factors associated with PICU survival before or during cardiac arrest with inclusion of 
dichotomised epinephrine dose category. 
Variable 
Odds Ratio 
for survival 
(n=122) 
95% CI P value 
No epinephrine (vs. one or 
more doses of epinephrine 
during resuscitation) 
11.98 2.31-61.99 0.003 
VF/VT (vs. 
PEA/asystole/bradycardia) 
3.95 0.96-16.27 0.057 
c-statistic: 0.669 Sens = 94%, Spec= 43%, PPV = 80%, NPV = 75% 
Factors entered into model: VF/VT (vs. PEA/asystole/bradycardia), no epinephrine (vs. one 
or more doses of epinephrine), defibrillation attempt, ROSC prior to ED admission versus 
continued CPR on admission and duration of cardiac arrest (arrest to ROSC). Total cases in 
model = 122. 
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Figure 6-14 Receiver operator curve for model 1 prediction of survival status 
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6.5.9 Model two: Univariate and multivariate logistic regression analysis  
The second model included additional variables available within four hours of PICU 
admission. Table 6-16 describes the univariate analysis of candidate variables. Physiological 
continuous variables associated with increased survival included minimum temperature and 
both minimum and maximum values for: pH, base deficit, lactate and glucose. Two 
unresponsive pupils, the requirement for continued inotropic support after resuscitation and 
insulin therapy were also associated with decreased survival. As expected, the paediatric 
index of mortality 2 (PIM2) performed well as a predictive score (Odds ratio for survival 0.04; 
p<0.001 for a 0.1 increase in probability of death by PIM2).  
Except for PIM2, all variables where p < 0.1 were included in a multivariate logistic 
regression analysis in addition to the variables identified for model one. PIM2 was excluded 
owing to collinearity as pupillary reaction and pH are included in the calculation of PIM2. 
Table 6-17 describes the multivariate logistic regression results. Two unresponsive pupils 
(Odds ratio 0.19; p=0.001) and increasing lactate at PICU admission (Odds ratio 0.85 p = 
0.015) were strongly associated with decreased survival. Receiver Operator Curve of model 
two is illustrated in Figure 6-15. Area under the curve (C-statistic) was 0.831 and Homer 
Lemeshow Goodness of Fit 0.08 which is acceptable. However, because of missing values, 
only 105 (78%) of patients were included in model 2 using complete case selection. The 
model predicted death in PICU with a sensitivity of 87% and specificity of 55% (positive 
predictive and negative predictive value of 84% and 62% respectively). 
A post hoc analysis was performed with the inclusion of lactate as a dichotomised variable 
(categorised as greater or less than 3 mmol/l at PICU admission) and removal of lactate as a 
continuous variable (due to colinearity with the dichotomised lactate variable). In a univariate 
analysis this dichotomised candidate variable was strongly associated with decreased 
survival (Odds ratio 0.25; p <0.001). Table 6-18 describes the multivariate logistic regression 
model with the inclusion of lactate greater than or equal to 3 mmol/l at PICU admission and 
the dichotomised, no epinephrine dose (versus one or more doses) during resuscitation. In 
the post hoc analysis of model two, lactate greater than or equal to 3 mmol/l at PICU 
admission (Odds ratio 0.23; p = 0.02) and two unresponsive pupils (Odds ratio 0.29; p=0.04) 
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were strongly associated with decreasing survival. No epinephrine (versus one or more 
doses) during resuscitation (Odds ratio 7.14; p = 0.03) was also associated with increased 
survival. The model predicted death in PICU with a sensitivity of 94% and specificity of 54% 
(positive predictive and negative predictive value of 85% and 77% respectively). 
Figure 6-16 depicts the probability of survival based on the logistic regression coefficient 
from model 2 which included continuous lactate at PICU admission and pupillary reactivity 
as factors. 
Using the combination of lactate level and pupillary reaction, the following prediction model 
was created from this sample population: Two unresponsive pupils and a lactate level on 
PICU admission greater than 9mmol/L or two responsive pupils and a lactate level greater 
than 18mmol/L both predicted a survival rate of only 10%. These cut-off points, available 
within four hours of PICU admission, could be used in the inclusion criteria or to stratify 
patients during randomisation in an RCT. Figure 6-17 shows the decision tree derived from 
the multivariate logistic regression model 2 and the actual number of patients in each group. 
This model identified 25 patients who could have been excluded owing to high probability of 
death with unreactive pupils and a lactate greater than 9 mmol/L; however, no patients 
fulfilled the second category of unreactive pupils and a lactate greater than 18 mmol/L. Only 
107 patients were included in the model owing to complete case selection. 
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Table 6-16 Model 2: Univariate logistic regression analysis: Additional factors 
available after ROSC up to four hours after PIC admission (excluding those already 
presented in Table 6-13) 
 
 
 
Unadjusted Odds Ratio 
for PICU survival 
(n=155) 
95% CI P 
value 
missing 
Probability of death score by 
PIM2 
0.04 (0.01-0.14) <0.001 0 
Minimum pH  5.32 (1.32-20.49) 0.015 9 
Maximum pH  17.06 (1.49-195.24) 0.023 9 
Minimum lactate (mmol/l) 0.86 (0.77-0.95) 0.004 19 
Maximum lactate  (mmol/l) 0.85 (0.77-0.94) 0.001 19 
Minimum glucose  (mmol/l) 0.87 (0.79-0.97) 0.008 10 
Maximum glucose  (mmol/l) 0.93 (0.87-0.99) 0.025 10 
Minimum base excess (mEq/l) 1.09 (1.03-1.14) 0.001 8 
Maximum base excess (mEq/l) 1.08 (1.02-1.14) 0.010 8 
Minimum Temperature (⁰C) 1.15 (1.0-1.33) 0.051 6 
Maximum temperature (⁰C) 1.19 (0.95-1.5) 0.133 6 
Temperature  < 32⁰C  0.42 (0.15-1.18) 0.1 6 
Two unresponsive pupils 0.12 (0.05-0.27) <0.001 23 
Insulin therapy 0.46 (0.18-1.14) 0.093 1 
Inotrope infusion  (after 
resuscitation) 
0.5 (0.25-1.0) 0.049 1 
Post hoc addition     
Lactate > 3 mmol/l  on PICU 
admission 
0.25 (0.12-0.52) <0.001 19 
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Table 6-17 Model 2: Multivariate logistic regression analysis of factors associated 
with PICU survival available up to four hours after PICU admission  
Variable Odds Ratio 
for survival 
(n=105) 
95% CI P value 
Two unresponsive pupils 0.19 0.07-0.52 0.001 
Maximum lactate (PICU admission) 0.85 0.75-0.97 0.015 
c-statistic = 0.831 Hosmer Lemeshow Goodness of Fit test = 0.080 (df=7) 
Sens = 87%, Spec= 55%, PPV = 84%, NPV = 62% 
 Variable in the model: VF/VT vs. PEA/asystole/bradycardia, PIM2, lowest base deficit, 
maximum lactate, maximum glucose, minimum pH, maximum pH, minimum core 
temperature, two unresponsive pupils. Total cases in model =105. 
 
 
Table 6-18 Model 2 (post hoc analysis): Multivariate logistic regression analysis of 
factors associated with PICU survival available up to four hours after PICU admission  
Variable Odds Ratio 
for survival 
(n=100) 
95% CI P value 
Two unresponsive pupils 0.292 0.09-.948 0.04 
No epinephrine (vs. one or more doses 
of epinephrine during resuscitation) 
7.14 1.22-46.96 0.03 
Lactate > 3mmol/l on PICU admission 0.227 0.07-0.77 0.02 
C statistic = 0.815  Hosmer Lemeshow Goodness of Fit test  p=0.747 (df=3) 
Sens = 94%, Spec= 54%, PPV = 85%, NPV = 77% 
Variable in the model: VF/VT vs. PEA/asystole/bradycardia, PIM2, lowest base deficit, 
maximum glucose, minimum pH, maximum pH, minimum core temperature, two 
unresponsive pupils, no epinephrine (vs. one or more doses of epinephrine), lactate 
>3mmols on PIC admission (vs. <3mmol/l). Total cases in model =100. 
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Figure 6-15 Receiver operator curve for model 2 prediction of survival status 
 
Figure 6-16 Model 2: Probability of survival based on lactate at admission to PICU 
 
Probability model based on regression coefficient from model 2 for varying lactate level on 
PICU admission with either reactive or two fixed (unresponsive) pupils. 
 
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
P
ro
b
a
b
ili
ty
 o
f 
s
u
rv
iv
a
l 
Lactate on PICU admission (mmols/l) 
Probability of survival based on lactate  
level  and pupil reaction at PICU admission 
Reactive Pupils
Fixed Pupil
Chapter 6  
208 
 
Figure 6-17 Model 2: Multivariate logistic regression derived decision tree using 10% 
survival as cut-off. 
 
Decision model derived from multivariate logistic regression model 2. Actual numbers 
calculated from population sample n= 107. Some groups resulted in zero numbers due to 
the extrapolation effect of the probability curve.  
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6.5.10 Decision tree model: Classification and Regression Tree analysis 
A decision tree prediction model was created using Classification and Regression Tree 
(CART) analysis with variables available during resuscitation and up to four hours after PICU 
admission on a random 50% of the population (Figure 6-18). The model identified pupillary 
reaction, duration of cardiac arrest and lactate levels on PICU admission as useful 
predictors. The model predicted death in PICU with a sensitivity of 87% and specificity of 
64% (positive predictive and negative predictive value of 81% and 70% respectively). In this 
model, 85% of patients with both unreactive pupils and duration of cardiac arrest greater 
than 20 minutes died. The „Risk‟ of the model = 0.203 therefore confirming the 
misclassification of 20% of cases. 
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Figure 6-18 CART decision tree model prediction of survival and death. 
 
The CART tree was empirically derived from a random 50% of cases. Prediction 
performance figures shown relate to the test data set comprising the remaining 50% of 
cases.  Risk of model 0.203 (SE 0.045). Data is split into segments that are as 
homogeneous as possible with respect to the dependent variable. 
Arrest to ROSC: time from cardiac arrest to return of spontaneous output (minutes). 
Improvement: the independent variable statistic improvement to the model by addition node. 
 
Sens = 87%, Spec= 64%, PPV = 81%, NPV = 70% 
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6.6 DISCUSSION 
 This is the largest reported out of hospital cardiac arrest (OHCA) study in the UK paediatric 
population covering one quarter of all UK PICU admissions over a seven year period (2004 
to 2010). The aim was to identify predictive factors of survival after OHCA in infants and 
children in order to potentially inform the design and analysis of future interventional trials 
after OHCA in the UK. 
The inclusion of only patients achieving a return of spontaneous circulation after a cardiac 
arrest of greater than one minute and requiring admission to PICU, allowed investigation of 
the population most at risk of hypoxic ischaemic brain injury and considered suitable for an 
intervention trial (e.g. therapeutic hypothermia). The overall survival rate to PICU discharge 
of 32% is lower than the 50% survival identified using the PICANet data in Chapter 5; 
however, is very similar to the reported 38% survival to hospital discharge rate by Moler et al 
(2011). The Moler study also found that age, bystander CPR and witnessing of arrest were 
not associated with survival. Predictive factors for survival to PICU discharge in the current 
study were identified by univariate logistic regression analysis. Factors associated with 
survival, available prior to cardiac arrest or during resuscitation, included: presenting in a 
shockable rhythm (VF or VT), shorter duration of cardiac arrest, return of spontaneous 
cardiac output prior to arrival in the emergency department and lower number of epinephrine 
doses. Additional factors associated with survival, available within four hours of PICU 
admission, included: higher pH, lower lactate, lower maximum glucose, higher base deficit, 
lower PIM2 score and two reactive pupils. 
After the primary multivariate logistic regression analysis, the only factor independently 
associated with survival available before cardiac arrest or during resuscitation was 
presenting in a shockable rhythm (VF/VT). Post hoc analysis identified the addition of no 
epinephrine versus one or more doses of epinephrine during resuscitation as a factor 
associated with survival which was also identified by Moler et al (2011). With the inclusion of 
variables available at the time of PICU admission, factors strongly associated with 
decreased survival included high blood lactate level and two unresponsive pupils. Post hoc 
inclusion of the dichotomised epinephrine dose (no epinephrine versus one or more doses of 
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epinephrine during resuscitation) and dichotomised lactate level (greater than or equal to 
3mmol/L versus less than 3mmol/L) at PICU admission changed the model and identified 
the association of two unresponsive pupils and higher plasma lactate within four hours of 
PICU admission with decreased survival and no epinephrine dose at resuscitation with 
increased survival. The CART decision tree analysis created a similar model identifying the 
use of either the duration of cardiac arrest or lactate level on PICU admission depending on 
pupillary reaction response. Performance of the prediction models one and two improved 
with the addition of physiological factors available within four hours of PICU admission. The 
CART decision tree and prediction model two were comparable with respect to sensitivity, 
specificity, positive and negative predictive values.  
6.6.1 Shockable rhythm  
In this study, 12% of patients with ROSC and admission to PICU presented in a shockable 
rhythm (either VF or VT) and this was associated with increased survival. The survival 
benefit of presenting in VF or VT has been identified in a number of OHCA studies (Young et 
al, 2004; Herlitz et al, 2007; Hickey et al, 1995; Mogayzel et al, 1995; Smith et al, 2006). 
Although, the true incidence of VF/VT in the paediatric OHCA population is not clear. Atkins 
et al (2009), in a large multicentre, registry study, identified 7% of patients with a shockable 
rhythm (ranging from 4 to 5% of infants and 15% of adolescents), though in 7% of patients 
this information was missing and in a further 11% the rhythm was un-interpretable. This is 
comparable with our current study, where the presenting cardiac rhythm was not recorded in 
10% of patient‟s case notes. However, our study confirms the importance of early 
identification of cardiac rhythm in the paediatric patient by first responders and emergency 
department staff. 
6.6.2 Duration of cardiac arrest 
Increased duration of cardiac arrest as a predictive factor for increased mortality has been 
described by many. Schindler et al (1996) studied children presenting after OHCA to an 
emergency department and reported no neurologically intact survivors following ongoing 
resuscitation in the emergency department, greater than 20 minutes. In that study, median 
duration of resuscitation in the emergency department for survivors was 9 minutes (range 6-
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18 minutes) versus 20 minutes (range 6-115 minutes) for non-survivors. In our study, 1 in 4 
patients with 21-30 minutes of CPR in the emergency department, who achieved a ROSC, 
survived. Improvement over the last two decades in resuscitation practices, pre-hospital care 
and post-intensive care management may all be potential factors in this finding. Interestingly, 
total duration of cardiac arrest or ROSC prior to emergency department admission was not 
independently associated with survival in the multivariate logistic regression model. 
However, duration of cardiac arrest was identified in the CART analysis decision tree for the 
group of patients with two fixed and unreactive pupils. In this subgroup of patients with two 
fixed pupils, a duration of cardiac arrest greater than 20 minutes resulted in death before 
PICU discharge in 85% of cases in the test sample. Our inclusion of only patients with 
ROSC will increase the observed difference noted between Schindler et al (1996) and this 
study, as there will be a number of OHCA patients not achieving ROSC in the emergency 
department who were not included in this study. 
Circumstances where prolonged resuscitation is suggested by international resuscitation 
guidelines include OHCA secondary to cold water near-drowning (Soar et al, 2010). In our 
study 12 patients were successfully resuscitated after near drowning. Median duration from 
cardiac arrest to ROSC in the drowning population was 54 (IQR [32 to 126]) minutes with 
continued resuscitation in the emergency department from arrival for 38 (IQR [9 to 82]) 
minutes; although survivors had shorter durations for both total and emergency department 
resuscitation times. All survivors in this group were hypothermic (less than 32°C) on arrival 
and these findings support the need to treat this population differently as hypothermic neuro-
protection at the time of cardiac arrest may allow potential recovery despite a prolonged 
period of resuscitation (Soar et al, 2010).  
6.6.3 Epinephrine use 
The use and timing of epinephrine during OHCA resuscitation is described clearly in 
resuscitation algorithms (Biarent et al, 2010).  This study identified that only 29% (14/50) 
survivors did not receive any epinephrine and there was a marked fall in survival rate from 
75% to 30% when any epinephrine was required. Moler et al (2011) found just over half 
(52%) of survivors in their study did not receive epinephrine and reported a very high 
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mortality (96%) in patients receiving three or more doses. Our study does not support this 
finding. As was found with prolonged resuscitation times, survival rates in patients receiving 
four, five or even six or more doses of epinephrine remained around 20 to 25% and 
therefore a resuscitation cut-off at the suggested level of three doses would not be 
appropriate based on our data. 
6.6.4 Length of time to PIC admission 
This study confirmed the finding from Chapter 5 that 74% of patients required transportation 
from another hospital into the PICU. As a result, time to admission from ROSC was 
considerable for both survivors and non-survivors and was a median of four hours 30 
minutes. An important finding was that individual emergency department‟s exposure to 
successfully resuscitated OHCA patients was infrequent. 111/150 patients transported to 
PICU were transported from 61 different emergency departments; therefore, each 
emergency department only transferred a median of one patient over the whole seven year 
period. These findings have important implications for potential post cardiac arrest trial 
design. Evidence supports the need for therapeutic hypothermia to commence as soon as 
possible after cardiac arrest. Previous hypothermia studies that demonstrated a benefit to 
neurological outcome in either adults or neonates (Bernard et al, 2002; HACA, 2002; 
Azzopardi et al, 2009), have advocated commencement of therapeutic hypothermia within 
six hours. The optimum therapeutic window in infants and children is not known but could 
theoretically fall within this time frame. Practical considerations in trial design include when 
and how patients can be enrolled into studies, when and how consent can be obtained and 
whether it is feasible for temperature management to begin early after ROSC. One option 
would be to prospectively obtain informed consent of parents of OHCA patients on arrival at 
the admitting PICU. However, the opportunity for families to be approached and to consider 
the implications of the trial will be severely limited given the importance of early initiation of 
therapy. A second option, which requires emergency medicine teams to recruit patients at 
the initial presenting hospital, risks potentially investing time and money in supporting a large 
number of emergency departments which will probably admit only one or two patients during 
the whole study period. A third, more efficient recruiting option, would be to utilise the 
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specialist retrieval services, which are now established, and transport patients from 
emergency departments to the PICU. This would significantly minimise the number of 
personnel involved in delivery of the trial protocol, maximise expertise and allow earlier 
recruitment and enrolment within the therapeutic time period before PICU admission.   
6.6.5 Blood lactate level 
Blood lactate level at PICU admission was significantly lower in survivors and a strong 
predictor of survival after OHCA in our study. This is similar to Kliegel et al (2004), who 
reported adult survivors after OHCA had lower lactate levels on emergency department 
admission (median, 7.8 mmol/L (IQR, 5.4-10.8) versus non-survivors 9 mmol/L (IQR 6.6-
11.9). Donnino et al (2007), in a retrospective study of successfully resuscitated adults after 
OHCA, found similar lactate levels between survivors and non-survivors on emergency 
department admission. However, in a multivariable analysis, they found high lactate 
clearance at 12 hours was significantly associated with early (24 hour) survival (p<0.05). 
(Donnino et al, 2007). Lactate has also been identified as an important predictive factor in all 
PICU patients, adding to the performance of the PIM2 score (PICANet, 2011). Moler et al 
(2011) excluded lactate from their logistic regression because of missing values. In our 
study, lactate was not available immediately after ROSC and was only infrequently 
measured in the emergency department (35% (54/155) of patients). We therefore utilised the 
score available up to four hours after admission to PICU. This may therefore reflect 
improvement in clearance of lactate over time from ROSC to PICU admission in survivors; 
however early, post-ROSC lactate levels were not available for comparison. Lactate is a 
marker of anaerobic metabolism and reflects ischaemic stress. It has been identified as a 
predictor of survival after sepsis, septic shock, cardiac bypass (Allen, 2011; Hatherill et al, 
2000; Mikkelsen et al, 2009; Siegel et al, 1996) and is likely to reflect the pathophysiological 
damage occurring before, during and after resuscitation. For example, preceding conditions 
such as asthma may result in high lactate levels due to tissue hypoxia compared to a 
sudden cardiac arrhythmia. During resuscitation, better CPR may also increase lactate 
levels due to tissue washout phenomenon. Lactate levels can also be increased by excess 
epinephrine administration or microcirculatory failure (Al Thanayan et al, 2008). Despite 
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these confounding issues, high PICU admission lactate was predictive of survival outcome in 
this cohort and became incorporated in both the multivariate logistic regression model 2 and 
the CART analysis.  We therefore recommend that blood lactate level is included in risk-
stratification criteria for prospective interventional studies.  
6.6.6 Temperature 
Temperature variation and relationship to survival after cardiac arrest is of considerable 
interest. In this study, temperature was infrequently recorded on arrival to the emergency 
department or at the time of ROSC. However, in 42% of patients with recorded 
temperatures, there was no difference in temperature between survivors and non-survivors. 
At the time of leaving the emergency department the difference in temperature between 
survivors and non-survivors was approaching significance (35.9 (IQR [34.9 to 36.5])⁰C vs. 
34.7 (IQR [33.2 to 36.3])⁰C; p=0.051). By PICU admission survivors were 1⁰C warmer (36.5 
(IQR [35.6 to 37.2])⁰C) than non-survivors (35.5 (IQR [33.4 to 37.0])⁰C; p=0.007). In our 
study, patients admitted after near-drowning were included (n=12). The median lowest 
recorded temperature in the emergency department for the near-drowning population was 
27.3 (IQR [26 to 30.3], range 14 to 35.8)⁰C. Only two patients after near-drowning had a 
minimum temperature greater than 32⁰C and neither survived. 
During the analysis of temperature as a candidate variable for survival prediction, a number 
of important confounders were identified. Patients who required transportation from a 
different emergency department demonstrated an increase in temperature from the 
emergency department to PICU admission compared to patients admitted directly from the 
emergency department to PICU, who showed a fall in temperature. Those transported had a 
significantly longer time period between the emergency department and PICU admission 
and opportunity for spontaneous rewarming, or application of warming measures. Patients 
who subsequently received therapeutic hypothermia in PICU tended to decrease their 
temperature between the emergency department and PICU admission compared to those 
who eventually received standard therapy; although, this difference was only seen in the 
patients who were transported. These observations may imply that transport teams were 
Chapter 6  
217 
 
already aware of the targeted temperature approach and either actively cooled, or actively 
avoided warming patients during the transport.  
6.6.7 Hypothermia 
Spontaneous hypothermia after cardiac arrest has been observed in both paediatric and 
adult studies (Lyon et al, 2010; Hickey et al, 2000; Takino & Okada, 1991; Fink et al, 2010). 
The median minimum temperature in the first 12 hours after OHCA in the study by Meert et 
al (2009) was 34.1 (IQR[32.5 to 35.6])⁰C and would not have been influenced by subsequent 
therapeutic hypothermia (as only used in 3/138 patients). Comparing the survivors and non-
survivors of the same population, Moler et al (2011) identified survivors had significantly 
higher, minimum temperatures by 2⁰C in the first 12 hours after ROSC compared to non-
survivors (35.5 (IQR[33.7 to 36.2])⁰C vs. 33.5 (IQR[32.3 to 34.8])⁰C; p>0.01). Compared to 
our study, minimum temperature after ROSC to four hours after PICU admission was very 
similar for both sets of non-survivors (33.3⁰C vs. 33.5⁰C); however median temperature for 
survivors in Moler et al (2011) was higher by 1⁰C (35.5⁰C vs. 34.5⁰C). This might have been 
explained by the greater use of targeted temperature therapy causing a reduction in median 
minimum temperatures in our study. 
6.6.8 Hyperthermia 
The association of hyperthermia after brain injury and poor neurological outcome or death 
has been repeatedly observed after cardiac arrest (Bembea et al, 2010; Suffoletto et al, 
2009; Hickey et al, 2000; Zeiner et al, 2001). International resuscitation guidelines have 
therefore repeatedly stressed the need to avoid hyperthermia after paediatric cardiac arrest 
(ILCOR, 2006; Kleinman et al, 2010). Therefore, identifying 29% (45/155) who experienced 
hyperthermia (temperature greater than 38⁰C) within the first 24 hours is a concern, as all 
but one episode of hyperthermia occurred after PICU admission. Although this was not 
associated with a significant effect in survival, it is possible that unmeasured 
neurodevelopmental injury may have occurred. The proportion of hyperthermic patients 
identified signifies that recommendations pre-dating the start of this study were not followed; 
however, the reason for this is not clear from this study and will require further evaluation.  
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Median, maximum temperatures measured only in the emergency department, or with 
inclusion of temperature up to four hours after PICU admission, were similar for survivors 
and non-survivors.  
Comparison of median temperatures every four hours after PICU admission up to 24 hours 
did not show an increase trend in temperature in either survivors or non-survivors. Rebound 
hyperthermia has been noted to occur 6-12 hours after successful resuscitation in patients 
not undergoing active targeted temperature control (Takino & Okada, 1991; Hickey et al, 
2000; HACA, 2002) and in the control (standard therapy) arm of the European Hypothermia 
after Cardiac Arrest randomised control trial (HACA, 2002). Bembea et al (2010), identified 
that fever in the first 24 hours was associated with worse outcome. However, the time 
window for vulnerability is not clear. In an animal study, fever at 24 hours but not 48 hours 
was associated with increased CA1 hippocampal cell death (Hickey et al, 2003). Bembea et 
al (2010) interestingly reported that “any hyperthermia” after adjusted multivariate analysis 
was associated with a non-significant trend towards better neurological outcome and 
survival versus children with no hyperthermia. In an editorial accompanying this report (Fink, 
2010), it was postulated that pre-conditioning with hyperthermia prior to arrest may have 
influenced this finding (although without supportive pre-arrest temperature data this is only 
speculative). However, this hypothesis is supported by animal studies where pre-
conditioning hyperthermia induced heat-shock protein 70 and reduced brain injury in rats 
that were subsequently exposed to ischaemia at normothermia (Chopp et al, 1989; Ota et al, 
2000). 
This study has identified the occurrence of both severe hypothermia (<32°C) and 
hyperthermia after OHCA in children and the association of severe hypothermia with 
increased mortality. Overall, temperature recording was infrequently performed or recorded, 
especially in the emergency department. This may be as a result of lack of awareness of the 
importance of temperature management after OHCA or as a result of the retrospective 
design of this study relying on documentation of information. The difference in the proportion 
of patients receiving targeted temperature management across the three PICUs is 
consistent with the observations in Chapter 4 which reported the variation in use of the 
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therapy by UK, paediatric intensive care consultants. The main implications of this finding, 
with respect to the current study, will be to include only Unit 2 patients when comparing 
outcomes of therapeutic hypothermia versus normothermia (Chapter 7). Inclusion of Unit 1 
and Unit 3, who have very small populations receiving therapeutic hypothermia, has the 
potential to introduce additional confounding variables and reduces the ability to extract the 
observed differences between the two potential treatments. With regards to future 
interventional RCTs, considerable efforts will be required to improve the temperature 
monitoring in the emergency department and procedures for temperature control to ensure 
standardisation of practice and compliance with prospective temperature monitoring and 
control protocols. 
6.6.9 Extracorporeal life support 
ECLS was used in only three patients during this study. One patient requiring full cardiac 
support and rewarming for extreme hypothermia and two, after a period of ROSC, for poor 
cardiac function and hypoxia. One survived to PICU discharge but was discharged to a 
hospice for terminal care and died a few days later. The use of ECLS during resuscitation in 
patients who do not regain ROSC (known as extracorporeal life support CPR or ECPR) has 
become an established tool in refractory in-hospital cardiac arrest and in cases of severe 
hypothermia. In selected cases survival with good neurological outcome has been reported 
in 30-40% of patients (Huang et al, 2012; Joffe et al, 2012). Its use in the OHCA population 
is much more controversial owing to the poor survival outcomes and has been described by 
only a few adult centres (Kagawa et al, 2010). Recently though, a preliminary report of a ten-
fold increase in neurologically intact survival where ECPR has been used for refractory VF 
cardiac arrest in Japanese emergency department has been announced (Asai et al, 2012). 
Although promising, further analysis of these findings will be required when published in full. 
ECPR, unfortunately, is an extremely expensive resource and likely to only be available in 
tertiary teaching hospitals.  
6.6.10 Limitations: Neurological outcome 
Survival with a good neurological outcome is the major target of resuscitation and post-
resuscitation therapy. Very poor neurological outcome will be regarded as worse than not-
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surviving by some families. A major limitation to this study was the lack of neurological 
outcome data. The original plan was to calculate the Paediatric Cerebral Performance 
Category (PCPC) score at PIC discharge and hospital discharge. Because of the 
methodological constraints of the study, data were only extracted from medical records. 
Unfortunately, only limited information relating to neurological function could be obtained 
from medical records and clinic letters and in a number of cases, where patients were 
transferred back to their referring hospital, no follow-up data were available. Therefore, with 
only limited PCPC data available, it was not possible to accurately report or analyse. 
Because of the importance of this information, a full Regional Ethics Committee application 
has now been submitted with a view to contacting families of surviving infants and children 
of all three hospitals to undertake a follow-up study to supplement the results of this study. 
6.6.11 Limitation: Missing data 
An inherent problem of retrospective medical studies is missing data and this study is no 
exception. Firstly, the missing cases identified as potential OHCA patients from Unit 3, 
weakens the overall conclusions and risks introducing case selection bias, especially as the 
case notes of deceased patients are generally easier to access and review. This may 
explain why Unit 3 had the lowest reported survival rates. The second problem regarding 
missing data was in the situation when medical records were available but data was missing 
from them. One example is the lack of blood lactate measurements in the emergency 
department, when other blood gas parameters (pH, base deficit etc) were recorded. This is 
possibly because blood gas analysers did not include lactate measurement as standard. The 
lack of recorded core temperatures in the emergency department may be due to either the 
temperature not being taken or taken and not recorded, but for what reason? Was the 
temperature not taken because the patient „felt‟ warm enough which would therefore raise 
the study population‟s mean/median values, or was it just not considered even if the patient 
was cold? If the temperature was taken and not felt to be important, was it therefore also not 
recorded? This study is unfortunately not able to answer these questions, but it should be 
considered for future trial implications. A final scenario is that missing data, such as 
aetiology of OHCA, is likely to represent the inherent difficulties associated with identifying a 
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cause of arrest in this population. Although, our missing data rate, in this respect, is 
comparable to other retrospective and prospective cardiac arrest observational studies. 
 The consequence of missing data was most notable in the multivariate logistic regression 
analysis. In this study, we elected to handle missing data by not imputing or substituting by 
mean or regression approaches (White & Carlin, 2010). In the multivariate logistical 
regression models, complete case selection (or listwise deletion as defined in the SPSS 
statistical package) of cases was adopted, therefore including only cases with all included 
variables. The disadvantage to this approach is that the sample size is reduced, the potential 
for type I and II errors are increased and the model may not accurately represent the whole 
study sample or the general population. Both multivariate logistic regression model 1 and 2 
included only 65-77% of complete case. We were reassured by the finding that both model 
results remained consistent if only the final identified variables were used in a repeat forward 
step-wise analysis (which allowed an increased number of cases to be included). However, 
owing to most of the variables included in the model being closely correlated to each other, 
there is the potential for the model to change and produce different strongly associated 
factors with only a few additional cases. The advantage to our complete care selection 
approach was that we were not creating new values which may reinforce wrong 
assumptions of the logistic regression models and is the method most favoured in recent 
guidance (Groenwold et al, 2012; White & Carlin, 2010). This is especially important in view 
of the small overall sample size of our study population and as mentioned, the close 
correlation of candidate variables. 
Our missing data rates were comparable with other published studies. The multicentre 
registry study (National Registry of Cardiopulmonary Resuscitation) had incomplete data on 
presenting cardiac rhythm in 22% of cases (Nadkarni et al, 2006), the large North American 
study by Young et al could not report aetiology in 11% of cases and Moler et al (2010) had 
missing data for a large proportion duration of total cardiac arrest and lactate levels and 
omitted them from their analysis.  The solution to the problem of missing data may be the 
use of prospective collected, protocolised, specific clinical data.  
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6.6.12 Limitation: Study size 
A strength of this study was the inclusion of a large population from three large UK PICUs, 
accounting for 23% of all PICU admissions in the UK. However, the study required data 
collection over a seven year period and changes in resuscitation management, patient PIC 
admission criteria and PIC post-cardiac arrest care may have influenced outcome. We found 
no change in the proportion of survivors over the time period although post-cardiac arrest 
interventions changed. Although the study accounts for nearly a quarter of all patients in the 
UK and findings were consistent with other published studies, there is a possibility that case 
selection and management of OHCA patients in these PICUs is not representative of the 
rest of the UK. In addition, we identified differences between the three units included within 
the study. For example, unit one did not have an emergency department co-located with the 
PICU, therefore, all their patients required transportation thus delaying time to admission. As 
previously stated, there was also a significant difference in the proportion of patients 
receiving therapeutic hypothermia and targeted temperature management on PICU. 
Although, overall survival rates across the three units were not significantly different.  
6.6.13 Limitation: Pre-hospital management and CPR quality 
Owing to the retrospective nature of this study and the focus on emergency department and 
PICU data collection, limited data was available regarding pre-hospital management of 
paediatric patients prior to emergency department admission. As identified in this study only 
8% of children achieved a ROSC prior to admission to the emergency department; however, 
it is not possible to ascertain the reasons why ROSC was achieved after arrival but not 
during pre-hospital care. This critical and challenging time pre-hospital is potentially a vital 
period where reduction of further ischaemia reperfusion injury can be achieved. However the 
risk to benefit ratio between implementing advanced life support techniques and resultant 
delays in transporting patients is extremely difficult to balance. Assessment of paramedic 
and ambulance crew interventions for OHCA including both patients who do and do not 
achieve ROSC will be required in a future study. This may potentially identify further areas 
for improving our outcome prediction models or more importantly cardiac arrest survival.   
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6.6.14 Limitation: CART analysis 
The prediction tool created in this study using CART was a balance between simplicity and 
accuracy. Multiple adjustment settings to the decision tree are possible in its creation and 
the use of a training and test sample reduced further the size of the population to create the 
tree. Therefore, caution regarding the applicability of the findings to other OHCA populations 
or individuals must be stressed. 
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6.7 CONCLUSION 
Through the collection of the largest study population of infants and children achieving 
ROSC and admission to PICU after OHCA, this study has identified multiple factors 
associated with PIC survival. We confirmed the importance to survival of identifying and 
treating a shockable rhythm during resuscitation in the paediatric population and identified 
the strong association with mortality of raised blood lactate level and two unresponsive 
pupils on admission to PICU. Analysis of the resuscitation variables of patients admitted to 
PICU has also informed key areas of trial design, including: baseline mortality rates, timing 
and opportunity for recruitment and consent, current variability in temperature monitoring, 
variability in targeted temperature management, and factors strongly associations with 
mortality. The prediction model could be used as a risk-stratified randomisation or analysis 
tool in a future RCT, in addition to setting inclusion/exclusion criteria to remove patients 
likely to die despite any potential post-resuscitation intervention. This would increase the 
efficient use of a clinical trial study population, reducing the number of patients required and 
maximising research cost-utility. 
 
Table 6-19 Chapter 6 and RCT feasibility 
What have we learnt from this study towards the feasibility of a UK randomised controlled 
trial? 
Only a third of patients admitted to PIC after OHCA survive to PICU discharge. This is 
comparable with published studies; however, lower than the estimate from the NETPACK 
study (Chapter 5). 
Presenting rhythm and need for epinephrine during resuscitation, plus high lactate and 
presence of two unresponsive pupils at PIC admission, are key associated factors with 
poor survival in this population and will need to be factored into the design of an RCT. A 
potential decision tree model is presented. 
Median time to PICU admission after OHCA is four and a half hours and may involve 
transfer from a large number of referring hospitals. Early recruitment will require additional 
input by specialist transport teams. 
There was wide variation in the proportion of infants and children receiving therapeutic 
hypothermia amongst the three PICUs in this study.  
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7 Comparison of the use of 
therapeutic hypothermia with 
standard temperature therapy 
after paediatric out of hospital 
cardiac arrest. 
 
  
She tasted the porridge from the first bowl. 
“This porridge is too hot!” she exclaimed. 
So, she tasted the porridge from the second bowl. 
“This porridge is too cold,” she said 
So, she tasted the last bowl of porridge. 
“Ahhh, this porridge is just right,” she said happily and she ate it all up. 
 
Goldilocks and the Three Bears: Robert Southey (1837) 
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7.1 ABSTRACT 
7.1.1 Introduction 
Therapeutic hypothermia (TH) may improve survival and reduce brain injury for children after 
out of hospital cardiac arrest (OHCA).  International resuscitation recommendations to 
consider TH were adopted by our tertiary paediatric intensive care unit (PICU) in 2007.  
Evaluation of patient temperature management and outcomes may inform the feasibility of 
performing future TH trials and its potential benefits or harm in children. 
7.1.2 Aims 
To assess the benefits and safety of TH (core temperature 32-35⁰C) versus standard 
temperature management (ST) (>35⁰C) after paediatric OHCA.  
7.1.3 Methods 
 Retrospective cohort study set in a UK tertiary PICU. Infants and children greater than 24 
hours until their 16
th
 birthday admitted to PICU after an OHCA (January 2004 to December 
2010). 
7.1.4 Results 
 We studied 73 patients admitted to PICU after out of hospital cardiac arrest. Thirty eight 
patients (52%) received TH. Compared to ST, the TH group received more bystander CPR 
(80 vs. 47%; p=0.005), a trend towards longer duration of cardiac arrest (40mins (27-58) vs. 
30mins (22-48); p=0.264) and a lower core temperature at PIC admission (34.3⁰C vs. 
36.1⁰C; p=0.007). In patients receiving TH, return of spontaneous circulation to target 
temperature duration was 5.5hrs (1.5-8hrs). If core temperature was >35⁰C (n=18/36) at the 
start of TH induction, target temperature was reached within 2.5 hrs (2-4hrs) at a rate of 
0.9⁰C/hr (0.5-1.5). Median TH target temperature was 33.5⁰C (33-34⁰C) for a duration of 23 
hours (17-25hrs). Rewarming lasted 10hrs (6.5-15hrs) at a rate of 0.3⁰C/hr (0.23-0.45). 
There was no difference in hospital survival (TH: 34% vs. 23% ST; p=0.284). TH group had 
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a significantly longer PICU length of stay (4.1 days [3.0-6.8] vs. 1.3 day [0.5-6.7]; p=<0.001). 
All patients experiencing a core temperature <32⁰C died. 
7.1.5 Conclusions 
This is the first UK and largest study comparing the use of TH with ST after OHCA. TH was 
effectively administered in the paediatric population with limited adverse events; however, it 
did not increase survival to hospital discharge. Further prospective evaluation is warranted.   
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7.2 INTRODUCTION 
Therapeutic hypothermia (TH) may be a treatment which improves survival and reduces 
brain injury for children after out of hospital cardiac arrest (OHCA). The 2010 International 
liaison committee on resuscitation (ILCOR) recommendations state: 1) TH (32 to 34°C) may 
be beneficial for adolescents who remain comatose following resuscitation from sudden, 
witnessed, out-of hospital, VF cardiac arrest and 2) TH (32 to 34°C) may be considered for 
infants and children who remain comatose following resuscitation from cardiac arrest 
(Kleinman et al, 2010).  The evidence to support the recommendations for TH by ILCOR is 
based on extrapolation of neonatal and adult RCTs, as no paediatric RCTs have been 
published. However, neonatal studies were performed on patients after hypoxic ischaemic 
encephalopathy where cardiac arrest often did not occur and the adult studies were 
performed in a group of patients specifically presenting in a shockable rhythm (ventricular 
fibrillation or ventricular tachycardia). Therefore, there remains a strong need for additional 
paediatric evidence regarding TH to inform clinical practice. 
There is some limited paediatric specific observational evidence as described in detail in the 
Cochrane systematic review (Chapter 3) but this evidence lacks essential information 
regarding paediatric post cardiac arrest management pertinent to future trial design. Only 
two retrospective observational studies (Fink et al, 2010; Doherty et al, 2009) and one 
(unpublished) prospective observational study (Buttram et al, 2009) compared TH with 
standard therapy (ST) in the paediatric population. None of the observational studies 
demonstrated a significant difference in paediatric cardiac arrest survival or the proportion 
with good neurological outcome when treated with TH. The main limitations of these studies 
included; small numbers, relatively old studies (before and after the publication of the two 
main RCTs supporting TH in adults (Bernard et al, 2002; HACA, 2002), unbalanced groups 
with regards: increased severity of illness, use of extracorporeal life support (ECLS) and 
higher propensity scores associated with TH use. Also the majority (95%) of patients in the 
Doherty et al (2009) study were after in-hospital arrests as were 50% in the study by Fink et 
al (2010). There was also a lack of reporting of data with regards; time delay to admission, 
route of admission (e.g. from another hospital), transportation time, time to initiate TH, time 
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to reach target temperature and physiological differences between paediatric patients 
treated with TH and ST. All these factors would be potentially useful in future trial design and 
feasibility of performing a prospective interventional study in this population.  
Although overall adjusted mortality and neurological outcomes for patients receiving TH and 
ST were similar in both studies, important additional observations regarding temperature 
control were identified. Fink et al (2010) reported that inadvertent hypothermia (<32°C) in the 
TH group was associated with increased in-hospital mortality. They also reported a high rate 
of hyperthermia (>38°C) although not associated with worse survival outcome. Inadvertent 
overcooling has also been identified in adult (Merchant et al, 2006), paediatric (Topjian et al, 
2011) and neonatal (Sarkar & Barks, 2010) hypothermia studies and remains an area of 
concern requiring accurate temperature control during therapy application (Polderman & 
Herold, 2009). Further evaluation of temperature control and application of TH in the 
paediatric population is therefore important. 
The ILCOR recommendations, based on the adult and neonatal evidence, to consider TH 
after paediatric cardiac arrest, were adopted by our tertiary paediatric intensive care unit 
(PICU) in January 2007.  Paediatric Intensive Care consultants had the autonomy to decide 
whether to use targeted temperature management in addition to routine post-cardiac arrest 
care. 24 hours of TH at a temperature of 32-34°C with gradual rewarming was generally 
adopted as per ILCOR guidance, although a formalised treatment protocol was not 
published until November 2009 explicitly stating the desired duration of 24 hours, a 
temperature target of 33°C and a rewarming rate of 0.25°C per hour. Prior to January 2007 
and in patients after 2007 not receiving TH, standard temperature therapy (ST) after OHCA 
in our PICU followed recommended best practice which involved maintaining normothermia 
(36.5-37.5°C) and avoiding hyperthermia (>38°C).   
An evaluation of the post cardiac arrest management and eventual outcomes of patients 
receiving TH compared to patients receiving ST will inform the potential effect of the therapy 
on survival in the post OHCA population. In addition, valuable information will be obtained to 
inform the feasibility of designing a post cardiac arrest intervention study using targeted 
temperature therapy. This includes data on implementation of therapy, time to reach target 
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temperature, stability and rewarming rate. Adverse event rates and the difference in 
physiological responses to TH versus ST will also be available. 
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7.3 AIMS 
 
7.3.1 Primary Aim 
1. To ascertain hospital survival rates in children receiving therapeutic hypothermia 
(TH) and compare with those receiving standard temperature management (ST) 
after paediatric out of hospital cardiac arrest. 
 
7.3.2 Secondary Aims 
1. Evaluate time to commencement, rate of cooling, duration, depth, stability and rate 
of rewarming of administered TH. 
2. Assess adverse clinical and physiological effects of TH. 
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7.4 METHODOLOGY 
7.4.1 Settings and participants 
This retrospective, single-centre, cohort study included infants and children admitted to the 
PICU at Birmingham Children‟s Hospital after out-of-hospital cardiac arrest (OHCA) over a 
seven year period (Jan 2004- Dec 2010). Data were collected in conjunction with the multi-
centre study described in Chapter 6 with additional data regarding targeted temperature 
management and physiological parameters. 
Birmingham Children‟s Hospital PICU is a large, regional paediatric centre admitting 1300 
infants and children per year.  National and local databases identified potentially eligible 
patients. These included the PICANet admission coding for preceding cardiopulmonary 
resuscitation (CPR) and preceding hospital cardiac arrest, local PICU discharge coding 
system for terms relating to cardiac arrest and out-of-hospital cardiac arrest, and an existing 
cardiac arrest and acute life threatening events registry. 
7.4.2 Study design 
Inclusion: Patients aged 24 hours old, up to their 16
th
 birthday, admitted to PICU after an 
OHCA with successful return of spontaneous circulation were included. OHCA was defined 
as no cardiac output and pulseless for greater than one minute as confirmed by a trained 
medical practitioner/paramedic prior to arrival at an emergency department.  
Exclusion: Patients were excluded if they were younger than 24 hours of age or had an 
OHCA secondary to birth asphyxia. This age limit was to exclude patients admitted after 
perinatal hypoxic ischaemic encephalopathy, as standard treatment protocols regarding the 
use of TH are already established and this patient population is admitted to a neonatal 
intensive care unit separate from our PICU. 
7.4.3 Data collection and assessment  
Retrospective reviewing of individual case notes, PICU nursing charts and computerised 
patient records was performed. Data were recorded electronically onto a piloted Excel 
(Microsoft, USA) spreadsheet and inputted, analysed and saved securely within the NHS 
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Trust fire-walled computer server. A data-entry guide and instruction booklet was created. 
One to one training was provided for three data collectors (Ms Gosney, Sanders and Dr 
Skone) by the chief investigator. Inputted data was verified at the inputting stage using data-
verification limits set in the excel programme which generated a warning message for values 
outside expected ranges (e.g. age limit set to 0-16 would alarm and not allow recording if 
values greater than 17 were entered). Individual queries were clarified directly with the chief 
investigator with regular reviewing of progress. Further data-verification was taken during 
analysis stage with significant outliers, unexpected or improbable values and missing values 
queried and re-checked with the primary records by the relevant data-collector.  
Patients were divided into two groups, therapeutic hypothermia (TH) and standard therapy 
(ST). The use of therapeutic hypothermia was defined a priori as documented active 
targeted temperature management to reduce to or maintain at a core temperature less than 
35°C.  
Data were collected using Utstein style recommended definition when available. Figure 7-1 
show the data collection domains and time points. Demographic data included; age, weight, 
sex, presence of chronic conditions prior to OHCA and requirement for transportation to 
PICU. A chronic condition was defined as a pre-existing medical condition likely to increase 
risk of an OHCA. Aetiology of arrest was extrapolated from medical documentation using 
information until the time of discharge or from post-mortem reports if available. Categories 
included; pulmonary, cardiac, submersion (including near-drowning), neurological (non-
traumatic), sepsis, inflicted traumatic brain injury, strangulation, near sudden infant death, 
trauma (including traumatic brain injury but excluding other injury related aetiologies already 
listed). Further comparative groupings of aetiology included asphyxial versus cardiac 
aetiology and non-traumatic versus traumatic (including all trauma aetiologies; submersion, 
strangulation, inflicted and non-inflicted traumatic brain, electrocution and „other‟ trauma).  
Cardiac arrest event characteristics were collected including: place of arrest, witnessed 
status, use of bystander cardiopulmonary resuscitation, first recorded rhythm on 
electrocardiograph (ECG) monitor by paramedic or emergency medicine staff, use and 
number of cardiac defibrillation attempts and doses of epinephrine. Date and time of 
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important key stages after OHCA were recorded as illustrated in Figure 7-2. Time intervals 
were calculated including duration of cardiac arrest (time of arrest to ROSC), duration of 
resuscitation from emergency department arrival to ROSC, time from ROSC to PICU 
admission and length of stay in PICU.  
Physiological variables routinely available between ROSC and PICU admission were 
collected. Data was recorded whilst in the emergency department, during transportation or 
on arrival to PICU. Further data was collected at four hourly intervals after PICU admission.  
Two sets of physiological data were analysed. First, maximum and minimum variables 
between ROSC and four hours post PICU admission were compared between TH and ST 
groups to identify differences in respect of covariates known to be associated with increased 
mortality (Chapter 6). Secondly, physiological variables were collected at 4 hourly intervals 
from PICU admission until 72 hours post admission (or death or PIC discharge, if earlier). 
These included; core temperature, heart rate, systolic blood pressure, mean blood pressure, 
partial pressure of oxygen (PaO2) and carbon dioxide (PaCO2) in the blood. These 
physiological variables were compared between two time periods: first 24 hours and 24-72 
hours after PIC admission. The mean values for each variable was compared between the 
TH and ST groups. Heart rate and systolic blood pressure are presented in normalised units 
corrected for age using mean reference values (Elf et al, 2002). 
Haematological values were compared including: haemoglobin, total white cell count, 
platelets, prothrombin time and activated partial thromboplastin time. The proportion with 
thrombocytopaenia (platelet count less than 150 x 10
9
/litre of blood) was recorded. 
Biochemical values included sodium, potassium, magnesium, urea and creatinine levels. 
Core temperature was collected, if recorded, at additional time points; at the time of OHCA, 
ROSC, admission to ED, leaving ED, admission to PICU and every four hours from PICU 
admission (defined as time zero) to 24 hours post admission. Core temperatures were 
defined as either rectal, oesophageal or bladder, as measured. Data were collected for all 
available temperature measurements. Episodes of excess hypothermia were defined as 
temperature less than 32°C and hyperthermia greater than 38°C on core temperatures.  
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Key time points during the application of TH were identified through the review of patients‟ 
charts. These included, commencement of TH, reaching target temperature, 
commencement of rewarming and reaching final post-rewarming temperature (Figure 7-3). 
Duration of time and change in temperature was calculated between each time point. 
Occurrence of seizures within the time period ROSC to 72 hours, presence of two 
unresponsive pupils at PICU admission and any major complication was also collected.  
Post cardiac arrest treatments and investigations included; use and type of mechanical 
ventilation, inotropic support, extra-corporeal life support (ECLS), renal replacement therapy 
(including haemofiltration and peritoneal dialysis), insulin therapy, anti-seizure therapy, use 
and type of neuro-imaging and neuro-electrophysiological investigation.  
The primary outcome was survival at hospital discharge. We also attempted to assess 
neurological outcome using the paediatric cerebral performance category (PCPC) score 
(Fiser et al, 2000) at PICU discharge and hospital discharge, calculated using information 
from the medical notes. However, the recording of information to guide category scoring was 
missing in up to 50% of survivors and therefore neurological outcome scoring could not be 
used in the current analysis.  
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         Figure 7-1 Study Flow chart showing data collection areas at key time point. 
 
HR: heart rate, BP: blood pressure (systolic and mean), Mode: conventional ventilation or 
high frequency oscillation, FiO2, fractional inspired concentration of oxygen, ABG: arterial 
blood gas, FBC: full blood count, Chemistry: including urea, creatinine, and magnesium. 
RRT: renal replacement therapy, ECLS: extracorporeal life support, EEG/CFAM: 
electroencephalography and cerebral function monitoring. 
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Figure 7-2 Key time points for recording events and core temperature after OHCA 
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Figure 7-3 Stages of therapeutic hypothermia, rates and duration of therapy 
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7.4.4 Therapeutic hypothermia application 
In 2007 the intensive care unit consultant team, after an evidence-based review, actively 
considered therapeutic hypothermia after out of hospital cardiac arrest at Birmingham 
Children‟s Hospital. The decision to commence therapy was made solely by the admitting 
paediatric intensive care consultant on a case by case basis. A formal protocol was not 
introduced until November 2009. However, accepted practice involved initiation of 
therapeutic hypothermia on the PICU with the use of servo-controlled water blanket cooling 
mattresses (Blanketroll II, Cincinnati Sub Zero, Ohio, USA) to rapidly induce therapeutic 
hypothermia to a temperature between 33 to 34⁰C for 24 hours followed by controlled 
rewarming, by 0.5⁰C every 2 hours, using the servo-controlled blanket, back to 
normothermia (37⁰C). Neuromuscular blocking drugs (e.g. Rocuronium) were used to 
prevent or treat shivering as well as receiving sedation and analgesia using intravenous 
morphine and midazolam. Patients were invasively ventilated with arterial blood gases 
monitored. PaCO2 analysis was performed at 37⁰C  and not adjusted for patient temperature 
(alpha-stat method) (Murkin, 2007). Standard neuroprotection PaCO2 target range was 4.5 
to 5.0kPa.  Cardiovascular support in the form of inotropes was applied to maintain age 
appropriate blood pressure. Intracranial pressure monitoring was not used on this 
population. Clinical neurological assessment and additional neurological monitoring or 
imaging was performed if required; however, appropriate, active withdrawal of intensive care 
occurred following established UK guidelines which do not always require formal ancillary 
neurological assessment (RCPCH, 2004). 
7.4.5 Statistical Analysis 
We planned a priori for two separate analyses of the cohort to inform the feasibility of a 
randomised controlled trial.  This chapter reports on the second analysis comparing patients 
receiving TH with those receiving ST to evaluate outcome and physiological differences 
between TH and ST.  
Data were tested for normality by using the Shapiro-Wilk‟s W test. Descriptive data were 
reported as median and interquartile range (IQR) or mean ± 95% confidence interval of the 
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mean for continuous variables and as frequencies and percentages for categorical variables. 
Parametric continuous data were analysed using the unpaired Student t-test and non-
parametric continuous data with the Mann Whitney U test or Kruskal-Wallis, as appropriate.  
Categorical data were analysed using the Chi
2 
or Fisher‟s exact tests, as appropriate.  
A p value of <0.05 was considered statistically significant throughout. Data analyses were 
performed using either IBM-SPSS Statistics version 19.0 software (SPSS Inc, Chicago, 
USA) or Minitab 16 (USA). 
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7.5 RESULTS 
7.5.1 Demographics 
73 patients fulfilled the inclusion criteria (Figure 7-4). 38 (52%) received therapeutic 
hypothermia (TH) and 35 (48%) standard therapy (ST). Table 5-3 reports the demographic 
comparison of the two groups. There were no differences in age or weight in patients 
receiving either treatment. However, more males received TH (p= 0.049). Overall 45% of 
patients had an underlying chronic condition. All chronic conditions were similar across the 
two groups except that no patient with a genetic condition (e.g. Down‟s syndrome) received 
TH (p=0.048). Half the patients required transportation from a secondary hospital. There 
was a significant increase in patients receiving TH over the seven year study period 
(p<0.001) (Figure 7-5).  
 
Figure 7-4 Flow chart of included patients 
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Table 7-1 Demographics and relationship to treatment groups 
 Total Group 
n =73 
TH 
n=38 
ST 
n = 35 
p
b
  
Age (years) 1.0 (0-5.0) 1.5 (0-5.8) 1.0 (0-4.0) 0.735 
Weight (kg) 8 (4-15) 10 (6-20) 6 (4-12) 0.061 
Age category (Utstein
a
)    0.565 
 1-30 days 7 (10%) 5 (13%) 2 (6%)  
 31 days to < 1 yr 23 (32%) 10 (26%) 13 (38%)  
 1yr to < 4yrs 21 (29%) 11 (29%) 10 (29%)  
 4yrs to < 12yrs 9 (13) 4 (11%) 5 (15%)  
 12yrs to < 16yrs 12 (17%) 8 (21%) 4 (12%)  
Male 25 (34%) 17 (45%) 8 (23%) 0.049 
Chronic Condition 33 (45%) 15 (39%) 18 (51%) 0.305 
Two or more chronic 
conditions 
14 (19%) 7 (18%) 7 (20%) 0.535 
 Neurological 17 (23%) 9 (24%) 8 (23%) 0.933 
 Respiratory 13 (18%) 7 (18%) 6 (17%) 0.887 
 Cardiac 4 (5%) 1 (3%) 3 (9%) 0.265 
 Prematurity 3 (4%) 1(3%) 2 (6%) 0.604 
 Genetic 5 (5%) 0 4 (12%) 0.048 
 Metabolic 4 (5%) 2 (4%) 2 (3%) 0.707 
 Gastrointestinal 1 (1%) 1 (3%) 0 1.0 
 Renal 1 (1%) 0 1 (3%) 1.0 
Transported from 
different admitting 
hospital 
37 (51%) 17 (45%) 18 (53%) 0.336 
 
a 
Utstein pre-defined age groups with modified upper age limit to less than 16 years (Zaritsky 
et al, 1995). Results expressed as Median (Inter-quartile range) or number (percent). 
b 
Chi
2 
test or Fishers exact test was used for categorical variable and Mann Whitney U test 
for continuous variables. 
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Figure 7-5 Percentage of patients receiving therapeutic hypothermia 
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Dashed red line indicates first publication date of ILCOR guidelines for paediatric therapeutic 
hypothermia use: Published on-line April 17th 2006 - “Induction of hypothermia (32 to 34°C) 
for 12 to 24 hours should be considered in children who remain comatose after resuscitation 
from cardiac arrest.” (ILCOR, 2006) 
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7.5.2 Aetiology 
Therapeutic hypothermia was used more frequently in patients whose cause of arrest was 
unknown and less in patients presenting with cardiac arrest associated with accidental 
traumatic brain injury or other traumatic injury (Table 7-2).  
 
Table 7-2 Aetiology of arrest and relationship to treatment groups 
 Total Group 
n =73 
TH 
n=38 
ST 
n = 35 
p
b
  
Not Known 12 (16%) 9 (23%) 3 (9%) 0.12 
Pulmonary 16 (22%) 9 (24%) 7 (20%) 0.78 
Cardiac 5 (7%) 4 (11%) 1 (3%) 0.19 
Trauma (including accidental 
traumatic brain injury) 
10 (14%) 2 (5%) 8 (23%) 0.04 
Submersion 6 (8%) 3 (7%) 3 (9%) 1.0 
Neurological 7 (10%) 2 (5%) 5 (14%) 0.25 
Sepsis 5 (7%) 2 (5%) 3 (9%) 0.67 
Inflicted traumatic brain injury 1 (1% 1 (3%) 0 1.0 
Strangulation 3 (4%) 2 (5%) 1 (3%) 1.0 
(near) Sudden infant death 
syndrome 
2 (3%) 0 2 (5%) 0.23 
Other 6 (8%) 4 (11%) 2 (6%) 0.68 
Results expressed as number (percent). 
b 
Fishers exact
 
test was used for categorical variable  
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7.5.3 Cardiac arrest resuscitation factors and time data 
Rates of OHCA occurring in the home or being witnessed were similar for patients receiving 
TH and ST (Table 7-3). However, patients receiving TH had significantly more reported 
episodes of bystander CPR. In all, six patients presented in a shockable rhythm (ventricular 
fibrillation or ventricular tachycardia) and 5 out of 6 received TH (p=0.202). The presenting 
rhythm was not known in 7 (10%) cases (3 received TH). Table 6-6 reports the time intervals 
for duration of cardiac arrest. Total CPR was similar for both groups although there was a 
trend towards an increased duration for children receiving TH (40 minutes versus 29 
minutes). However, the median duration of CPR in the emergency department was similar 
(12 versus 13 minutes).  An equally small proportion of patients (3% vs. 9%; p=0.237) had 
ROSC prior to arrival at the emergency department with a similar time from ROSC to final 
PICU admission for both group. 
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Table 7-3 Cardiac arrest resuscitation factors and relationship to treatment groups 
Cardiac arrest resuscitation 
events 
Total 
Group 
n =73 
TH 
n=38 
ST 
n = 35 
p
b
  missing 
Location own home (versus 
public place or other) 
45 (68%) 23 (70%) 22 (67%) 0.792 7 
Witnessed arrest 45 (65%) 23 (62%) 22 (69%) 0.567 4 
Bystander CPR 45 (65%) 30 (81%) 15 (47%) 0.003 4 
VF/VT
a
 (vs. PEA/ 
bradycardia/asystole) 
6 (9%) 5 (14%) 1 (3%) 0.202 7 
 Pulseless electrical 
 activity (PEA) 
10 (15%) 6 (17%) 4 (13%)   
 Bradycardia 7 (6%) 2 (16%) 5 (11%)   
 Asystole 43 (65%) 22 (63%) 21 (67%)   
 Ventricular 
 fibrillation (VF) 
5 (8%) 5 (14%) 0   
 Pulseless  Ventricular 
 tachycardia (VT) 
1 (2%) 0 1 (3%)   
Defibrillation attempted 10 (14%) 7 (18%) 3 (10%) 0.281 6 
Epinephrine doses during 
resuscitation
c
 
 3 (1-4) 3 (1-4) 0.825 4 
No epinephrine given during 
resuscitation 
6 (9%) 2 (5%) 4 (13%) 0.401 4 
CPR denotes cardiopulmonary resuscitation. 
a
First recorded rhythm after cardiac arrest. VF: 
ventricular fibrillation, VT: ventricular tachycardia, PEA: pulseless electrical activity 
a
Unavailable (missing) values were excluded from calculations of summary statistics. 
Results expressed as Median (Inter-quartile range) or number (percent). 
b 
Chi
2 
test or Fishers exact test was used for categorical variable. 
C
 median value rounded up to nearest whole value, Mann Whitney U test used for 
continuous data. 
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Table 7-4 Time data and relationship to treatment groups
 
 
 Total 
Group 
n =73 
TH 
n=38 
ST 
n = 35 
p
b
  missing 
Time duration from cardiac 
arrest onset to ROSC (mins) 
38 
(24-49) 
40  
(26-56) 
29  
(21-46) 
0.226 5 
ROSC prior to ED admission 8 (6%) 2 (3%) 6 (9%) 0.237 4 
Time from ED admission to 
ROSC (mins)
a
 
12  
(5-19) 
12  
(4-20) 
13  
(8-18) 
0.979 4 
Time duration from  ROSC to 
PICU admission (hrs:mins) 
02:57 
 (01:13-
04:34) 
02:50  
(01:24-
04:51) 
03:20  
(00:50-
04:29) 
0.666 5 
ROSC denotes return of spontaneous circulation. ED: emergency department, PICU 
Paediatric intensive care unit. Unavailable (missing) values were excluded from calculations 
of summary statistics. Results expressed as Median (Inter-quartile range) or number 
(percent). 
a
 Only patients receiving CPR at ED admission were included in calculation 
b 
Chi
2 
test was used for categorical variable and Mann Whitney U test for continuous 
variables. 
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7.5.4 Physiological variables 
Using the physiological variables associated with worse outcome after OHCA (identified in 
chapter 6), a comparison between patients receiving TH and ST was performed (Table 6-7).  
Maximum and minimum lactate, pH, glucose, base deficit and the Paediatric Index of 
Mortality 2 (PIM2) score results were all similar between the two treatment groups. 11% 
(8/73) patients had documented seizures and 64% (41/64) had two unresponsive pupils on 
PICU admission with no differences noted between treatment groups (Table 6-8). 
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Table 7-5 Prognostic outcome variables (available between ROSC to four hours after 
PICU admission) and relationship to treatment groups 
 Total Group 
n =73 
TH 
n=38 
ST 
n = 35 
p
b
  
missing 
Minimum pH  
6.9 
(6.7-7.2) 
6.9 
(6.7-7.2) 
6.9 
(6.7-7.2) 
0.740 3 
Maximum pH  
7.3 
(7.2-7.4) 
7.3 
(7.2-7.4) 
7.3 
(7.1-7.4) 
0.249 3 
Minimum lactate 
(mmol/l) 
3.5 
(2.2-8.3) 
3.6 
(2.4-7.8) 
3.3 
(1.9-9.8) 
0.610 14 
Maximum lactate 
(mmol/l) 
5.4 
(3.5-11.0) 
6.3 
(4.1-12.8) 
4.2 
(2.4-10.1) 
0.158 14 
Minimum glucose 
(mmol/l)  
9.5 
(5.9-12.8) 
10.3 
(6.2-12.3 
8.4 
(4.6-13.6 
0.348 4 
Maximum glucose 
(mmol/l) 
15.5 
(10.7-19.9) 
15.8 
(13.1-20.7) 
14.4 
(7.1-18.7) 
0.076 4 
Minimum base excess 
(mEq/l) 
-19.6 
(-24.7 to -13.1) 
-19.9 
(-25.4 to -
13.0) 
-18.1 
(-24.4 to – 
12.9) 
0.951 3 
Probability of death by 
PIM2
a
 
0.84 
(0.43-0.94) 
0.91 
(0.45-0.96) 
0.81 
(0.41-0.92) 
0.151 3 
Lactate > 3 mmol/l on 
PICU admission 
43 (78%) 28 (80%) 15 (75%) 0.666 14 
Values expressed as Median (interquartile range). 
a 
PIM2 (Paediatric index of mortality 2) (Slater et al, 2003) calculated on PICU admission 
data for all cases including patients transported by PICU specialist retrieval team 
b 
Unavailable (missing) values were excluded from calculations of summary statistics. Chi
2 
test was used for categorical variable and Mann Whitney U test for continuous variables. 
 
 
Table 7-6 Clinical neurological variables and relationship to treatment group 
 Total 
Group 
n =73 
TH 
n=38 
ST 
n = 35 
p
b
 Missing 
Seizures 8 (11%) 3 (8%) 5 (14%) 0.470 2 
Two unresponsive 
pupils 
41 (64%) 21 (58%) 20 (71%) 0.279 9 
Values expressed as numbers (percent of total group, survivors or nonsurvivors). Chi
2 
test 
was used for categorical variable 
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7.5.5 Core Temperature in Emergency Department and PIC admission 
Temperature at arrival to the emergency department, ROSC, and leaving the emergency 
department, were similar for patients subsequently receiving TH or ST in the PICU. Table 
7-7 show comparable temperatures and highlights the high number of missing values at 
each time point. Overall, in the emergency department, 30% (22/73) had no record of 
temperature measurement. 
All patients had a temperature at admission to PICU recorded (Table 7-8). Patients receiving 
TH were significantly cooler (34.3°C vs. 36.1°C; P=0.007). Incorporating all temperatures 
from ED admission to four hours post PIC admission (used in the predictive models in 
Chapter 6), patients receiving TH had significantly lower minimum and maximum 
temperatures. 
In a subgroup analysis of TH patients only, admission to PICU temperature was higher in 
survivors (35.4 (IQR [34.0 to 36.3])⁰C) versus non survivors (34.0 (IQR [32.6 to 35.6])⁰C) 
although this did not research statistical difference (p=0.140).  
Figure 7-6 illustrates the temperature profile of patients receiving TH and ST. There 
continued to be a significant difference in temperature between the two groups from PIC 
admission up to 40 hours after admission. 
Five (7%) patients in the study presented at the ED with temperatures less than 30°C, of 
these patients, one received TH and four ST.  
Four patients who received TH and two who received ST experienced severe hypothermia 
(temperature <32°C) after arrival to PIC (Table 7-9). All eleven patients, with any recorded 
temperature <32°C from ED admission to 24 hours post PIC admission, died prior to PIC 
discharge 
Hyperthermia (temperature >38°C) in the first 24 hours after PIC admission was significantly 
reduced in patients receiving TH (1/35; 3%) versus ST (12/32; 38%, p<0.001).  
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Table 7-7 Core temperature measurement in the emergency department (ED) in 
relationship to treatment groups 
Core temperature (°C) Total 
Group 
n =73 
TH 
n=38 
ST 
n = 35 
p
b
  Missing 
value 
Temperature at arrival to ED 
34.8 
(33.7-36.0) 
34.3 
(34.0-35.3) 
33.9 
(30.7-35.3) 
0.434 45 
Temperature at ROSC 
34.1 
(33.0-35.1) 
34.1 
(33.7-35.1) 
34.1 
(32.8-35.2) 
0.753 33 
Temperature leaving ED 
34.8 
(33.7-36.0) 
35.0 
(33.5-36.1) 
34.5 
(33.9-36.0) 
0.929 42 
Minimum temperature 
recorded in ED 
34.1 
(33-35.1) 
34.1 
(33.9-35.1) 
33.3 
(31.5-35.2) 
0.160 22 
Maximum temperature 
recorded in ED 
35.2 
(34.1-36.0) 
35.3 
(34.1-36.1) 
35.2 
(34.2-36.0) 
0.559 22 
Numbers expressed as Median (interquartile range). Mann Whitney U test was used for 
continuous variables.
 b 
Unavailable (missing) values were excluded from calculations of 
summary statistics.  
 
 
Table 7-8 Core temperature measurements at PICU admission and relationship to 
treatment groups 
Core temperature (°C) Total 
Group 
n =73 
TH 
n=38 
ST 
n = 35 
p
b
 Missing 
value 
Temperature at PICU 
admission  
35.2 
(33.5-36.5) 
34.3 
(32.8-35.9) 
36.1 
(34.0-37.0) 
0.007 9 
Minimum temperature  after 
ROSC To 4hrs post PICU 
admission 
33.5 
(32.5-34.8) 
33.1 
(32.5-34.1) 
34.1 
(32.5-36.0) 
0.068 4 
Maximum temperature  after 
ROSC To 4hrs post PICU 
admission 
36 
(34.9-37.0) 
35.8 
(34.5-36.5) 
36.5 
(35.5.-37.2) 
0.014 4 
Numbers expressed as Median (interquartile range). Mann Whitney U test was used for 
continuous variables. 
b 
Unavailable (missing) values were excluded from calculations of 
summary statistics.  
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Table 7-9  Relationship of severe hypothermia (<32°C) or hyperthermia (>38°C) to 
treatment groups 
 Total 
Group 
n =73 
TH 
n=38 
ST 
n = 35 
p
b
 Missing 
value 
Any temperature  <32°C ROSC to 
24hrs post PICU admission 
11 (16%) 5 (13%) 6 (19%) 0.525 4 
Any temperature  >38°C ROSC to 
24hrs post PICU admission 
13 (18%) 1 (3%) 12 (34%) <0.001 4 
b 
Unavailable (missing) values were excluded from calculations of summary statistics. Chi
2 
test or Fishers Exact test were used for categorical variable 
 
 
Figure 7-6 Temperature profile of patients receiving therapeutic hypothermia and 
standard therapy 
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hypothermia, ST: standard therapy. 
 
  
Chapter 7  
254 
 
7.5.6 Application of therapeutic hypothermia 
Thirty eight patients received TH. Figure 7-7 illustrates specific details of timing, 
temperatures and rates of induction and rewarming of the therapy for the TH group. Median 
temperature at the start of TH was 35.0 (IQR [33.8 to 36.2])°C. In the 50% of patients with a 
temperature >35°C at the start of TH, induction of temperature to target temperature 
occurred at a rate of 0.91 (IQR [0.5 to 1.5]) °C/hr. Four patients (11%) had overshoot 
hypothermia (<32°C) following induction. Median target temperature was 33.4°C and was 
maintained for a median of 22:30 (IQR [16:37 to 24:44]) hours:minutes. Rewarming occurred 
over a median of 10:30 (IQR [07:00 to 14:45]) hours:minutes at a rate of 0.3 (IQR [0.23 to 
0.44])°C/hr. Three patients receiving TH died prior to rewarming. Only 32% (11/34) re-
warmed slower than or equal to 0.25°C/hr. Hyperthermia (>38°C) after rewarming occurred 
in 29% (10/34). 
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Figure 7-7 Stages of therapeutic hypothermia, temperatures, rates and duration of cooling (n=38) 
 
Time duration expressed as 
hours:minutes. Temperature °C 
Temperature, time and rates 
expressed as Median (IQR) 
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7.5.7 Physiological effects of therapeutic hypothermia in comparison 
to standard therapy 
Comparison of the TH and ST groups with regards physiological, haematological, 
biochemical and acid base parameters are presented in Table 7-10, Table 7-11, 
Table 7-12 and Table 7-13 respectively. 
Overall, measured heart rate was lower in the TH compared with the ST group 
during the first 24 hours after ROSC (p=0.003). However, after normalisation for 
age (see methods section) this difference was no longer statistically significant 
(p=0.147). Systolic, normalised systolic and mean blood pressures were also 
similar between TH and ST groups (Figure 7-8). 
Bradycardia (defined as <10
th
 centile for age) and extreme bradycardia (<1
st
 centile 
age) occurred in twice as many patients treated with TH compared to ST. 42% 
(16/38) of TH patients had an episode where heart rate fell below 10
th
 centile for 
age compared to 19% (6/32) in the ST group (Fisher exact test p=0.04). Episode of 
extreme bradycardia (<1
st
 centile age) occurred in 21% (8/28) of TH patients 
versus 10% (3/30) of ST although this difference did not reach statistical 
significance (p=0.208). 
Arterial oxygen content (PaO2) was significantly higher during the first 24 hours in 
both groups compared to 28-72 hours. However, no difference was noted between 
TH and ST groups. 
Arterial carbon dioxide content (PaCO2) was similar between TH and ST groups; 
however, nearly half of patients in both groups experienced severe hypocarbia 
(PaCO2 <4.0kPa) during the first 24 hours after ROSC (TH: 16/38 (42%) vs. ST: 
14/30 (47%) p=0.707). This proportion reduced during the subsequent 48 hours in 
both groups (TH: 7/35 (20%) vs. ST: 2/15 (13%) p=0.705). 
Only white cell count, during 0-24 hours post ROSC, differed between TH and ST 
groups. All other haematological values were similar. 25% (9/35) of TH patients 
and 32% (10/31) of ST patients developed thrombocytopaenia during 0-24 hours 
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(p=0.511). This increased to 34% (12/35) and 58% (7/12) during the stage 25-72 
hours after ROSC (p=0.182).  Although data was missing after 25 hours in 23/35 
ST patients due to death or hospital discharge. 
Sodium levels in TH patients were statistically significantly higher in TH compared 
to ST patients 0-24 hours after ROSC (p=0.011). However, this only reflected a 
3mmol/L increment in measured plasma sodium and therefore unlikely to be a 
clinically significant difference. Magnesium levels were similar between TH and ST; 
however significantly reduced in both groups by 24-72 hours post PIC admission. 
All other biochemical variable measures were similar for TH and ST patients and 
did not significantly change between 0-24 hours and 25-72 hours (Figure 7-9).  
There was no difference in pH, base excess, lactate and glucose between TH and 
ST groups. All four parameters improved towards normal limits for both groups by 
25-72 hours (Figure 7-10). 
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Table 7-10 Cardiovascular and respiratory variables 
 0-24 hours 25-72 hours 
 TH 
n=38 
ST 
n = 35 
p
b
 TH 
n=38 
ST 
n = 35 
p
b
 
Heart Rate 
(beat per minute)  
134 
(114-142) 
148 
(127-166) 
0.003 
140 
(123-145) 
144 
(123-150) 
0.476 
Normalised 
HR 
1.02 
(0.95-1.71) 
1.20 
(1.02-1.37) 
0.147 
1.18 
(0.95-1.38) 
1.16 
(1.06-1.44) 
0.739 
Systolic BP 
(mmHg) 
102 
(83-117) 
96 
(85-114) 
0.563 
100 
(86-110) 
98 
(82-117) 
0.736 
Normalised 
Systolic BP 
1.11 
(0.96-1.22) 
1.15 
(0.90-1.28) 
0.697 
1.07 
(0.99 (1.16) 
1.20 
(1.00-1.39 
0.115 
Mean BP 
(mmHg) 
73 
(60-85) 
74 
(60-83) 
0.715 
74 
(65-81) 
70 
(62-85) 
0.878 
PaO2 (kPa) 
14.6 
(10.6-19.5) 
17.5 
(11.0-21.9) 
0.475 
11.8 
(10.0-13.3) 
10.3 
(9.2-15.5) 
0.743 
PaCO2 (kPa) 
6.1 
(4.9-8.5) 
6.5 
(4.5-8.3) 
0.743 
4.9 
(4.7-6.0) 
5.1 
(4.6-6.1) 
0.966 
Missing values for 3 patients all ST group; 0 to 24 hours. Missing values for 29 
patients (6 TH and 23 ST group); 25 to 72 hours.  Values expressed as Median 
(interquartile range). 
b
 Mann Whitney U test for comparison between TH and ST 
groups.Normalised to age specific reference range (Elf et al, 2002). 
 
Table 7-11 Haematological variables 
 0-24 hours 25-72 hours 
 TH 
n=38 
ST 
n = 35 
p
b
 TH 
n=38 
ST 
n = 35 
p
b
 
Haemoglobin 
(g/dL)  
11.7 
(9.8-13.6) 
11.5 
(9.6-12,8) 
0.266 
11.0 
(10.1-12.0) 
10.6 
(0.8-11.2) 
0.335 
White cell 
count (x109/L) 
9.7 
(7.1-14.0) 
15.3 
(7.3-20.7) 
0.031 
8.5 
(5.2-13.0) 
10.6 
(6.8-14.9) 
0.306 
Platelets (x109/L) 
244 
(188-337) 
262 
(154-417) 
0.852 
195 
(147-234) 
159 
(90-352) 
0.542 
Prothrombin 
time (seconds) 
14.0 
(12.5-5.3) 
14.5 
(13.0-6.0) 
0.386 
13.8 
(12.9-16.0) 
12.0 
(11.5-9.0) 
0.443 
Activated 
partial 
thromboplastin 
time (seconds) 
33 
(28-41) 
33 
(29-41) 
0.862 
22 
(28-36) 
28 
(26-33) 
0.030 
Missing values for 6 patients (2 TH and 4 ST; 0 to 24 hours). Missing values for 26 
patients (3 TH and 23 ST group); 25 to 72 hours. Median (interquartile range). 
b
 
Mann Whitney U test for comparison between TH and ST groups. 
Chapter 7: 
 
259 
  
 
 
 
Table 7-12 Biochemical variables 
 0-24 hours 25-72 hours 
 TH 
n=38 
ST 
n = 35 
p
b
 TH 
n=38 
ST 
n = 35 
p
b
 
Sodium 
(mmol/L) 
143  
(140-144) 
140  
(136-142) 
0.011 
143  
(139-147) 
143  
(138-146) 
0.604 
Potassium 
(mmol/L) 
3.7  
(3.3-4.3) 
4.0  
(3.5-4.7) 
0.086 
3.9  
(3.8-4.4) 
3.9  
(3.6-4.3) 
0.966 
Urea (mmol/L) 
5.5  
(4.4-8.8) 
5.8  
(3.9-10.2) 
0.510 
6.1  
(3.9-11.9) 
5.3  
(2.6-10.0) 
0.257 
Creatinine 
(μmol/L) 
59  
(39-81) 
52  
(39-70) 
0.667 
47  
(39-84) 
45  
(30-54) 
0.376 
Magnesium 
(mmol/L) 
0.98  
(0.83-1.13) 
0.90  
(0.81-1.14) 
0.438 
0.81  
(0.75-0.88) 
0.77  
(0.71-0.88) 
0.563 
Missing values for 12 patients (1 TH and 11 ST); 0 to 24 hours. Missing values for 
32 patients (7 TH and 25 ST group); 25 to 72 hours. Median (interquartile range). 
b
 
Mann Whitney U test for comparison between TH and ST groups. 
 
Table 7-13 Blood gas parameters & Plasma glucose 
 0-24 hours 25-72 hours 
 TH 
n=38 
ST 
n = 35 
p
b
 TH 
n=38 
ST 
n = 35 
p
b
 
pH 
7.21 
(7.13-7.31) 
7.21 
(7.10-7.32) 
0.664 
7.35 
(7.29-7.40) 
7.36 
(7.30-7.37) 
0.958 
Base 
Excess 
(mEq/L) 
-10.8 
(-13.7 to -7.4) 
-9.6 
(-12.6 to -6.0) 
0.305 
-5.6 
(-7.0 to -3.1) 
-4.2 
(-7.0 to -1.35) 
0.427 
Lactate 
(mmol/L) 
4.6 
(2.8-7.5) 
4.5 
(2.6-9.1) 
0.918 
1.7 
(1.1-2.9) 
1.7 
(1.3-2.1) 
0.842 
Glucose 
(mmol/L) 
11.3 
(9.3-12.9) 
9.6 
(6.3-12.6) 
0.129 
6.1 
(5.1-8.2) 
6.0 
(5.5-7.3) 
0.735 
Missing values for 4 patients all ST group; 0 to 24 hours. Missing values for 23 
patients (3 TH and 20 ST group); 25 to 72 hours. Median (interquartile range). 
b
 
Mann Whitney U test for comparison between TH and ST groups. 
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Figure 7-8 Physiological parameters comparing TH and ST at 0-24 hours and 25-72 hours 
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Figure 7-9 Biochemical variables comparing TH and ST at 0-24 hours and 25-72 hours 
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Figure 7-10 Acid base parameters comparing TH and ST at 0-24 hours and 25-72 hours 
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7.5.8 Additional PICU treatment interventions 
All patients received mechanical ventilation. More patients receiving TH required inotropic 
support compared to ST, although the difference in proportions was not statistically 
significant. Only one patient in the TH group received extra corporeal life support (ECLS) for 
refractory cardiac arrest and rewarming due to profound hypothermia on admission 
(admission core temperature 14°C). No patients received renal replacement therapy. Insulin 
therapy was more frequent in the TH group (34% vs. 17%; p=0.10), although not reaching 
statistical significance.  
MRI and EEG investigations were more common in the TH group, although a greater 
number of MRIs (71%; 17/24) and EEGs (89%; 17/19) were performed after 2007 and may 
also reflect a change in post cardiac arrest management during this later time period. 
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Table 7-14 Post arrest treatment & Investigational data in relationship to treatment 
group 
 Total 
Group 
n =73 
TH 
n=38 
ST 
n = 35 
p
b
  
Treatment     
 Mechanical ventilation 73 38 (100%) 35 (100%) 1.0 
 Inotropes after resuscitation 47 (64%) 28 (74%) 19 (54%) 0.084 
 Two or more inotropes 11 (15%) 8 (21%) 3 (9%) 0.19 
 HFOV 2 (3%) 2 (3%) 2 (3%) 1.0 
 ECMO 1 (1%) 1 (3%) 0 1.0 
 Renal replacement therapy 0 0 0  
 Insulin therapy 19 (26%) 13 (34%) 6 (17%) 0.097 
 Neuromuscular blockade 
     after PICU admission 
31 (42%) 16 (42%) 15 (43%) 0.948 
 Anti-seizure therapy 10 (14%) 6 (16%) 4 (11%) 0.74 
Investigation     
 Any neuroradiology 44 (60%) 26 (68%) 18 (51%) 0.138 
 MRI scan 24 (33%) 18 (47%) 6 (17%) 0.007 
 CT scan 30 (41%) 15 (39%) 15 (43%) 0.796 
 Any neuroelectrophysiology 
 investigation
c
 
19 (26%) 15 (39%) 4 (11%) 0.008 
 
b
Chi
2 
test was used for categorical. 
c
Includes: Electroencephalogram (EEG) and continuous 
amplitude integrated EEG 
MRI: magnetic resonance imaging, CT: Computer tomography 
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7.5.9 Outcome 
Table 7-15 reports outcome for patients receiving TH and ST. Overall survival to hospital 
discharge of patients admitted to PIC after OHCA was 29% (21/73). Survival to hospital 
discharge was 11% higher after TH compared to ST (34% vs. 23%), a relative risk increase 
of 48%; however, this difference did not reach statistical significance (p=0.284).   
Overall, patients receiving TH stayed in PIC longer compared to ST (Median 4.1 (IQR [3.0 to 
6.8] days vs. 1.3 (IQR [0.5 to 6.7]) days; p <0.001) respectively. Although this difference was 
accounted for by patients who died in PIC (TH: 4.1 (IQR [2.6 to 5.2]) days vs. ST: 1.2 (IQR 
[0.4 to 2.4]) days; p<0.001). Survivors receiving TH or ST had a similar length of stay in PIC 
(6.2 (IQR [3.0 to 7.8]) days vs. 6.7 (IQR [0.9 to 8.1]) days; p=0.805) respectively. There were 
also a similar proportion of patients in both groups who had withdrawal of life sustaining 
intensive care support prior to death. All (24/24) patients who died in PIC after receiving TH 
and 81% (22/27) after receiving ST had active withdrawal of intensive care support. 
Neurological outcome scoring by PCPC for survivors was unfortunately missing in a large 
number of cases of hospital survivors (45%; 10/22). In the cases with known PCPC scores, 
two patients who received TH and two ST had a bad neurological outcome (PCPC score 3 
to 4).  
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Table 7-15 Survival outcomes in relationship to treatment groups 
 Total 
Group 
n =73 
TH 
n=38 
ST 
n = 35 
p
b
  
Outcome     
 Survival to PICU discharge 22 (30%) 14 (37%) 8 (23%) 0.193 
 Survival to Hospital discharge 21 (29%) 13 (34%) 8 (23%) 0.284 
PICU Length of stay (LOS) (days) 
3.1 
(1.3-6.6) 
4.1 
(3.0-6.8) 
1.3 
(0.5-6.7) 
<0.001 
PICU LOS for survivors (days) 
6.5 
(2.9-7.6) 
6.2 
(3.0-7.8) 
6.7 
(0.9-8.1) 
0.805 
PICU LOS for non-survivors 
(days) 
2.4 
(0.8-4.7) 
4.1 
(2.6-5.2) 
1.2 
(0.4-2.4) 
<0.001 
Withdrawal of intensive care 
support (proportion of patients who 
died in PICU) 
46 (90%) 24 (100%) 22 (81%) 0.312 
Fulfilled brain death criteria 
(proportion of patients who died in 
PICU) 
9 (18) 5 (21%) 4 (15%) 0.730 
LOS: length of stay 
b
Chi
2 
test was used for categorical variable and Mann Whitney U test for 
continuous variables. 
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7.6 DISCUSSION 
This is the largest study to date comparing the effects of therapeutic hypothermia (TH) and 
standard therapy (ST) in children after out-of-hospital cardiac arrest (OHCA). TH was used 
in 52% (38/73) of patients and did not result in a statistically significant improvement in 
hospital survival compared to ST (34% versus 23%; p=0.284). 
Confounding factors known to influence survival, identified in Chapter 6, were equally 
balanced between patients in the TH and ST group. The only recorded differences at 
resuscitation and PIC admission between TH and ST patients were an increased incidence 
of bystander CPR and a non-significant trend towards increased duration of cardiac arrest in 
the TH group. This is in contrast to two previous paediatric observational studies. Doherty et 
al (2009) compared  patients receiving TH (n=29) with normothermia (n=50). They reported 
an increased use of TH after, predominately, in-hospital cardiac arrest and in patients with a 
much higher predicted risk of mortality (longer duration of arrest, use of extracorporeal life 
support and increased propensity score). The use of TH was associated with a worse six 
month mortality outcome (unadjusted odds ratio (OR) 3.62 (1.37-9.62; p=0.009) and poorer 
neurological outcome (unadjusted OR 2.92 (1.1-7.69; p=0.031) after paediatric cardiac 
arrest. After adjustment, however, neither mortality nor neurological outcomes were different 
between patients receiving hypothermia and normothermia. Fink et al (2010) compared 40 
children receiving TH compared with 141 receiving ST. Fifty one percent were after OHCA, 
91% asphyxial arrests and excluded all children with congenital cardiac disease. Patients 
receiving TH had longer cardiac arrest duration and higher admission lactate levels.  Overall 
the survival to hospital discharge was the same between patients receiving TH (45%) and 
ST (45%; p=1.0) with similar neurological outcome as assessed by the Glasgow Outcome 
Score (2.4 vs. 2.4; p=0.9). 
Our study, in agreement with these two other paediatric retrospective studies, failed to 
demonstrate a statistically significant increase in survival. However, this is the first paediatric 
observational study with balanced treatment groups where a signal towards improvement is 
demonstrated by an 11% absolute risk increase (48% relative risk increase) in hospital 
survival.  
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7.6.1 Aetiology – Trauma 
Therapeutic hypothermia was used less frequently in OHCA associated with trauma, 
including accidental traumatic brain injury. This is likely to reflect the decreased use of TH in 
all paediatric traumatic brain injury patients since the publication of the large RCT of TH 
versus normothermia after paediatric TBI in 2008 (Hutchison et al, 2008). Prior to this study, 
animal (Clifton et al, 1991) and small human studies (Adelson et al, 2005) suggested that TH 
may improve neurological outcome and survival after TBI. However, in this study, TH did not 
improve good neurological outcome (relative risk, 1.41 (95% confidence interval [CI], [0.89 to 
2.22]); p=0.14) and showed a trend towards increased mortality (relative risk, 1.40 (95% CI 
[0.90 to 2.27]); P=0.06). A large adult RCT of TH after TBI also reported a lack of benefit 
with TH treatment (Clifton et al, 2001). The complex pathophysiological interplay of hypoxic 
ischaemic and traumatic injury to the brain in these patients will be very difficult to separate 
in clinical trials of heterogeneous populations. Continued assessment of clinical benefit of 
TH in separate populations will be important before focusing on this small but important 
subpopulation. 
7.6.2 Aetiology – Drowning 
Six patients presented after near-drowning associated cardiac arrest, of which five were 
severely hypothermic (<30⁰C) at arrival to the emergency department. Half received TH 
although all six patients died before hospital discharge. In the late 1970s and early 1980s, 
the use of TH in drowned patients was advocated as part of the „H.Y.P.E.R‟ therapy 
approach to hypoxic brain injury (hyperhydration by diuretics, hyperventilation, hypothermia 
to treat hyperpyrexia, barbiturates to treat hyperexcitability, and neuromuscular blockade to 
treat hyper-rigidity) (Bohn et al, 1986; Conn et al, 1980; Conn et al, 1978). However, the 
work by Bohn and colleagues highlighted the poor outcomes associated with the use of TH 
in submersion victims this ending the use of TH as a critical care therapy at that time (Bohn 
et al, 1986; Modell, 1986).  Additional concerns were the use of lower levels of hypothermia 
therapy (30 to 32⁰C), poor stability of target temperature, variable duration (1 to 10 days) 
harmful effects of excess barbiturates and the associated increased risk of adverse side 
effects (e.g. arrhythmias and infection). The positive findings of subsequent animal, neonatal 
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and adult studies using TH at a higher (and apparently safer) temperature level (32 to 34⁰C), 
has supported TH recommendations in adult patients presenting after hypothermic cardiac 
arrest (Bierens et al, 2002). However, the current ongoing TH trials are excluding patients 
presenting with an admission temperature <32⁰C from entry (NCT00754481; NCT00878644; 
NCT00880087), therefore the answer to whether to use TH in this specific patient group, 
desperately in need of improved outcomes, will continue to be unclear.   
7.6.3 Cardiac arrest resuscitation factors 
All patients (5/73; 8%) presenting in ventricular fibrillation received TH, consistent with the 
stronger worded ILCOR recommendations for adolescents presenting in a shockable rhythm 
(Kleinman et al, 2010).  
Bystander CPR was more common in the group receiving TH. The association of bystander 
CPR and improved survival after OHCA is not clearly defined in the literature. In chapter 6, 
bystander CPR was not found to be associated with increased survival. This is similar to the 
Australian OHCA study by Deasy et al (2010) and pooled analysis findings in the systematic 
review by Donoghue et al (2005), although a recent study from Japan‟s National Utstein 
Registry of the Fire and Disaster Management Agency did identify bystander CPR as 
predictor of good outcome at one month after OHCA in patients under one year of age (Abe 
et al, 2012). Difficulties in quantifying bystander CPR with regards quality, effectiveness and 
prior training, especially in a retrospective study, add to the complexities of interpreting the 
effect on outcome. However, without CPR patients after OHCA rarely survive. Therefore, 
evidence of attempted bystander CPR may still have given additional benefit to the TH 
group. 
7.6.4 Seizures 
Seizures were identified in only 11% (8/73) of patients with no difference between those 
treated with TH or ST. Formal electroencephalography (EEG) monitoring was performed in 
26% (19/73) of patients with a significant increased use in TH patients. This contrasts with a 
prospective study of continuous EEG monitoring after cardiac arrest which reported that 
47% (9/19) children receiving TH had EEG detected seizures (Abend et al, 2009). Fink et al 
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(2010) reported overall 17.7% seizure rate in the first four days with no difference between 
TH and ST groups. The differences noted between the retrospective and prospective studies 
may be due to difficulties in detecting and recording seizures in this population. Seizures in 
our study were detected through formal EEG monitoring only when there was a high 
suspicion by the clinical team, rather than as a routine. The use of neuromuscular blocking 
drugs, causing neuro-paralysis, limits the ability to clinically observe seizure muscle activity. 
Potentially, the use of continuous EEG monitoring during this period, as performed by Abend 
et al (2009), may therefore be identifying „masked‟ seizure activity after hypoxic ischaemic 
insult. Supporting evidence from the neonatal population exists regarding a greater 
frequency of seizures after HIE in neonates, especially during the rewarming phase of TH 
application (Battin et al, 2004).  Untreated seizures, particularly status epilepticus, have 
been associated with worsening neurological outcome in critical care patients (Friedman et 
al, 2009; Hosain et al, 2005). Therefore, there needs to be a high degree of vigilance with 
regard to identifying and treating seizures. 
 In our study, access to specialist EEG monitoring during the study period was restricted to 
office hours (9am to 4pm: Monday to Friday). This situation was similar in the study by Fink 
et al (2009) (personal correspondence E.Fink). However, in our institution, from 2009, a 
continuous EEG monitoring service was introduced which utilised amplitude integrated EEG 
at the bed side. This service may increase the opportunity to detect seizures, although our 
current data is limited and further formal evaluation is required.  
7.6.5 Temperature 
Core temperatures in the TH or ST group were similar in the emergency department up to 
first recorded temperature at PICU admission. At this time point, patients in the ST group 
had significantly higher temperatures (36.1⁰C (ST) vs. 34.3⁰C (TH); p=0.007). Due to 
inherent limitations of the study, it was difficult to ascertain the exact reason for this 
difference. Firstly, the exact start time of TH initiation was often not documented. It is 
possible that in the emergency department, or during transport to the PICU, the clinical team 
were already working towards a „therapeutic target of hypothermia‟ if they anticipated, or 
were instructed by the admitting PICU that TH was to be performed on arrival. However, a 
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second possibility is the potential development of „spontaneous hypothermia‟ after cardiac 
arrest in the TH group, as a consequence of more severe neurological injury. Spontaneous 
hypothermia after OHCA has been described in both adult and paediatric populations.  In a 
study of 105 adults, who all received TH after VF cardiac arrest, temperature on admission 
to ICU was found to be a significant factor associated with survival (den Hartog et al, 2010). 
In that study, admission temperature below 35⁰C (the median admission temperature for the 
total cohort) was significantly associated with unfavourable neurological outcome (OR 3.8 
(95% CI [1.3 to 11.0]). Lyon et al (2010) also reported, in a similar observational study of 
adult VF cardiac arrest patients treated with TH, that admission to ICU temperature was 
significantly higher in patients who subsequently survived to hospital discharge compared to 
those who died (35.7⁰C vs. 34.3⁰C; p<0.05). However, in our study, in patients who received 
TH, lower hospital survival rates for patients admitted to PIC with a lower temperature did 
not reach statistical  difference (22% (4/18) if <34.3⁰C vs. 42% (8/19) if ≥34.3⁰C (p=0.29).  
The temperature measurements of the ST group showed a trend in the opposite direction. 
Starting with a median „maximum‟ recorded level in the emergency department of 35.2 (IQR 
[34.2 to 36.0])⁰C, the ST group temperature on admission to PIC increased to just below 
normothermic levels (36.1 (IQR [34.0 to 37.0]) ⁰C). We did not know what decisions were 
made in the emergency department regarding temperature control. However, the ability to 
increase the temperature in patients during this time may reflect that the patients had an 
intact physiological temperature control response, reflecting less severe neurological injury 
and therefore the converse response seen to spontaneous hypothermia as described above. 
In summary, observed temperature of the TH group was lower than ST on PIC admission. 
The reason for the difference could be multi-factorial; however, the impact on hospital 
survival could not be ascertained with the current study sample size and design. 
7.6.6 Therapeutic hypothermia application – induction and maintenance 
Evidence from animal studies and clinical consensus is that time to target temperature after 
ROSC should be as short as possible, whilst avoiding unintentional overshoot to 
temperature <32⁰C. In the current study, patients receiving TH reached the target 
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temperature after ROSC in a median of 5.5 (IQR [3.3 to 8.5]) hours. Actual time to reach 
target temperature from the start of TH initiation was much quicker. Patients with admission 
temperature to PIC >35⁰C reached target temperature within a median time of 2.5 (IQR 
[1.75 to 4.75]) hours equating to a speed of cooling of 0.91 (IQR [0.5 to 1.5]) ⁰C/hr.  
Comparison of cooling rate with other studies is difficult. Pragmatic studies of actual clinical 
practice, such as this current study, often include patients who are already close to the 
target temperature therefore requiring minimal temperature adjustment. Therefore, we chose 
to express our cooling rate for patients with a start temperature >35⁰C. Fink et al (2010) 
reported a mean time to cool of only 0 hours (range 0 to 4hours); however, 60% of patients 
in the TH group presented at or below the target temperature. Retrospective studies also 
rely on temperatures recorded on charts which are often at hourly intervals. Therefore, this 
can decrease the precision of identifying time differences due to rounding up or down. This 
may account for the faster cooling time reported by Topjian et al (2010). They prospectively 
investigated a TH treatment protocol used in 12 patients and reported a time to reach target 
temperature using surface cooling of a median time of only 1.5 (IQR [1 to 1.5]) hours, 
although median time from arrest was similar to our current study  (6 (IQR [5 to 6.5]) hours).  
Another problem is that the time durations reported are not standardised. Time points 
recorded are often arrest time or ROSC time and time reaching target temperature only and 
do not necessarily record when cooling methods are applied or how they are adjusted or 
supplemented (e.g. addition of ice packs or use of a second cooling blanket). This process, 
unless prospectively collected, is often not recorded in medical records or nursing charts. 
For example, adult literature reports wide variability in cooling rates. The HACA study 
reported time to target temperature in the TH group of 8 (IQR [4 to 16]) hours at a rate of 
0.3⁰C/hour, compared to the Australian RCT where target temperature was reached in 2.5 
(IQR [1.1 to 4]) hours; at a rate of 1.5⁰C/hour. Both studies used surface cooling, although 
this was started by paramedics in the field after ROSC during the Australian study and in the 
ED in the HACA study. The wide difference in cooling rates between these two studies is 
due to the delay in starting the therapy and a direct comparison of the actual cooling rates 
when the therapy is applied cannot be ascertained. This problem is increased in 
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retrospective studies where the decision making processes are also not recorded, so we are 
not able to know what human factors may play a part in the speed of cooling. 
Unintentional overshoot in temperature to <32⁰C occurred in 11% (4/38) of patients. This 
compares favourably to the proportion unintentionally overcooled by Fink et al (2010) (15%; 
6/40), Doherty et al (2009) (17%; 5/29) and was significantly less than Topjian et al (2010) 
(75%; 9/12). Increased mortality has been reported in subgroups who are overcooled (Fink 
et al, 2010) although the causal association has not been established. Our use of servo-
controlled cooling units, rather than manual temperature control by applying surface ice-
packs, may account for the reduction in unintentional overshoot.  
Finally, rapid reduction in temperature may additionally reflect more severe neurological 
injury. Patients with the fastest time to target temperature in the study by Haugh et al (2011) 
were reported to have a worse surival outcome compared to those where cooling time was 
slower.  
Hypothermia was maintained for 22.5 (IQR [16.5 to 24.7]) hours using servo-controlled 
Blanketroll II units, consistent with ILCOR recommendations. Assessment of stability of 
maintenance therapy was not possible owing to frequency of data time points (four hourly). 
Therefore, for formal assessment of temperature stability control with surface cooling 
methods in the wide range of paediatric patient weights and sizes, prospective continuous 
temperature monitoring will be required. 
In summary, our study reported similar length of time to reach target temperature and rate of 
temperature reduction after commencing cooling compared to other paediatric and adult 
studies. In addition, the method of cooling used in this study resulted in a low proportion of 
patients unintentionaly being overcooled. Although full interpretation of factors influcencing 
temperature reduction, TH inititiation, actual cooling rates of surface cooling devices for 
different sized paediatric patients and temperature variability were not available, a 
prospective study will be requried to evaluate this further.  
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7.6.7 Therapeutic hypothermia application – rewarming 
Controlled rewarming and the avoidance of overshoot hyperthermia (>38⁰C) are required to 
prevent haemodynamic instability, rapid electrolyte changes and worsening of neurological 
injury. Too rapid rewarming in experimental animal models has been demonstrated to 
increase neurological injury and reverse any advantages gained by applying TH (Hildebrand 
et al, 2005; Alam et al, 2006; Maxwell et al, 2005; Matsushita et al, 2001) and in humans, an 
additional harmful effect of rebound hyperthermia includes the loss of cerebrovascular auto-
regulation (Lavinio et al, 2007). Finally, electrolyte imbalance (e.g. hyperkalaemia) can also 
occur through rapid intracellular shift without sufficient time for renal elimination (Polderman 
et al, 2001). In this study, patients were rewarmed at a rate of 0.3 (IQR [0.23 to 0.44]) 
⁰C/hour, and only 32% re-warmed less than or equal to 0.25°C /hour. The optimal rewarming 
rate after TH in humans has not been established. There has been a decrease in the 
rewarming rates used in clinical studies of TH after cardiac arrest, TBI and stroke over the 
past 10 years. In TBI and stroke patients, where intracranial pressure monitoring has been 
possible, detrimental rises in intracranial pressure and reduction in cerebral perfusion 
pressure have been noted during rewarming, which have been associated with worse 
neurological outcome and incidence of cerebral herniation (Steiner et al, 2001).  The 
reported rewarming rates in post cardiac arrest trials vary from 1⁰C/hour to 0.25⁰C/hour; 
however, much slower rates have been used in TBI and stroke (e.g. 1⁰C every 24 hours). 
Standardised rewarming rates may also be inappropriate. Some researchers advocate using 
surrogate measurements of cerebral perfusion and blood flow with trans-cranial doppler 
ultrasound to guide rewarming rate after cardiac arrest, allowing a more bespoke approach 
and responding to individual patients‟ improvements in cerebral blood flow (Ringe et al, 
2011) 
Hyperthermia (>38⁰C) in the first 24 hours after rewarming occurred in 29% (10/34) patients. 
Evidence to support strong recommendations for avoiding hyperthermia after acute brain 
injury and potential detrimental effects was outlined in Chapter 6. Therefore, this finding is of 
concern. The incidence of hyperthermia may reflect continued rewarming effects after 
normothermia was reached or too rapid rewarming rates, in addition to the tendency of 
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hyperthermia to occur after brain injury (Bembea et al, 2010; Hickey et al, 2000; Busch et al, 
2006). However, it is not clear whether patients in our study continued to be actively 
temperature controlled with servo-controlled cooling devices after rewarming. Rebound 
hyperthermia has also been reported with other methods of rewarming such as 74% of 
adults using the endovascular cooling catheters (Pichon et al, 2007). Our study 
demonstrates a controlled rewarming rate close to the current recommend rates for post 
cardiac arrest TH management; however, rebound hyperthermia was still common. Strict 
monitoring of both temperature control and physiological effects of rewarming are essential 
during TH.  No human study has investigated the optimum rate of rewarming after TH for 
neurological injury and further evaluation of this important part of the therapy is required.  
7.6.8 Physiological differences 
Reduction in core temperature in humans is known to be associated with a concomitant 
reduction in heart rate in sedated patients (Polderman & Herold, 2009; Thoresen & 
Whitelaw, 2000). Myocardial contractility in euvolaemic patients can improve although 
diastolic function may be slightly impaired. The reduction in metabolic demand is normally 
greater than the reduced cardiac output so supply and demand remain constant or improve 
(Polderman & Herold, 2009). This phenomenon can be used clinically in the treatment of 
tachyarrhythmias after cardiac surgery (Kelly et al, 2010) and at an extreme level is an 
essential response to ensure survival in hibernating animals (Ahmad et al, 1979). 
Bradycardia and hypotension is therefore a consistent finding in studies of TH, irrespective 
of underlying disease process (Bernard et al, 2002; HACA, 2002; Jacobs et al, 2007; 
Hutchison et al, 2008; Azzopardi et al, 2009). The bradycardia is often asymptomatic and 
does not require treatment. However, the management of the associated hypotension is 
more controversial, with current TH studies and TH protocols advocating blood pressure 
maintenance at age appropriate levels, especially during re-warming. 
In the current study, overall heart rate was significantly lower in the TH versus the ST group 
during the first 24 hours of PICU admission. However, the difference was not significant 
when the values were normalised for age, despite the overall ages of the TH and ST groups 
being similar. This lack of statistical difference may be due to inclusion of heart rate values 
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during the induction and rewarming phases of TH as well as the small sample size. We did 
observe an increase in proportion with bradycardia (<10
th
 centile) in the TH group, consistent 
with the findings of other TH studies, with no reported associated problems. 
Mean and systolic blood pressures were similar for both TH and ST groups, when compared 
between the first 24 hours and subsequent 48 hour time period. However, more patients in 
the TH group received inotropic support (74% versus 54%; p=0.08) which may have 
contributed to the maintenance of normal blood pressure range in line with the clinical 
objectives and also may have caused an increase in heart rate relative to age. 
TH (32-34°C) can lead to thrombocytopaenia, although affects on the clotting cascade are 
not usually seen until lower temperatures (<30°C) are reached (Polderman & Herold, 2009). 
No previous TH study using a 32-34°C target has reported an increase in bleeding, although 
it should be noted that all studies excluded patients with active bleeding at trial enrolment 
and study size may have been insufficiently large to identify this risk.  Median platelet count 
fell in both TH and ST patients across the two time periods with a slight increase in the 
proportion with thrombocytopaenia. However, this study did not identify an association 
between TH and worsening thrombocytopaenia. There was also no deterioration in 
prothrombin time and activated partial thromboplastin time, as expected at this level of 
hypothermia. 
No clinically significant differences in electrolyte levels were identified between TH and ST 
patients, although magnesium levels were noted to drop below normal level in the second 
time period for both TH and ST patients. Electrolyte loss can occur secondary to increased 
renal excretion as a consequence of tubular insufficiency and intracellular electrolyte shift 
during TH (Polderman et al, 2001).  We identified a reduction in plasma magnesium levels in 
both TH and ST patients over time, although not in sodium or potassium. Development of 
hypomagnesaemia has been associated with increased mortality in critically ill patients and 
mitigating further neurological injury (Soliman et al, 2003; Polderman et al, 2003). 
Maintaining normal magnesium levels may also reduce TH induced shivering. Therefore, 
although we did not identify an increased loss of magnesium in patients undergoing TH 
Chapter 7 
 
277 
 
compared to ST, this is a potential area requiring improvement in post cardiac arrest 
management.  
Plasma glucose levels were initially raised and then reduced over the two time periods, 
although no difference between TH and ST patients was identified. Despite this, Insulin use 
was twice as common in the TH group. Hypothermia can cause insulin resistance and 
hyperglycaemia with increased requirement of insulin in patients receiving TH after cardiac 
arrest (Fink et al, 2010; Bernard et al, 2002). However, an additional explanation for 
increased insulin may have been due to a concurrent randomised controlled trial of tight 
versus liberal glucose control, being performed on the PICU from May 2008 onwards. This 
influenced insulin strategy for patients in and out of the trial during that time 
(ISRCTN61735247).  
Hypocarbia occurred in nearly 50% of both TH and ST patients in the first 24 hours of the 
study using alpha stat (non-temperature adjusted) measurement. If corrected for 
temperature the TH PaCO2 values would be lower (Murkin, 2007). Our hypocarbia rates 
were similar to an observational adult study of TH post OHCA which reported that severe 
hypocarbia (PaCO2 <4kPa) occurred in 46% (56/122) of samples during TH (Falkenbach et 
al, 2009). However, they were unable to draw conclusions regarding the association of 
hypocarbia and outcome due to other confounding factors. 
This observation of such a high proportion with severe hypocarbia is of concern as cerebral 
blood flow is affected by variations in PaCO2 and hypocarbia causes cerebral 
vasoconstriction and a reduction in cerebral perfusion. In addition, cerebral autoregulation 
controlling cerebral blood flow can be lost after hypoxic ischaemic brain injury which, 
combined with the detrimental effect of hypocarbia, can result in significant secondary 
neurological injury (Sundgreen et al, 2001; Murkin, 2007; Pappas et al, 2011). We did not 
find an effect on survival outcome but further improvement in ventilation management of 
post cardiac arrest patients appears important with more formal evaluation of the optimal 
PaCO2 target after OHCA. 
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7.6.9 Withdrawal of life sustaining critical care support  
TH has changed the traditional timing of clinical, electrophysiological and neuro-imaging 
investigation to predict outcome after hypoxic ischaemic brain injury (Abend et al, 2012; 
Young, 2009; Nakagawa et al, 2011; Fugate et al, 2010).  Pharmacological clearance of 
sedative drugs is also delayed by TH and therefore alters timing for neurological and brain 
death testing (Webb & Samuels, 2011). As a consequence PICU length of stay is prolonged 
in patients who do not survive as a result of devastating neurological injury but whose 
respiratory and cardiovascular systems are supportable by modern invasive critical care 
therapies.  
Length of PICU stay in our cohort was significantly longer in patients who received TH and 
did not survive (4.1 (IQR [2.6 to 5.2]) days) compared to ST non-survivors (1.2 (IQR [0.4 to 
2.4]) days), although it was similar for survivors. The length of time to death in the ST group 
is significantly shorter than reported in the similar group by Doherty et al (2009) (9.0 (IQR 
[5.0 to 22.3]) days) and Fink et al (2010) (5 (IQR [1 to 14]) days). The potential inclusion of 
only OHCA patients in our study, with associated worse hypoxic-ischaemic injury, may 
account for this difference. It is possible that end-of-life management of patients and families 
between different countries also differed. There was also a temporal trend of increasing time 
to withdrawal of intensive care support and death along with an increased use of MRI and 
EEG monitoring. This may reflect a change in clinical practice when predicting outcome with 
an increased use (and potential reliance) of multi-modal methods of prediction occurring 
over time. 
The health care cost of TH has been evaluated in adults with an estimated cost of 
US$100,000 per quality adjusted life year, although this is in the context of the therapy being 
shown to be beneficial in post VF arrest adults (Merchant et al, 2009). In paediatrics the 
health care costs of TH are not known and the current on-going therapeutic hypothermia 
trials in the USA (THAPCA studies) are not undertaking formal health economic evaluation 
(NCT00878644; NCT00880087).  However, the demonstrated increase in PICU length of 
stay (and associated costs) with TH use in this study indicates that health care costs will be 
rising with a change towards TH use but without clear clinical benefits. Therefore, to quantify 
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cost-effectiveness of TH properly, accurate and prospective evaluation of health care costs 
is needed in combination with a therapeutic intervention study of the clinical efficacy of TH.  
7.6.10 Limitations 
This study is affected by the same four limitations outlined in detail in chapter 6; being a 
retrospective study, with a small sample size, data collection limited to available data and a 
lack of neurological outcome data. We were also unable to fully adjust for selection bias and 
effects of temporal trend including the increasing numbers of patients per year over the 
study period.c195 
7.6.11 Limitations – single centre study 
We only included patients from a single centre. This may have had the advantage of 
reducing the variability of post cardiac arrest management that was demonstrated in Chapter 
6, and enabled a comparison between TH and ST whilst minimising additional confounders. 
However, this approach potentially limits the general applicability of the overall findings to 
the wider UK population. Also, even within a single centre, we identified changes in post-
cardiac arrest management over the seven year study period. Therapeutic hypothermia use, 
MRI neuro-imaging and neuro-electrophysiological (EEG/CFAM) monitoring all significantly 
increased in the second half of the study. There may also have been other changes that we 
were unable to identify, potentially confounding the overall findings of the study. For 
example, in 2005 new international resuscitation guidelines were published in an attempt to 
improve clinical practice (ILCOR, 2005). Our study was not designed to identify these 
changes and may have been too small to detect small changes in outcome rates. We are 
therefore unable to assess this impact, although other studies have also failed to 
demonstrate an impact on survival through the implementation of these guidelines (Deasy et 
al, 2011b; Fonte et al, 2011; Bigham et al, 2011). 
7.6.12  Limitation - Temperature monitoring 
When considering the implication of temperature on patients with neurological disease, 
knowledge of the brain temperature would of course be the ideal. Our current practice and 
this current study used core-temperature (oesophageal or rectal) as a surrogate for brain 
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temperature. Direct brain temperature monitoring is currently too invasive and therefore not 
possible in most paediatric neurological conditions, including hypoxic ischaemic injury after 
cardiac arrest. Patients after traumatic brain injury, through the use of temperature probes 
incorporated within intracranial pressure monitors, can have single site brain temperature 
monitored (Polderman, 2008; Rumana et al, 1998; Mellergard & Nordstrom, 1991; Verlooy et 
al, 1995; Nybo et al, 2002). In this group of patients, brain temperature has been shown to 
exceed core temperature by as much as 2°C, possibly due to hyper-metabolism in injured 
areas triggered by the excitotoxic cascade and cerebral thermopooling. This phenomenon 
may occur in the injured brain after cardiac arrest, although this is yet to be investigated. 
Also the effects of surface or invasive cooling methods on human brain temperature are not 
known.  There are additional non-invasive methods to measure brain temperature such as 
the zero-gradient method (Simbruner et al, 1994) and Proton Magnetic Resonance 
Spectroscopy temperature measurement (Cady et al, 1995; Corbett et al, 1997; Jayasundar 
& Singh, 2002). Therefore, these non-invasive methods may be potential investigational 
tools, able to assess the actual brain temperature of post-cardiac arrest patients and be 
feasible during the administration of whole body cooling TH. 
.  
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7.7 CONCLUSION 
This is the largest study to date comparing the effects of TH with ST after OHCA. TH was 
effectively administered in the paediatric population with limited adverse effects. Half of 
patients reached target temperature by 5.5 hours with a low proportion of unintentional 
hypothermia although post therapy hyperthermia was a common problem. We identified a 
temporal trend of increasing TH use with resultant increase in PICU length of stay and 
adjunctive neurological imaging and investigations. However, TH did not increase survival to 
hospital discharge in patients with similar clinical presentations to a group receiving ST. 
 In the paediatric population, further prospective evaluation is necessary to support the use 
of TH for post-OHCA patients. Current recommendations should stress the avoidance of 
excess hypothermia (<32⁰C) and hyperthermia (>38⁰C) and the goal of maintaining a 
„Goldilocks Temperature‟ – not too hot and not too cold. However, the definitive answer to 
the ideal temperature remains unknown. Further studies are required to demonstrate 
whether TH is cost-effectiveness, safe and importantly improves the proportion of patients 
with good neurological survival after OHCA. 
 
Table 7-16 Chapter 7 and RCT feasibility 
What have we learnt from this study towards the feasibility of a UK randomised 
controlled trial? 
There remains no paediatric specific evidence supporting the use of TH after OHCA in 
children 
TH can be administered in the clinical setting within a median of 5.5 hours; however, factors 
affecting delay are not fully understood.  
Patients experiencing extreme hypothermia (<32⁰C) before or after PIC admission did not 
survive. Causal association with mortality is not defined; however, avoidance of unintentional 
overshoot during hypothermia induction is strongly recommended. 
TH prolongs PIC length of stay compared to ST, increasing health care associated costs. 
Cost-effectiveness evaluation of TH is therefore essential in addition to demonstrating clinical 
benefit. 
In 2010, 80% of OHCA patients received TH as standard care at Birmingham Children‟s 
Hospital 
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8 Summary and conclusion 
 
  
. 
“Now this is not the end. It is not even the beginning of the end.  
But it is, perhaps, the end of the beginning.“ 
 
Sir Winston Churchill (British Politician: Born 1874) 
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8.1 OVERVIEW 
Therapeutic hypothermia is a potential therapy to improve the survival rate and increase the 
proportion of patients with a good neurological outcome after paediatric cardiac arrest. To 
demonstrate its efficacy, a randomised controlled trial (RCT) recruiting infants and children 
would be required. Therefore, this thesis aimed to assess the feasibility of performing a RCT 
of therapeutic hypothermia for neuroprotection after paediatric cardiac arrest in the UK 
through a programme of research. The broad feasibility questions; should we, could we and 
how would we conduct a RCT were evaluated through eight thesis research questions. To 
answer these questions the following studies were undertaken; a systematic Cochrane 
review of the paediatric literature (Chapter 3), two surveys of clinical practice in paediatric 
intensive care and emergency medicine (Chapter 4), an epidemiological study of post 
cardiac arrest admissions to UK PICUs (Chapter 5), a multicentre, retrospective, cohort 
study of post cardiac arrest management (Chapter 6) and a single centre, retrospective, 
cohort study of therapeutic hypothermia and standard temperature management (Chapter 
7).  No single study provided the answer but the accumulation of the information (with 
acknowledged limitations) can answer the research questions summarised below. 
8.2 RESEARCH QUESTIONS 
8.2.1 Is there currently sufficient evidence to support (or refute) the beneficial 
effects of therapeutic hypothermia after paediatric cardiac arrest? 
A systematic review of current literature regarding the use of hypothermia for 
neuroprotection in children after cardiopulmonary resuscitation was performed using 
Cochrane methodology. This review confirmed that there is currently no published RCT data 
examining therapeutic hypothermia as a neuroprotection therapy in children after cardiac 
arrest. Four paediatric RCTs are currently on-going or finished and awaiting analysis. Two of 
these are large multicentre trials (NCT00878644; NCT00880087) examining the benefits of 
therapeutic hypothermia (33±1°C) versus normothermia (36.75±0.75°C) after out of hospital 
and in hospital cardiac arrest separately. They have been successfully funded through 
national funding organisations. Clinicians have successfully recruited patients to these trials, 
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although only in North America and Canada. Publication of findings from these trials is not 
expected until 2014/2015 at the earliest, although the study is aiming to demonstrate a 14% 
absolute improvement in survival with good neurological outcome which may be unrealistic 
in a heterogeneous patient population. The review concludes that there is not enough 
evidence to support (or refute) the beneficial effects of therapeutic hypothermia after 
paediatric cardiac arrest; however, absence of evidence does not mean that there is 
evidence of no effect. Therefore, the review supports the need for continued research within 
the paediatric age group. 
An additional benefit of the process of conducting the Cochrane review is personal 
communication with international experts across the world. This revealed a willingness to 
advise upon, participate in, and support our endeavours towards performing a RCT of 
therapeutic hypothermia after paediatric cardiac arrest. 
8.2.2 What is currently practiced in the UK regarding therapeutic hypothermia 
after paediatric cardiac arrest?  
In Chapter 4, two surveys were conducted to establish the current practice of targeted 
temperature management and future trial acceptability amongst paediatric intensive care 
(n=149) and paediatric emergency care consultants (n=77). Both groups of clinicians have 
key roles in post cardiac arrest patient management and decision making regarding 
therapeutic practices and enrolment of their patients into interventional studies. The surveys 
concluded that at the time of questioning, approximately half of UK paediatric intensive care 
consultants used therapeutic hypothermia after paediatric cardiac arrest. It was infrequently 
used in the emergency department, and if used, often only after advice from a paediatric 
intensivist. There was also wide variation in the temperature, duration and rewarming rate of 
therapeutic hypothermia used amongst responders, reflecting the lack of clear evidence and 
recommended protocols in paediatrics.  
 
Chapter 6 also demonstrated the variation in the use of therapeutic hypothermia. The 
retrospective, cohort study of infants (older than 24 hours) and children (before their 16
th
 
birthday) admitted to three large UK PICUs after OHCA over a seven year period (January 
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2004 to December 2010), showed wide variation in the proportion of infants and children 
receiving therapeutic hypothermia. In Unit 1 only 6% (3/50) of OHCA patients received TH 
compared with Unit 3 (22%, 7/32) and Unit 2 (52%, 38/73). This confirmed that the self-
reported variation in behaviour found in the survey was supported by variation in actual 
clinical behaviour. 
 
8.2.3 Does clinical equipoise exist amongst the paediatric intensive and 
emergency care communities? 
This fundamental question was also explored in Chapter 4 and forms the foundation as to 
whether clinicians will support a RCT and be willing to recruit patients. When specifically 
asked regarding clinical equipoise, 73% of paediatric intensivist and 52% of emergency 
medicine physicians agreed or strongly agreed to have clinical equipoise regarding the ideal 
post resuscitation temperature management and would randomly assign patients to 
therapeutic hypothermia or normothermia therapy. The lower agreement from the 
emergency physicians was accompanied by a larger proportion claiming a neutral view as 
opposed to disagreement. In addition to clinical equipoise, there was strong support for a 
RCT and for consultants to enrol their own patients into this. The variation in actual clinical 
use of therapeutic hypothermia, demonstrated between three units in Chapter 6, also 
supports the position of clinical equipoise. However, in Chapter 7, the use of therapeutic 
hypothermia was shown to increase significantly over the study period at Birmingham 
Children‟s Hospital and by 2010, 80% of OHCA patients received the therapy. Therefore, the 
position of clinical equipoise may be changing and this will require constant review. 
 
The paediatric intensivist and emergency medicine surveys were conducted in November 
2008 and June 2010, respectively.  Very little new paediatric literature has emerged since 
conducting these surveys to influence clinicians‟ views. Nevertheless, it will be necessary to 
re-investigate clinical equipoise during a consultation process regarding protocol design and 
individual PICU participation in a potential trial. In addition, agreement to participate in a 
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RCT was made without knowledge of the trial protocol. A formal agreement to participate 
would be required after full explanation of the trial design. 
8.2.4 What is the current epidemiology of children who are successfully 
resuscitated and admitted to PICU after cardiac arrest in the UK?  
Through the extraction and analysis of IHCA and OHCA PICU admissions from the 
prospectively collected national PICANet database study in Chapter 5, information on 1703 
children was obtained from 30 PICUs in the UK and Eire between January 2003 and June 
2010.  
The incidence rate of OHCA admissions to PICU was 1.3 per 100,000 children (0 to 15 
years) per year; however, it was not possible to calculate an IHCA incidence rate. IHCA and 
OHCA each accounted for 0.8% (IQR [0.6–1.0]) of all PICU admissions. PICU survival was 
significantly higher for IHCA patients (76% versus 50%; p<0.01) and higher than other 
comparable published studies. 
Differences between IHCA and OHCA were reported, justifying the need for separation of 
the two populations in a RCT. IHCA patients were younger, had more pre-existing chronic 
conditions and less patients had two unresponsive pupils. For both IHCA and OHCA 
patients, two unresponsive pupils, the use of vasoactive drugs, presence of certain chronic 
conditions or transfer from another hospital to PICU all affected survival.  
For non-survivors in particular, treatment with therapeutic hypothermia may increase both 
length of ventilation and PICU stay especially when allowing time for formal neurological 
assessment. This may have a significant effect on both families and potential health care 
related costs which should be evaluated in future studies. 
Additional data regarding OHCA patients were reported from Chapter 6. The three PICUs 
admitted approximately 21% of all infants and children requiring PICU in the UK. This study 
reported lower survival rates after OHCA compared with the PICANet data (32% (50/155) 
versus 50% (423/841) and significantly higher rates of patients with two unresponsive pupils 
(84% versus 22%). This increases the concerns regarding the limitations of the PICANet 
database and the potential errors in classification and categorisation of post cardiac arrest 
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patients from the database. The significance of these differences is in relation to the actual 
number of post cardiac arrest admissions and the baseline rate of survival after OHCA. Both 
these factors are fundamental to the sample size and effect size estimations, potentially 
causing an underestimation, although not to a magnitude likely to affect the overall 
conclusion of the following question. 
8.2.5 What is the potential size of the paediatric post-cardiac arrest population 
admitted to PICU and is this sufficient for a UK RCT of therapeutic 
hypothermia? 
Cardiac arrest rates and estimation of required study sample size for an intervention study 
indicates that the UK would not be able to perform the trial without international 
collaboration. To demonstrate a possible 10% absolute treatment effect in a UK 
interventional trial after IHCA and OHCA would take at least 3.7 and 6.9 years respectively 
involving 66% (20/30) of the largest UK PICUs. However, even with an optimistic ratio of 
50% identified patients being entered into a study, the UK would require funding for nearly 
14 years to recruit to an OHCA study and 7.5 years for an IHCA study using 20 PICUs to 
demonstrate a realistic 10% difference in outcome. After adjusting for the lower survival rate 
after OHCA observed in Chapter 6 and 7, the UK population would still be insufficient to 
recruit to a UK only RCT. 
An option for the UK would be to perform an RCT with an objective to „supplement‟ the 
patient numbers in the current THAPCA in-hospital and out of hospital cardiac arrest studies. 
These two studies are aiming to show a 14% absolute effect size change in the primary 
outcome.   By performing a UK study, the additional patient numbers achievable within three 
to four years, if combined with the THAPCA study, could demonstrate an absolute effect size 
change closer to 11%. For example, using the baseline hospital survival rate in the ST group 
of 23% (Chapter 7), an estimated 11% treatment effect size and absolute increase in 
hospital survival with TH (absolute difference seen in Chapter 7), 80% power (1-β) and 
within a 95% confidence level (α level), a future study would require 264 patients in each 
arm (i.e. 528 patients in total). Compared to the target of 350 patients recruited to the  
THAPCA out of hospital cardiac arrest study (NCT00878644), this is an additional 178 
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patients. This number of patients is an achievable target in the UK and although the smaller 
UK study would not be large enough to demonstrate a clear difference on its own, 
information in a different health care system would be gained, increasing the general 
applicability of the RCT findings.  
Experience from the neonatal HIE trials is that individual RCTs have failed to demonstrate 
statistically significant benefit from TH. Only through meta-analysis of a number of RCTs has 
the impressive improvement in survival and neurological outcome been demonstrated 
(Edwards et al, 2010). In another example, three European RCTs of decompressive 
craniectomy for middle cerebral artery infarction were examined in a pooled, individual 
patient data meta-analysis, prior to completion of the studies (Vahedi et al, 2007). This was 
owing to slow enrolment and conflicting interim analyses of the individual studies regarding 
the benefits and harm of surgery. Therefore, the meta-analysis aimed to avoid unnecessary 
(and unethical) continuation of randomisation in the individual trials and allowed a conclusive 
result to be reported much sooner. 
The major barrier to this approach would be gaining national funding for a RCT which would 
be anticipated to not be sufficiently large to demonstrate a treatment effect on its own.  A 
realistic response from funders could therefore be to wait for the publication of the THAPCA 
studies prior to starting a UK study. Whether this would be the correct approach is extremely 
difficult to predict. The delay may increase the time taken to gain a definitive answer to 
whether therapeutic hypothermia is beneficial, thereby subjecting more patients to a 
potentially harmful therapy. However, waiting for the THACPA study results may also be the 
correct one if the trial produces a definitive answer.   
8.2.6 Can outcome after paediatric cardiac arrest be predicted to assist risk-
stratification of patients in a RCT? 
Prediction of outcome after cardiac arrest will be of value in determining potential inclusion 
and exclusion criteria for an intervention trial, and a prediction tool could be used in a risk-
stratified analysis of the RCT population.  
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In Chapter 6, identified variables, associated with PIC survival, were analysed and included 
in a multivariate logistic regression model and Correlation and Regression Tree (CART) 
analysis to create a prediction tool. One hundred and fifty five OHCA patients met study 
entry criteria. 32% (50/155) survived to PIC discharge. A multivariate logistic regression 
model with factors available before and during resuscitation identified presenting in a 
shockable rhythm as strongly associated with survival. Including factors available up to four 
hours after PIC admission, raised blood lactate level and two unresponsive pupils were 
identified as strong predictors of mortality. The CART analysis prediction tool also added the 
duration of cardiac arrest as an additional discriminator to blood lactate level and two 
unresponsive pupils to create a more practical prediction tool for bedside use. 
The next step would be prospective validation of the prediction tools in a larger OHCA 
population. This could be performed within a RCT or in a large prospective observational 
study. The use of the tool in a risk-stratified analysis may improve the ability (and statistical 
power) to detect sub groups in a study who are likely to benefit or be harmed by the 
treatment, rather than assuming an average effect across the total trial population. Chapter 6 
has demonstrated the heterogeneous nature of paediatric OHCA patients, with a wide 
variation in aetiologies, co-morbid conditions and resuscitation related factors affecting 
survival. Therefore, paediatric cardiac arrest research appears to be an ideal area in which 
to evaluate improved methods for risk-stratifying and adjusting for the potentially 
confounding variables in this complex patient population. 
8.2.7 Can therapeutic hypothermia be implemented quickly, safely and 
consistently in children? 
Important features of therapeutic hypothermia delivery have been identified in animal and 
clinical studies; rapid commencement and induction of cooling, avoidance of extreme 
overshoot hypothermia (<32°C), stable maintenance period and controlled gradual 
rewarming to normothermia avoiding rebound hyperthermia (>38°C). Therefore, assessment 
of how quickly patients are admitted to a PICU, how quickly therapeutic hypothermia is 
commenced and target temperature reached, and assessment of adverse events directly or 
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indirectly related to the therapeutic hypothermia is important to maximise the potential 
benefit of the therapy. 
In Chapter 6, median time to admission at the three PICUs after OHCA was four and a half 
hours, and involved 73% being transferred from a large number of different referring 
hospitals. This will greatly reduce the time remaining within the therapeutic window, currently 
postulated to be six hours post cardiac arrest, in order to approach, recruit and randomise 
patients into a RCT after arrival to PICU.  
In Chapter 4, emergency department physicians expressed a willingness to be part of a RCT 
of post cardiac arrest TH and most emergency departments had suitable equipment to 
maintain or reduce temperatures. However, the infrequency of resuscitated paediatric 
cardiac arrest patients in the majority of hospitals admitting children would make this 
logistically very difficult. Early recruitment will ideally require input by specialist transport 
teams who attend the secondary hospital and transfer the patients to the tertiary PICU. The 
increasing retrieval service infrastructure in the UK, with dedicated transport networks, 
should increase the feasibility of recruiting patients and implement a research protocol. 
Chapter 7 compared the use of therapeutic hypothermia with standard temperature therapy 
after paediatric OHCA. This was a retrospective cohort study set in a UK tertiary PICU 
including infants and children greater than 24 hours until their 16
th
 birthday admitted to PICU 
after an OHCA (January 2004 to December 2010). In patients receiving TH (n=38), return of 
spontaneous circulation to target temperature duration was 5.5 (IQR[1.5-8]) hours, 
demonstrating that current single centre practice enabled at least 50% of patients to be at 
the maintenance phase of TH within the six hour „therapeutic window‟. If core temperature at 
the start of TH induction was greater than 35⁰C, target temperature was reached within 2.5 
(IQR[2-4]) hours at a rate of 0.9 (IQR[0.5-1.5]) ⁰C/hr, an induction rate consistent with other 
paediatric studies (Topjian et al, 2011). Median TH target temperature was 33.5⁰C (33-34⁰C) 
for a duration of 22:30 (IQR [16.37 to 24:44]) hours:minutes. Rewarming lasted 10:30 (IQR 
[07:00 to 14:45]) hours:minutes at a rate of 0.3 (IQR [0.23-0.45]) ⁰C/hr.  
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Eleven percent of patients experienced overshoot hypothermia (<32⁰C) during induction and 
29% hyperthermia (>38⁰C) after rewarming. Patients experiencing extreme hypothermia 
(<32⁰C) before or after PIC admission did not survive, although a causal association could 
not be established. The demonstration of instability in temperature control reinforces the 
need for further evaluation of induction and rewarming techniques in addition to strict 
treatment protocols. The potential relationship with extreme hypothermia and hyperthermia 
and worse outcome necessitates improved control during these key stages of therapy in a 
prospective study, in order to eliminate the confounding effect on outcome. 
8.2.8 Does therapeutic hypothermia improve survival after out of hospital 
cardiac arrest and are there significant physiological adverse effects? 
In Chapter 7, there was no demonstrated difference in hospital survival between patients 
treated with TH versus ST (34% vs. 23%; p=0.284). Compared to ST, the TH group only 
differed with respect to receiving more bystander CPR, a trend towards longer duration of 
cardiac arrest and a lower core temperature at PIC admission. There remains no paediatric 
specific evidence supporting the use of TH after OHCA in children. This study reconfirms the 
findings of the two previously published retrospective cohort studies that TH did not improve 
survival outcome after OHCA cardiac arrest, even when comparing two populations more 
closely matched (Doherty et al, 2009; Fink et al, 2010). 
We did not identify significant physiological differences or adverse events between patients 
treated with TH and ST. A significant reduction in plasma magnesium and high rates of 
hypocarbia were observed in both groups and warrant further evaluation due to the 
theoretical improvement in outcome which may be observed if these are better controlled. 
Also, the study did not show any increase in adverse events in patients receiving TH. 
However, the retrospective design of the study may have limited its ability to identify all 
adverse events and this will require further prospective evaluation. 
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8.3 FUTURE DIRECTIONS FOR RESEARCH 
“No research will answer all queries that the future may raise. It is wiser to praise the work 
for what it has accomplished and then to formulate the problems still to be solved.” 
Theobald Smith (American epidemiologist; Born 1859) 
   
The question of whether therapeutic hypothermia after paediatric cardiac arrest is the correct 
treatment remains an important and unanswered question for children and the UK National 
Health Service.  The next step following this thesis will be to consider whether to develop a 
protocol for a RCT of therapeutic hypothermia versus normothermia after paediatric cardiac 
arrest using the wealth of knowledge gained through the research studies presented here. 
The major barrier of patient numbers could be overcome by international collaboration. 
Previous successful partnerships with Canadian, Australian, New Zealand and European 
paediatric critical care research networks may facilitate this process. However, the problems 
in securing funding for a multi-million pound study and the legislative barriers that will be 
faced will make this a very difficult option. The second option of a „supplementary‟ UK study 
to support the US THAPCA study has already been discussed, including the funding 
concerns which will be faced in performing a UK study too small to demonstrate a significant 
difference in the primary outcome. Waiting to run the next paediatric therapeutic 
hypothermia trial until the publication of the THAPCA studies in three to four years time may 
be the preferred option by the funders, especially with current limited health research 
finances. 
In addition to a definitive RCT, this thesis has identified a number of other key areas 
requiring further research of both paediatric cardiac arrest and our understanding of 
therapeutic hypothermia. Chapter 5 identified the strengths and limitation of the PICANet 
database. Development of this database to include data collection of key Utstein defined 
resuscitation variables, post-cardiac arrest interventions occurring on PICU (e.g. therapeutic 
hypothermia) and neurological outcome status of patients admitted to PICU would be a 
significant advancement. PICANet is supported by all UK PICUs and already has validation 
and data monitoring processes in place. This simple increase in data collection, even for a 
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limited period of time, would provide an extremely useful source and allow better 
interpretation of cardiac arrest management and the relationship with both survival and 
neurological outcome. 
The prediction tool developed in Chapter 6 also requires validation in a larger prospective 
population. A simple and achievable method to collect this data would be through the 
enhanced PICANet database described above. Even with only a limited increase in cardiac 
arrest and resuscitation variables (length of cardiac arrest, admission lactate, presenting 
rhythm and use of therapeutic hypothermia) a rapid validation of the tool could be 
performed. This would be the ideal situation, prior to using it for as a risk-stratified 
randomisation or minimisation tool within a RCT. 
Feasibility of TH application, induction, maintenance and rewarming was demonstrated in 
Chapter 7. However, it was not possible to define the factors which can improve the speed 
of TH commencement and the optimum method of inducing and maintaining TH. A 
prospective evaluation of TH application with collection of data examining human factors, 
environmental factors, equipment factors and patients related factors on the impact of TH 
administration would be ideal. In addition, a comparative study of re-warming rates and 
control of overshoot hyperthermia would also significantly add to an understudied area of 
therapeutic hypothermia research. 
Chapter 7 also identified that seizure rates after OHCA appeared lower than other studies 
(Abend et al, 2009; Fink et al, 2010); however, patients were not monitored continuously 
during periods of neuromuscular blockade and electroconvulsive seizures may have been 
missed. Neonatal and paediatric intensive care use of amplitude integrated EEG (aEEG, a 
bedside, simplified, continuous EEG monitor) is evolving and may be ideal for post cardiac 
arrest patients. A prospective evaluation of post cardiac arrest patients would enable an 
assessment of whether potentially detrimental seizures are being missed and whether 
seizure recognition and early treatment can improve neurological outcome. 
Increased requirement and length of paediatric intensive care, with associated cost has 
been identified with the increased use of TH but without demonstrating a significant increase 
in survival. TH also delays the window for current neurological prognostication. In this study 
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a high proportion of patients received active withdrawal of intensive care support after 
clinicians and families accepted that continued treatment was futile. Therefore, in addition to 
the clinical criteria proposed in the prediction tool, continued investigation of early prognostic 
biomarkers such as: plasma biomarkers (S100B, neurone specific endolase), radiological 
imaging (MRI and Magnetic Resonance Spectroscopy) and neurophysiological monitoring 
(aEEG/EEG) may improve our understanding of who may benefit from prolonged treatment 
with TH. It is also recommended when conducting these studies, that the process of 
withdrawal of intensive support, decision making and documentation becomes standardised 
(Nielsen et al, 2011). 
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8.4 CONCLUSION  
Is it feasible to perform a post cardiac arrest, randomised controlled trial of therapeutic 
hypothermia for neuroprotection in UK children? Posing the questions: should we, could we 
and if so, how would we? 
First, should we perform a post cardiac arrest, randomised controlled trial of therapeutic 
hypothermia for neuroprotection in UK children? The answer is yes. This thesis has 
demonstrated through a systematic review of the literature and questioning the medical 
community on current knowledge and position of clinical equipoise, that there is insufficient 
paediatric specific evidence to inform current clinical practice but a desire and support to 
conduct further research. A retrospective comparison of therapeutic hypothermia and 
standard temperature therapy in two similar post OHCA paediatric populations is presented 
but did not show a significant increase in survival with therapeutic hypothermia. Cardiac 
arrest in children remains a devastating condition and further research to improve survival 
rates and neurological outcomes are still desperately needed. 
Secondly, could we perform a post cardiac arrest, randomised controlled trial of therapeutic 
hypothermia for neuroprotection in UK children? The answer is not on our own. The UK post 
cardiac arrest paediatric population is too small to recruit to a RCT large enough to be able 
to demonstrate a realistic treatment effect size change without a long and expensive study. 
Especially as IHCA and OHCA patients would be studied separately and appropriate 
inclusion and exclusion criteria are required to minimise heterogeneity. However, a smaller 
RCT could be performed within the UK, supplementing the on-going THAPCA studies 
((NCT00878644; NCT00880087), by using similar outcome measures and allowing future 
meta-analysis, ideally with individual patient data. 
Finally, how would we perform a post cardiac arrest, randomised controlled trial of 
therapeutic hypothermia for neuroprotection in UK children? The outcome prediction tool 
utilising post resuscitation factors and clinical information at the time of PICU admission will 
allow risk-stratification of patients during recruitment and in post-trial analysis. Recruitment 
of patients transferred from secondary hospital would require trial involvement by regional 
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transport teams to ensure enrolment within the theoretical narrow therapeutic window. 
Current use of therapeutic hypothermia reported in this thesis requires improvement to 
minimise potential increased harm associated with extreme hypothermia (<32⁰C) and 
rebound hyperthermia (>38⁰C). However, induction rates, duration of treatment, temperature 
and rewarming rates were satisfactory in patients receiving therapeutic hypothermia and the 
current method could be used in a future study.  
Further research is needed, including the development of a RCT protocol in addition to 
assessing the chances of UK national funding of a study prior to the publication of the 
THAPCA studies. Enhancement of the current PICANet database may be one simple 
method to improve our understanding of paediatric cardiac arrest and post cardiac arrest 
management in the UK. It is hoped that the research conducted for this thesis will be the 
beginning of further progress to improve the outcome of children suffering cardiac arrest.  
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9 Appendix  
 
 
 
“Not only is an „appendix‟ useless, but it is sometimes the cause of death” 
 
In. The Descent of Man and Selection in Relation to Sex. 
Charles Darwin (English naturalist, born 1809) 
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9.1 Systematic review search terms 
9.1.1 Ovid MEDLINE search strategy  
1.  exp Hypothermia/ or exp Hypothermia, Induced/ or hypothermia.mp. or (cooling or 
temperature regulat*).ti,ab. 
2. exp Heart Arrest/ or Ventricular Fibrillation/ or Cardiopulmonary Resuscitation/ or 
Tachycardia, Ventricular/ or neuroprotection.mp. or asystole.ti,ab. or dysrhythmia.mp. or 
((heart or cardiac or ventricular or circulatory) adj3 arrest).mp. or (ventricular adj5 
(fibrillation or tachycardia or arrhythmia)).mp. or pulseless electrical activity.mp. or 
electromechanical dissociation.mp. or cardiopulmonary resuscitation.mp. or (PEA or EMD 
or OOHCA).ti,ab. or non-perfusing rhythm.mp. 
3. 1 and 2 
4. ((randomized controlled trial or controlled clinical trial).pt. or randomized.ab. or 
placebo.ab. or drug therapy.fs. or randomly.ab. or trial.ab. or groups.ab.) not (animals not 
(humans and animals)).sh. 
5. 3 and 4 
9.1.2 Search strategy for CENTRAL, the Cochrane Library  
#1 MeSH descriptor Hypothermia explode all trees 
#2 MeSH descriptor Hypothermia, Induced explode all trees 
#3 hypothermia or (cooling or (temperature near (low or regulat*)) or hibernat* or 
cryotherapy or refrigeration):ti,ab 
#4 (#1 OR #2 OR #3) 
#5 MeSH descriptor Heart Arrest explode all trees 
#6 MeSH descriptor Ventricular Fibrillation explode all trees 
#7 MeSH descriptor Cardiopulmonary Resuscitation explode all trees 
#8 MeSH descriptor Tachycardia, Ventricular explode all trees 
#9 neuroprotection or asystole:ti,ab or distrithmia or ((hearth or cardiac or ventricular or 
circulat*) near arrest) or (ventricular near (fibrillation or tachycardia or arrhythmia)) or 
pulseless electrical activity or electromechanical dissociation or cardiopulmonary 
resuscitation or (PEA or EMD or OOHCA):ti,ab or non-perfusing rhythm 
#10 (#5 OR #6 OR #7 OR #8 OR #9) 
#11 (#4 AND #10) 
9.1.3 Search strategy for EMBASE (Ovid SP)  
1. exp hypothermia/ or exp induced hypothermia/ or exp cryotherapy/ or hypothermia.mp. or 
(cooling or (temperature adj3 (low or regulat*)) or hibernat* or cryotherapy or 
refrigeration).ti,ab. 
2. heart arrest/ or heart ventricle fibrillation/ or resuscitation/ or heart ventricle tachycardia/ or 
neuroprotection.mp. or asystole.ti,ab. or distrithmia.mp. or ((hearth or cardiac or ventricular 
or circulat*) adj3 arrest).mp. or (ventricular adj5 (fibrillation or tachycardia or 
arrhythmia)).mp. or pulseless electrical activity.mp. or electromechanical dissociation.mp. or 
cardiopulmonary resuscitation.mp. or (PEA or EMD or OOHCA).ti,ab. or non-perfusing 
rhythm.mp. 
3. 1 and 2  
4. (placebo.sh. or controlled study.ab. or random*.ti,ab. or trial*.ti,ab. or ((singl* or doubl* or 
trebl* or tripl*) adj3 (blind* or mask*)).ti,ab.) not (animals not (humans and animals)).sh. 
5. 3 and 4 
9.1.4 Search strategy for CINAHL (EBSCO host)  
S1 ( (MH "Hypothermia") OR (MH "Hypothermia, Induced") OR (MH "Hypothermia 
(NANDA)") OR (MH "Cryotherapy") ) OR ( hypothermia or (cooling or (temperature and (low 
or regulat*)) or hibernat* or cryotherapy or refrigeration) )  
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S2 ( (MH "Heart Arrest") OR (MH "Ventricular Fibrillation") OR (MH "Tachycardia, 
Ventricular") OR (MH "Resuscitation, Cardiopulmonary") ) OR ( neuroprotection or asystole 
or distrithmia or ((hearth or cardiac or ventricular or circulat*) and arrest) or (ventricular and 
(fibrillation or tachycardia or arrhythmia)) or pulseless electrical activity or electromechanical 
dissociation or cardiopulmonary resuscitation or (PEA or EMD or OOHCA) or non-perfusing 
rhythm )  
S3 S1 and S2  
S4 ( (MH "Randomized Controlled Trials") OR (MH "Random Assignment") OR (MH 
"Prospective Studies") OR (MH "Multicenter Studies") OR (MH "Single-Blind Studies") OR 
(MH "Triple-Blind Studies") OR (MH "Double-Blind Studies") OR (MH "Clinical Trials") ) OR ( 
random* or controlled clinical trial or placebo )  
S5 S3 and S4  
9.1.5 Search strategy for ISI Web of Science and BIOSIS Citation Index  
#1 TS=(hypothermia or (cooling or (temperature SAME (low or regulat*)) or hibernat* or 
cryotherapy or refrigeration)) 
#2 TS=(neuroprotection or asystole or distrithmia or ((hearth or cardiac or ventricular or 
circulat*) and arrest) or (ventricular SAME (fibrillation or tachycardia or arrhythmia)) or 
pulseless electrical activity or electromechanical dissociation or cardiopulmonary 
resuscitation or (PEA or EMD or OOHCA) or non-perfusing rhythm) 
#3 #2 AND #1 
#4 TS=(random* or (controlled SAME trial*) or prospective or multicenter) or TS=((blind* or 
mask*) SAME (single or double or triple)) 
#5 #4 AND #3 
  
Chapter 9 
 
301 
 
9.2 Systematic review data extraction form  
 
Study ID 
 
Authors 
 
Medline Journal ID 
 
Year of Publication 
 
Language 
 
 
Type of study:    RCT  Cohort     Case-control  
(Circle relevant study type) 
 
Comment on study design: 
 
 
 
 
QUALITY OF CONCEALMENT OF RANDOM ALLOCATION 
 
Domain Description 
Review Author’s 
Judgement 
Sequence Generation 
 
 
 
 
YES  /  NO /  
UNCLEAR 
Allocation concealment  
 
 
 
 
YES  /  NO /  
UNCLEAR 
Blinding of participants, 
personnel and outcome 
assessors. 
Outcome: 
 
YES  /  NO /  
UNCLEAR 
Blinding of participants, 
personnel and outcome 
assessors. 
Outcome: 
 
YES  /  NO /  
UNCLEAR 
Incomplete outcome data 
Outcome: 
 
 
 
YES  /  NO /  
UNCLEAR 
Incomplete outcome data 
Outcome: 
 
 
 
YES  /  NO /  
UNCLEAR 
Other sources of bias 
 
 
 
 
YES  /  NO /  
UNCLEAR 
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INCLUSION/EXCLUSION CRITERIA  
      Yes    No  
Clearly defined 
 
  
Inclusion criteria 
 
 
 
 
 
 
Exclusion criteria 
 
 
 
 
 
 
PARTICIPANTS 
Number of eligible participants 
 
 Number enrolled in study  
Number of males 
 
 Number of females  
Number of children <18 
 
 Number in treatment group  
 
Treatment Group   Control Group 
Witnessed arrest 
 
  
Time to ROSC 
 
  
 
INTERVENTION 
Control Group   Treatment Group  
 
Method of cooling 
 
  
Time to Randomisation 
 
  
Time to start of cooling 
 
  
Time to target temperature 
 
  
Depth of cooling 
 
  
Length of cooling 
 
  
COMMENTS ON TREATMENT 
 
 
 
 
Yes     No    Unclear 
Withdrawals 
 
   
 
OUTCOME   Control Group    Treatment Group 
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Days  in hospital 
 
  
Ventilator Free days 
 
  
Survival to admission 
 
  
Survival to intensive care 
discharge 
 
  
Survival to hospital discharge 
 
  
6 months survival 
 
  
12 months survival 
 
  
Long term survival > 12 months 
 
  
Neurological outcome at 
Hospital discharge 
  
Neurological outcome at 6 
months 
  
Neurological outcome at 12 
months 
  
Long Term Neuro outcome  > 
12months 
  
Adverse Events 
 
 
 
 
 
  
Cost Effectiveness Evaluation 
 
  
 
CHANGES IN PROTOCOL 
 
 
CONTACT WITH AUTHOR 
 
 
COMMENTS ON THIS STUDY 
 
 
 
 
 
 
 
 
 
 
 
Chapter 9 
 
304 
 
9.3 List of experts contacted for systematic review 
Contact Name Institution 
1 Jamie Hutchison Sick Kids Hospital, Toronto, Canada 
2 Ericka Fink University of Pittsburgh, USA 
3 Frank Moler University of Michigan, USA 
4 Mike Dean University of Utah, USA 
5 Vinay Nadkarni Children‟s Hospital of Pennsylvania, USA 
6 Stephen Bernard Alfred Hospital, Melbourne Australia 
7 Fritz Sterz University of Vienna, Austria 
8 Michael Holzer University of Vienna, Austria 
9 Alexis Topjian Children‟s Hospital of Pennsylvania, USA 
10 Robert Tasker Harvard University, USA 
11 Hannelore Ringe Berlin, Germany 
12 Patrick Kochanek University of Pittsburgh, USA 
13 John Beca Auckland, New Zealand 
14 Marianne Thoresen University of Bristol, UK 
15 Ken Nagao Tokyo, Japan 
17 Qian Quan Beijing, China 
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9.4 Published protocol for Cochrane review 
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9.5 Survey one questionnaire 
Questionnaire regarding the use of induced hypothermia as a therapy after cardiac 
arrest in children for paediatric intensive care consultants 
 
 
Please answer the following questions using the options available  
 
1) Do you believe that the use of therapeutic hypothermia after cardiac arrest in children 
results in improved survival? Yes/No/Don‟t know 
 
2) Do you use induced hypothermia as a therapy after resuscitation from cardiac arrest in 
children who have a return of spontaneous circulation? Never/Seldom/Often/Always 
 
a) If you answered Never or Seldom: Which of the following describe your reason for not 
using therapeutic hypothermia after resuscitation from cardiac arrest? [you may choose 
more than one] 
 
 Do not look after post-cardiac arrest patients 
 Not enough research evidence 
 Not part of APLS guidelines 
 Too technically difficult 
 Patient consent concerns 
 Cooling method too slow 
 Not considered it as a therapy 
 Initial attempts unsatisfactory 
 
If you answered Never to question 2 please proceed to question 17, otherwise please 
proceed to question 3.  
3) Does your clinical practice change if the child has an in-hospital cardiac arrest rather than 
an out-of hospital cardiac arrest? Yes/No 
 
4) Do you induce hypothermia as a therapy after in-hospital cardiac arrest in children? 
Never/Seldom/Often/Always 
 
5) Do you induce hypothermia as a therapy after out-of-hospital cardiac arrest in children? 
Never/Seldom/Often/Always 
 
6) Does your unit have a specific protocol for implementing hypothermia therapy? 
Yes/No/Don‟t know 
 
7) Which method of cooling do you commonly use to induce hypothermia? [you may choose 
more than one] 
 Air blanket 
 Ice-cold [4°C] intravenous fluid 
 Ice packs to skin 
 Wet linen 
 Water blanket 
 Intravascular cooling device 
 
 
8) Which method of cooling do you use to maintain hypothermia? [you may choose more 
than one] 
 Air blanket 
 Ice-cold [4°C] intravenous fluid 
 Ice packs to skin 
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 Wet linen 
 Water blanket 
 Intravascular cooling device 
 
9) Where would you actively start to induce hypothermia in your patients? 
a) The Emergency Department Yes/No 
b) Referring hospital prior to transfer Yes/No 
c) The Intensive care unit. Yes/No 
 
10) Do you have a fixed length of time [as opposed to variable length] you would routinely 
maintain hypothermia? Yes/No 
 
11) How long do you routinely maintain hypothermia? [please specify hours if fixed and 
range of hours if variable]  ………..hours   
 
12) What temperature do you aim to cool to? 
 36-37 °C 
 35-36 °C 
 34-35 °C 
 33-34 °C 
 32-33 °C 
 <32 °C 
 
13) Do you control the speed of rewarming? Yes/No 
 
14) If yes what is your target rate for rewarming?.......°C/hr  
 
15) Do you use active rewarming devices? Yes/No 
 
16) Which [if any] of the following influences your current use of hypothermia as a therapy 
after cardiac arrest? [you can select more than one]  
 
a. Length of time to return of spontaneous circulation (ROSC) after effective CPR. 
Yes/No/Don‟t know 
 
If yes please select the group of patients you would consider starting hypothermia therapy 
 ROSC after < 5 mins  
 ROSC after 5 - 10mins  
 ROSC after 10 – 20 mins  
 ROSC after 20 – 30 mins  
 ROSC after 30 – 60 mins 
 ROSC after > 60 mins 
 
b. Whether the arrest was witnessed or not Yes/No/Don‟t know 
 
If yes please select the group of patients you would consider starting hypothermia therapy 
 Witnessed cardiac arrest 
 Unwitnessed cardiac arrest 
 
c. Age of patient Yes/No/Don‟t know 
 
If yes please select the group of patients you would consider starting hypothermia therapy 
 Less than 7 days old 
 7 to 28 days 
 28 days to 1 year 
 1 to 5 years 
 5 to 10 year 
 Older than 10 years 
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d. Pupillary reaction [in patient who had not received Atropine] Yes/No/Don‟t know 
 
If yes please select the group of patients you would consider starting hypothermia therapy 
 Fixed and dilated pupils immediately after return of spontaneous circulation 
(ROSC) 
 Fixed and dilated pupils 1 hour after ROSC 
 Reactive pupils immediately after ROSC 
 
e. Delay between ROSC and opportunity to start hypothermia therapy Yes/No/Don‟t know 
 
If yes please select the group of patients you would consider starting hypothermia therapy 
 Delay of 1hour post ROSC before being able to commence hypothermia 
 Delay of 4 hours  
 Delay of 6 hours 
 Delay of 12 hours  
 Delay of 24 hours 
 
Please enter where appropriate your agreement of the following statements using the 
scale of: Strongly agree/Agree/No opinion or neutral/Disagree/Strongly disagree.  
 
17) The publication of a large randomised controlled trial currently being designed in the 
USA in the use of hypothermia in children after cardiac arrest would convince me of the 
benefit or lack of benefit for its use in my patient population?  
Strongly agree/Agree/No opinion or neutral/Disagree/Strongly disagree 
 
18) A multi-centre randomised controlled trial conducted in the United Kingdom in the use of 
hypothermia in children after cardiac arrest is necessary in addition to a USA study to 
convince me of its use in my patient population? 
Strongly agree/Agree/No opinion or neutral/Disagree/Strongly disagree 
 
19) I currently feel there is clinical equipoise regarding the use of hypothermia versus 
normothermia after cardiac arrest in children. 
[Clinical equipoise: defined as 'there existing an honest, professional disagreement among 
expert clinicians about the preferred treatment'] Freedman B. Equipoise and the ethics of 
clinical research. NEnglJMed. 1987 Jul 16;317(3):141-5. 
Strongly agree/Agree/No opinion or neutral/Disagree/Strongly disagree 
 
20) Would you support a randomised controlled trial in the UK investigating the use of 
hypothermia after cardiac arrest in children comparing - 
a) Hypothermia therapy versus normothermia? Yes/No/Don‟t know 
b) Variation in duration of hypothermia e.g. 24 versus 48 hours? Yes/No/Don‟t 
know 
c) Variation in method of inducing and maintaining hypothermia e.g. use of cold 
[4°C]     intravenous saline versus cooling blankets? Yes/No/Don‟t know 
 
21) It is ethical to perform a randomised controlled trial of hypothermia therapy in children 
after cardiac arrest? 
Strongly agree/Agree/No opinion or neutral/Disagree/Strongly disagree 
 
22) It is ethical to use deferred consent in clinical trials investigating therapies immediately 
after cardiac arrest? 
Deferred consent: defined as 'obtaining Informed consent [from parent or guardian] as soon 
as reasonably practicable after the initial emergency. This would be a requirement of 
continued participation in the trial; but its absence would not preclude initial entry into a trial. 
The use of deferred consent would only be used after specific approval by an ethics 
committee.' 
Strongly agree/Agree/No opinion or neutral/Disagree/Strongly disagree 
 
23) In a randomised controlled trial of hypothermia versus normothermia after cardiac arrest 
the following are important clinical outcome measures.  
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Answer for the following:  Strongly agree/Agree/No opinion or neutral/Disagree/Strongly 
disagree 
 Mortality 
 Neurological outcome 
 Adverse events from induced hypothermia [e.g. sepsis, ARDS, coagulopathy] 
 Length of stay in PICU 
 Ventilator free days 
 
24) Would you randomise your patients to a multi-centre UK study of hypothermia after 
cardiac arrest in children? Yes/No/Don‟t know 
 
25) Do you feel the use of hypothermia as a therapy should be recorded on PICANet data 
collection records? Yes/No/Don‟t know 
 
26) Please indicate your current clinical position: 
 full time consultant in PICU 
 Consultant with some sessions in PICU 
 Length of time as consultant (years) 
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9.6 Survey two questionnaire 
Survey of the use of therapeutic hypothermia after cardiac arrest in UK 
paediatric emergency departments.  
 
Demographics  
 
1) Which of the following best describes your current role? 
a) Consultant in Emergency Medicine 
b) Consultant in Paediatric Emergency Medicine 
c) Consultant in Emergency Medicine with dual accreditation in Paediatrics 
2) Which of the following best describes your Emergency Department? 
a) Paediatric Emergency Department within a Tertiary Children‟s Hospital 
b) Emergency Department with Audio-Visual separation of children and adults 
c) Emergency Department with no Audio-Visual separation of children and adults 
Other (please specify) 
 
3) On average how many children are seen in your Emergency Department per year? 
 
4) Are children who have suffered a cardiac arrest managed in your Emergency 
Department? 
a) Yes 
b) No 
 
Current practice in Therapeutic Hypothermia  
 
5) Are you aware of the published research regarding the use of therapeutic hypothermia in 
adults (18 yrs) who have a return of spontaneous circulation (ROSC) following out-of-
hospital cardiac arrest? 
a) Yes 
b) No 
 
6) Do you use therapeutic hypothermia as a therapy for adults (>18 yrs) who have a return 
of spontaneous circulation (ROSC) following out-of-hospital cardiac arrest? 
a) Never 
b) Seldom 
c) Often 
d) Always 
e) N/A 
 
7) Does your Emergency Department have a specific protocol for implementing hypothermia 
therapy in adults >18 yrs? 
a) Yes 
b) No 
c) Don't know 
 
8) Does your Emergency Department have a specific protocol for implementing hypothermia 
therapy in children <16 yrs? 
a) Yes 
b) No 
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c) Don't know 
 
9) Do you currently have access to any of the equipment listed below in your Emergency 
Department which could be used to induce 
therapeutic hypothermia in a child? (you can select more than one) 
a) Cold air circulating blanket 
b) Ice Cold (4ºCelsius) intravenous fluid 
c) Ice packs to be applied to skin 
d) Wet linen 
e) Cold water circulating Blanket 
f) Intravascular cooling device 
Other (please specify) 
 
10) Do you believe that the use of therapeutic hypothermia after cardiac arrest in children 
(<16 yrs) improves clinical outcome? 
a) Yes 
b) No 
c) Don't know 
 
11) In the management of children (<16yrs) who have had or shown a return of spontaneous 
circulation (ROSC) following resuscitation from cardiac arrest, how often do you use 
therapeutic hypothermia in your Emergency Department? 
a) Never 
b) Seldom 
c) Often 
d) Always 
 
If you answered 'Often' or 'Always' proceed directly to question 13. 
12) Which of the following describes your reason(s) for not using therapeutic hypothermia 
after resuscitation from paediatric cardiac arrest? 
(you can select more than one) 
a) I do not look after patients post cardiac arrest 
b) There is not enough research evidence to support its use 
c) Therapeutic hypothermia is not in the APLS guidelines 
d) Therapeutic hypothermia is technically too difficult to initiate 
e) I have concerns that patients are unable to give informed consent 
f) The cooling method to which I have access is too slow 
g) I have never considered hypothermia as a therapy in post arrest children 
h) Hypothermia is not advocated by my local Paediatric Intensive Care Unit 
i) I do not have any equipment available to initiate cooling 
Other (please specify) 
 
13) Which method(s) of cooling do you commonly use to induce hypothermia (all age 
groups)? (you can select more than one) 
a) Cold air circulating blanket 
b) Ice Cold (4ºCelsius) intravenous fluid 
c) Ice packs applied to skin 
d) Wet linen 
e) Cold water circulating Blanket 
f) Intravascular cooling device 
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Other (please specify) 
 
14) What temperature (degrees celcius) do you aim to cool to? 
a) 36-36.9 
b) 35-35.9 
c) 34-34.9 
d) 33-33.9 
e) 32-32.9 
f) 31-31.9 
g) 30-30.9 
h) Don‟t know 
 
15) On what basis do you select patients to induce therapeutic hypothermia? (you can select 
more than one) 
a) Likelihood of patient recovery after the arrest 
b) Absence of life limiting condition 
c) Absence of need for vasoactive drug support 
d) Presence of coma for >1hr post successful resuscitation 
e) Availability of equipment 
f) On advice from PICU 
g) Don‟t know 
Other (please specify) 
 
Research Opinion/Support  
 
Regarding the following statements, please select whether you: Strongly agree, Agree, No 
opinion or Neutral, Disagree, Strongly disagree  
 
16) There is clinical equipoise regarding the use of therapeutic hypothermia versus 
normothermia after cardiac arrest in children? 
(Clinical Equipoise: defined as “the existence of an honest, professional disagreement 
among expert clinicians about the preferred treatment”) Freedman B: Equipoise and the 
ethics of clinical research. N Engl J Med 1987 Jul 16;317(3): 414-5 
a) Strongly agree 
b) Agree 
c) No opinion or Neutral 
d) Disagree 
e) Strongly disagree 
 
17) It is ethical to perform a randomized controlled trial of hypothermia in children after 
cardiac arrest 
a) Strongly agree 
b) Agree 
c) No opinion or Neutral 
d) Disagree 
e) Strongly disagree 
 
18) It is ethical to use deferred consent in clinical trials investigating therapies commenced 
immediately after cardiac arrest 
(Deferred consent: defined as “Obtaining informed consent (from parent or guardian) as 
soon as is reasonably practicable after the initial emergency. This would be a requirement of 
continued participation in the trial; but its absence would not preclude initial entry into a trial. 
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The use of deferred consent would only be used after specific approval by an ethics 
committee”) 
a) Strongly agree 
b) Agree 
c) No opinion or Neutral 
d) Disagree 
e) Strongly disagree 
 
19) Would you support a randomized controlled trial in the UK investigating the use of 
hypothermia after cardiac arrest in children 
comparing: 
a. Hypothermia versus Normothermia 
a) Yes 
b) No 
c) Don't know 
b. Variation in the method of inducing and maintaining hypothermia 
a) Yes 
b) No 
c) Don't know 
 
20) Would you, in principle, allow your patients in the Emergency Department to be included 
into a multi-centre randomized UK study 
of hypothermia after cardiac arrest in children? 
a) Yes 
b) No 
c) Don't know 
If you answered 'No' could you briefly explain your answer? 
 
 
21) Would you be willing to commence therapeutic hypothermia in your Emergency 
Department as part of a research protocol? 
a) Yes 
b) No 
c) Don't know 
If you answered 'No' or 'Don't know' could you briefly explain your answer? 
 
 
Please write any further comments you have regarding the use of hypothermia after cardiac 
arrest in children and the prospect of future UK research and your involvement in this area: 
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9.7 Published paper: Survey of the use of therapeutic 
hypothermia post cardiac arrest 
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9.8 Published paper: Survey of the use of therapeutic after 
cardiac arrest in UK paediatric emergency departments 
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9.9 Chronic condition coding 
Table 9-1 Chapter five: Chronic condition groupings and subgroups for 
epidemiological study 
Chronic 
Condition 
Groups 
Subgroups Chronic Condition 
Groups 
Subgroups 
Respiratory Asthma Cardiac Endocarditis/Myocarditis 
 Pulmonary Hypertension  Cardiomyopathy 
 Congenital Anomaly (e.g. 
Tracheo-oesophageal 
fistula/Congenital 
diaphragmatic hernia) 
 Simple Cardiac: (Ventricular 
septal defect /Atrial septal 
defect /Coarctation/  
Patent ductus arteriosis/  
Aortic or pulmonary stenosis) 
 Upper airway obstruction 
(including Cleft palate) 
 Complex cardiac (single 
ventricle/TAPVD/LCAPA/TG
A/TOF/AVSD) 
 
 Chronic Respiratory Disorder 
(e.g. Cystic Fibrosis) 
 Rhythm disorder (e.g. 
prolonged QT syndrome) 
 Chronic Lung Disease  Cardiac Syndrome 
(Marfan‟s) 
 Tracheostomy  Heart transplant 
 Other  Other 
Neurological Brain Malformation Liver Any chronic liver disorder 
 Brain Tumour Haematological Any haematological 
condition 
 Cerebrovascular event or 
anomalies 
Oncological Solid tumour 
 Central nervous system 
Infection (e.g. meningitis) 
 Non-solid tumour 
 Convulsions  Bone marrow transplant 
 Genetic syndrome Metabolic or 
endocrine 
Any metabolic disorder 
 Hydrocephalus Prematurity  Born < 28 weeks gestation 
 Neuromuscular  Born ≥ 28 and <32weeks 
gestation 
 Spinal anomalies  Born ≥ 32 and <36weeks 
gestation 
 Neonatal hypoxic ischaemic 
encephalopathy 
Gastrointestinal Necrotising enterocolitis 
 Brain Trauma (Non-
accidental/accidental) 
 Other 
 Intraventricular bleed (non-
trauma) 
Renal Any chronic renal disorder 
 Myasthenia gravis Genetic Genetic syndrome (e.g. 
Trisomy 21: Down's) 
 Chronic Degenerative (e.g. 
Leigh's Leucodystrohpy) 
Immune-deficiency Any immunodeficiency 
syndrome 
 Other  Other (relevant) Other significant chronic 
condition  
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9.10 Conference abstract 
 
CARDIAC ARREST REQUIRING INTENSIVE CARE ADMISSION: A UNITED KINGDOM 
EPIDEMIOLOGY STUDY. 
 
B. Scholefield
1
; H. Duncan
1
; P. McShane
2
; R. Parslow
2
; R. Tasker
3
; F. Gao
4
; K. Morris
1
 
 
1
Birmingham Children‟s Hospital, Birmingham, United Kingdom 
2
University of Leeds, United Kingdom 
3
University of Cambridge, United Kingdom 
4
Univeristy of Warwick, United Kingdom 
 
Objectives: To describe the epidemiology of children (0-18yrs) admitted to UK paediatric 
intensive care units (PICUs) after in-hospital (IHCA) and out-of-hospital cardiac arrest 
(OHCA). To inform the design of a UK post-cardiac arrest intervention trial (The Cold-PACK 
Study: Post Arrest Cooling in Kids). 
 
Methods: Extraction and analysis of IHCA and OHCA admissions from the prospectively 
collected national PICANet Database containing information on admissions to 30 PICUs in 
the UK and Eire between January 2003 and June 2010. 
 
Results: 1703 children were admitted to PICU following cardiac arrest (51% IHCA, 49% 
OHCA). OHCA admission to PICU overall population incidence rate was 1.3 per 100‟000 
children per year (patients <1yr of age incidence rate = 8.9). IHCA and OHCA each 
accounted for 0.8% (IQR 0.6–1.0) of all PICU admissions. Median age of IHCA was 
significantly lower. Preceding chronic conditions were more common in IHCA (79%) than 
OHCA patients (48%). 74% of OHCA were admitted from other hospitals requiring retrieval 
to PICU compared to 41% of IHCA. 17% of OHCA cases were trauma related of which 65 
(8%) were near-drowning and 28 (3%) hanging. Pupils were fixed and dilated in 22% of 
OHCA admissions with a 96% PICU mortality. PICU survival was significantly higher for 
IHCA patients (76% versus 50%; p<0.01). 
 
Conclusions: The UK rates of survival from PICUs after IHCA and OHCA appear higher than 
previously reported. There is a high proportion with preceding chronic conditions and 
important UK population incidence rates are available to guide trial feasibility in the UK.  
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9.11 Letter of support from Birmingham Children’s Hospital 
director of research and development 
Letter of support for the RETRO-PACK (RETROspective Post Arrest Cooling in Kids) studies 
which are presented in Chapters 6 & 7. Please note the shortened term for the studies has 
not been presented in this thesis. The PRO-PACK study is a follow-on study which does not 
form part of this thesis.  
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